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GPR50, an X-linked orphan G protein-coupled receptor (GPCR), is a risk factor for 
bipolar disorder (BD) in female subjects. It has been shown that GPR50 plays a part 
in neurite outgrowth, glucocorticoid receptor signalling and leptin signalling by 
interacting with major factors involved in these events. Yeast two-hybrid screens 
have identified multiple putative GPR50 interactors involved in neurodevelopment, 
stress response and apoptosis, lipid and glucose metabolism, as well as regulation of 
NMDA receptors and GABA transmission. Among these interactors, RTN3, RTN4, 
SREBP2 and SNX6 are known regulators of β-secretase (BACE1), a key enzyme in 
Aβ generation, myelination of the central/peripheral nerve, and neurite 
outgrowth/synapse formation.  
Preliminary data indicated that GPR50 expression significantly increased 
endogenous BACE1 activity in HEK293 cells, so I hypothesised that there is a 
functional interaction between the two. 
In this thesis, I investigated the relationship between GPR50 and BACE1 by 
identifying the effects of GPR50 on BACE1 expression and function, which may 
provide an explanation of GPR50’s potential association with psychiatric disorders 
and Alzheimer’s disease. 
Firstly, studies on expression levels revealed that when GPR50 was over-expressed, 
BACE1 protein expression was up-regulated in SH-SY5Y cells, but down-regulated 
in HEK293 cells, suggesting a differentiated regulative system between cell lines. 
Then I confirmed the physical association between endogenous GPR50 and BACE1 
in HEK293 cells by co-localisation and co-immunoprecipitation studies. Their 
putative interaction sites were located at the plasma membrane and the 
filopodia/lamellipodia-like structures in HEK293 cells, and at the neurites in mouse 
primary neuronal cells.  Subcellular fractionation of adult mouse brain revealed that 
endogenous Gpr50 and Bace1 were co-fractionated in the presynaptic vesicles. 
Secondly, I showed that, in contrast to HEK293 cells, GPR50 overexpression had no 
effects on β-secretase activity in mouse primary cortical neurons. However, the BD-
associated variant GPR50del significantly decreased β-secretase activity compared to 
the more common variant GPR50, and showed a trend of diminishing β-secretase 
activity compared to the control condition. Subcellular fractionation experiments 
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showed that in HEK293 cells, there was an increased ratio of mature BACE1 against 
immature BACE1 localised in the plasma membrane fractions, indicating a role in 
regulation of BACE1 trafficking to one of its putative activity sites; whereas in 
mouse primary cortical neurons, GPR50del increased co-fractionation of immature 
Bace1 with endoplasmic reticulum (ER) marker calreticulin, thus potentially 
retarding the maturation of Bace1. Importantly, the regulative trend of 
GPR50/GPR50del on β-secretase activity is cell line-specific and is highly correlated 
to their effects on β-secretase intracellular distribution. 
Thirdly, I found that the mRNA levels of human GPR50 and BACE1 were 
negatively correlated in the dorsolateral prefrontal cortex of female subjects sampled 
after birth. Mouse Gpr50 and Bace1 mRNA levels were negatively correlated across 
the telencephalon regions, and had a trend of negative correlation across the 
hypothalamic regions. Co-localisation of the two proteins was detected in multiple 
mouse brain regions, with the strongest co-localised signals occurring in CA2 
pyramidal neurons, arcuate hypothalamic nucleus and dorsomedial nucleus of the 
hypothalamus. 
Finally, preliminary experiments in Alzheimer’s disease model TgSwDI mice, 
suggested that the expression level of Gpr50 in layer V of the entorhinal cortex was 
positively correlated with Aβ deposition. Decreased Gpr50 expression was identified 
in the hippocampus of 9 months transgenic animals compared with age-matched 
controls. This indicates that Gpr50 expression might be altered in this mouse model 
co-ordinately with Aβ deposition. 
The findings in this thesis provide further evidence of GPR50’s correlation to 
psychiatric illnesses and its interaction with enzyme BACE1 highlights a potential 













Mental illnesses, also known as psychiatric disorders, pose a serious threat to human 
health, and the number of individuals affected worldwide is increasing each year. The 
latest facts and figures on mental health showed that approximately 450 million 
people in the world have a mental health problem, and 1 in 4 families worldwide is 
likely to have at least one member with a behavioural or mental disorder (Halliwell 
et al, 2007). Although there has been great progress in the research on mental 
illnesses, their aetiology has so far not been clarified. The lag in basic research 
significantly affects the diagnosis and treatment of these diseases, especially the early 
identification and intervention before the appearance of the main symptoms. The 
major types of mental illnesses are represented by bipolar disorder and 
schizophrenia. Another category of mentally related disease that is frequently 
investigated is dementia, and its most common form is known as Alzheimer’s disease 
(Ballard et al, 2011). The development of the three brain diseases is determined by 
both genetic and environmental factors. 
The goal of this thesis was to investigate the possible functional and physical 
interaction between two mental illness-associated proteins: G protein-coupled 
receptor 50 (GPR50), and beta-site APP-cleaving enzyme 1 (BACE1). GPR50 is an 
orphan G protein-coupled receptor, which has been suggested as a risk factor for 
mental illnesses through genetic association or with specific protein expression in 
patients with bipolar disorder, schizophrenia and Alzheimer’s disease (Hamouda et 
al, 2007; Macintyre et al, 2010; Thomson et al, 2005). BACE1 is a key enzyme that 
initiates the pathological features of Alzheimer’s disease and the dysfunction of 
which results in phenotypes related to schizophrenia and bipolar disorder (Hussain et 
al, 1999; Marballi et al, 2012; Savonenko et al, 2008). To identify the effects of 
GPR50 expression on BACE1 function may further inform GPR50’s association with 
psychiatric illnesses and neurocognitive disorders. 
This chapter will introduce the discovery and known functions of GPR50 and 
BACE1, their putative links to each other and the three aforementioned illnesses in 
which GPR50 and BACE1 are predicted to play a role. 
1.1 G protein-coupled receptor 50  
1.1.1 The discovery of GPR50 
GPR50 belongs to the G protein-coupled receptor (GPCR) superfamily with seven 
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transmembrane (7TM) spanning domains. GPR50 is a member of the melatonin 
receptor (MT) subfamily that includes three members melatonin receptor 1A Mel1a, 
melatonin receptor 1b Mel1b and melatonin receptor 1c Mel1c/GPR50. Mel1a and 
Mel1b are expressed in all vertebrates and encode the proteins melatonin receptor 1 
(MT1) and melatonin receptor 2 (MT2). Mel1c was found only in Xenopus, chicken 
and zebrafish (Ebisawa et al, 1994; Reppert et al, 1995). The ortholog of Mel1c, 
GPR50 was detected exclusively in mammals and later identified as a member of the 
MT subfamily due to its sequence identity to the three melatonin receptors (Drew et 
al, 2001; Drew et al, 1998; Dufourny et al, 2008; Reppert et al, 1996). MT1 and MT2 
are native binding receptors for the “hormone of darkness”, melatonin, which 
regulates circadian rhythms and seasonal photoperiodisms (Dubocovich & 
Markowska, 2005). 
The gene of human GPR50 is localised to Xq28, and mouse Gpr50 lies in the 
proximal portion of chromosome X (Gubitz & Reppert, 1999). There are two 
isoforms of GPR50 protein. The full-length human GPR50 protein consisting of 617 
amino acids with a long proline-rich C-terminal tail, shares approximately 45% 
homology with MT1 and MT2. In the following experimental chapters, if not noted, 
“GPR50” was referred to as the full-length protein. The other isoform GPR50del 
differs in the C-terminal, with four amino acids missing (ΔTTGH, amino acid 
residues 502-505) and one amino acid substitution Thr532Ala (in complete linkage 
disequilibrium with ΔTTGH). The shorter isoform occurs with an allele frequency of 
approximately 30% (Grunewald et al, 2009). The role of GPR50 as a melatonin-
related receptor is unclear, as it does not bind to melatonin or other known ligands. 
Some important functions of GPR50 can be indicated by its expression patterns, by 
its interacting partners and from its loss-of-function studies.  
1.1.2 GPR50 expression 
GPR50 is highly expressed in dorsomedial hypothalamus (DMH) neurons, the 
tanycytes and the pituitary (Levoye et al, 2006). The DMH is a nodal point of 
neuroendocrine/autonomic circuitries. Almost all major nuclei and areas of the 
hypothalamus feed information to the DMH, which receives circadian information 
from the superchiasmatic nucleus, senses leptin and other feeding cues, and sends 
information to the ventrolateral preoptic area, the locus coeruleus, and the orexin 
neurons (Mieda et al, 2006). Tanycytes are ependymal cells, with a possible role of 
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transferring chemical signals from cerebrospinal fluid (CSF) to the central nervous 
system (CNS) (Rodriguez et al, 2005). The pituitary secretes nine hormones to 
regulate the homeostasis of the endocrine system, including body processes of 
growth, blood pressure, breast milk production, sexual function, thyroid gland 
function, energy metabolism, temperature adjustment, water balance, pigmentation 
and pain relief (Barron, 2010). Thus, the expression pattern of GPR50 supports its 
functional role in the hypothalamic-pituitary-adrenal (HPA) axis. In addition, lower 
levels of GPR50 were detected in the monoaminergic neurons in the brain stem 
nuclei (Grunewald et al, 2009), and this suggests a wider role of GPR50 in 
neurotransmitter signalling in the endocrine system and stress response. There are 
additional GPR50-expressing cites reported by different research groups. Here I 
focus on the regions that are well-recognised with GPR50 expression and regions 
that help to establish a link with the function of BACE1. A detailed description of 
GPR50 expression sites will be introduced in a later chapter. 
1.1.3 GPR50 interactors 
GPR50 is a member of the G-protein coupled receptor (GPCR) superfamily, which 
constitutes more than 1000 molecules (Gether, 2000). GPCRs sense extracellular 
ligands and activate intracellular signal transduction pathways and, ultimately, 
cellular responses (Figure 1.1). In the inactive state, GPCR is bound to a G-protein 
complex, a trimer of Gα, Gβ, and Gγ subunits. When activated by the binding of a 
ligand, GPCR undergoes a conformational change which is transmitted to the Gα 
subunit. Upon stimulation, Gα exchanges GDP for GTP, and this triggers its 
dissociation from the Gβγ dimer and from the receptor. Different types of Gα (Gαs, 
Gαi/o, Gαq/11, Gα12/13) and Gβγ subunits interact with corresponding intracellular 
proteins (such as adenylyl cyclase, phospholipase C). This in turn activates or 
inhibits downstream second messengers (such as cAMP, diacylglycerol), the 
alteration of which results in gene expression regulation and diverse biological 
effects such as proliferation, differentiation, development, cell survival, 
angiogenesis, hypertrophy and cancer (Marinissen & Gutkind, 2001). The response 
of GPCR is terminated upon GTP hydrolysis by Gα, which then binds Gβγ and the 
receptor. This process can be markedly accelerated by the binding of regulators of G 




Figure 1.1 The signalling pathway of G-protein coupled receptor. This figure was adapted 
from (Marinissen & Gutkind, 2001; Wu et al, 2012). GPCRs can be stimulated by binding of 
diverse ligands, including biogenic amines, amino acids, ions, lipids, peptides and proteins. 
The activation of GPCR signal transduction cascade ultimately results in the regulation of 
key biological functions such as cell metabolism and cancer. AC, adenylyl cyclase; PLC, 
phospholipase C; DAG, diacylglycerol; IP3: Inositol triphosphate; RGS, regulator of G protein 
signalling; FSH, follicle-stimulating hormone; GEF, guanine nucleotide exchange factor; LH, 
leuteinizing hormone; LPA, lysophosphatidic acid; PAF, plateletactivating factor; PI3K, 
phosphoinositide 3-kinase; PKC, protein kinase C; S1P, sphingosine-1-phosphate; TSH, 
thyroid-stimulating hormone. EPAC: Exchange factor activated by cAMP; MAPK: Mitogen-
activated protein kinase; GSK-3β: Glycogen synthase kinase-3β; RHOA: Ras homolog gene 
family, member A; ROCK: Rho-associated protein kinase. 
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GPR50 is an orphan GPCR without any known ligand. This has caused difficulty in 
understanding its function. However, many GPCRs have the ability of forming 
homodimers or heterodimers to exert functions in signalling and regulation, so 
looking for interacting partners of orphan GPCRs provides a strategy to investigate 
their potential roles. GPR50 can form heterodimers with its homologue MT1 to 
prevent melatonin binding, G-protein coupling and β-arrestin binding (Figure 1.2) 
(Levoye et al, 2006). Therefore, GPR50 has an inhibitory effect on MT1 signalling. 
In addition, truncating GPR50 CTD did not affect its heterodimerisation with MT1, 
but cleared of its antagonist effects on MT1 (Figure 1.2). This indicates that the CTD 
is required for GPR50 functioning. 
 
Figure 1.2 Regulation of MT1 signalling by heterodimerisation with GPR50. This picture 
was adapted from (Jockers et al, 2008). Forming heterodimers with GPR50 prevents high-
affinity agonist binding, heterotrimeric G-protein coupling and β-arrestin binding to MT1. 
Forming heterodimers with C-terminal truncated GPR50 mutant does not affect MT1 
functions. MT1, melatonin receotor 1; MLT, melatonin. 
Two studies have been published using yeast two-hybrid analysis to identify putative 
GPR50 interactors (Grunewald et al, 2009; Li et al, 2011). Grunewald et al used two 
forms of human GPR50 C-terminal tail (GPR50: the insertion form; GPR50del: the 
deletion form) as baits in a yeast two-hybrid study and screened against a human 
adult brain cDNA library (Grunewald et al, 2009). 23 putative interaction proteins 
were identified, including genetic factors that are involved in four areas of interest: 
neurodevelopment (ABCA2, CDH8, PCDH9, PAX6, RTN3, RTN4, SHOT1), stress 
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response (SATB1, RTN4, ST13) and lipid metabolism (ABCA2, OSBP2, SREBP2), 
together with regulation of NMDA receptors and GABA transmission (PICK1, 
SLC12A5, MADD) (Table 1.1). An independent yeast two-hybrid study using the 
intracellular CTD of GPR50 as bait screened against a mouse testes cDNA library (Li 
et al, 2011) identified 11 putative GPR50 C-terminal interactors, which contained 
two overlapping factors with the first study: SNX5 and SNX6. These two proteins 
are components of the retromer complex, which is involved in the subcellular 
trafficking of a number of molecules including the neurotransmitter receptors (Choy 
et al, 2014). Here, I will introduce several putative interactors: RTN4, ABCA2 and 
TIP60 that have had follow-up studies, which can provide clues to the function of 
GPR50 in neuronal development and endocrine homeostasis. 
Table 1.1 GPR50 yeast two-hybrid screen hits. The table was adapted from (Grunewald et 
al, 2009). Shown here are: symbol, full gene name and splice variant number, followed by 
the number of times each variant was captured by either the insertion (Ins), or the deletion 
(Del) form of the GPR50 C-terminal tail. PBS, predicted biological score. 
 
a) GPR50 and RTN4-A (Nogo-A) 
Among the GPR50 interactors identified by yeast two-hybrid studies, reticulon 
family member, RTN4, also known as Nogo, was ranked as one of the most likely 
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interactors with the highest predicted biological score (PBS).  
The Nogo gene generates three major products Nogo-A,-B and -C. All the Nogo 
isoforms share a reticulon-homology domain (RHD) of 188 amino acids at the C-
terminal. Nogo-A is the longest isoform and is an inhibitor of axonal regeneration 
(GrandPre et al, 2000) and neurite outgrowth (Oertle et al, 2003). Its protein is 
mainly expressed in oligodendrocytes, but also in subpopulations of neurons. Nogo-
A is found at synapses of mature pyramidal neurons in the hippocampus and plays a 
part in restricting short-term synaptic plasticity (Delekate et al, 2011).  
Endogenous Gpr50 co-localised with Nogo-A at the synaptic spines in mouse 
primary cortical neurons and co-fractionated with Nogo-A in the postsynaptic 
densities of adult mouse brain (Grunewald et al, 2009; Grunewald et al, 2012). 
Overexpressed GPR50 and Nogo-A can be co-immunoprecipitated in vitro. This 
physical interaction appeared to cause functional effects, as GPR50 overexpression 
increased neurite length in neuronal cells, and attenuated the outgrowth inhibiting 
characteristics of Nogo-A overexpression (Grunewald et al, 2009). Although results 
from GPR50 knockdown experiments or the in vivo binding affinity of GPR50 to 
Nogo-A are yet to be determined, GPR50 may play an important role in neuronal 
development, by interfering with the function of Nogo-A. 
b) GPR50 and ABCA2 
ATP-binding cassette sub-family A member 2 (ABCA2), another putative interactor 
of GPR50 (Grunewald et al, 2009), is a member of the superfamily of ATP-binding 
cassette (ABC) transporters, and is predominantly expressed in the brain tissue 
(Vulevic et al, 2001; Zhao et al, 2000).  
ABCA2 is implicated in oligodendrocyte maturation and neural development. Rat 
Abca2 was detected in late progenitor and immature oligodendrocytes, with an 
increasing level during the postnatal stage (Zhou et al, 2002). Persistent expression 
of Abca2 was seen in the grey matter and white matter throughout the spinal cord 
into adulthood, indicating a role in the onset of myelination in the CNS (Zhou et al, 
2002). In mouse brain, Abca2 protein was found in the neurons of the 
cortex/hippocampus and translocated from neuronal soma to the axis of the neurite 
during neural differentiation (Broccardo et al, 2006). In addition, the ABCA2 
promoter sequence contains potential binding sites for transcription factors (NF-1, 
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ETF, EGR2 and WT1) that are involved in the regulation of neural differentiation 
(Kaminski et al, 2001).  
Mouse mRNA levels of Gpr50 and Abca2 are correlated across a time span from E18 
to week 5, and are more positively associated at the E18 time point when the activity 
of neuronal development is the highest (Grunewald et al, 2012). Thus, the role of 
GPR50 in the neuronal development might also be related to the function of ABCA2.  
c) GPR50 and TIP60 
A signalling role for GPR50 has been suggested by its connection with HIV-1 tat 
interactive protein, TIP60. The putative interaction between the two was identified in 
a yeast two-hybrid screen in mouse and confirmed by co-immunoprecipitation and 
co-localisation studies (Li et al, 2011).  
TIP60 is a transcriptional co-activator with histone acetyltransferase (HAT) activity, 
which plays essential parts in chromatin remodelling (Hejna et al, 2008), 
transcription regulation (Nordentoft & Jorgensen, 2003), DNA repair (Hejna et al, 
2008) and apoptosis (Ikura et al, 2000), normally by forming complexes with other 
factors. TIP60 is able to enhance the transcriptional activity of a number of 
transcription factors including nuclear hormone receptors (NHR), the Myc family of 
transcription factors, APP intracellular domain (AICD) and nuclear factor kappa light 
chain enhancer of activated B cells (NF-κB) (Sapountzi et al, 2006). In particular, a 
complex consisting of TIP60, AICD, the transcriptional protein Fe65 stimulates 
histone acetylation and regulates the expression of genes which are linked to 
microtubule dynamics (Muller et al, 2013) and apoptosis-driven neurodegeneration 
(Lorbeck, 2010). Hence, the role of GPR50 can be further speculated, through its 
interaction with multi-functional TIP60.  
The expression of TIP60 or GPR50 augmented the expression of FK506-binding 
protein 5, which is a target of TIP60-activated glucocorticoid receptor (GR) 
signalling (Li et al, 2011). Co-expression of TIP60 and GPR50 enhanced this 
measure even more. Knockdown of either TIP60 or GPR50 attenuated this effect, 
suggesting a synergetic effect of the two in GR signalling. The target genes 
controlled by GR signalling include nuclear receptors, cytokines, peptidases, 
transcription factors, kinases, and enzymes, which are involved in diverse molecular 
processes of metabolism and biosynthesis (Phuc Le et al, 2005). Additionally, GR 
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functioning is sensitive to the levels of glucocorticoids, which are released in a 
circadian manner and in response to stress (Chung et al, 2011). Thus, the function of 
GPR50 may also be associated with factors required for maintaining endocrine 
homeostasis and stress response. 
1.1.4 GPR50 knockout mice 
The function of GPR50 can also be investigated by analysing the consequences of 
GPR50 gene deletion or down-regulation. Several studies have revealed the 
phenotypes of GPR50 knockout (KO) mice. Here, I will summarise the key functions 
of GPR50 suggested by these studies. 
a) Deletion of Gpr50 affects energy metabolism 
GPR50 KO mice exhibited resistance to diet-induced obesity, which affects not the 
food intake but the food consumption efficiency, indicating an altered energy 
metabolism (Ivanova et al, 2008). Indeed, the attenuated weight gain of these mice 
resulted from a reduction in body fat. Moreover, GPR50 KO mice lost significantly 
less body weight during fasting when compared with wild-type mice, suggesting an 
altered response to negative energy balance. The intensity of wheel-running activity 
in GPR50 KO mice was enhanced, which means these animals were hyperactive, in 
line with elevated levels of oxygen consumption and carbon dioxide production. In 
summary, GPR50 loss-of-function leads to an alteration in the energy metabolic 
status and hyperactivity in mice. 
b) Deletion of Gpr50 affects glucocorticoid receptor signalling 
Circulating corticosterone levels were raised in the GPR50 KO mice, although this 
was not statistically significant (Ivanova et al, 2008). Therefore, these mice showed 
elevated stress levels, strengthening a possible link between GPR50 and GR 
signalling. GPR50 KO mice were not responsive to the stimulation of gluconeogenic 
pathways and were deprived of the inhibitory effect of glucocorticoid on 
proopiomelanocortin expression in the pituitary (Li et al, 2011). Thus, 
glucocorticoid-related functions are affected in mice lacking Gpr50, which may 
indicate that the function of GPR50 is related to GR signalling, probably via the 




c) Deletion of Gpr50 affects leptin signalling 
Upon food deprivation, GPR50 KO mice consistently entered a state of torpor with 
dropped oxygen consumption rate and reduced nocturnal body temperature (Bechtold 
et al, 2012). Leptin is a nutrition responsive hormone primarily secreted by 
adipocytes (Zhang et al, 2005). As a regulator of food intake and energy expenditure, 
leptin is able to block torpor (Gavrilova et al, 1999). However, leptin administration 
failed to attenuate torpor in the GPR50 KO mice as in the wild-type control, 
suggesting that the leptin signalling system was affected when Gpr50 was lacking. 
This effect was specific to leptin-induced thermogenesis, but not food intake, which 
indicated that leptin efficacy in feeding and thermogenic actions were differentiated 
and that only the latter was modulated by GPR50. Moreover, Gpr50 expression in the 
DMH was reduced in leptin-deficient mice but restored to wild-type levels by leptin 
treatment, which was confirmed by in vitro promoter-driven luciferase assay 
(Bechtold et al, 2012). The association with leptin supports the role of GPR50 in the 
regulation of energy metabolism. 
In summary, GPR50 plays an important role in neuronal development, 
neurotransmitter signalling and endocrine regulation. To further understand the 
functions of GPR50, in this thesis, I have studied the interaction between GPR50 and 
BACE1, as they have overlapping roles and both are implicated in mental illnesses.  
In the following sections I will introduce BACE1, the mental illnesses related to its 
functions and the existing evidence linking these two proteins. 
1.2 Beta-site APP cleaving enzyme 1, BACE1 
1.2.1 The discovery of BACE1 
Beta-site APP cleaving enzyme 1 (BACE1), also formerly called memapsin 2 and 
aspartyl protease 2 (Aps2), was identified over a decade ago by five research groups 
in the search for the secretase responsible for the initiation of Alzheimer’s disease 
(AD) pathology (Gavrilova et al, 1999; Hussain et al, 1999; Lin et al, 2000; Sinha et 
al, 1999; Vassar et al, 1999; Yan et al, 1999).  
The gene for human BACE1 is located on chromosome 11q23.3. BACE1 protein, 
consisting of 501 amino acids, is a type-I membrane-associated aspartic protease that 
exhibits all the previously determined characteristics of β-secretase. The 
accumulation of amyloid-β (Aβ) plaques in the brain is one of the hallmarks of AD. 
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Research has revealed that BACE1 is the prerequisite for β-cleavage of amyloid 
precursor protein (APP) in vivo and acts as the key rate-limiting enzyme of Aβ 
deposition (Sinha et al, 1999). Overexpression of BACE1 leads to increased levels of 
Aβ (Bodendorf et al, 2002), whereas deletion of BACE1 results in little or no Aβ 
generation (Luo et al, 2001). 
Other non-APP substrates include the APP homolog proteins APLP1 and APLP2 (Li 
& Sudhof, 2004), neuregulins (NRG) (Hu et al, 2008), neural cell adhesion 
molecules (Zhou et al, 2012), β-galactoside α2,6-sialyltransferase I (ST6Gal-I) 
(Sugimoto et al, 2007), P-selectin glycoprotein ligand-1 (PSGL-1) (Lichtenthaler et 
al, 2003), low-density lipoprotein receptor-related protein (LRP) (von Arnim et al, 
2005), the voltage-gated sodium channel (Nav1) β subunits (Navβ2/4) (Gersbacher et 
al, 2010; Miyazaki et al, 2007), etc. BACE1 mediated cleavage of these proteins may 
activate certain signal transduction pathways, indicating that BACE1 is an important 
enzyme with multifunctional interactions. Thus, the regulation of BACE1 expression 
may be central to diverse physiological events far beyond the pathology of AD. 
1.2.2 BACE1 expression 
BACE1 mRNA is found with highest expression levels in the pancreas, with 
moderate levels in the brain, and with low levels in most other peripheral tissues 
(Vassar et al, 1999; Yan et al, 1999). However, the β-secretase activity is high only in 
the brain, but almost undetectable in the pancreas (Sinha et al, 1999). This suggests 
that BACE1 cleavage activity is more related to brain functions. 
1.2.3 The trafficking of BACE1 
The activity of BACE1 is regulated by its subcellular localisation. BACE1 is initially 
synthesised as a pro-peptide (proBACE1) in the endoplasmic reticulum (ER), where 
glycosylation and transient acetylation take place co-translationally, yielding an 
immature BACE1. ProBACE1 is immediately subjected to addition of complex 
carbohydrates and removal of the BACE1 pro-domain by furin convertases, 
producing the mature form. This process mainly occurs in the Golgi compartment. 
N-glycosylation is known to regulate the enzymatic activity of BACE1 (Charlwood 
et al, 2001). Therefore, even though proBACE1 can exhibit a minor level of β-
secretase activity (Klaver et al, 2010), the catalytic activity of BACE1 is greatly 
enhanced after maturation (Vassar et al, 2009). The co-localisation of BACE1 with 
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substrate APP has been reported to occur at the plasma membrane, the endosomal 
system and the trans-Golgi network (TGN), but there is still controversy regarding 
the subcellular compartments where BACE1 acts to cleave APP. It is also reported 
that BACE1 cycles between the cell surface and the endosomal system, and becomes 
activated during its cellular trafficking (Shimizu et al, 2008). Moreover, as BACE1 
activity is optimal in an acidic environment, the activation of substrate cleavage by 
BACE1 is theoretically most efficient within the TGN and the early endosomes.  
Transporters that are able to change the intracellular localisation of BACE1 are 
thought to regulate β-secretase activity, thus altering the levels of its cleavage 
products. Regulatory mechanism of BACE1 trafficking can be summarised into three 
categories. Each mechanism will be elucidated with a corresponding regulator 
respectively as follows.  
a) Regulators retain BACE1 within the ER 
Overexpression of reticulon protein RTN3, which can act as an inhibitor of BACE1 
activity, significantly increased the retention of BACE1 within the ER, the pH 
environment of which is neutral, so not optimal for BACE1 activity (He et al, 2004; 
Shi et al, 2009). In vivo, this enhanced ER retention resulted in reduced levels of an 
intermediate BACE1 cleavage product from APP in the cortical regions of transgenic 
mice overexpressing RTN3.  
b) Regulators sort BACE1 into compartments for optimal cleavage activity 
The retromer component sorting nexin 6 (SNX6) is able to modulate BACE1 levels 
in the TGN (Okada et al, 2010). Reducing SNX6 in cultured cells enhanced the 
retrograde transport of BACE1 from cell surface to the TGN. This measure increased 
BACE1-mediated APP cleavage, leading to an increase of Aβ production. On the 
contrary, SNX6 overexpression decreased the APP cleavage by BACE1, resulting in 
a reduction in Aβ levels. 
c) Regulators transport BACE1 to the lysosomes for degradation 
Golgi-localised γ-ear-containing ADP ribosylation factor-binding (GGA) proteins 
bind directly to the DXXLL motif of BACE1 C-terminal via a VHL domain and 
regulate the sorting of BACE1 among different subcellular compartments in a 
BACE1 phosphorylation-dependent manner (Wahle et al, 2005). Depletion or ectopic 
expression of GGA3 resulted in increased BACE1 levels and activity because of 
13 
 
impaired lysosomal degradation, while the overexpression of GGA3 reduced the 
levels of BACE1 and Aβ peptides (Kang et al, 2010; Tesco et al, 2007).  
The intracellular trafficking system of BACE1 has been widely investigated with a 
view to further understanding its function in the β-secretase pathway that is 
responsible for Aβ generation. However, there is a group of functional substrates 
apart from APP, which may induce BACE1 activity in distinct subcellular sites.  
Here, I will introduce several brain disease-associated BACE1 substrates, including 
APP and homologues, neuregulin 1 and homologues, and neural cell adhesion 
molecules, which illustrate the potential role of BACE1 in neuronal development, 
myelination and synaptic functions.  
1.2.4 Main BACE1 substrates 
a) Amyloid precursor protein (APP) and homologues 
In human, the APP gene is located on chromosome 21. Alternative splicing generates 
at least 11 isoforms of APP, ranging from 365 to 770 amino acids in length. APP 
protein is membrane-integrated, and expressed in the brain and most peripheral 
tissues. Certain isoforms are the major Aβ peptide producing proteins: APP695, 
APP751 and APP770 (Zheng & Koo, 2006). APP695 is primarily expressed in 
neurons, while APP751 and APP770 are found mostly in non-neuronal glial cells 
(LeBlanc et al, 1991). Changes in the ratio of neuronal APP isoforms have been 
suggested to be associated with AD (Johnson et al, 1990; Matsui et al, 2007). 
Apart from being the precursor molecule, the proteolysis of which generates Aβ, APP 
has been implicated in normal biological functions. The other end product of APP 
generated by BACE1 cleavage, AICD, is capable of nuclear signalling (Konietzko, 
2012). APP itself is required for the axon/dendrite outgrowth in neurons (Allinquant 
et al, 1995; Herard et al, 2006; Perez et al, 1997), but human APP in Drosophila 
resulted in synaptic abnormalities in the larval neuromuscular junction (Mhatre et al, 
2014). APP prevents iron accumulation and oxidative stress in vivo, while the 
ferroxidase activity of APP is inhibited by zinc in AD (Duce et al, 2010). Thus, APP 
may act as a regulator of neuronal development, synapse formation, and iron export.  
Amyloid-β precursor-like proteins, APLP1 and APLP2 are the two homolog 
molecules of APP, and are also cleaved by BACE1. The sites required for β/γ-
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secretase cleavage of APP are not conserved in APLP1 and APLP2, thus they lack 
the capacity to generate Aβ peptides (Li & Sudhof, 2004).  
Loss-of-function studies in mice indicate that APP and APLP1/2 have overlapping or 
synergetic functions that are essential to normal metabolism and neurobehavioural 
development during the early postnatal stage (Heber et al, 2000; Herms et al, 2004; 
Phinney et al, 1999; Senechal et al, 2008; von Koch et al, 1997; Weyer et al, 2011). 
Functional investigation reveals that all three APP family members are up-regulated 
during induced neuronal differentiation (Adlerz et al, 2003) and are capable of 
interfering in the function of the regulators of synaptic vesicle exocytosis (Okamoto 
& Sudhof, 1997; Orcholski et al, 2011; Swistowski et al, 2009), neuronal plasticity 
(Ashley et al, 2005) and signalling (Biederer et al, 2002). Thus, BACE1 cleavage 
may control the regular turnover of APP/APLP1/APLP2, thus regulating some 
important bio-physiological processes, such as neuronal development and synaptic 
functions. 
b) Neuregulin 1 (NRG1) and homologues 
NRG1 is one of four proteins in the neuregulin family that act on the receptors of 
epidermal growth factor (EGF) family. NRG1 contains an EGF-like domain which is 
released upon cleavage (possibly by BACE1) and signals by stimulating ErbB 
receptor tyrosine kinases. NRG1 gene encodes at least 33 isoforms distinguished by 
six different membrane topologies (types I–VI) (Mei & Xiong, 2008), which allows 
it to perform various functions, including regulating the normal development of the 
nervous system (Britsch, 2007) and the maintenance of heart integrity (Liu et al, 
2006).  
Studies in BACE1 knockout mice revealed that type III NRG1 and type I NRG1 are 
BACE1 substrates (Hu et al, 2006; Willem et al, 2006). Axonal type III NRG1 in the 
peripheral nervous system (PNS) mediates the generation of Schwann cell 
precursors, their subsequent differentiation and migration along the axons of 
neurons, and also adjusts the thickness and length of myelin sheaths to match the 
axon calibre, through regulating the membrane growth of Schwann cells (Birchmeier 
& Nave, 2008; Nave & Salzer, 2006; Perlin et al, 2011). In the CNS, type III NRG1 
promotes the myelination of oligodendrocytes without affecting their differentiation 
(Taveggia et al, 2008). Schwann cell-derived type I NRG1 has been shown to be 
more efficient than the type III in the activation of the regeneration and 
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remyelination processes after peripheral nerve injury (Stassart et al, 2013).  
NRG1 homologue, NRG3 was also identified as a BACE1 substrate in loss-of-
function studies of BACE1 (Hu et al, 2008). NRG3 binds to the extracellular domain 
of ErbB4, which stimulates the tyrosine phosphorylation of this receptor (Zhang et 
al, 1997). The primary role of NRG3 has been identified in the development of 
epidermal organs including the skin, hair, and mammary glands (Panchal et al, 2007). 
Moreover, recent data showed that the expression level of Nrg3 is associated with the 
impulsive response in the medial prefrontal cortex of mice (Loos et al, 2014). 
In summary, BACE1 may contribute to the development and myelination of CNS 
and PNS, as a sheddase that can release the functional domain of NRG1 and NRG3. 
c) Neural cell adhesion molecules (CAMs) 
Ectodomain shedding is the first step for activating the expression and function of 
specific molecules on the cell surface (Hayashida et al, 2010). This process is 
normally mediated by certain sheddases including ADAM and BACE1. Recently, 
BACE1 was identified as a sheddase of a variety of neural CAMs, exemplified by 
seizure related protein 6 (SEZ6), neuronal cell adhesion molecule L1, close homolog 
of L1 (CHL1) and contactin-2 (Kuhn et al, 2012). These CAMs are widely expressed 
in the developing nervous system, especially in the neurons undergoing growth 
(Hillenbrand et al, 1999; Osaki et al, 2011; Zuellig et al, 1992). The expression and 
function of neural CAMs are closely related to neuronal functions, including neural 
cell adhesion/migration, neurite outgrowth, axon projection, dendritic orientation, 
neuron proliferation/differentiation and synapse formation (Baeriswyl & Stoeckli, 
2008; Demyanenko et al, 2004; Dihne et al, 2003; Godenschwege et al, 2006; 
Gunnersen et al, 2007; Maretzky et al, 2005; Mechtersheimer et al, 2001; Montag-
Sallaz et al, 2002; Wolman et al, 2008). These processes are important in the 
maintenance of normal learning and memory (Savvaki et al, 2008; Stogmann et al, 
2013). 
The finding that ectodomain shedding of neural CAMs can be mediated by BACE1 
points to a central function of this sheddase in the development and correct wiring of 
the normal brain, far more than its involvement in Aβ deposition in the diseased 
brain. 
The putative functions of BACE1 in neuronal development and myelination have 
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also been suggested by investigation in vivo using mice with overexpression of 
BACE1 or deletion of Bace1 described below. 
1.2.5 BACE1 overexpression transgenic mice 
The transgenic mice with overexpressed human BACE1 (BACE1-tg mice) showed a 
strictly neuronal expression of BACE1 protein mainly in the deep cortical layers, 
hippocampus and colliculi, as well as Purkinje cells in the cerebellum (Mohajeri et 
al, 2004). In BACE1-tg mice, intracellular deposition of Aβ but no amyloid plaque 
was seen at the age of 14 months in BACE1 immunoreactive neurons of the 
hippocampus, the temporal cortex and the amygdala.  
The phenotypes of BACE1-tg mice are dependent on the dose of BACE1 
overexpression (Harrison et al, 2003; Rockenstein et al, 2005). Weakness and 
spasticity of the hind limbs as well as learning deficits have been reported only in 
robust BACE1 expresser lines (Rockenstein et al, 2005). The BACE1-tg mice with 
impairments were further revealed as having degeneration of neurons in the 
neocortex/hippocampus and degradation of myelin sheaths, which might be related to 
a diminished cAMP/PKA/CREB pathway (Chen et al, 2012b). In addition, the 
neurotransmitter systems were changed in BACE1-tg mice, represented by an 
overproduction of serotonin in the cerebellum, the hippocampus, the hypothalamus, 
the nucleus accumbens and the caudate striatum, as well as a disorganised dopamine 
turnover with an increase in the hypothalamus, the striatum but a decrease in the 
hippocampus (Harrison et al, 2003). Thus, BACE1 is implicated in the regulation of 
neurodegeneration, myelination and neurotransmission, independent of Aβ 
deposition.  
1.2.6 BACE1 knockout mice 
BACE1 loss-of-function studies are very useful to discover new BACE1 substrates, 
such as NRGs. Investigations focusing on different phenotypes of BACE1 knockout 
(KO) mice may help to clarify the specific functions of certain substrates. The 
important features of these mice related to my thesis will be introduced as follows. 
a) Amyloid clearance 
BACE1 KO mice showed abrogated production of Aβ peptides (Luo et al, 2001; 
Roberds et al, 2001). BACE1 KO/APP-tg mice did not develop amyloid plaques even 
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in aged animals, suggesting that BACE1 dosage is essential to Aβ deposition. These 
observations confirmed the key position of BACE1 in the AD pathology. 
b) Phenotypes 
BACE1 KO mice were initially described as healthy, but later studies revealed that 
these animals displayed a higher mortality rate during early life, hyperactivity and 
age-dependent cognitive deficits (Dominguez et al, 2005; Laird et al, 2005). 
Importantly, BACE1 KO mice shared a number of behavioural traits that resemble 
those found in NRG1+/− mice (mice with one copy of NRG1 type III gene), such as 
impaired prepulse inhibition, hyperactivity, supersensitivity to a psychostimulant, a 
lack of social recognition, and deficits in working and inhibitory avoidance 
memories, which are referred to as schizophrenia-like phenotypes (Savonenko et al, 
2008).  
c)  Hypomyelination and neural deficits 
Another significant abnormality in BACE1 KO mice that has been highlighted is an 
altered myelination mechanism in the CNS and the PNS. The process of myelination 
was slightly delayed and myelin thickness of hippocampal/optical/sciatic nerves was 
markedly reduced in these mice, indicating that BACE1 gene deletion causes 
hypomyelination (Hu et al, 2008; Hu et al, 2006). Compared to wild-type mice, 
lower levels of myelin basic protein and proteolipid protein were detected in both 
developing and adult brains of BACE1 KO mice. This process appeared to stem from 
decreased levels of proteolytically cleaved NRG1 and consequently reduced 
activation of down-stream Akt phosphorylation, which regulates the gene expression 
of myelin proteins (Hu et al, 2013b). Akt signalling in myelination is CNS-specific 
(Flores et al, 2008; Hu et al, 2006) and increasing Akt activity in oligodendrocytes is 
sufficient to reverse the hypomyelination phenotype in BACE1 KO mice (Hu et al, 
2013b).  
The CA1 and CA3 regions of hippocampus in BACE1 KO mice exhibited alterations 
in mechanisms of presynaptic release, synaptic transmission and synaptic plasticity, 
indicating that BACE1 is associated with synapse functions (Laird et al, 2005; Wang 
et al, 2008a). The role of synaptic NRG1/ErbB4 has been implicated in the 
maturation and maintenance of excitatory spines in the hippocampus (Li et al, 2007). 
BACE1 KO mice exhibited lower spine density, decreased number of mature spines 
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and altered spine morphology of CA1 pyramidal neurons, which is in line with a 
reduced level of ErbB4 in the PSD95-associated pool (Li et al, 2007).  
Collectively, the hypomyelination and neural deficient phenotypes observed in 
BACE1 KO mice correlate with a disturbed NRG1/ErbB4 signalling pathway, which 
has been suggested in schizophrenia (Nicodemus et al, 2006; Norton et al, 2006). 
Furthermore, another group of functional substrates, neural CAMs which are 
required for neurogenesis and synaptogenesis, may also be indicative of the negative 
effects upon BACE1 abolishment in the nervous system. 
d) Altered signalling system 
Enhanced glucose tolerance and increased insulin sensitivity were seen in BACE1 
KO mice compared with their wild-type littermates (Meakin et al, 2012). On a high-
fat diet, these mice retained their ability to dispose glucose and also their insulin 
sensitivity, unlike the insulin resistance found in wild-type mice. Therefore, 
inhibition of BACE1 in mice appears to improve glucose homeostasis. 
BACE1 KO mice had reduced body weight due to decreased adiposity when 
compared to the wild-type control, and like GPR50 KO mice, were resistant to high-
fat diet-induced obesity, indicated by a decreased level of serum leptin (Meakin et al, 
2012). These mice had higher but less efficient energy expenditure, suggested by 
higher resting metabolic rate/respiratory quotient but unchanged faeces mass. This 
observation was explained by an elevated thermogenesis of BACE1 KO mice. 
Further studies revealed that upon BACE1 deletion, the mice had increased leptin 
sensitivity (Meakin, 2013). This report suggests that BACE1 is involved in the 
modulation of hypothalamic leptin function in mice. In addition, a significant 
increased level of serum corticosterone was observed in BACE1 KO mice on a high-
fat diet, suggesting a stress response, even though no difference was detected in the 
locomotor activity. 
Interestingly, the metabolic phenotypes observed in BACE1 KO mice are very 
similar to those in GPR50 KO mice. Therefore, BACE1 and GPR50 might have 
cooperative functions in body weight maintenance and thermogenesis that are related 
to leptin signalling.  
In summary, BACE1 KO mice studies indicate that complete abolishment of BACE1 
activity may have deleterious side effects, thus future research should be alert to the 
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potential mechanism that may occur with BACE1 inhibitors designed to ameliorate 
Aβ deposition in AD. Aside from being the key enzyme of Aβ generation, BACE1 is 
implicated in the neuronal development, myelination, synaptic functions and 
neurotransmitter signalling.  
The functions of GPR50 and BACE1 in neural activities and signalling pathways 
seem to be overlapping, suggesting a correlation between the two under normal 
conditions. Their shared roles could be co-regulated in mental illnesses, and the 
alteration of their correlation will provide clues to the understanding of certain 
altered physiological processes during disease onset and progression. 
1.3 Mental illnesses 
Here I will introduce the three aforementioned mentally related illnesses that may 
link to GPR50 and BACE1. 
1.3.1 Bipolar disorder  
a) Symptoms of bipolar disorder 
Bipolar disorder (BD) has an increasing morbidity and mortality, which makes the 
disease highly recognised as a serious psychiatric disorder (Martinowich et al, 2009). 
Symptoms of patients suffering from BD are characterised by two extremes of mood 
swings between mania and depression, which are accompanied by eating and 
sleeping disorders. People with BD may have episodes of depression more regularly 
than mania, or mania more often than depression. Between episodes of depression 
and mania, periods of “normal” mood are sometimes but not always seen. These 
conditions may recur after medical treatment, and will probably leave residual 
effects, such as brain functional impairments. Studies of computerised tomography 
and magnetic resonance imaging frequently reported that compared with healthy 
controls, BD patients have enlarged lateral ventricles and third ventricles, more 
cortical sulcal prominence, and increased white matter hyperintensities (Ahn et al, 
2004; Goodwin et al, 2007; Tighe et al, 2012). 
b) Heredity of bipolar disorder 
The aetiology of BD is poorly investigated, but heritable factors have been proven to 
be influential. Twin studies reported that the concordance rate for BD was 
significantly greater among monozygotic twins (78%) than among dizygotic twins 
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(29%), suggesting a heritability of 63% (Smoller & Finn, 2003). Adoption studies 
showed that biological relatives of BD patients were significantly more likely to 
suffer from this disorder than adoptive relatives (Taylor et al, 2002). Furthermore, the 
recurrence risk for BD in first-degree relatives of BD patients was approximately 
9%, nearly 10 times that of the general population (Barnett & Smoller, 2009). 
However, a concordance rate of less than 100% among monozygotic twins also 
indicates the involvement of environmental factors.  
Despite the abundant evidence of a genetic contribution to BD, there are no specific 
candidate genes that are the causation factors alone. The pathogenesis of BD is 
multifactorial, which results from a combination of risk genes or potential proteins, 
including GPR50 (Xq28), CUX2 (12q23-q24), ANK3 (10q21), CACNA1C (12p13), 
TRPM2 (21q22.3), and NAPG (18p11) (Ferreira et al, 2008; Glaser et al, 2005; 
Thomson et al, 2005; Weller et al, 2006; Xu et al, 2009). With an increasing number 
of genome-wide association study (GWAS) ongoing, there are new genes added to 
the list of risk loci for BD, such as recently discovered ODZ4 (11q14.1), TRANK1 
(3p22.2) and ADCY2 (5p15.31) (Chen et al, 2013; Muhleisen et al, 2014; 
Psychiatric, 2011). The proteins of these genes have important functions in neuronal 
development, ion conduction, inflammation, transcription, cell adhesion and 
signalling cascade.  
In particular, multiple polymorphisms of GPR50 gene were found associated with 
BD and major depressive disorder (Macintyre et al, 2010; Thomson et al, 2005). The 
variant within GPR50 exon 2 that results in the deletion isoform (ΔTTGH) was 
found associated with an increased risk of BD, especially in female subjects, and was 
correlated with the age of onset, number of episodes, hypomanic symptoms, and 
initial thinking time in a highly phenotyped subgroup of women with early-onset 
major depressive disorder. Apart from one single-nucleotide polymorphism (SNP) 
Thr532Ala which is in complete linkage disequilibrium with the variant ΔTTGH, 
another SNP Val606Ile within exon 2 was also identified as a female-specific risk 
factor for major depressive disorder (Thomson et al, 2005) (Figure 1.3). However, 
two studies investigating Swedish BD patients and Hungarian children/adolescents 
with mood disorders failed to replicate the GPR50 insertion/deletion polymorphism 
findings (Alaerts et al, 2006; Feng et al, 2007). The failure to replicate may be due to 
the genetic heterogeneity of the populations or the small sample sizes. Additionally, 
the three psychiatric disorder-associated variants of GPR50 were also associated with 
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higher fasting circulating triglyceride levels (Bhattacharyya et al, 2006), which might 
reflect a predisposition to metabolic syndrome of these diseases.  
 
Figure 1.3 GPR50 gene structure and position of polymorphisms. The figure was adapted 
from (Thomson et al, 2005). A) The seven transmembrane domains of GPR50 are denoted 
by Roman numerals I-VII. B) The nucleotide changes of the polymorphisms resulting in 
alterations of the amino acid sequence.  
Elsewhere, NRG1 is a susceptibility gene associated with the mood-incongruent 
psychotic features of BD (Prata et al, 2009). And this points to BACE1 as a related 
factor, because NRG1 is a substrate of BACE1. In conclusion, the functions of both 
GPR50 and BACE1 may be related to the development of this mental disorder. 
1.3.2 Schizophrenia 
a) Symptoms of schizophrenia 
Changes in thinking and behaviour are the most obvious signs of schizophrenia, and 
different patients can experience symptoms in different ways. The symptoms of 
schizophrenia are usually classified into two categories:  
1) Positive symptoms: such as hallucinations or delusions.  
2) Negative symptoms: usually seen with a lack of social function that is 
expected in a healthy person, for example, lack of emotion, apathetic 
behaviour, disorganised speech and cognitive deficits. 
The first signs of schizophrenia, such as becoming socially withdrawn and 
unresponsive to communication, can be difficult to identify, as these symptoms often 
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develop during adolescence and can be mistaken for an adolescent rebellious period. 
The onset of symptoms can start from young adulthood, with a global prevalence of 
up to 1% (Zhang et al, 2013).  
Schizophrenia patients on average have larger intracranial cerebrospinal fluid (CSF) 
volumes, including the enlargement of lateral ventricles and cortical sulci, as well as 
abnormalities in grey matter volumes and white matter volumes (Zipursky et al, 
2013). Therefore, like BD, schizophrenia is considered as a disease of brain, but this 
notion is challenged by some researchers (Williams, 2012). 
b) Heredity of schizophrenia 
Like BD, there is strong but indirect evidence from family studies and twin studies 
that schizophrenia is highly heritable. The risk of developing schizophrenia in a 
random individual, in an individual with one affected first degree relative or two 
affected first degree relatives is on average 1%, 13% and 46% respectively. The 
monozygotic twin of a person with schizophrenia has a risk of 48% of developing 
this disorder, nearly three times that of a dizygotic twin, which is 17% (Cardno & 
Gottesman, 2000; Gottesman & Moldin, 1997). Schizophrenia endophenotypes result 
from the additive effects of alteration in multiple genes, combined with 
environmental factors. Thus, schizophrenia is regarded as a polygenic disorder. This 
also explains why different schizophrenia patients manifest with different sets of 
symptoms. The estimated heritability of schizophrenia ranges from 41% to 87% 
(Cannon et al, 1998), which has directed researchers to identify candidate genes 
responsible for or related to this psychiatric disorder.  
GWAS studies showed that schizophrenia is strongly associated with deletions in 
chromosomes 1q21.1, 15q13.3, and 22q11.21, duplications in 16p11.2, and SNPs in 
multiple chromosomes (Levinson et al, 2011; Ripke et al, 2013). The most recent 
GWAS study reported 128 linkage-disequilibrium-independent SNPs spanning 108 
physically distinct genomic loci, 83 of which have not been implicated in 
schizophrenia previously (Schizophrenia Working Group of the Psychiatric 
Genomics, 2014). In general, the majority of the risk variants for schizophrenia have 
small effects on the risk increase (Ripke et al, 2013). 
Among the risk genes, an SNP in NRG1 explained 6.9% of the genetic variation in 
the spatial processing function of schizophrenia subjects (Greenwood et al, 2011). 
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The discovery of this gene strengthened the importance of investigating BACE1, 
because the function of NRG1 can be mediated via its cleavage by this enzyme. 
Elsewhere, an intronic SNP of GPR50 rs2072621 was identified in female 
schizophrenia patients of a Scottish group (Thomson et al, 2005). The sample size of 
this investigation was very small, and there are no replicate studies. However, it 
remains interesting to study the involvement of GPR50 in schizophrenia, as a strong 
candidate gene RGS4 (regulator of G protein signalling 4) encodes a regulator of 
GPR50 expression (Vrajova et al, 2011). Besides NRG1 and GPR50, there are a 
number of other candidate genes for schizophrenia that may also be associated with 
BD, such as RGS4, G72, DISC1, NCAM1, DAO, GRM3, GRM4, GRIN2B, MLC1, 
SYNGR1, SLC12A6, CACNA1C as well as recently identified NDST3 and 
TSNARE1 (Kato, 2007; Lencz et al, 2013; Psychiatric, 2011; Sleiman et al, 2013). A 
statistical estimation study showed that the genetic correlation calculated as SNP-
based coheritability was high between schizophrenia and bipolar disorder (rg = 0.68 ± 
0.04 standard error, s.e.), compared to moderately correlated schizophrenia and 
major depressive disorder (0.43 ± 0.06 s.e.) or bipolar disorder and major depressive 
disorder (0.47 ± 0.06 s.e.) (Cross-Disorder Group of the Psychiatric Genomics et al, 
2013). 
1.3.3 Alzheimer’s disease  
Alzheimer’s disease (AD) is the most common form of dementia and is one of the 
debilitating illnesses that affect mainly elderly people. It is still controversial whether 
AD can be viewed as a mental illness, due to its specific post-mortem diagnosis, 
different treatment approaches, as well as the societal stigma of mental illnesses 
(Herro, 2011; Sivak, 2010). In the fifth edition of diagnostic and statistical manual of 
mental disorders (DSM-5) updated in 2013, dementias were renamed as 
neurocognitive disorders, with various degrees of severity (APA, 2013). Because AD 
is a memory-associated disease with brain dysfunction, in this thesis, I regard AD as 
a mentally related illness or brain disease, which has been mentioned in a previous 
paragraph. 
a) Symptoms of Alzheimer’s disease 
The early signs of AD are characterised by gradually declining memory and 
functional ability. As the disease advances, symptoms increase ranging from 
cerebral dysfunction to unpredictable behaviours, including confusion, irritability 
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and aggression, mood swings, language breakdown, long-term memory loss, 
declining sense and hallucinations. Gradually, the body loses all of the necessary 
functions, which eventually leads to death (Bird, 1993). 
b) Pathology of Alzheimer’s disease 
There is at present no cure for AD, but gene-related studies have revealed significant 
evidence about the pathogenic mechanism of this dementia. The hallmarks of AD 
brain include overproduction of amyloid plaques, accumulation of neurofibrillary 
tangles and neuronal degeneration, which results in a reduced brain volume.  
The main component of amyloid plaques is Aβ peptide, which is derived from the 
sequential proteolytic cleavage of APP by β-secretase (BACE1) and γ-secretase, 
known as the amyloidogenic pathway (Figure 1.4). BACE1 cleaves APP into two 
fragments: a secreted APP ectodomain (APPsβ) and a membrane-bound carboxyl 
terminal fragment (CTF), C99. Downstream γ-secretase cleaves C99 into Aβ 
peptides (Aβ40 or Aβ42) together with an APP intracellular domain (AICD) (Cole & 
Vassar, 2007). Aβ peptide liberation can be eliminated by the non-amyloidogenic 
pathway, which cleaves APP within its Aβ peptide domain by α-secretase, generating 
APPsα and C83 instead. C83 is proteolysed by γ-secretase, releasing non-toxic P3 
and the AICD. Thus, BACE1 is a key enzyme in the process of AD development.  
 
 
Figure 1.4 The proteolytic processing of APP. This figure was adapted from (Zhang, 2009). 





Neurofibrillary tangles are formed by hyperphosphorylation of a microtubule-
associated protein tau (Goedert et al, 1988). In general, it is believed that tau binds to 
microtubules and plays a part in their formation and stabilisation. When tau is 
hyperphosphorylated, it is unable to bind to the microtubules, which become unstable 
and disintegrate. The unbound tau aggregates in an insoluble form called 
neurofibrillary tangles. The precise mechanism of tangle formation is not completely 
understood, and it is still controversial whether tangles are a primary causative factor 
in AD or play a more peripheral role (Lee et al, 2005). 
The neurodegeneration mainly refers to loss of neurons and reduced synaptic density 
in certain brain areas, which are the contributors to the cortical atrophy of AD brain. 
The hippocampus formation is the most striking region with neuronal loss in AD 
subjects (West et al, 1994). The extent of the pyramidal cell loss in the hippocampus 
progresses with the severity of AD (Rossler et al, 2002). The hippocampus of normal 
aging individuals and AD patients was observed with an increase of GPR50-
immunoreactive cells undergoing degeneration in the dentate gyrus sub-region 
(Hamouda et al, 2007). Other afflicted brain areas include the entorhinal cortex, 
several neocortical areas (superior temporal sulcus, prefrontal cortex) and some 
subcortical brain structures (amygdala, Edinger-Westphal nucleus, substantia nigra) 
(Zilkova et al, 2006). Many regions of the neocortex and the hippocampus of AD 
brain demonstrate a decline in synaptic density (Scheff & Price, 2006). A greater loss 
of synapses than that of neurons was found in the temporal cortex and the frontal 
cortex, suggesting that synapse loss may precede neuronal loss in AD (Davies et al, 
1987). In addition, synapse loss is the major pathological correlate of cognitive 
dysfunction in AD (Terry et al, 1991). 
There are multiple reasons that can lead to the development of AD. Yet in this thesis, 
regarding to the involvement of BACE1, I sought to focus on the regulation of its 
cleavage activity and function in AD pathology.  
c) Heredity of Alzheimer’s disease 
AD has a strong genetic background, involving two categories of genes that have 
been identified as playing a role in affecting whether a person develops AD:  
1) Risk genes increase the likelihood of developing AD, but are not causative of 
this disease.  
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These genes are normally risk factors for the commonly seen late-onset AD in people 
over 65 years old. The most influential risk gene for AD is apolipoprotein E-e4 
(APOE-e4), which is a factor found in 20-25% of AD cases (Sleegers et al, 2010). 
Other known gene risk factors for AD include PICALM, CLU, CR1, BIN1, MS4A, 
CD2AP, EPHA1, ABCA7, SORL1 and TREM2 (Guerreiro et al, 2013; Harold et al, 
2009; Hollingworth et al, 2011; Jonsson et al, 2013; Naj et al, 2011). A recent GWAS 
study added 11 new risk factors (HLA-DRB5/HLA0DRB1, PTK2B, SLC24A4-
0RING3, DSG2, INPP5D, MEF2C, NME8, ZCWPW1, CELF1, FERMT2 and 
CASS4) to a growing list of gene variants that are associated with the onset and 
progression of late-onset AD (Lambert et al, 2014). These genes relate AD to 
multiple biological pathways, including amyloid and tau pathways, the immune 
response and inflammation, cell migration, lipid transport and endocytosis, 
hippocampal synaptic function, the cytoskeleton and axonal transport, as well as 
myeloid and microglial cell functions. 
2) Deterministic genes directly cause AD development, and people who inherit 
the variations of these genes will develop this disorder.  
Deterministic genes lead to “familial Alzheimer’s disease (FAD)”, because many 
family members in multiple generations are affected (St George-Hyslop, 1998). 
Symptoms of FAD develop before age 65 in most cases, and may appear as early as 
people’s 30s or 40s (Harvey et al, 2003). Variations of deterministic AD genes have 
been found in only a few hundred extended families worldwide, accounting for less 
than 6% of all AD cases (Hausner et al, 2014).  
To date, 12 AD-related mutations have been discovered in the APP gene, 69 
mutations in the presenillin-1 (PS-1) gene and 5 mutations in the presenillin-2 (PS-2) 
gene (Holmes, 2002). Researchers suggest that the different mutations in these three 
genes lead to a common result, the enhanced deposition of Aβ (Holmes, 2002), 
which is an event mediated by the protein investigated in this thesis, BACE1. 
Importantly, even though these mutations only account for around 10% of FAD 
cases, the prevention of AD heredity is essential.  
Twin studies have shown that the heritability for AD was estimated to be 58%-79% 
(Gatz et al, 2006). Thus, investigations on the function of related genes, such as the 




1.3.4 A summary of mental illness genetics 
As described earlier, all the three brain diseases have a genetic component. It is 
important to focus on investigating the functions of putative risk factors, which 
requires studies of the cell biology, the functional characteristics and the regulation 
system of those potential proteins involved. Importantly, as the major forms of 
psychosis seem to have overlapping risk genes, to investigate the functions of these 
factors may provide early clues about the role of a shared mechanism during the 
development of several psychiatric conditions, and may help to understand how and 
why individual patients develop certain symptoms. Such an understanding will 
eventually lead to the generation of suitable drugs for these conditions.  
1.4 The possible links between GPR50 and BACE1 
Summarised from earlier introductions, GPR50 and BACE1 are among such factors 
that are related to the three major brain diseases. GPR50 is a risk gene for BD and 
schizophrenia, and has region-specific expression related to neurodegeneration in AD 
patients. BACE1 is a key enzyme of Aβ generation in AD brains and also plays an 
essential part in the dysfunctional NRG1 signalling system of BD/schizophrenia. 
Thus, in this thesis, I focused on the functional implications of the two proteins and 
their interaction. Interestingly, there are potential links of the two factors in terms of 
their functions. GPR50 and BACE1 share overlapping predicted functions including 
neurodevelopment, such as neurite outgrowth and synaptogenesis, myelination and 
endocrine regulation. 
Here, I introduce two types of molecules that may link the role of GPR50 and 
BACE1 under normal or diseased conditions: co-interacting proteins and melatonin. 
1.4.1 The known interactors of GPR50 are associated with BACE1 
Several putative interactors of GPR50 identified by the yeast two-hybrid screening 
are co-interactors of BACE1. They play a role in BACE1 function in two ways: 
a) Putative co-interactors of GPR50 are directly involved in the regulation of 
BACE1 properties 
These co-interactors include: reticulon proteins RTN3/Nogo (RTN4), sorting nexin 
family member SNX6 and transcription factor SREBP2 (sterol regulatory element-
binding protein) that can alter the trafficking and expression of BACE1 (Deng et al, 
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2013; Grunewald et al, 2009; Mastrocola et al, 2011; Okada et al, 2010).  
RTN3 is known to inhibit β-secretase activity by impeding the trafficking of BACE1 
to cleavage-active sites (Deng et al, 2013). Yet, Crossing RTN3 into APP/PS1-tg 
mice reduced Aβ deposition in the cortex, the CA3 and the dentate gyrus regions of 
the hippocampus, but it induced dystrophic neurites in the CA1 region (Shi et al, 
2009). Therefore, RTN3 is regarded as a neuritic dystrophy inducer, as it is 
aggregated in the dystrophic neurites in the hippocampus (Hu et al, 2007). RTN3 
motivated apoptosis may be also related to the function of BACE1. Inhibition of 
BACE1 activity by RTN3 might lead to a reduced release of active neural CAMs, 
which are required for neuronal development and protection.  
RTN3 homolog Nogo-B/C also decreased BACE1 activity in vitro, but the inhibiting 
mechanism has not been fully investigated (He et al, 2004; Murayama et al, 2006). 
Nogo is known to inhibit cell adhesion, axonal regeneration and neurite outgrowth. 
Deleting Nogo restored the expression levels of markers for synapto-dendritic 
complexity and axonal sprouting, which contributed to the improvement of learning 
and memory deficits in APP-tg mice (Masliah et al, 2010). Elevated mRNA levels of 
Nogo and a significantly higher rate of a homozygous CAA insert were identified in 
the cortex of schizophrenia patients compared with controls (Novak et al, 2002). 
Further, Nogo-B transcript was found reduced in the frontal cortex of individuals 
having depression or BD compared with healthy individuals, while Nogo-C was 
significantly increased in tissues of schizophrenia brain (Novak & Tallerico, 2006). 
The expression levels of Nogo A/C and the presence of alleles with the 
schizophrenia-associated CAA insert were positively correlated. The altered 
expression and mutation of Nogo may dysregulate BACE1 activity, thus contributing 
to the abnormal neuronal organisation in brain diseases. 
GPR50 co-immunoprecipitates with RTN3/Nogo. It has a rescuing effect on the 
inhibition of neurite outgrowth mediated by Nogo-A (Grunewald et al, 2009). It is 
intriguing that GPR50 and BACE1 have an overlapping role in neuronal 
development. These two proteins might cooperate during the process of neurite 
extension through intermediate molecules RTN3/Nogo.  
As mentioned earlier, SNX6 is a negative regulator of BACE1 by promoting its 
retrograde trafficking away from ideal enzymatic compartments (Okada et al, 2010). 
Elsewhere, the activation of SREBP2 by exposing cells to high cholesterol induced a 
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hyper-expression of BACE1 (Mastrocola et al, 2011). These two proteins may also 
link GPR50 and BACE1 together. However, the functional interaction of GPR50 
with SNX6 or SREBP2 has not been established and requires further confirmation.  
b) Putative co-interactors of GPR50 participate in BACE1 activity during substrate 
processing 
Co-interactors that fall into this category include TIP60, ABCA2 and cadherin 
superfamily member CDH8. 
TIP60 is capable of rescuing APP-induced apoptosis and axonal transport defects in a 
Drosophila AD Model (Johnson et al, 2014; Pirooznia et al, 2012). Also, gene 
expression profiles activated by TIP60 can be modified by APP (Pirooznia et al, 
2012). Thus, it is suggested that under AD-linked neurodegenerative conditions 
triggered by excess APP, TIP60 overexpression induces the up-regulation of 
neuroprotective genes that facilitate cell survival, by forming a transcriptionally 
active complex with AICD/Fe65 (Johnson et al, 2014). Similarly, TIP60/Fe65 can 
also form complex with the intracellular domain of LRP (Kinoshita et al, 2003) or 
APLP1/2 (Li & Sudhof, 2004), which are processed through BACE1 proteolytic 
cleavage (Hogl et al, 2011; von Arnim et al, 2005; Yanagida et al, 2009). Thus, the 
activating function of TIP60 is in part related to BACE1 activity. Interestingly, an 
increased level of BACE1 activity can be mediated by overexpressing GPR50 
(Grünewald, 2011). This is consistent with the finding that GPR50 can enhance 
TIP60-induced transcriptional activity (Li et al, 2011), probably by forming complex 
with BACE1 cleavage products. Therefore, a putative interaction between GPR50 
and BACE1 can be an upstream regulatory unit of TIP60 signalling. 
ABCA2 can promote BACE1 cleavage of APP by enhancing APP expression and 
transporting APP to early endosomes (Chen et al, 2004; Davis et al, 2004b). There is 
disagreement on whether GPR50 is physically associated with ABCA2 (Anyanwu, 
2014; Grunewald et al, 2012). However, co-expression with ABCA2 leads to the 
internalisation of GPR50 from the cell surface (Anyanwu, 2014). Moreover, the 
mRNA levels of GPR50 and ABCA2 in developing mouse brain are positively 
correlated (Grunewald et al, 2012). Thus, APP-induced β-secretase activity might be 
linked to the function of GPR50 via ABCA2, and this requires further investigation 
on the association of GPR50 and BACE1.  
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CDH8 is a calcium-dependent CAM implicated in synaptic adhesion and axonal 
growth/guidance (Bekirov et al, 2008; Shimoyama et al, 2000). Recently, cadherin 
molecules including CDH2, CDH6 and CDH8 were identified as members of 
BACE1/BACE2 putative degradome by shRNA-mediated loss-of-function studies 
(Stützer, 2012). Meanwhile, GFP-CDH8 was found co-immunoprecipitated with 
GFP-GPR50, but as both plasmids were GFP-tagged, this physical interaction might 
result from GFP dimerisation (Grunewald et al, 2012). Mouse Gpr50 and Cdh8 were 
co-localised in the periventricular hypothalamus and the amygdala, and co-
fractionated from postsynaptic densities of mouse brain. Also, the mRNA level of 
Cdh8 is significantly correlated with GPR50 interactor Nogo-A. Hence, as CDH8, 
GPR50 and BACE1 are all implicated in neuron growth and related with one another, 
these three molecules might function as an interacting complex. 
1.4.2 Melatonin: a possible pathway node of regulation 
Melatonin, an endogenous hormone secreted by the pineal gland is known to regulate 
the circadian sleep-wake cycle. Significantly lower levels of melatonin were found in 
patients during euthymic, manic, and depressed episodes compared with healthy 
controls (Dallaspezia & Benedetti, 2009). Therefore, melatonin is considered as a 
trait marker and treatment candidate for the disturbance in circadian rhythms related 
to mental disorders.  
Previous studies indicated that the decreased levels of melatonin in AD patients were 
associated with its important role in reducing Aβ neurotoxicity (Srinivasan et al, 
2010). Treatment of APP695-tg mice with melatonin was reported to alleviate the 
learning and memory deficits of these animals, supported by a neuroprotection role 
of melatonin related to apoptosis modulation and protection of the cholinergic system 
(Feng et al, 2004). Another study showed that immunoreactive Aβ deposition was 
largely reduced in the hippocampus (43%) and entorhinal cortex (37%) of APP/PS1 
double transgenic mice by long-term oral administration of melatonin (Olcese et al, 
2009). The hippocampal Aβ generation induced by chronic intermittent hypoxia 
could be abolished by a daily melatonin administration, which reduced the 
expression level of BACE1 (Ng et al, 2010). Additionally, pro-inflammatory 
cytokines INF-γ and TNF-α are capable of stimulating APP processing by enhancing 
BACE1 expression (Yamamoto et al, 2007), and melatonin has an anti-inflammatory 
potential (Wang & Wang, 2006), thus acting against BACE1 up-regulation during 
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inflammation. Therefore, melatonin may alleviate the symptoms of AD by mediating 
the diminishment of BACE1 activity.  
As stated earlier, GPR50 does not bind to melatonin directly, but it can prevent the 
binding of melatonin to MT1 through heterodimerisation. Importantly, it has been 
found that GPR50 is able to increase BACE1 activity in vitro (Grünewald, 2011). 
This observation indicates that GPR50 may participate in the regulation of BACE1 
function through formation of heterodimers with MT1 and abolishing the negative 
affect of melatonin on BACE1. 
1.5 Aim of this thesis 
The introduction in this chapter shows that GPR50 has overlapping roles with 
BACE1 in normal cellular activities, and interacts with BACE1 regulators, 
particularly in relation to the pathology of mental illnesses. The aim of my PhD 
project is to further understand the function of GPR50 by investigating its potential 
interaction with the multifunctional sheddase BACE1. My overarching hypothesis is 
that GPR50 is involved in the function of BACE1, and by confirming the putative 
interaction between the two genes/proteins can give clues about their common roles 
under normal conditions and can further understand their association with mentally 
related illnesses. In this thesis, I want to answer the following questions: 
1) Is GPR50 able to regulate BACE1 expression? 
- In chapter 2, the involvement of GPR50 in BACE1 expression regulation 
was investigated by real-time quantitative PCR and western blotting.  
2) Is there a functional relationship between GPR50 and BACE1? 
- In chapter 3, the physical interaction between GPR50 and BACE1 was 
investigated by co-localisation and co-immunoprecipitation studies in 
mammalian cell lines and primary neuronal cultures.  
3) Is GPR50 capable of regulating β-secretase activity in neurons? 
- In chapter 4, the potential of GPR50 in the regulation of neuronal β-
secretase activity was investigated by the fluorometric activity assay in 
primary cortical neurons with altered level of GPR50 expression. 
4) Is GPR50 involved in the trafficking system of BACE1? 
- In chapter 5, the role of GPR50 in BACE1 trafficking was investigated by 
cell surface labelling technique and subcellular fractionation studies. 
5) Is GPR50 expression co-regulated with BACE1 in the brain and CNS? 
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- In chapter 6, the co-regulation of GPR50 and BACE1 expression was 
investigated by statistical correlation analysis in human dorsolateral 
prefrontal cortex and adult mouse CNS regions, followed by 
immunohistochemistry studies in adult mouse brain. 
6) Is Gpr50 expression altered under AD conditions, and can GPR50 levels be 
used as a predictor of β-secretase mediated Aβ deposition? 
- In chapter 7, the association of GPR50 with AD pathology was 
investigated by immunohistochemistry studies in an AD mouse model. 
Addressing these questions will provide insights into the investigation of an orphan 
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and subcellular localisation of 





Studies in this thesis focus on the cellular function of psychiatric illness risk factor 
GPR50 and its potential link to neurodegenerative disorder key enzyme BACE1. The 
primary step is to characterise the expression features of GPR50 and BACE1 in 
different cell lines and to validate the findings with others’ published data, which 
will be introduced in the following sections. By doing so, the integrity of the 
proceeding investigation can be guaranteed. The first aim of this chapter is to 
validate the antibodies and plasmids, as well as to summarise the expression 
characteristics of the two proteins. Then, to follow up the finding that overexpressed 
GPR50 is capable of regulating BACE1 activity in HEK293 cells (Grünewald, 2011), 
I investigated whether GPR50 overexpression alters the expression levels of BACE1. 
2.1.1 The expression of GPR50 
GPR50 is endogenously expressed in human cerebral endothelial hCMEC/D3 cells 
(Levoye et al, 2006), rat pituitary cell line GH3 (Li et al, 2011), mouse primary 
neuronal cultures (Grunewald et al, 2009) and HEK293T cells (Grunewald et al, 
2009). There is no endogenous GPR50/Gpr50 detected in human neuroblastoma cell 
line SH-SY5Y or mouse neuroblastoma cell line N1E-115 (my unpublished 
observation). Endogenous and over-expressed GPR50 are localised mainly at the 
plasma membrane in HEK293 cells, and at synaptic spines and neurites in mouse 
primary neuronal cultures (Grunewald et al, 2009). A truncated form of GPR50 
(tGpr50) lacking the last two transmembrane regions and cytoplasmic domain has 
been cloned from mouse hypothalamus and pituitary, and localised in the cytoplasm 
when over-expressed (Li et al, 2011). Yet, there was no report about this GPR50 
form in human. Bipolar disorder-associated variant GPR50del is over-expressed at 
the cell surface, with no obvious alteration of localisation compared with GPR50 
(Grünewald, 2011). The deletion and SNP mutations of GPR50 are unique to human 
DNA sequence.  Western blotting confirmed the protein sizes of GPR50, GPR50del 
and tGpr50 are 67 kDa, 67 kDa and 29 kDa respectively. A dimer of GPR50 was 
also detected at around 130 kDa (Grunewald et al, 2009; Hamouda et al, 2007; 




2.1.2 BACE1 expression 
2.1.2.1 The expression sites of BACE1 
Endogenous BACE1 mRNA has been detected in diverse human neural and non-
neural cell lines and tissues, as well as in adult human tissues of the cerebrum, 
cerebellum, peripheral nerve and skeletal muscle (Satoh & Kuroda, 2000). However, 
BACE1 mRNA expression is not universal; for instance, it was not detectable in K-
562 erythroleukemia cells. There is more than one BACE1 mRNA species identified 
in human brain and cultured cells, suggesting multiple BACE1 isoforms (Ehehalt et 
al, 2002; Vassar et al, 1999). In addition, BACE1 mRNA variants are selectively 
regulated in response to neuronal differentiation and upon exposure to cytokines and 
growth factors (Satoh & Kuroda, 2000). 
The BACE1 protein is a type I membrane protein belonging to the pepsin-like family. 
In western blotting, overexpression of full-length human BACE1 (variant a) 
produces two protein bands which are generally believed to be immature BACE1 at 
around 60 kDa and mature BACE1 at around 70 kDa (Bennett et al, 2000). The 
immature BACE1 is the initial pro-protein that is synthesised at the endoplasmic 
reticulum (ER). Then pro-BACE1 undergoes processing in the Golgi to become fully 
active. Glycosylation and further addition of complex carbohydrates result in a larger 
mature BACE1 than the immature BACE1 even after the removal of the BACE1 
prodomain. The mature form of BACE1 circulates among the early endosomes, the 
plasma membrane and the trans-Golgi network (TGN) where it may exert enzymatic 
functions as a protease. Finally, as with most proteins, BACE1 is sorted to lysosomes 
for degradation. Therefore, BACE1 is likely to be found in various subcellular 
compartments.  
The aforementioned different BACE1 transcripts are a result of differential splicing 
within the exon 3 and/or exon 4 of BACE1 mRNA (Holsinger et al, 2013). 
Correspondingly, there are five spliced isoforms of BACE1 protein reported so far 
(Figure 2.1) (Bodendorf et al, 2001; Ehehalt et al, 2002; Mowrer & Wolfe, 2008; 
Tanahashi & Tabira, 2001; Tanahashi & Tabira, 2007). These shorter isoforms of 
BACE1 undergo different post-translational modifications compared to the full 
length BACE1 and most of them are retained in the ER, resulting in a deficiency or 
absence of β-secretase activity. The specific physiological function of these spliced 
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variants is not known. However, the expression of BACE1 spliced transcripts 
reduced β-secretase activity and Aβ production in HEK293 cells (Mowrer & Wolfe, 
2008). Thus, the promotion of BACE1 alternative splicing might be a potential 
therapeutic strategy for controlling BACE1 activity. 
 
Figure 2.1 The alternative splicing of the BACE1 transcript. The diagram was adapted from 
(Mowrer & Wolfe, 2008). The numbers followed “BACE1” indicate the peptide lengths of 
the transcripts. The use of normal splice sites and alternative splice sites of BACE1 
generates five RNA transcripts (BACE1 501, BACE1 476, BACE1 457, BACE1 455 and BACE1 
432). The alternative 5’-splice site (ALT 5’SS) is in exon 3, and the alternative 3’-splice site 
(ALT 3’SS) is in exon 4. Use of the normal 5’-splice site (NORM 5’SS) and the normal 3’-splice 
site (NORM 3’SS) results in the production of the full-length BACE1 501 transcript.  
2.1.2.2 Regulation of BACE1 expression 
Previous investigations have suggested that both the transcriptional and the 
translational initiation of BACE1 expression are tightly regulated.  The two 
regulatory mechanisms appear to be independent events for BACE1, for instance, the 
highest level of BACE1 mRNA is identified in the pancreas (Yan et al, 1999), while 
BACE1 protein and activity are most abundant in the brain (Sinha et al, 1999).  
1) Regulation of BACE1 transcription 
The basal promoter element for BACE1 transcription is a 91 bp fragment, which is 
the core region of neuron preferred promoter (Ge et al, 2004). The regulatory unit of 
BACE1 gene contains multiple transcription factor binding sites, including GC box, 
HSF-1, a PU box, AP1, AP2, and the lymphokine response element (Christensen et 
al, 2004). Transcription factor Sp1 is one of the activators that enhance BACE1 
expression, which sequentially induces an elevation of BACE1 protein level and 
C99/Aβ levels (Christensen et al, 2004). Normally, the activation of BACE1 
transcription requires a cascade of signal transduction pathways. The alteration of 
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signalling components under certain circumstances may contribute to the regulation 
of BACE1 transcription. 
Aβ42 can promote BACE1 promoter activity dependent on NF-κB signal 
transduction cascade (Buggia-Prevot et al, 2008; Giliberto et al, 2009). NF-κB 
signalling has been implicated in the process of inflammation, oxidative stress, 
apoptosis, synaptic plasticity and memory maintenance (Albensi & Mattson, 2000; 
Freudenthal et al, 1998; Granic et al, 2009; Mattson & Camandola, 2001). NF-κB 
levels are significantly increased in the brains of AD patients during the 
neurodegenerative process (Chen et al, 2012a; Lukiw & Bazan, 1998). Functional 
NF-κB-binding elements have been identified in the BACE1 promoter region. 
Enhanced NF-κB signalling facilitates BACE1 gene transcription and APP 
processing (Chen et al, 2012a). NF-κB also mediates the up-regulation of BACE1 
promoter activity by GSK3β (glycogen synthase kinase 3β) (Ly et al, 2013). 
Elsewhere, aldehydic end product of lipid peroxidation, 4-hydroxynonenal induces 
up-regulation of BACE1 transcription via the activation of c-Jun N-terminal kinase 
and p38 mitogen-activated protein kinase signalling pathways which are responsive 
to stress stimuli (Tamagno et al, 2002; Tamagno et al, 2005).  
2) Regulation of BACE1 translation 
The 5’ transcript leader (TL) located at the upstream of BACE1 mRNA acts as a 
translation silencer (De Pietri Tonelli et al, 2004). Within TLs, there are three 
upstream open reading frames (ORFs) that precede the main ORF. Recognition of 
AUGs in the first two upstream ORFs inhibits the efficiency of the downstream 
translation and this effect is cell-type differentiated (Rogers et al, 2004). Alternative 
splicing of BACE1 TL can reduce the number of upstream AUGs and therefore 
increase the efficiency of correct translation (De Pietri Tonelli et al, 2004). BACE1 
undergoes TL alternative splicing in both the exocrine pancreas and neuroblastoma 
cells, but not in normal human brain. Chronic activation of astrocytes can reduce the 
inhibiting effect of BACE1 TL on translation initiation independent of alternative 
splicing, which drives BACE1 translation efficiency up to a level observed in 
neurons. In addition, it has been proposed that the phosphorylation of translation 
initiation factor eIF2α (eIF2α-P) is able to enhance BACE1 translation through a 
variety of different putative mechanisms that overcome the mRNA secondary 
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structure of the 5’ untranslated region (UTR) and inhibitory upstream ORFs or 
through leaky ribosomal scanning (O'Connor et al, 2008). The regulation of eIF2α-P 
on BACE1 translation is mediated via protein kinase RNA- like ER kinase (PERK) 
signalling pathway (O'Connor et al, 2008). Activation of eIF2α was found increased 
in the frontal cortex of AD patients, and phosphorylated eIF2α levels correlated with 
elevated BACE1 protein levels (Mouton-Liger et al, 2012). 
The 3’-UTR of BACE1 mRNA transcript is also one of the regulatory elements for 
BACE1 translation. The known regulators following this pattern include AD-related 
microRNAs. For instance, the levels of microRNA miR-107 are negatively 
correlated with BACE1 expression in brains of AD cases with different degrades of 
pathology, probably by targeting the putative microRNA recognition elements 
(MREs) within the 3’-UTR of BACE1 mRNA (Wang et al, 2008b). MiR-29a/b-1 
also down-regulates BACE1 expression and activity (Hebert et al, 2008). 
Even though the elevation of BACE1 protein level and activity in the brains of AD 
patients does not necessarily require an increase in its mRNA level (Zhao et al, 2007), 
the up-regulation of BACE1 mRNA in AD brains may be region-specific, and may 
partly contribute to the elevation of BACE1 protein and activity (Coulson et al, 
2010). A slight increase of BACE1 protein level may result in a dramatic increase of 
Aβ peptide production (Li et al, 2006). Importantly, BACE1 expression regulation is 
normally accompanied by diverse adverse events that occur in brains undergoing 
damage or that induce the pathogenesis of brain illnesses (such as in AD): 
• Traumatic brain injury enhanced levels of BACE1 mRNA, protein and activity in 
the hippocampus and the cortex of rat (Blasko et al, 2004). 
• Transient cerebral ischemia in female rats resulted in elevated levels of BACE1 
protein and activity (Wen et al, 2004).  
• Under hypoxia conditions, hypoxia-inducible factor 1 was stabilised and bound 
to the 5’-RCGTG hypoxia-responsive element in the BACE1 gene promoter 
region, causing a boost in BACE1 mRNA transcription and resulting in an 
escalation of BACE1 protein level and activity, which was in accordance with Aβ 
deposition and memory deficit in APP23 transgenic mice subjected to hypoxia 
(Sun et al, 2006a; Zhang et al, 2007).  
• Inflammatory cytokine interferon γ elicited an upturn of BACE1 protein 
expression in human astrocytoma cells and primary astrocyte culture of AD 
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model Tg2576 mice through the signal transductor and the activator of 
transcription 1 (STAT1) (Hong et al, 2003). Interferon γ activated Janus kinase 2 
(JAK2) and extracellular-signal-regulated kinases (ERK1/2) signalling pathways, 
which caused the binding of phosphorylated STAT1 to the STAT1 binding 
sequences in BACE1 promoter region (Cho et al, 2007). 
• Oxidative stress induced by H2O2 at a toxic level up-regulated BACE1 
expression and activity (Kwak et al, 2011; Tan et al, 2013; Tong et al, 2005).  
• Under inflammatory conditions, overproduction of neuronal or inducible nitric 
oxide (NO) synthase produced NO in excess and causes nitrosative stress (Wink 
et al, 2000).  Low scale of NO overproduction decreased BACE1 mRNA level 
and sequentially its protein level and activity probably in response to the 
regulation of the cGMP-PKG signalling system, while high NO concentrations 
diminished BACE1 activity and Aβ production through post-translational N-
nitrosylation without any effect on BACE1 protein level (Kwak et al, 2011). 
In summary, the regulation of BACE1 transcription and translation is involved with 
various regulation factors and signalling systems and this ultimately affects BACE1 
activity.  As GPR50 is involved in the regulation of BACE1 activity, it might be a 
potential factor in BACE1 expression regulation. 
2.1.3 Introduction to experiments 
In this chapter, the antibodies used for GPR50 and BACE1 in this thesis are validated. 
To do this, the expression features of endogenous/exogenous GPR50 and BACE1 
were investigated in human neuroblastoma cell line SH-SY5Y, human embryonic 
kidney cell HEK293 and mouse primary cortical neurons by immunocytochemistry 
and western blotting. Then, the effects of GPR50 overexpression on BACE1 
expression levels were investigated in SH-SY5Y and HEK293 cells by real time 
quantitative PCR and western blotting. 
2.2 Materials and methods 
2.2.1 Mammalian cell culture 
SH-SY5Y and HEK293 cells were grown in 75 cm3 culture flasks in Dulbecco's 
Modified Eagle Medium (DMEM) containing 10% foetal bovine serum (FBS). Cells 
were cultured at 37oC with 5% CO2 and were split when cells were over 70% 
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confluent. For immunocytochemistry, cells were prepared on glass coverslips in 12-
well plates, with 1×105 cells per well. Transfection was performed using 
Lipofectamine 2000 and transfection media after overnight culture (see 2.2.4). For 
protein lysates preparation, cells were grown on 10 cm plates until a confluency of 
80-90%, which normally took 2 days with a starting cell number of 2×106 per plate. 
2.2.2 Primary neuronal culture 
Primary neuronal cultures were prepared from embryonic day 18 (E18) C57BL/6J 
mice. Mice were purchased from Biomedical Research Resources Unit, Western 
General Hospital, Edinburgh. The plugging date was marked as E0. The cortex was 
dissected and isolated from E18 pups in dissection buffer (HBSS + HEPES + 
GlutaMAXTM, Invitrogen) at a cool temperature. Dissected tissue was further 
dispersed in 0.1% TryExpress at 37°C for 45 min.  Neurons were isolated and seeded 
on poly-D-lysine (Sigma-Aldrich, St. Louis, USA) coated coverslips in 12-well 
plates and cultured in 2 ml neurobasal medium supplemented with 2% B-27 and 1% 
GlutaMAXTM for 3, 9 or 28 days-in-vitro (DIV3, DIV9, DIV28). Cultures were 
maintained in a humidified environment at 37°C with 5% CO2. Half of the media (1 
ml) was replaced every three days. 
2.2.3 Plasmids  
All materials were purchased from Invitrogen (Life technologies) unless stated 
otherwise. BACE1 gene has five isoforms (a-e), and the shorter isoforms are the 
result of the alternative splicing of parts of exon 3 and/or exon 4 (Figure 2.1). 
TrueClone plasmid (Origene) containing untagged full-length of BACE1 (variant a, 
the longest isoform) and untagged plasmid GPR50-pDEST40 were used in all the 
experiments. All the vectors were isolated from transformed E. coli DH10B, selected 
on agar plates with ampicillin and extracted using the Qiagen miniprep or maxiprep 
kits following the manufacturer’s instructions. All constructs were sequenced and 
checked for correct expression using their corresponding antibodies by western 
blotting. 
2.2.4 Lipofectamine 2000 transfection 
The optimised amounts of plasmid, Lipofectamine 2000 and transfection media used 
per transfection are summarised in Table 2.1. When different amounts of plasmid 
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were required between wells in an experiment, the empty vector pDEST40 was used 
to keep the DNA amount per well identical. 
Table 2.1 Lipofectamine 2000 transfection protocol 
 12 wells 6 wells 10 cm  
DNA GPR50 1 µg 2.5 µg 12 µg 
BACE1 2 µg 5 µg 12 µg 
GPR50+BACE1 1 µg+2 µg 2.5 µg+5 µg 12 µg+12 µg 
Lipofectamine 2000 4 µl 10 µl 40 µl 
Transfection media 50 µl+50 µl 125 µl+125 µl 500 µl+500 µl 
Dilute after incubation 200 µl 500 µl 2 ml 
Total volume/well 300 µl 750 µl 3 ml 
For SH-SY5Y cells and HEK293 cells, transfection media OptiMEM (Invitrogen) 
was used. The plasmids and Lipofectamine 2000 were separately diluted in 
OptiMEM and incubated at room temperature for 5 min. The two solutions were 
mixed and incubated at room temperature for a further 20 min. After the incubation, 
the mixture was diluted with 2×volume of OptiMEM. Before adding the diluted 
transfection mix, the plated cells were briefly washed with pre-warmed OptiMEM. 
The transfection mix was added to the cells, which were left to transfect for 6 hr at 
37oC with 5% CO2. Afterwards, the medium was replaced with pre-warmed 
DMEM/10% FBS and left overnight. 
For primary neuronal cells, Neurobasal medium plus B-27 was used as the 
transfection media. The plasmids/Lipofectamine 2000 mixture was incubated for 1 hr 
at 37oC before adding to the neurons. At the same time, the media in each well were 
collected in a clean tube and kept at 37oC. The media was reused because it contains 
the growth factors produced by neurons. The neurons were briefly washed and 
incubated in the transfection media for 1 hr. Then the transfection mixture was added 
to the transfection media on top of the neurons and left for 4 hr. After transfection, 
the mixture was replaced with the old media, which contained Neurobasal medium, 
B27, GlutaMAXTM and growth factors released by the neurons. Cells were left 




2.2.5 Immunocytochemistry (ICC)  
Transfected cells growing overnight were fixed with 500 µl ice cold methanol (pure) 
for 10 min and were then washed three times with PBS plus 0.2% Bovine Serum 
Albumin (BSA, Sigma-Aldrich). Fixed cells were blocked in PBS/0.2% BSA with 10% 
donkey serum (corresponding to the host of secondary antibody) for 30 min. After 
blocking, cells were incubated with primary antibodies diluted in PBS/0.2% BSA for 
1 hr at room temperature, followed by washing with PBS/0.02% BSA for 3×5 min. 
Secondary antibodies were diluted in PBS/0.2% BSA with 10% serum, and cells 
were incubated with the solution at room temperature for 1 hr. After another 3 
washes by PBS/0.2% BSA, all the coverslips were mounted with Mowiol/DAPI and 
kept in the dark for at least 24 hr. Antibodies used in this thesis and dilutions are 
summarised in Table 2.2. Secondary antibodies Alexa Fluor® dyes from Invitrogen 
(Life technologies), were normally used at a dilution of 1:500 for wavelength 488 nm, 
or 1:1000 for 594 nm and 647 nm (Table 2.3). Fluorescent photos were taken on a 
Nikon A1R confocal microscope with the z-stack programme. 
Table 2.2 Primary antibodies used in this thesis 
Antibody Host Immunogen Application  Supplier 





400-450 of human 
GPR50  
ICC (1:2000/1:500)* 
IHC (1:50/1: 10)* 
WB (1:5000/1:500) * 




GPR50 63 Rabbit 
polyclonal 
Residues 516-530 


























































ICC (1: 200) 






Residues 42-245 of 
human VLA-2α 
ICC (1:500) 






















150 of human EEA1 





Residues 3-281 of 
human EEA1 
ICC (1:500) 



























Purified full length 
native from rat liver 
ICC (1: 500) 








2179 of human 
p230 trans Golgi 







Residues  843-955 
of rat p115 







Within residues 350 
to the C-terminus of 
human LAMP2b 
ICC (1: 500) 




Residues  163-177 
of human RAB7 













Residues 1-90 of 
human RTN3 


















WB (1: 50,000) Sigma, S5768 
Aβ 6E10 Mouse 
monoclonal 
Residues 1-16 of 
human Aβ. 
WB (1:500) Sigma,  SIG-39320 
* There were two batches of GPR50 goat antibody with inconsistent performances, so different 
concentrations were used. 
ICC: immunocytochemistry; IHC: immunohistochemistry; WB: western blotting; IP: immunoprecipitation. 
 
Table 2.3 Fluorescent secondary antibodies used in this thesis 
Antibody Host Reactivity Working dilution Supplier 
Alexa Fluor 488 Donkey Goat  1: 500 Life technologies 
Alexa Fluor 594 Donkey Goat 1:1000 Life technologies 
Alexa Fluor 488 Donkey Rabbit 1: 500 Life technologies 
Alexa Fluor 594 Donkey Rabbit 1:1000 Life technologies 
Alexa Fluor 647 Donkey Rabbit 1:1000 Life technologies 
Alexa Fluor 488 Donkey Mouse 1: 500 Life technologies 
Alexa Fluor 594 Donkey Mouse 1:1000 Life technologies 
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2.2.6 Live cell surface labelling technique 
Cells were plated onto coverslips in a 12-well plate and incubated at 37oC overnight.  
To label BACE1 on the cell surface, the goat antibody raised against the ectodomain 
of human BACE1 were diluted in OptiMEM (1:200) and added to cells after a brief 
wash. The BACE1 mouse antibody was also tested for this technique, but with no 
success. The cells with the antibody were agitated at 4oC for 1 hr, followed by two 
washes with ice-cold PBS+1% BSA. Then 500 ml 4% PFA were added to each well 
for 10 min to fix the cells, which were incubated by secondary antibody donkey-anti-
goat 488 at room temperature for 1 hr. After incubation, cells were permeabilised 
with 0.2% Triton X-100 for 10 min, followed by a 20 min blocking step with PBS+1% 
BSA+10% donkey serum. Afterwards, total BACE1 were double stained by BACE1 
rabbit2 antibody with the plasma membrane marker VLA-2α mouse antibody or by 
BACE1 mouse antibody with GPR50 rabbit antibody. The primary antibodies were 
diluted in PBS+1% BSA. Then cells were washed and incubated with appropriate 
secondary antibodies diluted in PBS+1% BSA+10% donkey serum for 1 hr at room 
temperature. 
2.2.7 Western Blotting 
Protein lysates were extracted by RIPA buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1% 
NP-40, 0.1% SDS, 0.5% sodium deoxycholate, protease inhibitors added). Then 
proteins were separated on 7% NuPage Tris-Acetate gels (Invitrogen) and transferred 
onto PVDF membranes (Invitrogen), for 1.5 hr at a constant voltage of 30 V. 
Membranes were stained with Ponceau S for 1 min to check whether the transfer of 
proteins from the gels was successful. Ponceau S was washed off with dH2O, and the 
membranes were blocked overnight at 4oC in washing buffer (1×PBS/0.2% Tween 
20) containing 5% skimmed milk powder (Marvel). On the following day, 
membranes were washed briefly and incubated with diluted primary antibodies for 1-
1.5 hr at room temperature. A brief wash, one wash for 15 min and three washes for 
5 min each with the washing buffer were applied. Membranes were then incubated 
with horseradish peroxidase (HRP) conjugated secondary antibodies diluted in the 
washing buffer for 30 min at room temperature. The membranes were washed again 
as mentioned above and then detected using chemiluminescence (ECL-Plus, 
Amersham Biosciences, GE healthcare) and exposed to films. All the primary 
antibodies were diluted in the washing buffer during the staining and the dilutions 
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were shown in Table 2.2. All the secondary antibodies were purchased from Dako 
(Table 2.4). 
Table 2.4 Horseradish peroxidase conjugated secondary antibodies used in this thesis 
Host Reactivity Working dilution Supplier 
Swine Rabbit 1:3000 Dako 
Rabbit Goat 1:5000 Dako 
Goat Mouse 1:10,000 Dako 
2.2.8 Real-time quantitative PCR (qPCR) 
Total RNA was extracted from SH-SY5Y cells transfected with the same amounts of 
pDEST40 (empty vector control) and GPR50-pDEST40 (abbreviated as GPR50) by 
using RNase easy kit (Qiagen). The first strand cDNA was synthesised from 200 ng 
of DNase I-treated RNA as the template using oligo(dT) primers (Maxima H Minus 
Reverse Transcriptase, Thermo) for extension according to the instruction of the 
supplier. Prior to qPCR, all cDNAs and no-transcriptase controls were used as 
templates of reverse transcription PCR. Gel electrophoresis was performed to check 
the quality of cDNAs and the specificity of products. cDNAs were diluted 10-fold 
with DNAse/RNAse -free dH2O (Life technologies) before being used for qPCR. 
Real-time qPCR using SYBR Green Supermix (MgCl2; dATP, dCTP, dGTP, dUTP; 
AccuStart Taq DNA polymerase; SYBR Green I dye; 20nM fluorescein; Uracil-N-
glycosylase; stabilisers; from Quanta, 95067-100) in a 20 µl PCR system (Table 2.5) 
was performed on the Bio-Rad iCycler with the iQ software. Primers (Table 2.6) for 
GPR50, BACE1, as well as housekeeping genes transferrin receptor (TFRC), TATA 
binding protein (TBP) and ubiquitin C (UBC) were optimised over a gradient of 
annealing temperatures and 60.1oC was selected. PCR efficiencies for each pair of 
primers were achieved from standard curves produced by PCR of three sequential 
10-fold dilutions of corresponding cDNAs as templates. 
Table 2.5 Setting up real-time quantitative PCR reaction 
Component 20 μl reaction Final Concentration 
2X SYBR Green Supermix 10 μl 1X 
2 µM Forward Primer 2 µl 200 nM  
2 µM Reverse Primer 2 µl 200 nM 
cDNA or no-transcriptase control 2 µl (diluted) - 




Table 2.6 Primers used for real-time quantitative PCR 
Primer name Forward sequence Reverse Sequence Size/Genomic 
GPR50 1-2a CATGGTCATTTTGGCTGTGA ACCCGACCATCTGGCACT 176/3038 bp 
BACE1 1-2a TTTGTGGAGATGGTGGACAA TGGTAGTAGCGATGCAGGAA 164/18737 bp 
TFRC human CGCTGGTCAGTTCGTGATTA GCATTCCCGAAATCTGTTGT 210/1731 bp 
TBP human TGCCCGAAACGCCGAATATA TTTCTTGCTGCCAGTCTGGA 150/5037 bp 
UBC human GATTTGGGTCGCAGTTCTTG TCCAGCAAAGATCAGCCTCT 191/1003 bp 
a. primers also work in mouse. 
Targeted samples, standard curves and negative controls were run on the same plates. 
In case of splitting different genes into separate plates, at least two calibrators were 
included. All reactions were run in triplicate. Amplification was carried out 
according to a programme summarised in Table 2.7. After completion of the 
amplification reaction, a melting curve was generated by increasing the temperature 
in small increments (+0.5oC) and monitoring the fluorescent signal at each step.  
Table 2.7 Real-time quantitative PCR programme 
Initial denaturation 95oC 3 min 1 cycle 
Denaturation 95oC 15 s   
40 cycles Annealing 60.1oC 45 s 
Extension 72oC 30 s 
Melting 
95oC 1 min   
1 cycle 55oC 1 min 
+0.5oC 10 s 80 repeats 
2.2.9 DNA sequencing 
Plasmids were subjected to DNA sequencing when a new single clone of 
transformed E.Coli DH10B was picked for plasmid proliferation. For each reaction 
of 10 μl, 100 ng of plasmid was used for cycle sequencing reactions according to the 
manufacturer’s instructions (Big Dye Terminator v3.1 Cycle Sequencing Kit). The 
programme was described as follows: 96oC for 1 min; 25 cycles, 96oC for 10 s, 50oC 
for 5 s, 60oC for 4 min; 10oC for holding. The clean-up step of the extension products 
followed the protocol of ethanol/sodium acetate precipitation. Briefly, the 96-well 
reaction plate was removed from the thermal cycler and spun for a few seconds. 
Then 2 μl of 3 M sodium acetate (pH 4.6) and 50 μl of 95% ethanol were added to 
each well. The plate was sealed with aluminium tape and inverted several times. The 
mixture in the plate was incubated at room temperature for 15 min and then 
centrifuged at 1400-2000×g for 45 min. The plate was inverted on a piece of tissue 
and spun at 700×g for 1 min. Then 150 μl of 70% ethanol was added to each well. 
The plate was sealed, inverted several times and then centrifuged at maximum speed 
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for 10 min. After the spin, the plate was inverted on a piece of tissue and spun at 
700×g for 1 min. The samples were frozen if sequencing was not to be done on the 
same day. Sequencing was performed by the staff in Human Genetics Unit, 
University of Edinburgh. The sequencing results were checked and compared to 
expected sequences by BLAST against the reference genome in the UCSC database. 
2.3 Results 
2.3.1 Antibody characterisation  
Antibodies used in this thesis are all commercially available (see Table 2.2). These 
antibodies were tested on overexpressed proteins from untagged vectors for detection 
in SH-SY5Y cells by immunocytochemistry and western blotting. Endogenous 
protein expression was tested in HEK293 cells and mouse primary neuronal cultures. 
2.3.1.1 GPR50 antibodies 
Two commercial antibodies for GPR50 were used in this thesis. The performances of 
these two antibodies are summarised briefly in Table 2.8. 
Table 2.8 The competence of antibodies for GPR50 used in this thesis 
 Exogenous GPR50 
Endogenous GPR50 
Note 




goat √  √  √ 
Detects endogenous 
GPR50 in HEK293 cells by 
western blotting and 
Gpr50 in mouse brain by 
immunohistochemistry 
GPR50 
rabbit √  √  √ 
Not suitable for detecting 
Gpr50 in mouse brain by 
immunohistochemistry 
GPR50 goat and rabbit antibodies detected exogenous GPR50 at the cell surface of 
SH-SY5Y cells (Figure 2.2). Then I examined the sites of overexpressed GPR50 by 
double-staining with known subcellular compartment markers (Figure 2.3). It was 
shown that overexpressed GPR50 was strongly co-localised with the plasma 
membrane marker VLA-2α (Figure 2.3), confirming that GPR50 is mainly located at 
the cell surface. The co-localisation between GPR50 and the early endosome marker 
EEA1, the ER marker calreticulin, the Golgi marker 58K Golgi or the late endosome 
marker RAB7 was not convincing, because even though there was a seemingly 
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orange colour that could be merged from green (GPR50) and red channels (markers), 
GPR50 signal did not have the punctate structure of the endosomes or other internal 
compartments. In addition, the majority of GPR50 was not expected to localise in the 
ER, as most of GPCRs experience ER exit after synthesis and are exported along the 
secretory pathway to the plasma membrane so as to function as sensors of the 
extracellular information and then to activate inside signal transduction pathways 
(Magalhaes et al, 2012). Therefore, the merged signal might be an overlapping 
pattern of the cell surface GPR50 with the internal markers. However, the internal 
location of GPR50 cannot be ruled out, because it can be expressed internally in 
certain circumstances, such as in HEK293 cells (Grünewald, 2011). The subcellular 
localisation of overexpressed GPR50 appeared identical to endogenous GPR50 in 
HEK293 cells (Figure 2.5, also see Figure 3.9-3.10). 
In GPR50-transfected SH-SY5Y cells, the rabbit antibody of GPR50 detected a band 
at 67 kDa by western blotting (Figure 2.4). This is the expected size of GPR50, 
which is in line with previous reports (Grunewald et al, 2009) and is supported by the 
same observation using an in-house rabbit antibody GPR50 63.  The GPR50 goat 
antibody detected a doublet band at 67 kDa. It is not clear whether the smaller band 
is an alternative splicing product of GPR50 transcript, and it does not correspond to 
the truncated isoform of mouse Gpr50 (29 kDa) reported by Li and colleagues (Li et 
al, 2011). No bands were detected in untransfected samples, indicating GPR50 is not 
endogenously expressed in SH-SY5Y cells. This was in line with the finding that no 
immunoreactivity of GPR50 was found in untransfected SH-SY5Y (Figure 2.2). The 





Figure 2.2 Validation of GPR50 antibodies using immunocytochemistry in SH-SY5Y cells. 
Untagged GPR50 plasmid was transfected. GPR50-transfected cells and untransfected cells 
were singly immunostained with GPR50 goat or rabbit antibodies. Negative controls were 
only stained with secondary antibodies donkey-anti-goat 488 (green) or donkey-anti-rabbit 
594 (red) while the primary antibodies were skipped. The two antibodies showed similar 
patterns of overexpressed GPR50. No endogenous GPR50 was detected in SH-SY5Y cells. 
SH-SY5Y GPR50 goat GPR50 goat+DAPI No primary 



































GPR50 rabbit GPR50 rabbit+DAPI No primary 




Figure 2.3 The localisation of overexpressed GPR50 in SH-SY5Y cells. GPR50 goat 




Figure 2.4 Validation of GPR50 antibodies using western blotting in SH-SY5Y cells. 
Untagged GPR50 plasmid was transfected. Protein lysates were extracted by RIPA buffer. In 
each lane, 10 µg proteins were loaded and separated in 7% tris-acetate gels. GPR50 63 and 
rabbit antibodies recognised a single band at 67 kDa, the expected size of GPR50. GPR50 
goat antibody detected a doublet band. No bands were detected in untransfected cells, 
indicating that GPR50 is not endogenously expressed in SH-SY5Y. 
Endogenous GPR50 is expressed in HEK293 cells with a percentage of 1-10% 
depending on the age of the cells (Grünewald, 2011). GPR50 goat antibody showed a 
punctate staining pattern in the internal compartments of untransfected HEK293 cells, 
which is uncommon for GPR50 (Figure 2.5). These signals were found in all the 
cells, suggesting that the labelling of GPR50 goat antibody was unspecific in 
detecting endogenous GPR50. GPR50 rabbit antibody appeared to stain specific cells 
with an acceptable percentage of endogenous GPR50 in HEK293 cells (two cells 
were stained in a 21-cell group).  However, both GPR50 goat and rabbit antibodies 
detected endogenous human GPR50 in HEK293 cells with an expected size of 67 
kDa in western blotting (Figure 2.8). In mouse primary cortical neurons, the two 
antibodies co-localised well in picking up overexpressed GPR50 (Figure 2.6). The 
GPR50 goat antibody showed additional staining which was originally thought to be 
endogenous mouse Gpr50. However, the blocking peptide failed to erase the signals 
detected by GPR50 goat antibody in untransfected neurons (Figure 2.7). GPR50 
rabbit antibody was also unable to recognise endogenous Gpr50 in primary cortical 
neurons by immunocytochemistry, even though by western blotting it detected a 63 
kDa band from brains of embryonic mice (E18) and new born pubs (P0) (Figure 2.8). 
According to the predicted sizes of Gpr50 (Uniprot: 67 kDa for human GPR50, 65 
kDa for mouse Gpr50), this band should be the endogenous Gpr50, as mouse Gpr50 
protein consists of 591 amino acids, shorter than its human homologue which 




Figure 2.5 Validation of GPR50 antibodies using immunocytochemistry in HEK293 cells. 
Cells were transfected with untagged GPR50 plasmid or untransfected. 
Immunocytochemistry was carried out by double-staining cells with GPR50 goat antibody 
and rabbit antibody. Negative controls were only stained with secondary antibodies 
donkey-anti-goat (DAG) 488 and donkey-anti-rabbit (DAR) 594 while the primary antibodies 
were skipped. GPR50 goat and rabbit antibodies co-localised perfectly in cells transfected 
with GPR50. Some weaker signals indicated by a white arrow might represent endogenous 
GPR50 in HEK293 cells. GPR50 goat antibody stained all the untransfected cells with an 
unspecific pattern, as most of the signals were internal speckles, uncommon for the 
majority of GPR50. Whereas, GPR50 rabbit antibody appeared to stain specific cells with a 
percentage common to the proportion of endogenous GPR50 in HEK293 cells. 
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Figure 2.6 Validation of GPR50 antibodies using immunocytochemistry in primary cortical 
neurons. Untagged GPR50 plasmid was transfected. DIV15 post-transfection neurons were 
double-immunostained with GPR50 rabbit antibody together with goat antibody or goat 
with the pre-absorption of blocking peptide. Negative controls were only stained with 
secondary antibodies donkey-anti-goat (DAG) 488 and donkey-anti-rabbit (DAR) 594 while 
the primary antibodies were skipped. GPR50 goat and rabbit antibodies co-localised well in 
cells obviously labelled with GPR50 rabbit. GPR50 goat detected additional signals indicated 
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Figure 2.7 GPR50 antibodies were unable to detect endogenous Gpr50 using 
immunocytochemistry in primary cortical neurons. Untransfected DIV15 neurons were 
double-immunostained with GPR50 rabbit antibody together with goat antibody or goat 
with the pre-absorption of blocking peptide. Negative controls were only stained with 
secondary antibodies donkey-anti-goat (DAG) 488 and donkey-anti-rabbit (DAR) 594 while 
the primary antibodies were skipped. Both the antibodies failed to show a credible signal 
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Figure 2.8 Endogenous GPR50/Gpr50 was detected in HEK293 cells and mouse brain using 
western blotting. E18: embryonic day 18; P0: postnatal day 0, new after birth; positive 
control: HEK293 cells overexpressed with GPR50. 
2.3.1.2 BACE1 antibodies 
In this thesis, four commercial antibodies for BACE1 were used in different 
experiments according to their performance in the detection of human/mouse 
BACE1, endogenous/exogenous BACE1 and immature/mature BACE1 (see Table 
2.9 for a brief summary). Antibodies used for each experiment were specified at the 
beginning of each chapter.  
Table 2.9 The competence of antibodies for BACE1 used in this thesis 
 Exogenous BACE1 
Endogenous BACE1 
Note 




rabbit1 √     
Rabbit1 and 2 antibodies 
have the same epitope at 
the C-terminal 
BACE1 
rabbit2 √ √ √ √ √ 




mouse √  √   
Mouse and goat 
antibodies  have the 
same epitope at the N-
terminal 
BACE1 
goat √  √ √ √ 
Detects endogenous 
BACE1 better in 
immunocytochemistry 
According to the intracellular trafficking system of BACE1, it will be expressed in 
multiple subcellular organelles {(Cole & Vassar, 2007); also detailed in chapter 5}. 
As is shown in Figure 2.9, BACE1 antibodies detected overexpressed BACE1 in 
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various intracellular locations in SH-SY5Y cells. The BACE1 mouse antibody and 
two rabbit antibodies labelled almost identical signals for BACE1. Previous 
immunocytochemistry studies showed that BACE1 can be found in the plasma 
membrane, the early endosomes, the ER, the Golgi and the late 
endosomes/lysosomes (Griffiths et al, 2011; Guglielmotto et al, 2012; Kang et al, 
2010). My results showed that BACE1 was co-localised with the plasma membrane 
marker pan cadherin (Figure 2.10), confirming that a proportion of BACE1 is cycled 
to the cell surface. The majority of BACE1 is expressed internally, as supported by 
its co-localisation with the early endosome marker EEA1, the Goigi marker 58K 
Golgi and the late endosome marker RAB7 (Figure 2.10). This agrees with previous 
studies. However, there is no obvious co-localisation between BACE1 and the ER 
marker calreticulin, contradictory to a former report (Griffiths et al, 2011).  
Next, the expression of exogenous BACE1 at the plasma membrane was verified by 
the cell surface labelling technique. The BACE1 mouse and goat antibodies are 
raised against the N-terminal extracellular domain of human BACE1, so they are 
more likely to detect plasma membrane-bound BACE1 on the cell surface, before 
cells are permeabilised. A previous report showed that it is difficult to label cell 
surface BACE1 by its own antibody, and it could only be surface-labelled with an 
antibody against V5 when the BACE1 sequence was tagged with the V5 epitope 
(Kinoshita et al, 2003).  Here, the BACE1 mouse antibody failed to produce valid 
fluorescent signal during the cell surface labelling process (Figure 2.11), even though 
it worked well in fixed permeabilised cells (Figure 2.9). However, the BACE1 goat 
antibody successfully identified BACE1 on the cell surface (Figure 2.12, 2.13). In 
SH-SY5Y cells, an external signal was detected by the goat BACE1 antibody, which 
was unlikely to enter the cells because the staining was performed in chilled live 
cells, prior to permeabilisation. The signal was found co-localised with the plasma 
membrane marker VLA-2α and total BACE1 which were stained after 
permeabilisation, confirming that it was a part of BACE1 expressed at the plasma 
membrane (Figure 2.12). In addition, this BACE1 pool was also co-localised with β-
catenin (Figure 2.13), which is mostly tethered with E-cadherin as a component of a 
protein complex that forms the adherens junctions (Du et al, 2009). The labelling of 




Figure 2.9 Validation of BACE1 antibodies using immunocytochemistry in SH-SY5Y cells. 
Untagged BACE1 plasmid was transfected. Cells were double-immunostained with BACE1 
mouse and rabbit1/2 antibodies. Negative controls were only stained with secondary 
antibodies donkey-anti-mouse (DAM) 594 and donkey-anti-rabbit (DAR) 488 while the 
primary antibodies were skipped. BACE1 mouse and rabbit1 antibodies co-localised 
perfectly at multiple sites. BACE1 rabbit2 detected additional signals which were not 
recognised by the mouse antibody. These weaker signals (indicated by a white arrow) may 
represent endogenous BACE1 in SH-SY5Y cells. 
SH-SY5Y BACE1 mouse BACE1 rabbit1 Merge 
BACE1 mouse 
 

































Figure 2.10 The localisation of overexpressed BACE1 in SH-SY5Y cells. BACE1 rabbit2 




Figure 2.11 The BACE1 mouse antibody failed to label BACE1 at the surface of SH-SY5Y 
cells. Top panel, a top slice from a z-stack; middle panel, a middle slice from a z-stack; 
bottom panel, no primary antibody control, was only stained with secondary antibodies 
donkey-anti-mouse (DAM) 488 and donkey-anti-rabbit (DAR) 594 while the primary 
antibodies were skipped. 
  






































Figure 2.12 Cell surface labelling of BACE1 in SH-SY5Y cells (1). Cells were stained by the 
goat antibody, co-stained with VLA-2α mouse antibody or BACE1 rabbit2 antibody. No 
primary antibody controls were only stained with secondary antibodies donkey-anti-goat 
(DAG) 488, donkey-anti-mouse (DAM) 594 and donkey-anti-rabbit (DAR) 647 while the 
primary antibodies were skipped. The localisation of surface-labelled BACE1 was indicated 
by the white arrows. 
  






































Figure 2.13 Cell surface labelling of BACE1 in SH-SY5Y cells (2). Cells were stained by the 
goat antibody co-stained with β-catenin rabbit antibody. Top panel, a top slice from a z-
stack; middle panel, a middle slice from a z-stack; bottom panel, no primary antibody 
control, was only stained with secondary antibodies donkey-anti-goat (DAG) 488 and 
donkey-anti-rabbit (DAR) 594 while the primary antibodies were skipped. The localisation 
of surface-labelled BACE1 was indicated by the white arrows. 
In western blotting, two bands at around 55 kDa and 65 kDa were detected by both 
N-terminal antibody (mouse) and C-terminal antibodies (rabbit1&2) (Figure 2.14), 
corresponding to immature BACE1 and mature BACE1. The molecular weights 
observed for BACE1 were slightly smaller than the generally reported sizes of 60 
kDa for immature BACE1 and 70 kDa for mature BACE1.  This discrepancy is not 
uncommon as prestained protein ladders may have different migration abilities in 
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various SDS-PAGE buffer and gel systems due to the coupling of chromophores 
which affect the prediction of the molecular weight. Other researchers have also 
showed the 65 kDa mature BACE1 using the rabbit1 antibody (Xie et al, 2007; Xu et 
al, 2014). 
 
Figure 2.14 Validation of BACE1 antibodies using western blotting in SH-SY5Y cells. 
Untagged BACE1 plasmid was transfected. Protein lysates were extracted by RIPA buffer. In 
each lane, 10 µg proteins were loaded and separated in 7% tris-acetate gels. BACE1 mouse 
and rabbit1/2 antibodies recognised two bands at 55 kDa and 65 kDa indicated by black 
arrows, corresponding to immature and mature BACE1. The blocking peptide for BACE1 
rabbit2 antibody completely eliminated the signals. Note that no signal was detected in 
untransfected cells, but this did not mean that BACE1 was not endogenously expressed in 
SH-SY5Y cells (see 2.3.2.2). 
The BACE1 goat antibody co-localised well with BACE1 rabbit2 antibody in 
picking up exogenous BACE1 in both HEK293 cells and primary cortical neurons 
(Figure 2.15, 2.18). However, the BACE1 goat antibody was more competent in 
recognising endogenous BACE1/Bace1, which could be labelled by BACE1 rabbit2 
antibody with a concentration double of that used for overexpressed BACE1 (Figure 
2.16, 2.19). All the signals indicated by BACE1 rabbit2 antibody could be eliminated 
by its blocking peptide. The endogenous expression of BACE1/Bace1 was also 






Figure 2.15 Validation of BACE1 antibodies using immunocytochemistry in HEK293 cells. 
Untagged BACE1 plasmid was transfected. Cells were double-immunostained by BACE1 
goat antibody together with BACE1 rabbit2 antibody or rabbit2 with the pre-absorption of 
blocking peptide. Negative controls were only stained with secondary antibodies donkey-
anti-goat (DAG) 488 and donkey-anti-rabbit (DAR) 594 while the primary antibodies were 
skipped. BACE1 goat and rabbit2 antibodies co-localised well in cells obviously labelled with 
rabbit2. BACE1 goat detected additional signals (indicated by a white arrow) which may 
represent endogenous BACE1 in HEK293 cells. The signals indicated by BACE1 rabbit2 were 
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 Figure 2.16 Endogenous BACE1 was detected in HEK293 cells by immunocytochemistry. 
Untransfected cells were double-immunostained by BACE1 goat antibody together with 
BACE1 rabbit2 antibody or rabbit2 with the pre-absorption of blocking peptide. Negative 
controls were only stained with secondary antibodies donkey-anti-goat (DAG) 488 and 
donkey-anti-rabbit (DAR) 594 while the primary antibodies were skipped. BACE1 goat and 
rabbit2 antibodies co-localised in nearly every cell. The signals indicated by BACE1 rabbit2 
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Figure 2.17 Detection of endogenous BACE1 in HEK293 cells. This was further supported by 
a third antibody using immunocytochemistry. Untransfected cells were double-
immunostained with BACE1 goat and mouse antibodies. Negative controls were only 
stained with secondary antibodies donkey-anti-goat (DAG) 488 and donkey-anti-mouse 
(DAM) 594 while the primary antibodies were skipped. The two antibodies co-localised in 






























Figure 2.18 Validation of BACE1 antibodies using immunocytochemistry in primary 
cortical neurons. Untagged BACE1 plasmid was transfected. DIV4 post-transfection neurons 
were double-immunostained with BACE1 goat and rabbit2 antibodies. Negative controls 
were only stained with secondary antibodies donkey-anti-goat (DAG) 488 and donkey-anti-
rabbit (DAR) 594 while the primary antibodies were skipped. BACE1 goat and rabbit2 
antibodies co-localised well in cells obviously labelled with rabbit2. BACE1 goat detected 






























Figure 2.19 Endogenous Bace1 was detected in mouse primary cortical neurons using 
immunocytochemistry. Untransfected DIV4 neurons were double-immunostained by 
BACE1 goat antibody together with BACE1 rabbit2 antibody or rabbit2 with the pre-
absorption of blocking peptide. Negative controls were only stained with secondary 
antibodies donkey-anti-goat (DAG) 488 and donkey-anti-rabbit (DAR) 594 while the primary 
antibodies were skipped. BACE1 goat and rabbit2 antibodies co-localised in neurons. The 





































Figure 2.20 Endogenous Bace1 was detected in mature primary hippocampal neurons 
using immunocytochemistry. Untransfected DIV28 neurons were separately 
immunostained by BACE1 goat and mouse antibodies. Negative controls were only stained 
with secondary antibodies donkey-anti-goat 488 or donkey-anti-rabbit 488 while the 
primary antibodies were skipped. Both the two antibodies detected endogenous Bace1 in 
mature neurons. 
 
Figure 2.21 Endogenous BACE1/Bace1 was detected in HEK293 cells and mouse brain 
using western blotting. E18: embryonic day 18; P0: postnatal day 0, new after birth; 
positive control: SH-SY5Y cells overexpressed with BACE1. 






















By western blotting, BACE1 rabbit2 detected both immature and mature endogenous 
BACE1/Bace1 in protein lysates prepared from untransfected HEK293 cells, adult 
mouse brain and embryonic mouse brain (Figure 2.21). The blocking peptide 
validated the detection of this antibody. The diffuse band at around 65 kDa indicated 
a highly glycosylated Bace1. It predominated in the mouse brain samples, suggesting 
a high β-secretase activity in the brain because glycosylation appears important for 
the enzymatic activity of BACE1 (Charlwood et al, 2001). BACE1 goat antibody 
also recognised two bands, but the top band was not as dominating as the one probed 
by rabbit2. This band was slightly smaller, which might represent a partly 
glycosylated BACE1. The immunogen sequence of BACE1 goat antibody covers the 
four glycosylation sites at the N-terminal. Therefore, this observation might also 
indicate that glycosylation affects antibody binding. 
2.3.1.3 Primary antibody omitting experiments 
In immunofluorescence double-staining experiments, it is essential to make sure that 
there is no cross-immunoreactivity between primary antibodies and secondary 
antibodies. In other words, the secondary antibody for one primary antibody must not 
react to the other primary antibody. In previous sections, most of the primary 
antibodies (for instance, the subcellular markers) used for double staining have been 
tested by the staff in our lab. I, myself, tested the primary antibodies for GPR50 and 
BACE1 used in this thesis, exampled by GPR50 goat and BACE1 rabbit2 antibodies.  
As is shown in Figure 2.22, the donkey-anti-goat 594 secondary antibody was able to 
expose GPR50 signal only when GPR50 goat antibody was used. The donkey-anti-
rabbit 488 secondary antibody exposed BACE1 signal only when BACE1 rabbit2 
antibody was used. Therefore, there was no cross-immunoreactivity in this 
experiment. Other antibodies showed a good performance similarly (not shown). 
Thus, all the antibodies listed in this thesis were suitable for use in 





Figure 2.22 Cross-immunoreactivity test in immunocytochemistry double-staining 
experiments. SH-SY5Y cells were double-transfected with untagged GPR50 and BACE1 
plasmids. Top panel: cells were incubated only with GPR50 goat primary antibody, followed 
by staining with both secondary antibodies, donkey-anti-goat (DAG) 594 and donkey-anti-
rabbit (DAR) 488; middle panel: cells were incubated only with BACE1 rabbit2 primary 
antibody, followed by staining with both secondary antibodies, DAG594 and DAR488; 
bottom panel: cells were incubated with both GPR50 goat and BACE1 rabbit2 primary 
antibodies, followed by staining with both secondary antibodies, DAG594 and DAR488. 
2.3.1.4 Conclusion 
Preliminary testes validated the integrity of antibodies for GPR50 and BACE1 used 
in this thesis.  Immunocytochemistry performed with major antibodies showed viable 
staining patterns of subcellular distribution that have been described in earlier 
research. Uncertain staining pattern of GPR50 goat antibody has been pointed out 
and will be cautiously attended to in subsequent experiments. Western blotting 
analysis with each antibody detected proteins of the expected sizes. Thus, the 
antibodies can be confidently used in this thesis according to their effectiveness in 
different experiments. 




































2.3.2 GPR50 is involved in the regulation of BACE1 expression 
The overexpression of GPR50 is capable of elevating endogenous β-secretase 
activity of human BACE1 (Grünewald, 2011). To investigate whether this regulation 
result is attributed to the alteration of BACE1 expression upon GPR50 
overexpression in HEK293 cells, I compared the mRNA and protein levels of 
endogenous BACE1 with or without exogenous GPR50 in HEK293 and SH-SY5Y 
cells. 
2.3.2.1 The protein level of mature BACE1 is decreased by GPR50 overexpression in 
HEK293 cells 
The relative densities of BACE1 bands detected by BACE1 rabbit2 antibody were 
calculated in ImageJ and normalised against those of GAPDH. In HEK293 cells, 
GPR50 overexpression decreased the protein level of mature BACE1 by around 60%, 
but had no significant effect on immature BACE1, compared with the control 
condition (Figure 2.23).  The β-secretase activity is mainly contributed by mature 
BACE1, as immature BACE1 exhibited trivial enzymatic activity (Zhong et al, 2007). 
GPR50 is known to increase BACE1 activity significantly in this cell line, which 
cannot be explained by the regulative effect of GPR50 on BACE1 protein expression. 
Another mechanism (trafficking of BACE1) that may affect BACE1 activity via 
GPR50 was investigated in chapter 5. 
 
Figure 2.23 The effect of GPR50 overexpression on endogenous levels of BACE1 protein in 
HEK293 cells. A) Mature BACE1 (65 kDa) and immature BACE1 (55 kDa) in cells transfected 
with empty vector pDEST40 or GPR50. B) Normalised endogenous mature BACE1 protein 
levels, N=3, *p=0.0035<0.05 by paired Student’s t-test. C) Normalised endogenous 
immature BACE1 protein levels, N=3, NS: p=0.29>0.05 by paired Student’s t-test. 
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2.3.2.2 The analysis of endogenous BACE1 in neuroblastoma cell line SH-SY5Y 
PCR products of cDNA synthesised from untransfected and BACE1-transfected SH-
SY5Y cells were sequenced and verified as BACE1 fragments. As is shown in 
Figure 2.24.A, a moderate level of endogenous BACE1 mRNA was detected in SH-
SY5Y cells.  Yu and colleagues identified a higher level of BACE1 mRNA in SH-
SY5Y than in HEK293 cells, which was attributed to the differences in promoter 
strength that regulate the transcriptional activation (Li et al, 2006). It was also 
suggested that BACE1 promoter activity is greater in neuronal cells than in non-
neuronal cells (Sun et al, 2005). However, the protein level of BACE1 in SH-SY5Y 
cells can be very low (Qing et al, 2004), concomitant with a minor Aβ level (Xue et 
al, 2006). The western blotting results revealed a single band at around 60 kDa, 
which was lacking when BACE1 rabbit2 antibody was pre-absorbed by the blocking 
peptide.  The molecular weight of the detected protein is neither the expected size of 
65kD mature BACE1 nor 55 kDa immature BACE1, unlike in HEK293 cells and 
mouse brain in which both of the isoforms exist (Figure 2.21). It is likely that this 
BACE1 is an intermediate isoform prior to complete maturation, which has been 
reported by others (Costantini et al, 2007; Ko & Puglielli, 2009).  
 
Figure 2.24 The expression levels of endogenous BACE1 in SH-SY5Y cells. A) Endogenous 
BACE1 mRNA. B) Endogenous BACE1 protein. Transfected control: SH-SY5Y cells transfected 
with untagged BACE1 plasmid. BACE1 rabbit2 antibody was used in this experiment. 
2.3.2.3 The mRNA level of endogenous BACE1 is decreased by GPR50 
overexpression in SH-SY5Y  cells 
Six biological replicates were performed for the real-time PCR experiment. 
Expression levels of endogenous BACE1 and overexpressed GPR50 were 
normalised against three housekeeping genes: TFRC, TBP and UBC. One replicate 
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was identified as a potential outlier based on the normal range of BACE1 mRNA 
level among the six replicates, according to the interquartile range rule (see 7.2.4 for 
detail). Upon overexpression of GPR50, there was a significant decrease of BACE1 
mRNA level compared with the control condition, after the removal of the outlier 
replicate (Table 2.10, Figure 2.25).  
Table 2.10 The relative mRNA expression levels of BACE1 in SH-SY5Y cells transfected 
with pDEST40 or GPR50 
 pDEST40 GPR50 
Replicate A 1 0.984647 
Replicate B 1 0.811340 
Replicate C 1 0.769962 
Replicate D 1 0.447656 
Replicate E 1 3.041578 
Replicate F 1 0.476823 
With E Average 1 1.088668 
Standard deviation 0 0.893347 
Standard error 0 0.364707 
Without E Average 1 0.698086 
Standard deviation 0 0.230099 
Standard error 0 0.042645 
 
 
Figure 2.25 The effect of GPR50 overexpression on endogenous levels of BACE1 mRNA in 
SH-SY5Y cells. A) Validation of GPR50 transfection. The peaks indicated three experimental 
replicates for a successful amplification of GPR50 from cDNA of GPR50-transfected cells. 
The pDEST40-transfected cells did not express GPR50 endogenously, so there was no 
GPR50 amplification, indicated by a flat line. A flat line for the dH2O control suggested that 
there was no contamination during the qPCR process. A flat line for the no-transcriptase 
control (Minus RT) suggested that there was no contamination during the processes of RNA 
extraction and cDNA synthesis. B) Normalised endogenous BACE1 mRNA levels. The same 
amounts of empty vector pDEST40 were transfected as the control of the untagged GPR50 
plasmid, N=6, *P=0.039<0.05 by paired Student’s t-test. 
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2.3.2.4 The protein level of  BACE1 is increased by GPR50 overexpression in SH-
SY5Y cells 
Next, I determined whether GPR50 overexpression has an effect on BACE1 protein 
level in SH-SY5Y cells by western blotting. It was found that exogenous GPR50 
induced a 47% increase of endogenous BACE1 protein level in SH-SY5Y cells 
versus the empty vector control (Figure 2.26). It is interesting that the regulative 
impact of GPR50 expression on BACE1 protein level was opposite to that on 
BACE1 mRNA level. This indicates that GPR50 is a multi-functional factor, which 
may be involved in the different stages of BACE1 regulation system. Another 
possibility is that GPR50 participates in the inhibitory feedback loop of BACE1 
protein level on its gene transcription (mRNA level). 
 
Figure 2.26 The effect of GPR50 overexpression on endogenous levels of BACE1 protein in 
SH-SY5Y cells. A) BACE1 in cells transfected with empty vector pDEST40 or GPR50; B) 
Normalised endogenous BACE1 protein levels, N=3, *p=0.0035<0.05 by paired Student’s t-
test. Antibodies: BACE1 rabbit2, GPR50 goat, GAPDH mouse. 
2.4 Discussion 
In this chapter, antibodies used in this thesis were validated.  The subcellular 
localisation of exogenous GPR50 and BACE1 were confirmed in SH-SY5Y and 
HEK293 cells, and the results are in agreement with the published data. Further, 
diversified regulative effects of exogenous GPR50 on BACE1 expression levels were 
identified in these two cell lines. 
2.4.1 The subcellular location of GPR50 and BACE1 
The subcellular localisation of GPR50 was mainly at the cell surface. Although the 
internally expressed GPR50 was detectable, the location of this pool was not clear, as 
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the co-localisation of GPR50 with other subcellular markers was not convincing. 
This observation was not a result of overexpression, as the endogenous GPR50 
detected in HEK293 cells was also predominantly located at the plasma membrane, 
but occasionally at internal-like sites (Grünewald, 2011). It requires further 
investigation why a small percentage of this GPCR was not targeted to the cell 
surface. 
Earlier studies showed that overexpressed BACE1 was found in post-ER sites 
including the plasma membrane, the early endosomes, the Golgi and the lysosomes. 
This result was validated by immunocytochemistry in this chapter. The co-staining 
pattern of BACE1 and the ER marker calreticulin showed no clear evidence for co-
localisation. A previous study showed part co-localisation between BACE1 and 
calreticulin in SH-SY5Y cells (Griffiths et al, 2011). However, it seems that the 
majority of BACE1 was located outside the ER, with a punctate staining style that 
might match similar patterns in other compartments, normally the TGN and the 
endosomes as observed by myself and others (Kang et al, 2012; Prabhu et al, 2012). 
Time-lapse recording showed that BACE1 fluorescent particles moved rapidly 
through the ER and accumulated predominantly in Golgi-like complexes (Sun et al, 
2006b). My observation also agrees with the fact that the maturation process of 
BACE1 is transient. In addition, a small amount of BACE1 was successfully labelled 
on the cell surface of SH-SY5Y cells, especially in the filopodia/lamellipodia 
structures, the formation of which can be induced by GPR50 overexpression 
(Grünewald, 2011). This pool of BACE1 may directly mediate cell surface 
proteolysis of cell adhesion molecules (Kuhn et al, 2012) or undergo 
internationalisation to the early endosomes for more robust β-secretase activity 
(Sannerud et al, 2011). 
2.4.2 The possible role of GPR50 in regulating BACE1 expression 
GPR50 overexpression resulted in a negative effect on BACE1 protein level in 
HEK293 cells. This adds more complexity in understanding GPR50’s regulative role 
in BACE1 function, as the result was not supporting the previous finding of the 
positive modulation of BACE1 activity by GPR50 overexpression in the same cell 
line (Grünewald, 2011). Other mechanisms related to BACE1 activity regulation 




Real-time qPCR and western blotting were performed in SH-SY5Y cells to 
investigate the regulative potential of GPR50 on BACE1 mRNA and protein levels 
respectively. Surprisingly, the decreased BACE1 mRNA level upon transfection of 
exogenous GPR50 did not lead to a declined protein level in SH-SY5Y cells. In 
contrast, a significant increase of BACE1 protein level was observed with GPR50 
overexpression, compared with the pDEST40 control in SH-SY5Y cells.  
There are several questions raised that might contribute to the contradiction of the 
regulation results of mRNA and protein in the same cell line: 
1) The samples used for qPCR and western blotting were not from the same 
cells, but prepared separately.  
2) The qPCR experiment made use of three housekeeping genes (TFRC, TBP 
and UBC) to normalise BACE1 mRNA levels, while a different 
housekeeping gene (GAPDH) was singly utilised in the western blotting to 
normalise BACE1 protein levels. 
3) Is the effect of GPR50 overexpression on BACE1 levels dose-dependent? 
4) Is it reasonable to remove outliers according to the dataset with a small 
sample size? 
5) Does the overexpression of empty vector pDEST40 have an impact on 
BACE1 levels? 
6) Are the housekeeping genes equally stable? 
7) Is it more reasonable to use single or multiple housekeeping genes? 
In summary, my results suggested that a differentiated regulative system of BACE1 
might exist between cell lines, such as between non-neural cells and neuronal cells.     
2.4.3 Further experiments 
Results in this chapter showed that GPR50 is involved in the regulation system of 
BACE1 transcription and translation. The next step is to study whether there is a 
direct interaction between the two proteins. Therefore, in chapter 3, I tested this 








3 The potential of GPR50 to be an 




The multiple potential interactors of GPR50 identified by the yeast two-hybrid 
analysis are associated with BACE1 expression (SNX6, SREBP2), trafficking 
(RTN3, SNX6) or activity (RTN4, ABCA2, CDH8) (Davis, 2011; Deng et al, 2013; 
Mastrocola et al, 2011; Murayama et al, 2006; Okada et al, 2010; Stützer, 2012).  
Preliminary findings showed that in HEK293 cells, overexpression of GPR50 
resulted in an increase of BACE1 activity and appeared with the opposite effect of 
known BACE1 co-interactors RTN3 and RTN4 (Nogo) (Grünewald, 2011). In 
chapter 2, I showed that overexpressed GPR50 affected the expression levels of 
BACE1, but this did not provide sufficient evidence on the regulation of BACE1 
activity. I proposed that GPR50 is involved in the physiological function of BACE1 
directly or through cooperating with co-interactors. Thus, in this chapter, I 
investigated whether GPR50 is an interactor of BACE1. 
3.1 Introduction 
3.1.1 Protein-protein interaction 
Diverse biological processes involve with a group of active proteins. These 
functional factors rarely act alone, but by forming a physical complex as a result of 
biochemical events and/or electrostatic forces, which is referred to as protein-protein 
interaction (PPI). Signal transduction, molecule trafficking and cell metabolism are 
all examples of PPI. These interactions are essential to the maintenance of the regular 
function in cells and organisms. Thus, aberrant PPIs can be indicative or causative of 
multiple diseases, such as neurodegenerative disorders and cancers (Kuzmanov & 
Emili, 2013). 
3.1.1.1 Types of protein-protein interaction 
PPI can be further characterised as stable or transient interactions. Stable interactions 
are commonly seen in multi-subunit protein complex. The subunits can be identical 
or different, known as homo-oligomers or hetero-oligomers. A variety of GPCRs 
interact to form homo-dimers/oligomers, which is important for G protein binding 
and activation (Palczewski, 2010). Co-expressed GPCRs may also form hetero-
dimers/oligomers to alter the performances of the components; for instance, GPR50 
is able to form a heterodimer with MT1, inhibiting the binding of G-protein and 
melatonin response (Levoye et al, 2006). 
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Transient interactions are temporary, but can be strong or weak, fast or slow, and 
always in a reversible manner. These interactions typically occur in certain cellular 
contexts, such as phosphorylation, conformational changes or trafficking to a 
particular cellular site. Transiently interacting proteins are involved in the majority of 
cellular processes, including protein modification, transport, folding, signalling, and 
cell cycling. For instance, newly synthesised BACE1 can only reach the Golgi 
apparatus after acetylation, by interacting with acetyltransferases, ATase1 and 
ATase2 in the ER/ER Golgi intermediate compartment; otherwise, the non-
acetylated nascent protein is degraded by PCSK9/NARC-1 (Coulson et al, 2010; Ko 
& Puglielli, 2009). 
3.1.1.2 Techniques to investigate protein-protein interaction 
There are numerous ways to detect PPI. Each of the methods has its own advantages 
and disadvantages, especially with the consideration of the sensitivity and specificity 
of the approach. The most commonly used techniques are briefly introduced as 
follows.  
• Yeast two-hybrid screening takes advantage of the integrity of the gene 
transcription system. Yeast cells are transfected with two plasmids separately 
containing the bait (cDNA of protein of interest or a certain fragment of the 
protein, fused with the DNA-binding domain of a yeast transcription factor, for 
example Gal4), and the prey (a library of cDNA fragments linked to the 
activation domain of the transcription factor proximal to a reporter gene) (Figure 
3.1). Transcription of the reporter gene only occurs when the bait and prey 
interact with each other so as to form a functional transcription factor. Thus, the 
interaction between proteins can be indicated by the presence of the expression 
product from the reporter gene. The advantage of yeast two-hybrid screening is 
the provision of high-throughput analysis, as this method allows the access to 
almost the entire cellular proteome (Bruckner et al, 2009). However, the yeast 
two-hybrid takes place in the nucleus. If two interacting proteins are not localised 
to the nucleus, they may be found to be non-interacting. Also, the outcome may 
include false positive binding partners, because the conformation of the bait or 
prey is easily affected (i.e. the extensive use of fusion proteins), which may alter 
the original binding property (Sobhanifar, 2003). Thus, a confidence score is 
normally calculated for each of the prey interactors (Global Predicted Biological 
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Score, Global PBS), inferring the likelihood of a true interaction. Other 
techniques are needed to verify the putative interactions, normally starting from 
those with the highest PBS score. For instance, in the yeast two-hybrid study of 
GPR50 interactors, Nogo was identified as a candidate with the highest score 
(PBS=A) (Grunewald et al, 2009). Following studies successfully validated the 
physical interaction between GPR50 and Nogo-A (Grünewald, 2011; Grunewald 
et al, 2009). 
 
Figure 3.1 The yeast two-hybrid screening system. This figure was adapted from 
(Walhout, 2006). X, the bait protein; BD, the binding domain of a transcription factor; Y, 
the prey protein; AD, the activation domain of a transcription factor. 
• Co-localisation refers to the observation of a spatial overlap between two (or 
more) fluorescent labels with different emission wavelength in fluorescence 
microscopy. This technique provides preliminary evidence to whether the 
different fluorophore-labelled proteins are located in the same site within the cell. 
The information obtained from co-localisation can be interpreted in two ways: 1) 
co-occurrence, which reflects the presence of two fluorophores in the same pixel 
(the two proteins are not necessarily related, for instance, BACE1 is located in 
EEA1-marked early endosomes, but BACE1 and EEA1 may not correlate, see 
Figure 2.10); 2) correlation, a statistically significant relationship between the 
two fluorophores, indicating a biological interaction between the two proteins. 
The statistical method to evaluate co-localisation indicated interaction is detailed 
in 3.2.3. A good example of perfect co-localisation is to detect the same protein 
with two different antibodies, as is shown in chapter 2 (Figure 2.5, 2.9). The 
strength of co-localisation is that it is easy to operate and can be useful to predict 
the interaction location of two proteins by applying subcellular compartments 
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markers. Yet, it is hard to explain the “non-perfect” interaction situations, which 
are affected by the presence of non-colocalising signals. Also, the technique 
relies on highly specific antibodies and clear fluorescent background. Co-
localisation is widely utilised as the first step to test the possibility of a true 
interaction between two proteins. 
• Co-immunoprecipitation (co-IP) is a popular technique for confirming the 
physical interaction between proteins (Figure 3.2). The “bait” protein is 
immunoprecipitated by its specific antibody, and a binding partner/protein 
complex, the so-called “prey”, will be co-precipitated from the protein lysate. 
The antibody-binding protein complex is then immobilised on protein A or 
protein G sepharose beads and any proteins not precipitated on the beads will be 
eliminated by washing. This concept of pulling a protein complex out of the cell 
lysates is sometimes called a “pull-down”. The protein complex is eluted from 
the beads and dissociated by SDS sample buffer. Proteins are then separated in 
SDS-PAGE gels, followed by western blotting with specific antibodies to identify 
the bait or prey. Co-IP is considered highly specific and compatible with most 
methods of downstream analysis (SDS-PAGE, immunoblotting, mass 
spectrometry). The main disadvantage is that there are occasionally difficulties in 
obtaining antibodies with high specificity and avidity (Miernyk & Thelen, 2008). 
Co-IP is often used for confirming the yeast two-hybrid screening results. 
 
Figure 3.2 The schematic diagram of co-immunoprecipitation  
• Fluorescence resonance energy transfer (FRET) is the mechanism of an 
excited donor transferring energy to an acceptor through a non-radiative process 
(defined as “resonance”). A donor molecule is excited by a photon within its 
excitation spectrum and then relaxes to the lowest excited singlet state, S1 
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(Figure 3.3). The relaxation of the electron energy results in the emission of a 
photon (fluorescence) by the donor fluorophore, concomitant with an energy drop. 
If there is an acceptor molecule within a short distance (<10 nm), energy transfer 
occurs from the donor to the acceptor, engendering acceptor fluorescence. In 
other words, the energy released when the donor electron returns to the ground 
state (S0) may simultaneously excite the acceptor molecule. Then the excited 
acceptor emits a photon and returns to its ground state. Thus, by attaching proper 
fluorophores to proteins that might interact with each other, the proximity of 
these putative interactors can be measured by determining if fluorescence 
resonance energy is transferred from the donor to the acceptor (Xu, 2001). A 
limitation of FRET is the requirement for external illumination to excite the 
donor fluorophore, which can lead to photobleaching, autofluorescence or direct 
excitation of the acceptor fluorophore. To avoid these disadvantages, 
bioluminescence resonance energy transfer (BRET) has been developed, in 
which the donor fluorophore is replaced by a luciferase that emits 
bioluminescence in the presence of a substrate and consequently excites the 
acceptor fluorophore. BRET has a great potential in assessing PPIs in living cells 
and in real time (Xu, 2001). For instance, Levoye et al identified GPR50 
homodimer and GPR50/MT1/2 heterodimers in living HEK293 cells by using 
BRET (Levoye et al, 2006). 
 
Figure 3.3 The schematic diagram of fluorescence resonance energy transfer. This 
diagram was adapted from (Selvin, 2003). S1, singlet state; S0, ground state. 
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3.1.2 Introduction to experiments 
To confirm the possible interaction between GPR50 and BACE1, I performed 
preliminary biological tests in mammalian cells, described as follows.  
1) To examine if there is a possibility of GPR50 and BACE1 proximity, co-
localisation by immunocytochemistry was carried out in cells over-expressing 
human GPR50 and BACE1 and in cells expressing the two proteins 
endogenously.  
2) To verify the results observed in the co-localisation experiments, subcellular 
fractionation was performed to check whether GPR50 and BACE1 co-
fractionate in fractions containing specific organelles. 
3) To further validate if GPR50 and BACE1 are physically associated, co-
immunoprecipitation experiments were performed at both exogenous and 
endogenous levels. 
3.2 Materials and methods 
3.2.1 Tissue culture and relative techniques 
HEK293, SH-SY5Y and murine neuroblastoma cell line N1E-115 were grown in 12-
well plates and 10 cm plates (see 2.2.1). Primary neuronal cultures used for 
immunocytochemistry were prepared from the hippocampi of E18 CD1 mice 
(purchased from Biomedical Research Resources Unit, Western General Hospital, 
Edinburgh). Plasmids used in this chapter were described in 2.2.3. The transfection 
protocol was summarised in 2.2.4. For the methods of immunocytochemistry, cell 
surface labelling and western blotting, see 2.2.5, 2.2.6 and 2.2.7 respectively. All the 
fluorescence images were taken on a Nikon A1R confocal microscope with a size of 
1024×1024 in the z-stack programme. 
3.2.2 Antibodies  
The primary antibodies used in this chapter and their application conditions are 
summarised in Table 3.1. The full information for these antibodies can be found in 
2.2.5 (Table 2.2). The fluorescent secondary antibodies and horseradish peroxidase 




Table 3.1 Primary antibodies used in chapter 3 
Antibody Host Immunogen Application in this 
chapter 
GPR50  goat Goat polyclonal Within residues 400-450 of human 
GPR50  
ICC (1:2000/1:500)* 
WB (1:5000/1:500) * 
IP (2.4 µg/1mL) 
GPR50 63 Rabbit polyclonal Residues 516-530 of human GPR50 WB (1:1000) 
GPR50 rabbit 
 
Rabbit polyclonal Residues 294-317 of human GPR50 ICC (1:200) 
WB (1:1000) 
BACE1 rabbit1 Rabbit polyclonal Residues 485-501 of human BACE1 ICC (1:500) 
WB (1:1000) 
BACE1 rabbit2 Rabbit polyclonal Residues 485-501 of human BACE1 ICC (1:5000) 
WB (1:10,000) 
BACE1 mouse Mouse monoclonal Residues 22-460 of human BACE1 ICC (1:500) 
WB (1:1000) 
BACE1 goat Goat polyclonal Residues 22-460 of human BACE1 ICC (1:200) 
VLA-2α  
 
Mouse monoclonal Residues 42-245 of human VLA-2α ICC (1:500) 
WB (1: 1000) 
β-catenin 
 




EEA1 mouse2 Mouse monoclonal Residues 3-281 of human EEA1 WB (1: 5000) 
Calreticulin  
mouse 
Mouse monoclonal Calreticulin-maltose binding fusion 
protein 
WB (1:10,000) 
58K Golgi  Mouse monoclonal Purified full length native from rat liver WB (1: 500) 
LAMP2b  
 
Rabbit polyclonal Within residues 350 to the C-terminus 
of human LAMP2b 
WB (1: 500) 
RTN3 Rabbit polyclonal Residues 1-90 of human RTN3 WB (1:2000) 
PSD-95 Mouse monoclonal Purified recombinant rat PSD-95 WB (1: 5000) 
Synaptophysin Mouse monoclonal Rat retina synaptosome WB (1: 50,000) 
* There were two batches of GPR50 goat antibody with inconsistent performances, so different 
concentrations were used. 
3.2.3 Intensity correlation analysis (ICA) 
Qualitative analysis of co-localisation was achieved by using the ICA plugin in 
ImageJ. This plugin generates intensity correlation analysis (Li et al, 2004), 
Pearson’s correlation coefficients and Mander’s overlap coefficients (Manders, 1993).  
The process can be run using the whole image or region of interest (ROI). The 
images were background subtracted and auto-thresholded during analysis.  
3.2.3.1 Intensity correlation quotient (ICQ)  
The key features of ICA method include coloured scatter plot, ICA plots and 
intensity correlation quotient (ICQ). Paired pixel staining intensity values for dye A 
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Xi= the ith value of variable X, 
Xmin = the minimum value for variable X,  
Xmax = the maximum value for variable X. 
A scatterplot of the normalised A versus B staining intensities is generated, which 
shows different patterns representative of different staining relationships (Figure 3.4, 
left column). The means of normalised A and B are determined (A� and B�) and the 
Product of the Differences from the Mean (PDM) is calculated for each paired pixel: 
PDM = (Ai- A�)×(Bi – B�). ICA plots are generated by Ai (or Bi) versus PDM. The 
simulated staining patterns of ICA plots are summarised in Figure 3.4, middle and 
right columns.  
For each image, the number of pixels that generate positive or negative PDM values 
is counted. A ratio of the number of positive values to the total number of pixel pairs 
reflects the degree of dependency between A and B. The ICQ is generated by 
subtracting 0.5 from this value, which is used to identify whether the staining 
intensities are associated in a random (ICQ~=0), dependent (0 <ICQ ≤0.5) or 
segregated (0>ICQ≥ -0.5) manner. Non parametric sign test is carried out to judge 
whether the median of differences between two sets of intensity values equals 0 
(ICQ=0).  
3.2.3.2 Pearson’s correlation coefficient (Rr)  
Pearson’s correlation coefficient Rr is generated by correlating paired intensity 
values of A and B (𝑅𝑟 =
∑(𝐴𝑖−?̅?)×(𝐵𝑖−𝐵�)
�∑(𝐴𝑖−?̅?)2×∑(𝐵𝑖−𝐵�)2
). Conventionally, the values for Rr range 
from 1 to -1. A value of 1 indicates perfect correlation, -1 means perfect exclusion 
and zero represents a random relationship. However, this is not totally the case for 
images. While reliable co-localisation always gets a value close to 1, exclusion does 
not give a value of -1. Negative values and those close to zero only mean that there is 




Figure 3.4 Stimulated models of intensity correlation analysis. This figure was adapted 
from (Li et al, 2004). The left columns of A-D represent a scatterplot of 1000 paired 
normalised values of Ai versus Bi intensities. The middle and right columns show plots of 
individual Ai and Bi against their respective PDM values. A) Intensity plot of random staining, 
ICQ=0.023, p>0.05; B) intensity plot of dependent staining, ICQ=0.39, p<0.001; C) intensity 
plot of segregated staining, ICQ=-0.269, p<0.001; D) intensity plot model simulating random 
A staining distribution but with segregated B staining, ICQ=-0.12, p<0.001. 
3.2.3.3 Mander’s overlap coefficient (R)  
Mander’s overlap coefficient (𝑅 = ∑(𝐴𝑖)×(𝐵𝑖)
�∑(𝐴𝑖)2×∑(𝐵𝑖)2
) does not take into account the 
average intensity values, meaning that it generates values that are distributed from 0 
to 1. Zero corresponds to non-overlapping images and the value of 1 reflecting 100% 
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co-localisation between both images. The coefficient R is strongly affected by the 
ratio of red to green pixels and should only be used when there are roughly equal 
numbers of pixels from the two channels (Nred/Ngreen pixels~1). The split 
coefficients of Mander’s co-localisation (M1= ∑ 𝐴𝑖,𝑐𝑜𝑙𝑜𝑐𝑎𝑙
∑ 𝐴𝑖
 and M2= ∑ 𝐵𝑖,𝑐𝑜𝑙𝑜𝑐𝑎𝑙
∑ 𝐵𝑖
) are 
normalised against total pixel intensity, therefore avoiding issues relating to absolute 
intensities of the signal. There is one coefficient per channel calculating the 
proportion of pixels in this channel that coincide with pixels in the other channel, so 
the split coefficients mainly represent how well one channel overlaps the other. 
However, as these coefficients are sensitive to local variations of intensity, this 
interpretation of the Mander’s coefficients as percentage of intersection only holds 
when the intensities are homogeneous. A more general interpretation is described as 
the amount of pixels in one channel whose intensities match with some pixels in the 
other channel. 
3.2.4 Subcellular fractionation-sucrose density gradient fractionation 
3.2.4.1 Subcellular fractionation from HEK293 cells 
HEK293 cells were grown for 36 hr in 10 cm dishes and transfected when cells 
reached a confluency of nearly 90%. The cultured cells were left overnight post-
transfection before being collected on ice using a cell scraper and suspended into 
sucrose buffer {0.25 M sucrose, 10 mM Tris-HCl buffer (pH 7.4), 1 mM Mg(Ac)2,  
protease inhibitor}. The lysates were passed through a 23 gauge needle 20 times, 
followed by incubation on ice for 20 min. The homogenates were loaded onto the top 
of a discontinuous gradient comprised of 1.5 ml of 2 M sucrose, 2.5 ml of 1.3 M 
sucrose, 2.5 ml of 1.16 M sucrose, 2 ml of 0.8 M sucrose, 2 ml of 0.5 M sucrose, and 
1 ml of 0.25 M sucrose prepared in 10 mM Tris-HCl buffer (pH 7.4) and 1 mM 
Mg(Ac)2. The gradients were then centrifuged at 10,000×g (22,000 rpm, SW41 Ti 
Beckman) for 18 hr at 4oC. Twelve 1 ml fractions were collected from the top, 
followed by methanol-chloroform precipitation. Proteins were detected by western 
blotting after electrophoresis on a 4-12% Bis-tris Nupage gel.  
3.2.4.2 Subcellular fractionation from adult mouse brains 
Brains were removed from ten 8-10 week old adult C57BL/6 mice and homogenised 
in solution A (320 mM sucrose, 1 mM HEPES, pH7.5, 1 mM NaHCO3, 1 mM 
MgCl2, protease inhibitor) on ice by a borosilicate glass homogeniser (Dounce, 7ml, 
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tight; 2 brains/10 ml, 10 strokes). From this point on, all the materials and buffers 
were kept at 4°C throughout the preparation. The homogenates were centrifuged at 
1000×g for 10 min (Beckman, JA25.5). The supernatant (S1) was collected. The 
pellet (P1) was re-suspended in 10 ml of solution A and 3 strokes were applied with 
the homogeniser. The homogenates were centrifuged again and the supernatant was 
added to S1. The pellet, which contains nuclei and large cellular debris, was 
discarded. S1 was centrifuged at 13,800×g for 10 min (Beckman, JA25.5).  Both the 
supernatant (S2) and the pellet (P2, crude synaptosome) were collected. S2 was 
centrifuged at 165,000×g for 2 hr (Beckman, TLA-100.3). The supernatant (S3, 
cytosol) was discarded and the pellet (P3, light membranes) was washed twice with 
solution B (40 mM sucrose). P2 was re-suspended in 18 ml of solution B and applied 
3 strokes in the homogeniser. The P2 suspension was added to the sucrose density 
gradient (3 ml 1.2 M, 3 ml 1.0 M, 3 ml 0.85 M) and centrifuged at 82,000×g for 2 hr 
(Sorvall, TH-641). After spinning, four layers were formed isolated by three enriched 
stripes, which were the synaptosome, the ER-Golgi and the myelin, from the top to 
the bottom. The pellet was the mitochondria. The fractions were carefully collected 
using a plastic pastette. 
For presynaptic fractions, half of the synaptosomal fraction was diluted with 5 
volumes of solution B and centrifuged at 32,800×g for 20 min (Beckman, TLA-
100.3). The supernatant was removed. The pellet was re-suspended in 3 ml of 
solution C (1 M HEPES-NaOH buffer, pH 7.4, used for osmotic shock) and applied 3 
strokes with the homogeniser. The homogenates were incubated for 45 min at 4ºC 
and centrifuged at 32,800×g for 20 min (Beckman, TLA-100.3). Both the supernatant 
(LS1) and pellet (LP1, synaptosomal membranes) were collected. LS1 were 
centrifuged at 165,000×g for 2 hr. The supernatant (LS2, synaptosomal cytosol) and 
the pellet (LP2, synaptic vesicles enriched fraction) were collected separately.  
For postsynaptic densities (PSD), the other half of the synaptosomal fraction was 
diluted with equal volume of solution D (1% Triton X-100) and incubated for 15 min 
at 4ºC. The homogenates were divided into 3 tubes: “1/6”, “1/6” and “4/6” fraction 
and centrifuged at 39,000 rpm for 30 min (Beckman, TLA-100.3). The pellet of the 
first “1/6” fraction was washed once with 1 ml of solution B and stored as “one-triton” 
fraction. The pellet of the second “1/6” fraction was washed once with solution B 
and re-extracted with 1 ml of solution E (0.5% Triton X-100) for 15 min at 4ºC 
(“two-triton” fraction). The pellet of the “4/6” fraction was washed once with 
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solution B and re-extracted with 1 ml of solution F (3% N-lauroylsarcosinate) for 15 
min at 4ºC (“one-triton+Sarcosyl” fraction).  After the incubation, the three fractions 
were centrifuged at 61000 rpm for 1 hr (Beckman, TLA-100.3). All the pellets were 
washed once with 1 ml of solution B and re-suspended separately in solution H 
(40mM Tris-HCl, pH8.0; 0.3% SDS + protease and phosphatase inhibitor cocktail) 
and sonicated on ice until dissolved. Protein concentrations were measured using the 
Bradford assay (Bio-Rad DC protein assay kit). 
 
Figure 3.5 A diagram of subcellular fractionation from adult mouse brains. This photo was 
cited from (Grünewald, 2011). 
3.2.5 Co-immunoprecipitation (Co-IP) 
After transfection and overnight culture, cells grown on 10 cm plates were firstly 
washed using 5 ml ice cold PBS with protease inhibitor cocktail (1 tablet/50 ml, 
Roche), followed by adding 750 µl of RIPA buffer. Cells were collected using a cell 
scraper and incubated at 4oC on a wheel at a speed of 20 rpm for 30 min, and 
subsequently centrifuged at 13,000 rpm for 10 min. The supernatant was collected 
into a new tube. If the cell lysates were too viscous, due to the release of genomic 
DNA, lysates were sonicated for 10 s on ice. 50 µl of supernatant was taken out as a 
positive lysates control and preserved in an equal amount of Laemmli sample buffer 
(4% SDS, 20% glycerol, 100 mM Tris pH 6.8, and 0.2% bromophenol blue). The 
concentrations of protein lysates were determined by the Bradford assay, using Bio-
Rad DC protein assay kit, which were adjusted to 2 mg/ml with RIPA buffer.  1 ml 
protein lysates were incubated at 4oC with 2.4 µg of antibody used for 
immunoprecipitation for 2 hr to overnight. To capture the antigen/antibody, 20 µl of 
IgG-sepharose beads (100 µl beads in 300 µl PBS) was added to the lysates, and 
incubated for 1.5 hr on a roller. Then, beads were spun down by centrifugation at 4oC, 
13,000 rpm for 3 min and washed 5 times with RIPA buffer. The complex of 
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antigen/antibody was released from beads by adding 40 µl Laemmli sample buffer 
and incubated at 40oC for 10 min. This step causes the IgG heavy chain to move 
from 50 kDa to 140 kDa in an SDS-PAGE gel as compared to boiling the lysates. 
The supernatants were collected by centrifugation at 10,000 rpm for 3 min. 
3.3 Results 
3.3.1 Exogenous GPR50 and BACE1 co-localise in mammalian cell lines and 
primary neuronal cultures  
The subcellular localisation results in SH-SY5Y cells shown in chapter 2 indicate 
that GPR50 and BACE1 do not seem to have much overlap in expression. Briefly, 
GPR50 is mostly located in the external plasma membrane, whereas, BACE1 is 
mainly localised in diverse intracellular organelles, with a small proportion on the 
cell surface. From this observation, it is suggested that if the two proteins interact, 
the most likely area of co-localisation will be the plasma membrane. I investigated if 
GPR50 and BACE1 co-localise in SH-SY5Y cells, HEK293 cells and mouse primary 
hippocampal neurons.  
In double-transfected SH-SY5Y cells, GPR50 and BACE1 appeared to co-localise at 
the external compartments, the plasma membrane and the neurite extensions (Figure 
3.6). The ICA plots were skewed towards positive values for both red and green 
intensity pixels, indicating a dependent staining pattern of the two colours in the ROI. 
The scatter plot of red pixels versus green pixels showed with a positive correlation 
(Rr=0.425). The pseudocoloured PDM images exposed the exact sites where GPR50 
and BACE1 co-localised, as is shown by the yellow colour that the strongest co-
localisation occurs at the plasma membrane and the extended neurites. Mander’s 
overlap coefficient (R=1.046) reflected a strong overlapping between the localisation 
of the two proteins. Specifically, in this ROI, 99.7% of GPR50 shared its location 
with BACE1, and 98.6% of BACE1 shared its location with GPR50. These two co-
localisation figures were independent of the absolute intensity values of GPR50 and 
BACE1.  Finally, the ICQ value (ICQ=0.202) confirmed that the staining of the two 
colours was a significant dependent pattern (p<0.05). The co-localisation was 
moderate, as it is clearly seen that the region selected contained intracellular 
organelles with overexpressed BACE1, but lack of GPR50. Similar dependent 
pattern of red and green intensity pixels was observed in HEK293 cells with a strong 
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co-localisation of exogenous GPR50 and BACE1 at the plasma membrane (Figure 
3.7). 
Neuronal Gpr50 was reported to be expressed at the post-synaptic densities 
(Grunewald et al, 2009), and Bace1 was located at the synapse where APP cleavage 
takes place (Cao et al, 2012; Kandalepas et al, 2013). The co-localisation of 
exogenous GPR50 and BACE1 at neurites was more obviously seen in mouse 
primary hippocampal neurons (Figure 3.8), which was supported by a significant 
ICQ value (ICQ=0.222, p<0.05). The strongest co-localisation appeared at the 
neurite tips and dendritic spines (Figure 3.8, F1-3), similar to the co-localisation 
pattern of GPR50 and the neurite outgrowth inhibitor Nogo-A (Grunewald et al, 
2009).  
3.3.2 Endogenous GPR50 and BACE1 are co-localised in HEK293  
I further investigated whether endogenous GPR50 and BACE1 follow the co-
localisation pattern of their exogenous proteins. As SH-SY5Y cells do not express 
GPR50 endogenously and our GPR50 antibodies worked poorly in the detection of 
endogenous Gpr50 in mouse primary neuronal cultures, I performed this experiment 
in HEK293 cells. 
Of HEK293 cells, 1-10% expresses endogenous GPR50 at the cell surface, 
depending on the age of the cells (Grünewald, 2011). A moderate level of 
endogenous BACE1 was detected in the HEK293 cell line used, and its distribution 
pattern is similar to exogenous BACE1, with most of the protein located in the 
internal compartments and a small percentage at the plasma membrane. Co-
localisation of endogenous GPR50 and BACE1 was found at the plasma membrane 





Figure 3.6 Co-localisation of overexpressed GPR50 and BACE1 in SH-SY5Y cells. A) GPR50 (red), the white shut line indicated region of interest (ROI) that was 
analysed; B) BACE1 (green); C) merged photo of GPR50, BACE1 and DAPI; D) GPR50 ROI; E) BACE1 ROI; F) merged ROI; G) ICA plot of GPR50; H) ICA plot of 
BACE1; I) pixel scatter-plot of red intensities (GPR50) v.s. green intensities (BACE1); J) pseudocoloured PDM image with PDM scale bar: the hot yellow colour 
indicates a positive PDM value, representing the synchronisation between the two colours; K) positive PDM values resulting from both pixels above the mean; L) 
positive PDM values that have pixels in each channel which are both below the mean; M) ICA parameters. The PDM value is the product of the differences from 
the mean. For each pixel, PDM = (red intensity- mean red intensity)×(green intensity – mean green intensity). Rr: Pearson’s correlation coefficient; R: Mander’s 
overlap coefficient; ch1: channel 1 (GPR50); ch2: channel 2 (BACE1); ch1: ch2, the red: green pixel ratio; M1 and M2: Mander’s co-localisation coefficients for 
channel 1 and channel 2; ICQ: intensity correlation quotient; non-parametric sign test was used to test if ICQ was significantly different from 0 (random 
staining). Scale bar: 20 µm. Antibodies: GPR50 goat, BACE1 rabbit2. In total, six different ROIs from six cells were analysed to determine the co-localisation 
result, ICQ=0.237±0.028. 
 























Figure 3.7 Co-localisation of overexpressed GPR50 and BACE1 in HEK293 cells. A) GPR50 (red), the shut line indicated the ROI; B) BACE1 (green); C) merged 
photo of GPR50 and BACE1; D) GPR50 ROI; E) BACE1 ROI; F) merged ROI; G) ICA plot of GPR50; H) ICA plot of BACE1; I) scatter-plot of red intensities v.s. green 
intensities; J) pseudocoloured PDM image with PDM scale bar; K) positive PDM values resulting from both pixels above the mean; L) positive PDM values 
resulting from both pixels below the mean; M) ICA parameters. Scale bar: 50 µm. Antibodies: GPR50 goat, BACE1 rabbit2. In total, five different ROIs from five 


















Figure 3.8 Co-localisation of overexpressed GPR50 and BACE1 in mouse primary hippocampal neurons. A) GPR50 (red), the shut line indicated ROI; B) BACE1 
(green); C) merged photo of GPR50, BACE1 and DAPI; D) GPR50 ROI; E) BACE1 ROI; F) merged ROI, F1-3: enlarged areas; G) ICA plot of GPR50; H) ICA plot of 
BACE1; I) scatter-plot of red intensities v.s. green intensities; J) pseudocoloured PDM image with PDM scale bar; K) positive PDM values resulting from both 
pixels above the mean; L) positive PDM values resulting from both pixels below the mean; M) ICA parameters. Scale bar: 50 µm. Antibodies: GPR50 goat, BACE1 




Figure 3.9 Co-localisation of endogenous GPR50 and BACE1 in HEK293 cells. A) GPR50 
(red), the shut line indicated ROI; B) BACE1 (green); C) merged photo of GPR50, BACE1 and 
DAPI; D) GPR50 ROI; E) BACE1 ROI; F) merged ROI; G) ICA plot of GPR50; H) ICA plot of 
BACE1; I) scatter-plot of red intensities v.s. green intensities;  J) pseudocoloured PDM image 
with PDM scale bar; K) positive PDM values resulting from both pixels above the mean; L) 
positive PDM values resulting from both pixels below the mean; M) ICA parameters. 
Antibodies: GPR50 rabbit, BACE1 mouse. Scale bar: 50 µm. In total, six different ROIs from 
six cells were analysed to determine the co-localisation result, ICQ=0.199±0.038. 
3.3.3 Endogenous GPR50 is co-localised with cell-surface BACE1 
To confirm the co-localisation of GPR50 and BACE1 at the plasma membrane, I 
used a live cell staining technique to label BACE1 at the cell surface prior to 
permeabilisation of cells. GPR50 was detected in a second step after 
permeabilisation. An abundant pool of external BACE1 was detected in HEK293 
cells, which clearly lined along the cell surface (Figure 3.10), and much stronger than 
the punctate pattern in SH-SY5Y cells (Figure 2.12, 2.13). This also indicated that 











SY5Y cells. It seems that in HEK293 cells,  there were more cells singly labelled 
with GPR50 or surface BACE1 than cells that expressed both (Table 3.2), but there 
was strong co-localisation between the two in cells with both of them (Figure 3.11). 
 
Figure 3.10 Endogenous GPR50, cell surface BACE1 and total BACE1 in HEK293 cells. The 
circled area represented a cell labelled with both GPR50 and surface BACE1 (see Figure 
3.11). Antibodies: GPR50 rabbit (red), BACE1 goat (green) for surface BACE1, BACE1 mouse 
(purple) for total BACE1. 
Table 3.2 The expression pattern of GPR50 and cell-surface BACE1 in a group of cells 
  GPR50 surface BACE1 
Relicate A Total number 100 100 
Expressed in the same cells 40 28 
Expressed in different cells 60 72 
Relicate B* Total number 57 79 
Expressed in the same cells 27/47.4% 27/34.2% 
Expressed in different cells 30/52.6% 52/65.8% 
Relicate C Total number 100 100 
Expressed in the same cells 31 24 
Expressed in different cells 69 76 
* There were less than 100 cells expressed with surface BACE1 or GPR50 in 
total in this replicate 
In a single cell containing both GPR50 and surface BACE1 (Figure 3.11), the ICA 
plots for the two were both positively skewed, which meant that the staining of 
GPR50 and surface BACE1 were dependent on each other. The near to 1 Mander’s 
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overlap coefficients indicated that the location of GPR50 and surface BACE1 in this 
cell was almost identical. Moreover, a significant positive ICQ of 0.32 confirmed the 
correlation of the two staining patterns.  Importantly, the ICQ value of GPR50 and 
surface BACE1 was significantly larger than that of GPR50 and total BACE1 (see 
Figure 3.9, ICQtotal=0.199±0.038, ICQsurface=0.306±0.019, N=6, p<0.00039 by t-test). 
This may indicate that GPR50 is more correlated to the BACE1 pool in the plasma 
membrane. 
 
Figure 3.11 Co-localisation of GPR50 and cell surface BACE1 in a HEK293 cell 
endogenously expressed with both. A) ICA plot of GPR50 (red); B) ICA plot of cell surface 
BACE1 (green); C) scatter-plot of red intensities (GPR50) v.s. green intensities (cell surface 
BACE1); D) GPR50; E) cell surface BACE1; F) merged photo; G) pseudocoloured PDM image 
with PDM scale bar; H) positive PDM values resulting from both pixels above the mean; I) 
positive PDM values resulting from both pixels below the mean; J) ICA parameters. 
Antibodies: GPR50 rabbit, BACE1 goat. In total, six different ROIs from six cells were 
analysed to determine the co-localisation result, ICQ=0.306±0.019. 
3.3.4 Exogenous GPR50 and BACE1 are located in the same fractions by 
subcellular fractionation 
Following the ICC experiments, sucrose subcellular fractionation was performed to 
locate over-expressed GPR50 and BACE1 from double-transfected HEK293 cells, or 
endogenous Gpr50 and Bace1 from adult mouse brain. As GPR50 and BACE1co-
localised in certain compartments of cells, it was expected that the two proteins 
would co-fractionate from fractions containing the subcellular organelles where co-




3.3.4.1 Overexpressed GPR50 and BACE1 from HEK293 cells are located in the 
same fractions  
Exogenous GPR50 and BACE1 appeared to co-fractionate in the same fractions 
(Figure 3.12) including the plasma membrane (marked by VLA-2α), where by 
immunocytochemistry their co-localisation was found. Meanwhile, one must be 
cautious that some of the plasma membrane fractions also contained early endosomes 
(fraction 5-6, marked by EEA1), lysosomes (fraction 5-12, marked by lamp2b) and 
broken ER (fraction 10-12, marked by calreticulin). It has been reported that a 
proportion of overexpressed BACE1 was distributed in the early endosomes, which 
was diminished with the existence of RTN3 (Shi et al, 2009). In my results, BACE1 
was not predominantly present in the early endosomes when co-transfected with 
GPR50, but only in fractions 5 and 6 that contained both the early endosomes and the 
plasma membrane. The endogenous 23 kDa RTN3 which is known to be a BACE1 
activity inhibitor (Murayama et al, 2006), was also found in the same fractions in 
which both GPR50 and BACE1 were co-localised. 
 
Figure 3.12 Subcellular fractionation of protein lysates from HEK293 cells co-transfected 
with GPR50 and BACE1. VLA-2α, EEA1, LAMP2b, calreticulin and 58K Golgi are subcellular 
compartment markers for the plasma membrane (PM), the early endosomes (EE), the 
lysosomes, the ER, and the Golgi respectively. Antibodies GPR50 goat and BACE1 rabbit2 
were used. This experiment was successfully repeated once. 
3.3.4.2 Endogenous Gpr50 and Bace1 from adult mouse brain are located in the 
presynaptic fractions  
Next, I performed subcellular fractionation of wild-type adult mouse brain to further 
confirm the co-localisation of endogenous Gpr50 and Bace1 (Figure 3.13). Fractions 
99 
 
of the presynaptic terminals and postsynaptic densities (PSDs) were separated from 
synaptosomes, as indicated by markers synaptophysin and PSD-95 respectively. 
Presynaptic terminals are specialised structures that release neurotransmitters and 
form synapses with other cells, while the PSDs are in close proximity to the 
presynaptic active zone and organise the neurotransmitter receptors.  
The subcellular localisation of Gpr50 is reportedly enriched in PSDs of the mouse 
brain (Grunewald et al, 2012). I failed to replicate the result by the GPR50 goat 
antibody, probably due to the suboptimal quality of the second batch of this antibody. 
However, the GPR50 rabbit antibody detected several bands in the less insoluble 
PSDs (PSD1 and PSD2), but not in the fraction closer to the PSD core (PSD3). The 
positive control from E18 embryonic brain revealed that the 63 kDa band is likely to 
be the mouse Gpr50. The band was also present in the fraction of synaptic vesicles 
(LP2).  
 
Figure 3.13 The distribution of endogenous Gpr50 and Bace1 in adult mouse brain by 
subcellular fractionation. S1: homogenates after first spin (nuclei and large cellular debris 
were removed). S2: homogenates after second spin (most of nuclei and large cellular debris 
were pelleted). P2: crude synaptosome. P3: light membranes. LP1: synaptosomal 
membrane. LP1: LS2+LP2. LS2: synaptosomal cytosol. LP2: synaptic vesicles. PSD: post 
synaptic densities (PSD1: One-Triton, PSD2: Two-Triton, PSD3: One-Triton+Sarcosyl). PSD95: 
post synaptic marker. Synaptophysin: pre-synaptic marker. Embryo: homogenates of E18 
embryotic brain extracted with 1% CHAPS (positive control). BG: the positive control, 
representing over-expressed GPR50 and BACE1 that were double-transfected in HEK293 
cells.  Gpr50, mature Bace1 and immature Bace1 are indicated by green, pink and red 
arrows respectively. The asterisks indicate non-specific bands from the secondary antibody. 
Antibodies GPR50 rabbit and BACE1 rabbit2 were used. This experiment was successfully 
replicated once. 
Both mature Bace1 (65 kDa) and immature Bace1 (55 kDa), were present in multiple 
fractions, including the light membranes and ER-Golgi fractions, the normal sites 
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where BACE1 is expressed in mammalian cell lines, and synaptosomes, the location 
where BACE1 cleavage of APP, CHL1 and L1 (neural cell adhesion molecules) 
takes place (Zhou et al, 2012). There was a small portion of mature Bace1 located in 
the myelin layer, the formation of which is highly regulated by Bace1 substrate 
Neuregulin1 type III (Fleck et al, 2013; Taveggia et al, 2008) and which is also a 
potential novel site for Aβ peptide generation in the central nervous system (Skaper 
et al, 2009). Interestingly, Bace1 was enriched in the synaptosomal membrane (LP1) 
and synaptic vesicles (LP2), but very little Bace1 was detected in PSDs, which is in 
agreement with a previous study (Kandalepas et al, 2013). In addition, Bace1 was co-
fractionated with Gpr50 in the fraction of synaptic vesicles. 
This observation corresponds to the result that overexpressed GPR50 and BACE1 
co-localise at the axonal tips of primary neuronal cells. Similar results were observed 
in a second replicate of this experiment. 
3.3.5 Exogenous BACE1 is co-immunoprecipitated with GPR50 in 
mammalian cell lines 
To further confirm if the co-localisation of GPR50 and BACE1 indicates physical 
interaction between the two, co-immunoprecipitation experiments were performed. 
The antibodies used in this section are summarised in Table 3.1. Briefly, the size of 
human GPR50 protein is around 67 kDa. Two bands at 55 kDa and 65 kDa 
corresponding to immature BACE1 and mature BACE1 were detected by western 
blotting.  
In HEK293 cells, GPR50 was successfully immunoprecipitated by the GPR50 goat 
antibody from protein lysates with overexpressed GPR50. The immunoprecipitation 
of endogenous GPR50 was not detected possibly because the cell line used in this 
experiment was HEK293 of a young passage number (only 1% expressing 
endogenous GPR50).  No obvious endogenous BACE1 was detected either.  BACE1 
was co-immunoprecipitated with GPR50 only in protein lysates prepared from 
double-transfected cells (Figure 3.14.A). No signal of BACE1 was detected in 
control samples of untransfected cells, or cells singly transfected with GPR50 or 
BACE1 after co-immunoprecipitation. 
Overexpressed BACE1 was also co-immunoprecipitated with GPR50 in SH-SY5Y 
cells (Figure 3.14.B). This might indicate that overexpressed GPR50 is involved in 
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the function of BACE1 related to brain activities. However, this result was obtained 
from one test and was not repeated due to the poor quality of the second batch of 
GPR50 goat antibody and lack of time. 
In mouse neuroblastoma cell line N1E-115 cells, an increasing amount of BACE1 
was co-immunoprecipitated with the same amount of overexpressed GPR50 when 
the input of BACE1 was elevating (Figure 3.14.C). This experiment was replicated 
once and the same result was observed. These results indicate that the physical 
interaction between GPR50 and BACE1 is relatively stable. 
To further confirm the physical interaction between GPR50 and BACE1, the 
immunoprecipitation of BACE1 was also attempted in order to test if GPR50 was co-
immunoprecipitated. However, no BACE1 antibody pulled down BACE1 
successfully (date not shown), so this experiment was terminated. 
3.3.6 Endogenous BACE1 is co-immunoprecipitated with GPR50 in HEK293 
cells  
Next I tested whether endogenous GPR50 and BACE1 are physically associated by 
co-immunoprecipitation. HEK293 cells of high passage numbers were used to 
guarantee a detectable level of endogenous GPR50 (~10%), which was successfully 
pulled down by GPR50 goat antibody (Figure 3.15).  
The BACE1 mouse antibody detected two bands in protein lysates prepared from 
untransfected HEK293 cells: one at around 55 kDa for immature BACE1 and the 
other at 65 kDa for mature BACE1. The size of BACE1 that was co-
immunoprecipitated with GPR50 is 68 kDa, slightly larger than the mature BACE1 
detected in the lysates. I realised that this was a discrepancy between the sizes of 
proteins detected in the lysates and in the co-immunoprecipitated protein complex. 
Therefore the same membrane was stripped and re-probed with the BACE1 rabbit2 
antibody. There were extra bands exposed together with the two bands detected by 
the BACE1 mouse antibody, and one of them was at 68 kDa.  
It is known that BACE1 is highly glycosylated and can measure up to 75 kDa 
depending on the glycosylation system in specific cell lines (Tamagno et al, 2012). 
The 68 kDa band might be a more glycosylated mature BACE1, which is supposed 
to have higher β-secretase activity than the simply glycosylated BACE1 (Charlwood 
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et al, 2001). I also detected multiple bands of mature BACE1 in HEK293 cells after 
subcellular fractionation (see Chapter 5). This experiment was repeated and the same 
results were observed. Thus, my results reveal that at the endogenous level, GPR50 
is physically interacting with BACE1, and importantly with a more active form of 
this protease in HEK293 cells.  
 
Figure 3.14 Co-immunoprecipitation of overexpressed GPR50 and BACE1 in cultured cell 





Figure 3.15 Co-immunoprecipitation of endogenous GPR50 and BACE1 in HEK293 cells. NS: 
unspecific band. WB: western blotting; IP: immunoprecipitation. P69 and p73 are passage 
numbers of HEK293 cells, here representing two independent replicates (run on the same 
gel) of this experiment. 
3.4 Discussion 
In this chapter, I have shown that GPR50 and BACE1 were co-localised and co-
fractionated in cells at both exogenous level and endogenous level. A sub-pool of 
endogenous BACE1 was present at the plasma membrane of HEK293 cells, and it 
co-localised with endogenous GPR50 in cells that expressed both. The neuronal 
GPR50 and BACE1 were co-localised at the neurites in SH-SY5Y cells and primary 
hippocampal neurons. Co-immunoprecipitation studies further confirmed the 
physical interaction between the two proteins. At the endogenous level, GPR50 was 
associated with a more mature form of BACE1, strengthening the hypothesis that 
GPR50 is involved in the regulation of BACE1 activity. However, it must be noted 
that some of the experiments need more replicates to draw a robust conclusion (i.e. 
the co-immunoprecipitation of GPR50 and BACE1 in SH-SY5Y cells). A reverse co-
immunoprecipation (pull down BACE1 instead) should also be performed when a 




3.4.1 The interaction between GPR50 and BACE1 
The co-localisation of GPR50 and BACE1 occurred at cell external compartments, 
including the plasma membrane, the neurites and the filopodia-like structures in 
different cell lines.   
GPR50 was able to increase filopodia and lamellipodia-like structures in 
Neuroscreen-1 cells and primary cultured neurons, indicating that GPR50 might be 
involved in the activation of actin dynamics by GTPases Rho/Rac/Cdc42 
(Grünewald, 2011). GPR50 was also shown to attenuate the effect of neurite 
outgrowth inhibitor Nogo-A, supporting a role of GPR50 in neuronal development 
(Grunewald et al, 2009). GTPases RhoA and Rac1 are molecules affecting Nogo 
signalling and mediating the growth inhibiting characteristics of Nogo-A (Gross et al, 
2007; Niederost et al, 2002). Therefore, GPR50 may play a part in the GTPase 
signalling pathway. Recent studies revealed that BACE1 is the major sheddase of 
molecules involved in neurite outgrowth (SEZ6, L1, LRRN1, neurotrimin, CHL1, 
brain EGF-repeat containing transmembrane protein, voltage-gated sodium channels 
β2 subunit) and synapse formation (neurexin-1a and neuroligins) (Kim et al, 2007; 
Kuhn et al, 2012). Interestingly, inhibition of RhoA downstream effector ROCK2 
negatively regulated BACE1 cleavage of APP by promoting the transportation of 
BACE1 from the early endosomes to the lysosomes (Herskowitz et al, 2013). 
Another GTPase Rab11 positively mediated the axonal sorting of BACE1 to 
presynaptic terminals in hippocampal neurons (Buggia-Prevot et al, 2014). The co-
localisation sites of GPR50 and BACE1 seem to locate at the areas where BACE1 
cleavage is likely to take place. In addition, GPR50 overexpression up-regulated 
BACE1 activity in HEK293 cells (Grünewald, 2011), which indicates that the 
interaction of GPR50 and BACE1 may be closely related to the functional cleavage 
by BACE1 signalled by GTPase system. It is worth mentioning that the intervention 
of GPR50 in BACE1 activity is not necessarily restricted to APP cleavage. My co-
localisation results suggest that GPR50 may play a signalling role in the diverse 
function of BACE1 as a protease, such as the above mentioned performance in 
shedding of neurite outgrowth factors. 
Co-immunoprecipitation experiments further confirmed that GPR50 was physically 
associated with BACE1. In previous studies, both mature and immature BACE1 
were found co-immunoprecipiated with another factor.  Interacting with mature 
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BACE1 may affect the trafficking system of this enzyme, and ultimately regulate its 
activity levels, for example sortilin (Finan et al, 2011; Murayama et al, 2006). 
Whereas, interaction with immature BACE1 might imply a role of the interactor in 
the maturation process of BACE1, such as previously reported presenilin-1 and prion 
protein (Griffiths et al, 2011; Hebert et al, 2003). The mature form of endogenous 
BACE1 could be pulled down together with endogenous GPR50 in HEK293 cells. 
This result indicates that GPR50 is likely to play a direct part in BACE1 function 
after maturation. Indeed, GPR50 overexpression significantly regulated endogenous 
BACE1 activity in HEK293 cells (Grünewald, 2011). 
Importantly, the physical interaction between GPR50 and BACE1 can be direct or 
indirect, as the pulled down protein complex by GPR50 antibody might consist of a 
group of molecules that link GPR50 to BACE1. The regulation of BACE1 is known 
to be involved with a complicated network of multiple factors, and the yeast two-
hybrid studies revealed several co-interactors of GPR50 and BACE1, for example, 
the reticulon proteins. Whether GPR50 is directly affecting BACE1 function or 
through sending regulative signals to their co-interactors is very interesting and needs 
further investigation.  Experiments such as FRET/BRET may help to answer this 
question. It is also worthwhile to study the effect of GPR50 knockdown or 
variation/mutation on the localisation and enzymatic activity level of BACE1. 
3.4.2 Further experiments 
Results in this chapter preliminarily confirm that there is physical interaction 
between GPR50 and BACE1. The co-localisation sites of the two include the 
location where BACE1 cleaves its substrates (such as neurites), and this may suggest 
that GPR50 is involved in the cleavage process of BACE1. It is already known that 
GPR50 regulates endogenous BACE1 levels in HEK293 cells (see chapter 2). The 
next step is to study if this outcome can also be verified in neuronal cells, in which 
intense co-localisation of GPR50 and BACE1 is found at the neurites. The neurons 
are also the cell origins where native β-secretase cleavage takes place in brain. 








4 The effect of GPR50 over-
expression on β-secretase 





In previous chapters, it was suggested that GPR50 has a functional connection with 
BACE1, as it is involved in the modulation of BACE1 expression (see chapter 2). 
Further, a physical association between GPR50 and BACE1 was identified (see 
chapter 3). These preliminary findings have strengthened the link of GPR50 to 
BACE1 and brain illnesses in which BACE1 acts as a key enzyme.  
Importantly, neurodegeneration is commonly seen in the brains with mental illnesses. 
Therefore, to investigate the pathology of these disorders, considerable studies have 
been carried out on the function of risk factors in neuronal cells. The neuronal 
functions of GPR50 have been suggested in several studies, including neuronal 
development and neurotransmitter signalling (Grunewald et al, 2009; Grunewald et 
al, 2012). As to BACE1, its function is also closely related to its neuronal activity, 
due to the diversity of β-secretase substrates in neurons. In chapter 3, it was revealed 
that exogenous GPR50 and BACE1 co-localised extensively at the neurites of SH-
SY5Y cells and primary hippocampal neurons, indicating a functional interaction at 
an important site for BACE1 activity. Additionally, GPR50 and BACE1 have 
overlapping roles in neuronal functioning, such as in promoting neurite extension 
(Grunewald et al, 2009; Miyazaki et al, 2007). Hence, in this chapter, I sought to 
further investigate the potential of GPR50 in the regulation of neuronal β-secretase 
activity. 
4.1.1 The neuronal function of GPR50 
As introduced earlier, the neuronal function of GPR50 was initially proposed by a 
yeast two-hybrid study, which identified multiple interactors of GPR50 with a 
neuron-related role. Among these were ABCA2, CDH8, PCDH9, PAX6 and 
shootin1, proteins known to be important for neurogenesis (Asahina et al, 2012; 
Broccardo et al, 2006; Carbe et al, 2013; Garel et al, 2000; Toriyama et al, 2010); 
and RTN3, RTN4 (Nogo), proteins that are relevant to neuronal damage (Karnezis et 
al, 2004; Shi et al, 2013). In particular, GPR50 was able to attenuate the inhibitory 
actions on neurite outgrowth by Nogo-A (Grunewald et al, 2009). Further, the 
overexpression of GPR50 alone was sufficient to induce an increase in the neurite 
length (Grunewald et al, 2009).  Hence, GPR50 appears to be a positive regulator 
during the elongation process of neurons. 
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The expression profile of GPR50 in the developing mouse brain also indicates a role 
during the neuronal development. Gpr50 mRNA was detected from E13, reached a 
peak at E18 and increased again at adolescent week 5 (Grunewald et al, 2012). As 
E18 is a developmental stage important for axon growth/guidance and synapse 
formation, the up-regulation of Gpr50 expression at this time point agrees with a role 
in neurogenesis. This speculation was supported by the finding that the mRNA levels 
of Gpr50 and Cdh8 were correlated at E18, as embryonic Cdh8 expression has been 
suggested in the neuromeric organisation of the early embryonic CNS and in the 
brain morphogenesis (Korematsu & Redies, 1997a; Korematsu & Redies, 1997b). An 
increase of Gpr50 mRNA level at week 5 is indicative of its potential during the later 
developmental stage, possibly in the neuron maturation and maintenance. 
Furthermore, GPR50 is predominantly expressed in NeuN-positive postmitotic 
neurons, but not in GFAP-positive astrocytes or O4-positive oligodendrocytes 
(Grunewald et al, 2012).  Thus, further research on GPR50 expression in neurons is 
essential to clarify its function, as well as to understand its interaction with the key 
molecules implicated in the neuronal development. 
4.1.2 β-secretase activity in neuronal cells 
Primary neuronal cultures and neuronal cell lines derived from human and rodents 
represent a useful tool to study neuronal factors and their effects on the basic 
physiological properties of neurons. As introduced in chapter 2, BACE1 is widely 
expressed in multiple tissues, but β-secretase activity is mostly concentrated in the 
brain. Neurons are the major source of endogenous BACE1 expression, even though 
there are low levels of BACE1 detected in microglia and astrocytes, normally under 
activated conditions, such as inflammation (Bourne et al, 2007; Zhao et al, 2011). 
In addition to APP, there are over 60 putative substrates of BACE1 identified 
through the technique of quantitative proteomics/mass spectrometry (Hemming et al, 
2009). The majority of these molecules are type I transmembrane proteins. Yet the 
shedding of GPI-linked proteins (i.e. ephrin-A5) and type II membrane proteins (i.e. 
Golgi integral membrane protein 4) by BACE1 were also validated.  Members of 
these putative substrates were divided into several functional categories, with half of 
them involved in contact-dependent intercellular communication. Substrates of this 
category include proteins implicated in neurodevelopment and migration, immune 
function, and cell fate determination. Other putative substrates have been described 
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to function as peptide and lipoprotein receptors, cellular adhesion molecules, 
proteases, and in intracellular protein trafficking. The discovery of diverse BACE1 
substrates has broadened the role of β-secretase activity in many biological processes. 
In particular, among the characterised molecules as BACE1 shedding target, some of 
them claim significant neuronal functions with high expression levels in neurons. For 
example, cleavage of Neuregulin 1 type III precursor protein by endogenous Bace1 
in primary neurons releases the EGF-like domain β-sEGF, which mediates the 
activation of ErbB receptors and triggers PI3 kinase downstream signalling (Fleck et 
al, 2013). BACE1 activity in neurons also regulates the release of neural adhesion 
molecules L1, CHL1 and contactin-2 from cell surface, which regulates axon 
guidance through interaction with other molecules and contributes to myelination 
(Gautam et al, 2014; Kuhn et al, 2012). Elsewhere, BACE1 shedding of neuronal 
signalling molecule Jagged1 controls the balance between astrogenesis and 
neurogenesis via Notch signalling during the early developmental stages of mouse 
hippocampus (Hu et al, 2013a). Moreover, BACE1, by cleaving β2 subunit of 
voltage-gated sodium channel (Nav1), modulates Nav1 α-subunit levels and controls 
the membrane excitability of hippocampal neurons (Kim et al, 2007).  
Thus, apart from the initiation of Aβ amyloid deposition, β-secretase activity in 
neurons induces pleiotropic neuronal effects, including myelination, cell adhesion, 
neurite outgrowth, axon guidance, cell signalling, and cognitive functions (Chen et al, 
2012a; Corbett et al, 2013; Willem et al, 2006; Zhou et al, 2012). As the biological 
function of BACE1 is far beyond its role in Aβ generation, one must be careful to 
predict the adverse events upon regulation of BACE1 activity in brain, which is 
likely to be achieved through understanding the function of specific substrates and 
regulators. In addition, the findings of BACE1 shedding of those cell surface proteins 
may clarify the dispute on the cellular location where BACE1 cleavage takes place. 
While mounting evidence showed that BACE1 processes APP in the early 
endosomes (Das et al, 2013; Sannerud et al, 2011), the localisation of other BACE1 
substrates at the cell surface, especially in the presynaptic sites (Alberi et al, 2013; 
Leshchyns'ka et al, 2006; Zhong et al, 2008), may support the BACE1 shedding in 




4.1.3 The role of GPR50 in regulating BACE1 activity 
GPR50 is implicated in the function of BACE1, as it has a potential in the regulation 
of BACE1 activity (Grünewald, 2011). It has been shown that in HEK293 cells, 
overexpression of GPR50 significantly increased BACE1 activity compared with the 
empty vector control (Figure 4.1), whereas the mental disorder related GPR50del 
showed no significant effect. The reticulon proteins RTN3, Nogo-A and Nogo-C are 
physical interactors of GPR50 (Grünewald, 2011). While RTN3 and Nogo-C reduced 
BACE1 activity in HEK293 cells, Nogo-A overexpression had no effects 
(Grünewald, 2011). Further, no difference in BACE1 activity has been found when 
HEK293 cells were co-transfected with GPR50 or GPR50del and RTN3 or Nogo-C 
compared to the control. GPR50 thus appears to partially counteract the inhibiting 
effects of RTN3 and Nogo-C on BACE1 activity (Grünewald, 2011). 
 
Figure 4.1 The effects of overexpressed GPR50 or GPR50del on BACE1 activity in HEK293 
cells. The figure was adapted from (Grünewald, 2011). 
4.1.4 Introduction to experiments 
GPR50 immunoreactivity has been detected in the neurodegenerative cells of post-
mortem AD brain (Hamouda et al, 2007). Meanwhile, the yeast two-hybrid study by 
Grünewald and colleagues have revealed that GPR50 interacts with BACE1 activity 
regulators (RTN3, Nogo, SNX6, ABCA2, and CDH8) (Grunewald et al, 2009). With 
my previous findings confirming that GPR50 and BACE1 can physically associate 
(chapter 3), I hypothesised that GPR50 is an effector of BACE1 activity through 
protein-protein interaction, thus an alteration of their interaction induced by certain 
factors, such as an abrupt increase of GPR50 expression, may indicate a state of 
disease, including brain diseases. 
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Specifically, I wanted to further investigate if the regulatory effects of 
GPR50/GPR50del on BACE1 activity in HEK293 cells also take place in neuronal 
cells, which are more relevant to the function of BACE1 in mental illnesses. 
Interestingly, GPR50 co-localised with BACE1 at the cell surface and neurites, as 
was shown in chapter 3. Also, endogenous Gpr50 and Bace1 were co-fractionated in 
the presynaptic vesicles (LP2 fraction of mouse brain). GPR50 may have an 
important role in the regulation of neuronal β-secretase activity, and the aim of this 
chapter is to investigate this hypothesis. Briefly, I measured the endogenous β-
secretase activity in the mouse primary cortical neurons upon the transfection of 
GPR50 or GPR50del, the risk variant in the GPR50 C-terminal domain associated 
with bipolar disorder and schizophrenia. At the same time, the knockdown of 
endogenous Gpr50 in neurons was attempted as a loss-of-function technique, in order 
to better understand its effect on Bace1 activity.  
4.2 Materials and methods 
The main methods have been introduced in chapter 2 and 3. The following 
paragraphs describe additional techniques that were mainly used for experiments in 
this chapter. 
4.2.1 Primary neuronal culture 
Primary neuronal cultures were prepared from embryonic day 18 (E18) C57BL/6 
mice (purchased from Biomedical Research Resources Unit, Western General 
Hospital, Edinburgh). See 2.2.2 for detailed protocol of dissection and neuron 
preparation. Neurons were isolated from the cortex and 5×106 cells/well were seeded 
on poly-D-lysine (Sigma-Aldrich, St. Louis, USA) coated 6-well plates and cultured 
in 4 ml neurobasal medium supplemented with 2% B-27 and 1% GlutaMaxTM for 3 
days-in-vitro (DIV3). Cultures were maintained in a humidified environment at 37°C 
with 5% CO2.  On DIV3, neurons were transfected by Lipofectamine 2000 and left 
for 24 hr post-transfection (see 2.2.4). On the next day, cells were washed with PBS 
and collected in fresh warm neurobasal medium. For each condition, 2×106 cells 
were used for β-secretase activity assay and the rest of the cells were subjected to 
total RNA extraction. Real-time qPCR was performed to confirm the successful 




4.2.2 β-secretase activity assay 
The β-secretase activity assay kit was provided by Abcam (ab65357). The assay 
makes use of a β-secretase-specific peptide conjugated to two reporter molecules 
EDANS and DABCYL. In the uncleaved form, the fluorescent emissions from 
EDANS are quenched by the DABCYL moiety because of their physical proximity. 
Cleavage of the peptide by β-secretase separates EDANS and DABCYL leading to 
the release of a fluorescent signal. The level of β-secretase activity in samples is 
proportional to the level of fluorescence intensity detected. 
On DIV3, neurons were transfected with equal amounts of pDEST40 (p40)/GPR50-
pDEST40 (GPR50)/GPR50del-pDEST40 (GPR50del) by Lipofectamine 2000 for 4 
hr, and then cultured at 37°C overnight for 24 hr. The neurons were washed with ice 
cold PBS, and scraped in fresh pre-warmed neurobasal media. Equal number of cells 
was counted using a cell counter, collected and re-suspended in 170 µl chilled 
extraction buffer (included in the kit). Cell lysates were placed on ice for 10 min and 
then centrifuged at 10,000×g for 5 min. The supernatant was collected in a new 
Eppendorf tube. For each condition, 50 μl lysate, 50 μl reaction buffer and 2 μl β-
secretase substrate were added to a 96-well Costar black plate in duplicate (Table 
4.1). The controls were prepared for each biological replicate, including: 1) 
background control, which used extraction buffer instead of cell lysates; no substrate 
control for each condition, the sample of which only contained cell lysates; 2) 
positive control, containing active recombinant BACE1 enzyme plus extraction 
buffer; 3) negative control, which added BACE1 inhibitor to positive controls (Table 
4.1). The mixture was then incubated in dark at 37ºC for 2 hr. Absorbance readings 
were performed in the EnVision multilabel plate reader (PerkinElmer) with 
excitation wavelength 340 nm and emission wavelength 495 nm. The absolute 
BACE1 activity levels were sample readings subtracted from their respective “no 
substrate” controls. The relative BACE1 activity levels were normalised against 
those in p40 (empty vector) transfected cells. The mean differences in relative 





Table 4.1 Sample preparation of β-secretase activity assay 
Background control 50 µl extraction buffer 
 
+50 µl reaction buffer 




50 µl extraction buffer+ 1.5 µl 
β-secretase+1.5 µl inhibitor 
Negative control: 
untransfected sample cells+inhibitor 50 µl lysates +1.5 µl inhibitor 
Positive control: 
β-secretase 
50 µl extraction buffer+ 1.5 µl 
β-secretase 
Positive control: 
untransfected  sample cells 50 µl lysates 
Samples 
p40 
50 µl lysates, duplicate 
+50 µl reaction buffer 




No substrate control 50 µl lysates +50 µl reaction buffer  
4.2.3 Knockdown of endogenous Gpr50 in primary cortical neurons 
Three different 29-mer shRNA constructs targeting human/mouse GPR50 coding 
sequence in an untagged pRS vector were purchased from Origene (TR312642). The 
shRNA sequences are: sh61 (5’-CTCGCACCTACACCTGCATCTTCAACTAT-3’), 
sh62 (5’-TTTCTAACCATGTTTGTGATCTTCCTCCT-3’), and sh63 (5’-
ATCAACCGTTACTGCTACATCTGCCACAG-3’).  A 29-mer scrambled shRNA 
cassette in the pRS vector was used as the control. The plasmids were isolated from 
E. coli DH10B and extracted with Qiagen Endofree maxiprep kits according to the 
manufacturer’s instructions. For each transfection in 6-well plates, 30 µg shRNA 
vectors (6 µl) were used. Other steps of transfection were carried out according to 
2.2.4.  Real-time quantitative PCR (qPCR, see 2.2.8) was performed to confirm the 
successful knockdown by Gpr50 shRNAs. 
4.3 Results 
Overexpressed GPR50 has been found to up-regulate BACE1 activity in HEK293 
cells (Grünewald, 2011), and my previous results showed a promising interaction 
between GPR50 and BACE1 at the endogenous level (see chapter 2). Considering 
that the regulation of BACE1 activity is most closely related to the brain function, I 
wanted to further investigate whether GPR50/GPR50del/deficient Gpr50 has effects 
on the activity levels of β-secretase in neurons. Mouse primary cortical neurons were 
used for this experiment, in which endogenous β-secretase activity has been detected 
for Aβ generation (Kao et al, 2004) and ectodomain shedding of neural cell adhesion 
molecules (Gautam et al, 2014). 
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4.3.1 Optimisation of transfection efficiency in SH-SY5Y cells and primary 
cortical neurons 
High transfection efficiency in cells is crucial to study the possible effect of 
overexpressed GPR50 on β-secretase activity. Different transfection regents were 
tested including Lipofectamine 2000 (Invitrogen), HappyFect (Tecrea), Nucleofector 
solution V (Lonza), Ingenio electroporation kit (Mirus) and TransIT-Neural® 
transfection reagent (Mirus). Cells were plated onto coverslips in 12-well plates, and 
transfected with GPR50-p40 (untagged). Cell viability was assessed by comparison 
with untransfected controls. Immunocytochemistry was carried out to calculate 
transfection efficiency by labelling cells with the GPR50 goat antibody. Transfection 
results using different regents in SH-SY5Y cells and primary cortical neurons are 
summarised in Table 4.2.  It is shown that Lipofectamine 2000 was the most efficient 
transfection regent and retained the highest cell viability among all tested methods in 
both cell lines. Transfection efficiency was further optimised in primary cortical 
neurons by adjusting the amount and proportion of plasmid and Lipofectamine 2000 
(Table 4.3). The number of neurons that were plated into culture wells was also 
optimised to guarantee neuron viability after transfection. The optimal input was 2 
µg plasmid/4 µl Lipofectamine 2000 (1:2) for 2×106 neurons in a well surface area of 
4 cm2 (12-well plate). In later experiments, 5×106 neurons were plated in 6-well 
plates (surface area 10 cm2), and a combination of 5 µg plasmid/10 µl Lipofectamine 
2000 was used for transfection to retain the optimised proportion of culture area: cell 
number: DNA amount: transfection reagent amount. 
Table 4.2 Test of different transfection regents in SH-SY5Y cells and primary cortical neurons 
 SH-SY5Y (1×105) Primary cortical neurons (2×106) 
Reagent Cell viability Transfection efficiency Cell viability Transfection efficiency 
Lipofectamine 2000 +++ 20-30% ++ 4.9%-9.3% 
HappyFect +++ 5-15% - NA 
Nucleofector solution V ++ 6.2% NA NA 
Ingenio electroporation  ++ 15.6% + 0% 
TransIT-Neural® NA NA +++ 0% 




Table 4.3 Transfection primary cortical neurons with Lipofectamine 2000 
Plasmid/µg Lipofectamine/µl Cell viability Transfection efficiency 
1 2 ++ 0% 
2 2 ++ <1% 
4 2 ++ 4.90% 
1 4 ++ 0% 
2 4 ++ 8.42% 
4 4 ++ 7.26% 
1 8 ++ 0% 
2 8 + 3.37% 
4 8 + 9.29% 
++: small percentage of cell death, +: half cells died. 
2×106 neurons were used in each test. 
4.3.2 Detection of Bace1/BACE1 activity levels in mouse primary cortical 
neurons and human neuroblastoma cell line SH-SY5Y  
The kit for β-secretase activity assay (Fluorometric) is commercially available 
(Abcam, ab65357) and has been described in use for β-secretase activity in human 
HEK293 cells (Grünewald, 2011), rat primary hippocampal neurons (Cui et al, 2011) 
and mouse cortex/hippocampus tissues (Barbero-Camps et al, 2013; Hook et al, 2011; 
Wen et al, 2011). Here, I sought to validate the application of this kit in mouse 
primary cortical neurons and human neuroblastoma SH-SY5Y cells. 
The absolute β-secretase activity levels of 1.5 µl recombinant BACE1 enzyme, 
5×105 primary cortical neurons and 5×105 SH-SY5Y cells were within a range of 
210000-260000 fluorescent units (Figure 4.2). These readings were equivalent to 
those measured for around 1×106 HEK293 cells (Grünewald, 2011). Adding 1.5 µl 
inhibitor to the three aforementioned enzyme sources of β-secretase resulted in a 
reduction of 45.0%, 14.3% and 2.0% in the florescence levels respectively. After 
consulting the manufacturers of the β-secretase activity kit, these numbers were 
deemed to be a sufficient indication that the kit was working. This meant that the 
Bace1 activity in primary cortical neurons could be diminished by the inhibitor 
provided, which indicated that there was a certain level of active β-secretase present 
in neurons. This scale of inhibition in neurons was comparable to that in HEK293 
cells (Grünewald, 2011). However, the inhibitor almost failed to suppress the 
florescence levels in SH-SY5Y cells, implying that even though there was 
endogenous BACE1 mRNA detected in this cell line (see chapter 2), its protein form 
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was not fully active. A partial explanation of this may be that the major form of 
endogenous BACE1 protein in SH-SY5Y cells is an intermediate product of the full-
length BACE1 before maturation, which has been reported previously (Costantini et 
al, 2007; Ko & Puglielli, 2009). Therefore, in the following experiments, only 
primary cortical neurons were used to assess the effect of GPR50/GPR50del 
overexpression and Gpr50 knockdown on β-secretase activity levels. 
 
Figure 4.2 The test of endogenous β-secretase activity levels in B) primary cortical neurons 
and C) SH-SY5Y cells, compared with A) the positive control of recombinant β-secretase. 
This experiment was performed twice. The absolute fluorescent unit here represents an 
empirical expression of fluorescence activity, commonly given in terms of arbitrary units 
proportional to detector response  (WHO, 2006). 
4.3.3 Optimisation of β-secretase activity assay kit in primary neuronal 
cultures 
In order to identify the effective detection range of β-secretase activity levels, the 
BACE1 positive control was titrated (Figure 4.3.A). It was found that the absolute 
fluorescent units fell into the exponential phase of detection by using 0.1-2.5µl 
recombinant BACE1 enzyme. Higher input was not tested because of the limited 
amount of enzyme provided. As the background reading is high (around 100000) due 
to the natural properties of such fluorescence quenching assay, I sought to set the 
valid range of fluorescent readings to 150000-300000. Then I tested the minimum 
cell input for primary cortical neurons that could yield a reading between the range 
(Figure 4.3.B), within the exponential phase of detection. This set a minimum cell 
number of 1.5×105 for primary neurons. As the “no-substrate” control also generated 
a value of 60000-80000, the cell number needed to be increased to a level that 
A B C 
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obviously exceeded that value. Finally, a number of 5×105 that generated a value of 
200000-300000 was used in the following experiments. 
 
Figure 4.3 The titration of β-secretase activity detection. A) The experiment to ensure the 
reading of β-secretase activity was located within an interval of sensitivity for detection. B) 
The examination of cell input for primary cortical neurons in β-secretase activity assay. 
4.3.4 Is Bace1 activity regulated by GPR50 overexpression? 
For protein overexpression, an equal amount of GPR50 and GPR50del was 
transfected in DIV3 primary cortical neurons, and pDEST40 was used as control. 
The total RNA was extracted from neurons that grew in the same pool as the neurons 
that were used for activity assay and qPCR was carried out to confirm the relative 
mRNA expression levels of GPR50/GPR50del/Gpr50 against the controls. As is 
shown in Figure 4.4, there was a low level of endogenous Gpr50 expressed in mouse 
primary cortical neurons, which is in line with previous findings (Grunewald et al, 
2009; Grunewald et al, 2012). It has been reported that endogenous Gpr50 mRNA in 
mouse brain was robustly expressed at E18 (half a day before birth), but its level 
decreased after birth (Grunewald et al, 2012). The GPR50 rabbit antibody did detect 
endogenous Gpr50 protein from mouse brains of E18 and P0 (the day of birth) (see 
chapter 2, Figure 2.8).  
Five independent replicates were performed for this experiment. GPR50 and 
GPR50del were successfully transfected in all replicates. The absolute Bace1 activity 
readings were normalised against p40 and evaluated by two-tailed paired t-test. No 
significant difference was identified with GPR50 overexpression (p=0.98 >0.05), but 
there was a trend of decrease in the Bace1 activity level observed with GPR50del-
transfected neurons (7.9% decrease, p=0.079<0.1), compared with the control. 
Interestingly, there was a significant loss of Bace1 activity in GPR50del-
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overexpressed neurons compared with GPR50-overexpressed neurons (8.1% 
decrease, p=0.021<0.05). 
 
Figure 4.4 Effects of GPR50/GPR50del overexpression on Bace1 activity in mouse primary 
cortical neurons. A) Normalised Bace1 activity in primary neurons transfected with 
pDEST40 (p40), GPR50 and GPR50del. N=5, the statistical analysis of significance was 
examined by paired Student’s t-test. B) Endogenous Gpr50 mRNA levels in neurons 
transfected with p40, GPR50 and GPR50del. These neurons were grown in the same pool as 
those used for activity assay. Hydroxymethylbilane synthase (Hmbs) was used as the 
housekeeping gene for equal loading control. The clean negative control (No transcriptase 
control) indicated that there was no contamination during the processes of total RNA 
extraction and cDNA synthesis. 
4.3.5 Is Bace1 activity regulated by Gpr50 knockdown? 
In order to assess β-secretase activity in a Gpr50 loss-of-function system, three 29-
mer shRNAs (shRNA61, 62, 63) targeting Gpr50 mRNA were transfected singly or 
jointly to reduce the endogenous expression level of Gpr50 in mouse primary cortical 
neurons (see 3.2.2). qPCR was performed for the detection of Gpr50 knockdown. As 
is shown in Figure 4.5.B, all the three shRNA constructs successfully diminished the 
mRNA levels of endogenous Gpr50 in 5×106 primary cortical neurons. ShRNA61, 62 
and 63 decreased Gpr50 level by 89.0%, 98.4% and 84.9% respectively. Thus, in 
later experiments, 30 µg shRNA62 or a mixture of the three shRNAs (10 µg 
shRNA61+10 µg shRNA62+10 µg shRNA63, 1/3 for each construct) were applied to 
obtain optimal knockdown result. The expression of human GPR50 plasmid in 
primary neurons was the positive control, which also indicated a successful 




Five independent replicates for the determination of β-secretase activity in Gpr50 
deficient neurons were performed. Unfortunately, the detection of endogenous Gpr50 
knockdown ended up unsuccessful in these replicates (Figure 4.6). The cell number 
of neurons in each culture well (5×106) and the transfection mixture proportion (30 
µg shRNA construct/10 µl Lipofectamine 2000) were identical throughout the 
experiment. However, while all the neurons (5×106) in the initial knockdown test 
(Figure 4.5) were used for measuring Gpr50 mRNA levels by qPCR, the neurons 
used for the following five replicates were split into two portions, 2×106 for the 
activity assay and around 3×106 for the qPCR experiment. It is possible that the 
Gpr50 mRNA expression can only be detected when sufficient neurons were 
harvested, 5×106 in this case. Indeed, from Figure 4.6, it is shown that the 
endogenous Gpr50 level was hardly detected in most replicates. Hence, a possible 
reason for the failure of Gpr50 knockdown is that the cell number used for mRNA 
detection was inadequate. In fact, it is not known whether the knockdown was 
actually not achieved or the detection of a successful knockdown failed. As it could 
not be guaranteed that the primary neurons had Gpr50 deficiency, the Bace1 activity 
assay was not analysed in cells that were transfected with scramble, shRNA62 or 
shRNA61+62+63. Further optimisation was not performed due to lack of time. 
 
Figure 4.5 The test of endogenous Gpr50 knockdown in mouse primary cortical neurons. 
A) ShRNA61, 62 or 63 targeting Gpr50 were transfected singly in mouse primary cortical 
neurons. Real-time qPCR was performed for the detection of Gpr50 mRNA. Hmbs was used 
as the housekeeping gene for the loading control. The adjacent lane, on the left of each 
lane with a positive band, was its no-transcriptase negative control. The GRP50 plasmid was 
transfected for the detection of successful transfection. The protein lysates of E18 mouse 
brain was used as the positive control for the detection of endogenous mouse Gpr50. B) 





Figure 4.6 The unsuccessful knockdown of endogenous Gpr50 in mouse primary cortical 
neurons. Scramble, shRNA62, shRNA61+62+63 were transfected in mouse primary cortical 
neurons. Real-time qPCR was performed for the detection of Gpr50 mRNA. Hmbs was used 
as the housekeeping gene for the loading control. 
4.4 Discussion 
In this chapter, the potential of Gpr50 in regulating endogenous β-secretase activity 
in neuronal cells was investigated. The β-secretase activity assay in neuroblastoma 
cell line SH-SY5Y was terminated because endogenous BACE1 activity was not 
detected. In mouse primary cortical neurons, no significant alteration of Bace1 
activity level was found upon GPR50 overexpression. However, GPR50del 
overexpression resulted in a trend of decline in Bace1 activity level compared with 
the empty vector control (p=0.079). Importantly, Bace1 activity level in primary 
neurons transfected with GPR50del was significantly lower (8.1%) than those 
transfected with GPR50 (p=0.021). Therefore, contrary to the up-regulation effect by 
GPR50, mental disorder-related GPR50del in neuronal cells appears to have an 
inhibitory effect on BACE1 functions, and this might indicate a disruption of the 
normal function exhibited by GPR50. Further functional studies (i.e. analysing 
specific BACE1 substrates) need to be carried out to confirm the consequence of 
GPR50 deletion/SNP on its general function, as well as the impact on β-secretase 
activity regulation. 
4.4.1 Endogenous BACE1 in SH-SY5Y cells 
Even though there is a moderate expression level of endogenous BACE1 mRNA in 
SH-SY5Y cells (see chapter 2), the protein level can be very low (Li et al, 2006; 
Sarajarvi et al, 2009). It has been reported that a biosynthetic intermediate form of 
BACE1 is endogenously expressed in SH-SY5Y cells (Costantini et al, 2007; Ko & 
121 
 
Puglielli, 2009). This intermediate product is less glycosylated than the fully mature 
BACE1 (Costantini et al, 2007), thus it has a lower molecular weight (see chapter 2). 
N-glycosylation is essential to BACE1 activity. A BACE1 mutant that contains only 
two out of the four N-glycosylation sites showed decreased BACE1 activity 
(Charlwood et al, 2001). The level of BACE1 activity was also reduced when treated 
with Tunicamycin, which inhibits N-glycosylation (Murayama et al, 2006). 
Therefore, it is expected that partly glycosylated BACE1 has lower or little activity. 
Additionally, BACE1 enzymatic activity correlates with mature BACE1 level instead 
of total BACE1 level (Zhong et al, 2007).  
There is another possibility that the translation system of endogenous BACE1 in SH-
SY5Y cells is similar to that in the pancreas, which possesses low levels of normal 
BACE1 protein and activity despite robust mRNA expression (Bodendorf et al, 
2001). Elsewhere, alternative splicing of the BACE1 transcript leader occurred in 
both the exocrine pancreas and neuroblastoma cells, but not in normal human brain 
(De Pietri Tonelli et al, 2004). Some shorter isoforms, such as BACE1 476 and 
BACE1 455, were abundantly expressed in the pancreas, but low in the brain 
(Mowrer & Wolfe, 2008). These BACE1 variants undergo different post-
translational modifications compared to the full length BACE1 501 and were 
demonstrated to be deficient in β-secretase activity (Ehehalt et al, 2002; Mowrer & 
Wolfe, 2008). Thus, it is likely that the endogenous BACE1 protein with a lower 
molecular weight is a product of alternative splicing in SH-SY5Y cells, but this 
needs further validation. 
In summary, I argue that the actual proportion of functional BACE1 protein is very 
low in SH-SY5Y cells, so there is nearly undetectable BACE1 activity. Hence, in 
chapter 5 where the trafficking system of endogenous BACE1 was investigated, I 
used HEK293 cells and mouse primary neuronal cultures instead of SH-SY5Y cells. 
4.4.2 The biological significance of β-secretase activity regulation by 
GPR50/GPR50del 
In HEK293 cells, GPR50 overexpression appears to up-regulate BACE1 activity by 
around 9% compared with the control condition, while GPR50del has no significant 
effects (Grünewald, 2011). Therefore, cells overexpressed with GPR50del may 
generally have lower β-secretase activity than cells overexpressed with GPR50. This 
is consistent with my findings in mouse primary cortical neurons, in which 
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GPR50del overexpression resulted in a significant 8.1% decrease of Bace1 activity 
compared to GPR50 overexpression. An interesting difference between the results 
found in the two cell lines is that GPR50 has significant effects on non-neuronal β-
secretase activity, whereas GPR50del exhibits a potential in regulating neuronal β-
secretase activity. Thus, the involvement of GPR50 protein in the regulation of 
BACE1 function might be cell type differentiated. The variation of deletion/SNP in 
GPR50 sequence is likely to switch the function of the protein from non-neurons to 
neurons, and this is in line with previous reports that GPR50del is associated with 
psychiatric disorders, in which neuronal β-secretase activity may be dysregulated (Ly 
et al, 2013; Savonenko et al, 2008; Vassar et al, 2009). In addition, it is worth 
mentioning that the transfection efficiency in HEK293 cells (>50%) is far higher 
than in primary neuronal cultures. According to Table 4.3, less than 10% neurons 
overexpressed GPR50 or GPR50del, which generated an 8% alteration of activity. 
Thus, GPR50del seems to be more effective in regulating neuronal β-secretase 
activity than GPR50 in non-neuronal β-secretase activity. It needs additional analysis 
of the generation of Bace1 cleavage products to answer the question if Bace1 activity 
inhibition of such a magnitude (8.1%) is of biological significance. 
RTN3 is a well characterised inhibitor of BACE1 activity. In HEK293 cells, 
transfection of exogenous RTN3 could diminish the relative level of endogenous 
BACE1 activity by 18-22% (Grünewald, 2011; He et al, 2004), which may 
consequently result in a reduction of up to 60% in the secretion of both Aβ40 and 
Aβ42 (He et al, 2004; Murayama et al, 2006). Considering the difference in 
transfection efficiency between the HEK293 cells and primary cortical neurons, and 
the inhibitory effect of RTN3 in HEK293 cells, one can argue that the regulation of 
Bace1 activity engendered by GPR50/GPR50del transfection in primary cortical 
neurons is likely to be biologically significant. 
Another type of BACE1 inhibitor, the components of the retromer complex SNX6 
and SNX12, have similar patterns of interaction with BACE1, as both of them 
negatively regulate BACE1 endocytosis and Aβ generation (Okada et al, 2010; Zhao 
et al, 2012). Interestingly, SNX12 inhibited APP processing without affecting β-
secretase activity (Zhao et al, 2012). This suggests a regulation mechanism, by which 
BACE1 interactors can still play a part in the functional cleavage, even though they 
do not have a significant effect on BACE1 activity. Nonetheless, it is important to 
note that, with the overall activity level of BACE1 unchanged, the enzyme in 
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different subcellular compartments (the plasma membrane, the endosomes, the Golgi, 
etc) may be redistributed for specific substrate cleavage, resulting in a local 
regulation of BACE1 activity. The effect of GPR50/GPR50del overexpression on 
BACE1 subcellular localisation was investigated in chapter 5. 
4.4.3 Future study: does GPR50/GPR50del affect substrate-specific β-
secretase activity? 
As introduced previously, BACE1 plays multiple roles in neuronal activity by 
cleaving diverse molecules. The activity levels detected in neurons may come from a 
joint effect of cleaving multiple substrates by β-secretase activity, reflecting diverse 
aspects of cell physiology. To better understand the function of β-secretase cleavage 
and its interacton with GPR50/GPR50del, it is essential to examine which molecules 
are involved in the regulation of β-secretase activity by GPR50/GPR50del. By using 
cells transfected with p40/GPR50/GPR50del, one can perform ELISA immunoassay 
and western blotting to measure and compare the levels of end products from β-
secretase cleavage, such as Aβ40/42, AICD, EGF; and intermediate products, such as 
C99, sβAPP, NRG1-βNTD, NRG1-βCTD. These products can be intracellular, 
membrane-bound or secreted. Therefore, it is also helpful to fractionate cells and to 
collect relevant culture media for separating different products and investigating the 
ratio of different cleavage activities. Additionally, quantitative proteomics/mass 
spectrometry (that is widely used for the detection of novel BACE1 substrates) 
(Hemming et al, 2009) can be carried out to identify the cleaved peptide(s) from the 
medium cultured with GPR50/GPR50del overexpressed neurons.  
In conclusion, results in this chapter revealed that GPR50 has a potential to regulate 
neuronal β-secretase activity. The deletion/SNP variation of GPR50 encoding 
sequence appears to be functionally effective, because GPR50del showed distinct 
function from the full-length isoform. This finding expands the association of GPR50 
polymorphism with mentally related illnesses, possibly by changing the normal 








5 Is the trafficking of BACE1 






In previous chapters, I have shown that GPR50 is physically associated with BACE1 
by co-immunoprecipitation experiments and is directly involved in the regulation of 
neuronal BACE1 activity. Transcriptional regulation of BACE1 is tightly related to 
the altered levels of its activity, as was detailed in chapter 2. However, the activity 
modulation is not necessarily dependent on the turnover of this enzyme (Tan et al, 
2013). There are distinct subcellular compartments in cells with different 
composition and pH values, so the proteolytic properties of BACE1 also depend on 
how this protein is spatially located (Cole & Vassar, 2007). This suggests that the 
trafficking system of BACE1 is equally if not more important in determining its 
activity than the regulation of gene expression. 
5.1.1 Post translational modification of BACE1 and trafficking  
It is well recognised that the amyloidogenic processing of amyloid precursor protein 
(APP) by BACE1 gives rise to the accumulation of Aβ peptides, the main hallmark 
in the AD brain. Other substrates have also been identified that decide the 
multifunctional importance of BACE1, for instance APLP1/2 (Eggert et al, 2004; Li 
& Sudhof, 2004), neuregulin-1/3 (Hu et al, 2008; Hu et al, 2006), Navβ2/β4 (Kim et al, 
2007; Miyazaki et al, 2007), CHL1 (Kuhn et al, 2012) , etc. As APP is the most 
commonly studied substrate of BACE1, here I will focus on introducing the 
regulation of BACE1 trafficking that is related to Aβ peptide production. The 
consensus has not been reached on the subcellular compartments where APP 
cleavage occurs. There are two putative sites of action: the early endosomes and the 
plasma membrane (Chia & Gleeson, 2011). Some researchers argue that the acidic 
environment (pH 4.0-5.5) of the early endosomes is optimal for BACE1 to operate 
(Siegenthaler & Rajendran, 2012). Deficiency in retromer components (i.e. sorting 
nexin family members SNX6, SNX12) is likely to block BACE1 in the endosomes, 
which promotes its cleavage activity in the amyloidogenic APP processing (Sullivan 
et al, 2011; Wang et al, 2012). However, there is also experimental data 
demonstrating that cholesterol and sphingolipids-rich lipid rafts in the plasma 
membrane are the sites of Aβ production (Rushworth & Hooper, 2010). Indeed, 
targeting BACE1 to the lipid rafts via an anchor glycosylphosphatidylinositol (GPI) 
up-regulates β-site processing of APP (Cordy et al, 2003) . Also, Marquer and 
colleagues observed that in live neuronal cells APP and Bace1 are in proximity at the 
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plasma membrane, and increasing the cholesterol level in the plasma membrane 
brings APP into the lipid rafts that already contain Bace1 (Marquer et al, 2011). 
Interestingly, there are two pathways for BACE1 to reach the early endosomes, 
either by being transported directly via Trans-Golgi network (TGN) after maturation, 
or through recycling from the plasma membrane through internalisation (Tan & Evin, 
2012). Thus, targeting BACE1 to the plasma membrane can also promote BACE1 
activity, as this pool of BACE1 may undergo endocytosis towards the endosomes for 
theoretically more efficient APP cleavage. 
The cycling of BACE1 is closely associated with a series of post translational 
modifications. Synthesised as a zymogen, immature BACE1 consists of a signal 
peptide (1-21), a pro-domain (22-45), a protease domain (46-460), a transmembrane 
domain (461-477) and a cytosolic tail (478-501) (Figure 5.1). There are two 
modifications that take place in the ER: the first step of glycosylation within the 
protease domain (Asparagine residues 153, 172, 223, 354), which is co-translational 
(Charlwood et al, 2001); and transient acetylation of seven lysine residues at N-
terminal (Lys126, 275, 279, 285, 299, 300, 307) that stabilises pro-BACE1 (Tan & 
Evin, 2012) and facilitates its trafficking through the secretory pathway. The pro-
domain assists in the proper folding of BACE1, and is removed in the Golgi. 
However, the presence of the pro-peptide does not inhibit BACE1 activity, as 
evidence suggests that this pro-sequence fails to block APP entering the active cleft 
of BACE1 (Shi et al, 2001). Also in the Golgi, further complex glycosylation is 
achieved, which increases the molecular weight of BACE1 by 30% and 
fundamentally controls BACE1 activity (Tan & Evin, 2012). Immature BACE1 is 
thought to have much less β-secretase activity due to lack of glycosylation (Zhong et 
al, 2007). Sulfation can be introduced on the N-glycosylation sites as a part of 
BACE1 maturation, and inhibition of endogenous heparan sulfate synthesis or 
sulfation induces elevated levels of BACE1 activity (Scholefield et al, 2003). 
The trafficking regulators are normally co-localised with BACE1 and are generally 
found linked to at least one of its modification processes (Figure 5.2). Most of the 
modification sites for trafficking are located in the cytosolic domain (Figure 5.1). 
Phosphorylation at serine 498 occurs exclusively on the fully maturated BACE1 after 
the removal of pro-peptide and complex glycosylation. This action facilitates the 
binding to GGA1 in the Golgi, permitting the cycling to the plasma membrane (von 
Arnim et al, 2004). Phosphorylation may also modulate the adjacent dileucine motif 
127 
 
(Leucine 499, 500) (Pastorino et al, 2002), which is essential to the internalisation 
sorted by GTPase ADP-ribosylation factor 6 (ARF6) (Sannerud et al, 2011). BACE1 
undergoes S-palmitoylation at four Cys residues (Cysteine 474, 478, 482, 485) at the 
junction of transmembrane and cytosolic domains (Vetrivel et al, 2009), and these 
modifications fulfil a role in locating BACE1 in the lipid rafts (Bhattacharyya et al, 
2013). Ubiquitination at lysine 501 is the recognition signal of GGA3 for targeting 
BACE1, which is transported to the lysosomes for degradation and consequently its 
turnover is regulated (Kang et al, 2010). In addition, down-regulation of retromers 
accelerates the endocytosis of BACE1 from the cell surface (SNX12) (Zhao et al, 
2012) or retrograde trafficking of internalised BACE1 from the early endosomes to 
perinuclear structures (SNX6) (Okada et al, 2010). 
 
Figure 5.1 A diagram representing BACE1. This diagram was adapted from (Tan & Evin, 
2012). Precursor BACE1 contains a signal peptide (SP), a pro-sequence (Pro) and a 
transmembrane domain (TM), followed by a cytosolic domain (CD). It undergoes 
glycosylation at four sites (represented with four-node symbols). The two motifs 
DTGS/DSGT form the enzymatic active site. Enlarged cytosolic domain shows the post-
translational modifications that affect BACE1 cellular trafficking: palmitoylation at three 
cysteine residues (C), phosphorylation at serine 498 (S) within the DXXLL sorting motif, and 
ubiquitination at lysine 501 (K). The fourth palmitoylation site (C474) was not shown as it is 




Figure 5.2 BACE1 cellular trafficking and representative regulators. ER: endoplasmic 
reticulum; TGN: trans-Golgi network; P: phosphorylation; U: ubiquitination. The black down 
arrows indicate down-regulation of the regulators. ARF6: ADP-ribosylation factor 6, a 
member of the ADP ribosylation factor family of GTP-binding proteins, is required for the 
internalisation of BACE1 from cell surface to endosomal compartments (Sannerud et al, 
2011). GGA1: a member of Golgi-localised, gamma adaptin ear-containing ARF-binding 
(GGA) protein family, regulates the retrograde trafficking of internalised BACE1 from 
endosomal compartments to TGN and the recycling of phosphorylated BACE1 to the cell 
surface (von Arnim et al, 2004; Wahle et al, 2005). GGA3: a member of GGA protein family 
mediates the transport of BACE1 to lysosomes for degradation (Kang et al, 2010). SNX6: a 
member of the sorting nexin (SNX) family that is a component of the retromer complex, the 
down-regulation of which facilitates the retrograde transport of cell surface-derived BACE1 
from the endosomes to the perinuclear structure, including TGN (Okada et al, 2010). SNX12, 
a member of the SNX family, the down-regulation of which facilitates the endocytosis of 
BACE1 (Zhao et al, 2012). VPS35: vacuolar protein sorting-associated protein 35, the largest 
subunit of retromer, promotes the retrieval of BACE1 from the endosomes to the Golgi 
(Wen et al, 2011). Sortilin: a Vps10p domain-sorting receptor, is a positive modulator of 




Table 5.1 Major factors involved in BACE trafficking and associated with Alzheimer’s disease 
Protein  General function Interaction with BACE1 Effect on BACE1 trafficking Investigation in 
Alzheimer’s disease 
References 
GGA1 Adaptor sorting 
protein 
(496–500) DXXLL motif 
Phosphorylated Ser498 
Recycle BACE1 from endosomes to 
plasma membrane via the Golgi 
Decreased in AD frontal 
cortex 
(Santosa et al, 2011; von Arnim et 
al, 2004; Wahle et al, 2005; Wahle 
et al, 2006) 
GGA3 Adaptor sorting 
protein 
(496–500) DXXLL motif 
Ubiquitinated Lys501 
Sort BACE1 from endosomes to 
lysosomes for degradation 
Marked decrease in AD 
frontal cortex 
(Kang et al, 2010; Santosa et al, 
2011; Tesco et al, 2007) 
RTN3* Neuronal function Transmembrane region Retain BACE1 in ER Enriched in RTN3 
immunoreactive dystrophic 
neurites (RIDNs) in AD brains 
(Deng et al, 2013; Murayama et al, 
2006; Shi et al, 2009) 
Seladin-1 Cholesterol 
biosynthesis 
Indirect Control cholesterol level in rafts;  
prevent casp-3 cleavage of GGA3 
Down-regulated in affected 
neurons in AD 
(Crameri et al, 2006; Greeve et al, 
2000; Sarajarvi et al, 2009) 
ARF6 Protein 
endocytosis 
(499–500) LL motif Sort BACE1 from plasma membrane to 
early endosomes  
Decreased level in AD brain (Sannerud et al, 2011) 




BACE1 and APP 
Prevent APP/BACE1 interaction in the 
Golgi  
Suspect gene for AD; 
decreased levels in AD brain. 
(Scherzer et al, 2004; Spoelgen et 
al, 2006; Willnow et al, 2010) 
 SNX6* Retromer subunit  Co-immunoprecipitation Its down-regulation facilitates 
recycling BACE1 from cell surface 
through the endosomes to perinuclear 
structure, including TGN 
Impaired retromer complex 
in AD  
(Okada et al, 2010; Small et al, 
2005) 
SNX12 Retromer subunit Co-immunoprecipitation Its down-regulation accelerates BACE1 
endocytosis 
Dramatically decreased in AD 
brain 
(Zhao et al, 2012) 
VPS35 Largest subunit of 
retromer 
Co-immunoprecipitation Retrograde trafficking of BACE1 from 
endosomes to Golgi 
Hemizygous deletion of 
Vps35 in Tg2576 mouse 
model leads to earlier-onset 
AD-like phenotypes 
(Wang et al, 2012; Wen et al, 2011) 
Sortilin Retromer-mediated 
retrograde transport 
Through cytoplasmic tail of 
sortilin; 
Co-immunoprecipitation 
Retrograde trafficking of BACE1 from 
endosomes to TGN 
With Increased levels in AD 
brain.  
(Finan et al, 2011; Gina, 2010) 
*Interactors of GPR50 identified by the yeast two-hybrid study (Grunewald et al, 2009) 
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It is worthwhile mentioning that the disorder of BACE1 trafficking is commonly 
associated with adverse cellular conditions, such as apoptosis and stress. In the brains 
of AD patients that may undergo neuronal apoptosis, the levels of GGA3 are 
significantly decreased, resulting in an accumulation of BACE1 in the early 
endosomes, and impairing its trafficking to the lysosomes where it is degraded 
(Tesco et al, 2007; Walker et al, 2012). Oxidative stress may diminish VPS35 levels 
in the brain, which may in turn damage the retrograde sorting of BACE1 from the 
endosomes (Wang et al, 2012; Wen et al, 2011). It is summarised in Table 5.1 the 
BACE1 regulators that play a part in BACE1 trafficking and have a link to AD. 
Interestingly, two of the major factors, RTN3 and SNX6, have been reported as 
GPR50 putative interactors, identified by the yeast two-hybrid study (Grunewald et 
al, 2009). Interaction between GPR50 and RTN3 has been identified by co-
localisation and co-immunoprecipitation experiments (Grünewald, 2011). This 
suggests that GPR50 may acts as a synergistic factor that regulates BACE1 
localisation in cells. Further, the mental disorder associated deletion/SNP variant 
GPR50 del appears to alter the normal function of GPR50, such as in the neurite 
extension and in the interaction with RTN3 (Grunewald et al, 2009; Grunewald et al, 
2012). Thus, in this chapter, the effect of both GPR50 isoforms was investigated on 
BACE1 trafficking. 
5.1.2 Ways to study BACE1 trafficking 
The critical role played by the trafficking machinery in regulating BACE1 activity, 
hence the production of Aβ in AD, has led to an increased interest in different 
approaches for studying the mechanisms of BACE1 trafficking. Three main 
techniques have been applied for studies of BACE1 transport across the subcellular 
compartments and during the internalisation.  
5.1.2.1  Immunocytochemistry identifying the pathways of BACE1 cycling by co-
staining with diverse subcellular markers 
Immunofluorescence labelling is a powerful technique involving a variety of 
antibodies. Cells can be fixed and permeabilised, followed by multi-staining of 
antibodies against BACE1 and subcellular markers. In chapter 2, I showed that 
overexpressed BACE1 was localised in the plasma membrane (marked by pan 
cadherin, VLA-2α and β-catenin), the endosomes (marked by EEA1), the Golgi 
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(marked by 58K Golgi) and the late endosomes (marked by RAB7). To investigate 
how a putative interactor affects BACE1 trafficking, this method can be applied to 
observe the redistribution of BACE1 among different compartments of cells 
overexpressed with or deficient of the interactor. For instance, Wen and colleagues 
investigated the potential role of VPS35 in BACE1 circulation, by making use of the 
co-immunostaining analysis of exogenous BACE1 with endogenous Vps35, cis-
Golgi marker GM130, and lysosome marker LAMP1 in NLT cells transfected with 
control or shRNA-Vps35 (Wen et al, 2011). It was revealed that in VPS35-deficient 
cells, BACE1 was no longer confined to the Golgi, but relocated to the 
endosomes/lysosomes, suggesting that VSP35 is crucial for BACE1 to be retained in 
the Golgi. 
Alternatively, antibodies that recognise specific extracellular epitopes can be 
introduced to trace BACE1 on the cell surface in live cells. Under non-permeabilised 
conditions, only proteins on the plasma membrane will be labelled. The antibody is 
generally assumed to stay bound to the protein throughout the endosomal pathway 
and become dissociated in lysosomes where both the targeted protein and the 
antibody are degraded (Arancibia-Carcamo et al, 2006). The antibody binding step is 
normally performed at 4°C, which blocks the membrane trafficking so as to inhibit 
the endocytosis of molecules. The media used to dilute the antibody is regularly 
buffered with HEPES and salts. In chapters 2 and 3, I showed that BACE1 was 
successfully labelled on the cell surface by the BACE1 goat antibody. For 
quantitative studies of the endocytosis and the internalisation, cells are returned to 
incubation at 37oC for desired period of time, and then fixed (by 4% 
paraformaldehyde). Kinoshita et al studied the localisation of APP and BACE1 on 
the cell surface and in the endocytic pathway, by labelling the two with antibodies 
against their extracellular regions at 4°C and allowing cells to undergo endocytosis at 
37°C for varying intervals (Kinoshita et al, 2003). Their results showed that at 0 
minute, APP and BACE1 were found co-localised in nearly identical clusters on the 
cell surface. At 15-30 minutes, complete co-localisation of the two signals was 
detected in the endosomes. By the time 60 minutes, distinct localisation of BACE1 




5.1.2.2 An immunoblotting approach to detect BACE1 in a given sample of tissue 
homogenate or cell extract subjected to subcellular fractionation and compare 
with different subcellular compartment markers  
Subcellular fractionation is one of the most commonly used methods for localisation 
assessment or protein enrichment. This technique provides a flexible tool to detect 
the abundance and the dynamic movements of proteins from tissues or cells at the 
organelle level.  
Mild homogenisation of tissues or cells is carried out as the first step to disrupt the 
capture of organelles and release them. The cytoplasmic structure and cytoskeletal 
organisation vary enormously between different cell lines and tissues, indicating that 
to keep compartments separate but intact, homogenisation conditions need to be 
optimised for samples of different origins. To keep the organelles as intact as 
possible, cold temperature (normally 4°C) is essential, and homogenising buffer is 
also a key factor, which basically contains: sucrose, for high osmolarity, specific ions 
(CaCl2, MgAc2) for stabilisation and mixture of protease inhibitors to protect protein 
constitutes from degradation. 
As soon as the homogenates are ready, they immediately undergo high resolution 
separation of multiple subcellular organelles by ultra-centrifugation through a density 
gradient. Distinctively charged particles move towards their equal densities of 
medium, which is known as the isopycnic point. Commonly used fractionation media 
include sucrose, Ficoll 400, Percoll, metrizamide, Nycodenz and iodixanol. The 
centrifugation is carried out in swinging bucket rotors with least disturbance. And 
post-fractionated gradients will be collected sequentially and used to identify certain 
targeted proteins by co-immunoblotting with known organelle makers. Subcellular 
compartment markers used in this chapter are summarised in Figure 5.3. 
Using subcellular fractionation to confirm the localisation of BACE1 is widely 
applied. In chapter 3, using sucrose gradient subcellular fractionation, I showed that 
in GPR50 and BACE1 co-transfected HEK293 cells, most of BACE1 was distributed 
in fractions containing the plasma membrane and the lysosomes; while in adult 
mouse brain, endogenous Bace1 was mostly present in fractions containing ER-Golgi, 
synaptosomes, and presynaptic fractions. Shi and colleagues observed altered 
localisation of BACE1 in subcellular compartments upon overexpression of RTN3, 
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by performing sucrose gradient centrifugation to HEK293 cells. In control cells, most 
of BACE1 was localised in the Golgi and a smaller portion in the early endosomes; 
whilst in RTN3 stably-expressed cells, the majority of BACE1 was detected in the 
ER fractions with only a low amount of BACE1 in the Golgi fractions (Shi et al, 
2009). It is believed that retaining BACE1 in the ER is the mechanism that accounts 
for the inhibition of BACE1 activity by RTN3 and reduced deposition of Aβ was 
observed in the brain of Tg-APPsw/PSEN1DE9 mice when crossed with Tg-RTN3 
mice. 
 
Figure 5.3 Subcellular fractionation markers used in this chapter.  The markers are shown 
in italics and underlined.  
5.1.2.3 A biochemical approach based on the covalent bonding of cell surface 
proteins with biotin, taking advantage of the strong interaction between biotin 
and streptavidin for the purification of biotinylated proteins 
In most cases, the membrane proteins are biotinylated on amino acid residues located 
in extracellular domains and subsequently enriched using magnetic streptavidin 
beads. Then the captured proteins are released from the beads and detected by 
specific antibodies for targeted members. This method is applied by some 
researchers for investigating BACE1 trafficking and internalisation, exploiting the 
134 
 
long ectodomain of this protein. For example, the cell surface protein biotinylation 
assay employed by Zhao et al showed that the endocytosis of BACE1 under normal 
conditions occurred at about 15 min after chasing began, whereas in cells with 
SNX12 down-regulation, an observable endocytosis of BACE1 was detected early at 
5 min after chasing, suggesting that reduced amount of SNX12 can accelerate the 
endocytosis of BACE1 (Zhao et al, 2012). 
5.1.3 Introduction to experiments 
In chapter 2, it was shown that the GPR50 is capable of decreasing mature BACE1 
protein level in HEK293 cells. However, this observation cannot explain why 
overexpressed GPR50 up-regulates BACE1 activity (Grünewald, 2011). In order to 
find out more about the mechanism of BACE1 activity regulation by GPR50, further 
investigations were carried out with a focus on the effect on BACE1 trafficking in 
this chapter. By use of immunocytochemistry and cell surface labelling techniques, 
the proportion of BACE1 located on the cell surface was analysed, and the impact of 
GPR50 expression was assessed. Next, subcellular fractionation was performed in 
HEK293 cells and primary cortical neurons in which the regulation of β-secretase 
activity by GPR50/GPR50del has been observed {(Grünewald, 2011); my chapter 4}. 
The localisation of both immature and mature BACE1 was tested for correlation with 
subcellular compartment markers, and any quantifiable shift was assessed.   
5.2 Materials and methods 
For tissue culture, transfection, immunocytochemistry, western blotting, cell surface 
labelling and real-time quantitative PCR, see 2.2.1-2.2.8 for detail. The following 
paragraphs describe additional techniques that were used for experiments in this 
chapter. 
5.2.1 Antibodies 
The primary antibodies used in this chapter and their application conditions are 
summarised in Table 5.2. The full information for these antibodies can be found in 
2.2.5. The working conditions of secondary antibodies used in immunocytochemistry 
and western blotting have been introduced in Table 2.3 and Table 2.4. 
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Table 5.2 Primary antibodies used in chapter 5 




Rabbit polyclonal Residues 294-317 of human GPR50 ICC (1:200) 
WB (1:1000) 
BACE1 rabbit2 Rabbit polyclonal Residues 485-501 of human BACE1 ICC (1:5000) 
WB (1:10,000) 
BACE1 goat Goat polyclonal Residues 22-460 of human BACE1 ICC (cell surface 
labelling, 1:200) 
VLA-2α  Mouse monoclonal Residues 42-245 of human VLA-2α WB (1: 1000) 
β-catenin 
 




EEA1 mouse2 Mouse monoclonal Residues 3-281 of human EEA1 WB (1: 5000) 
P115 Mouse monoclonal Residues  843-955 of rat p115 WB (1: 500) 
Calreticulin  
rabbit 
Rabbit polyclonal Full length human calreticulin WB (1:10,000) 
GAPDH Mouse monoclonal Recombinant GAPDH WB (1: 40,000) 
5.2.2 Sucrose density gradient fractionation 
The technique of sucrose density gradient fractionation used in HEK293 cells was 
described in 3.2.4.1. The usage of this method in primary neuronal cultures was 
introduced as follows. 
Primary cortical neurons from E18 embryos of C57BL/6 mice were cultured for 3 
days (DIV3) in a 6-well plate coated with poly-D-lysine. As neuronal cells do not 
divide after being plated, it is essential to count the cell number correctly and place 
enough cells to the plates. For one well of a 6-well plate, 5×106 cells were counted 
by a cell counter and plated to guarantee an optimal cell viability for transfection. For 
cultured neurons, the transient transfection of the three plasmids (pDEST40, GPR50 
and GPR50del)  using Lipofectamine 2000 (see 2.2.4) was verified by qPCR, due to 
relatively low transfection efficiency; while for HEK293 cells there was a much 
higher cell input and high transfection efficiency, western blotting was performed to 
confirm successful transfection. The cultured cells were left overnight post-
transfection before being scraped into sucrose buffer. The lysates were homogenised 
with a 23 gauge needle, followed by incubation on ice for 20 min. The homogenates 
were loaded onto the top of a discontinuous sucrose gradient and then centrifuged at 
10,000×g (22,000 rpm, SW41 Ti Beckman) for 18 hr at 4oC (see 3.2.4.1 for detail). 




Both HEK293 cells and primary cortical neurons express quantifiable mature and 
immature BACE1/Bace1. EEA1, VLA-2α and calreticulin were ready to use as 
subcellular markers for the early endosomes, the plasma membrane and the ER in 
HEK293, as was shown in chapter 3 (Figure 3.12). However, EEA1 and VLA-2α 
failed to work in primary cortical neurons. To replace these two markers for 
compartments known to hold mature BACE1, β-catenin was used for external 
compartments and p115 as cis-Golgi marker (Dejgaard et al, 2007; Park et al, 2008). 
Strictly speaking, β-catenin is not a “marker”, because there is also a “free pool” 
located in the nucleus (normally in the heaviest fractions), where it acts as a 
transcription co-activator (Orsulic et al, 1999). However, this is only a small 
proportion of β-catenin, with the majority pool bundled to E-cadherin in the plasma 
membrane (Du et al, 2009). There are also reports about β-catenin being located in 
caveolae by interacting with caveolin-1 (Galbiati et al, 2000). Hence, for primary 
neuronal cells in this experiment, β-catenin was employed as an alternative to VLA-
2α in HEK293 cells as the external compartment marker.  
In order to measure the distribution of BACE1/Bace1 and the subcellular markers, 
the amount of immunostained protein in each fraction was quantified by 
densitometry with ImageJ. The percentage of the proteins in each fraction from 1 to 
12 was calculated to reflect their distribution.  
5.2.3 Fitting of the general linear model with the interaction term 
Data from three biological replicates of the subcellular fractionation was pooled for 
each of the three independent groups: pDEST40-transfected cells (empty vector 
control, abbreviated as p40 in the following passages), GPR50-transfected cells and 
GPR50del-transfected cells.  Thus, there are 36 data points (3×12 fractions) for each 
of the three groups. Distribution (percentage in one fraction out of all fractions) of 
BACE1/Bace1 was predicted by correlating with that of the markers under the 3 
conditions using the general linear model, and the fitness of the prediction was 
compared. 
Asking if a predictor has different regression weights for different groups is 
equivalent to asking if there is an interaction between this predictor (i.e. β-catenin) 
and group membership (i.e. p40 group V.S. GPR50 group).  Specifically, by 
incorporating a dummy variable for group membership and an interaction term for 
group membership with an independent variable, one can better identify what effects, 
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if any, differ across groups. This can be achieved through the general linear model 
with an interaction term included in SPSS. The general equation is: 
Candidate = a+ b1 group + b2 predictor + b3 (group×predictor)  
If b3 is significant, then there is a difference between the predictor regression weights 
of the two groups. However, in terms of multiple predictors, this approach may get 
over complicated.  With three predictors, each interaction term is designed to tell us 
if a particular predictor has a regression slope difference across the groups. The 
equation evolves into: 
Candidate = a+ b1 G + b2 P1+ b3 (G×P1) + b4 P2 + b5 (G×P2) + b6 P3 + b7 (G×P3) 
G=group, P=predictor. 
Because the collinearity among the predictors,  the collinearity among interaction 
terms, as well as the collinearity between a predictor’s term and other predictors’ 
interaction terms all influence the weight of a single interaction term, there has been 
dissatisfaction with how efficiently this method works for multiple predictors. Thus, 
in the following analysis, single general linear models will be applied. 
An example will be illustrated by using β-catenin to predict mature Bace1 (mBace1) 
in groups p40 and GPR50. 
mBace1= a+ b1 condition + b2 β-catenin + b3 condition×β-catenin  
The “condition” here is a categorical variable that represents different groups, such 
as the two-category variable (p40, GPR50). A dummy variable can sort data into 
mutually exclusive categories by taking the value 0 or 1, such as (p40=1, GPR50=0). 
By including the interaction term of a dummy variable with an independent variable 
(such as β-catenin), it is able to indicate whether the absence or presence of one 
category (such as group GPR50) will shift the outcome of the predicted model; in 
other words, this tests whether there is a difference between categories in the model 
prediction of a dependent variable (such as mBace1) by an independent variable 
(such as β-catenin).  
SPSS refers the group that is coded as 1 to the dummy, whose values are set to 0. 
And the rest of the group(s) will be coded as 0, whose values are kept. In the 
example introduced here, a dummy variable labelled with “p40ref_GPR50com” is 
coded as p40=1 (reference group, p40ref_GPR50com=0), GPR50=0 (comparison 
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group, p40ref_GPR50com=1).  To better understand the coefficients, the main SPSS 
outputs of this model are listed in Table 5.3. The summary of this model is shown in 
Table 5.4. In the result section, only the summary tables will be presented. 
Table 5.3 The main SPSS outputs of the general linear model:  




Dummy .00 36 
1.00 36 
 
Tests of Between-Subjects Effects 
Dependent Variable:mBace1 
Source 
Type III Sum 
of Squares df 
Mean 
Square F Sig. 
Partial Eta 
Squared 
Corrected Model 4996.024a 3 1665.341 28.561 .000 .558 
Intercept 26.980 1 26.980 .463 .499 .007 
p40ref_GPR50com 72.106 1 72.106 1.237 .270 .018 
β-catenin 4635.379 1 4635.379 79.498 .000 .539 
p40ref_GPR50com × 
β-catenin 
154.730 1 154.730 2.654 .108 .038 
Error 3964.958 68 58.308    
Total 13960.982 72     
Corrected Total 8960.982 71     






Error t Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
Intercept -.532 1.703 -.312 .756 -3.929 2.866 
p40ref_GPR50com=.00 2.739 2.463 1.112 .270 -2.176 7.654 
p40ref_GPR50com=1.00 0a . . . . . 
β-catenin 1.064 .136 7.838 .000 .793 1.335 
p40ref_GPR50com=.00× β-
catenin 
-.329 .202 -1.629 .108 -.731 .074 
p40ref_GPR50com=1.00× 
β-catenin 
0a . . . . . 






According to the parameter estimates in Table 5.3, the predicted model is: mBace1=-
0.532+2.739 p40ref_GPR50com+1.064 β-catenin-0.329 p40ref_GPR50com×β-
catenin. 
When p40ref_GPR50com=0, mBace1=-0.532+1.064 β-catenin. 
When p40ref_GPR50com=1, mBace1=-0.532+2.739+1.064 β-catenin-0.329 β-
catenin 
Thus, for p40 group, the intercept is -0.532 and the slope is 1.064; for GPR50 group, 
the intercept is -0.532+2.739 and the slope is 1.064-0.329. SPSS calculates the 
significance of differences in intercepts (+2.739) and slopes (-0.329) that occur in the 
two groups. These two parameters reflect the basic levels of the dependent variable 
and the effect size of a predictor respectively. 
Table 5.4 A summary of the general linear model for the example: 
 mBace1=-0.532+2.739 p40ref_GPR50com+ 1.064 β-catenin-0.329 p40ref_GPR50com×β-
catenin 
a. Adjusted r2=0.538 
 
F P-value Partial Eta Squared 
Corrected model a 28.561 4.6×10-12** 0.558 
p40ref_GPR50com 1.237 0.270 0.018 
β-catenin 79.498 4.8×10-13** 0.539 
p40ref_GPR50com × β-catenin 2.654 0.108 0.038 
Predicted slopes P40: 1.064; GPR50: 0.735 
** p<0.01  
5.3 Results 
5.3.1 The relation between endogenous GPR50 and cell-surface BACE1 
In chapter 3, I showed that, in HEK293 cells, endogenous GPR50 was co-localised 
with endogenous cell surface BACE1. It was also seen that, in a group of cells, there 
were more cells singly labelled with GPR50 or surface BACE1 than cells that 
expressed both of them. Here I wanted to investigate whether the expression of 
GPR50 reduced the amount of BACE1 at the cell surface. 
5.3.1.1 Intensity correlation analysis of staining patterns of endogenous GPR50, cell 
surface BACE1 and total BACE1 in HEK293 cells 
As HEK293 cells grow in clumps and single cells seem not to survive the cell surface 
labelling at a low temperature, it is very difficult to statistically quantify the 
140 
 
relationship between GPR50 and surface BACE1 in single cells. Thus, the intensity 
correlation analysis of co-localisation between the two proteins in a group of cells 
was carried out.  
It was mentioned in chapter 3 that intensity correlation analysis (ICA) plot of 
correlated staining generates an hourglass figure with a positive skew, while that of 
segregated staining yields one with a negative skew (see 3.2.3). The values for 
Pearson’s correlation coefficient (Rr) range from 1 to -1. A value close to 1 indicates 
reliable correlation, while negative values and those close to zero can be resulted 
from mixed patterns. Mander’s overlap coefficients (R, M1, and M2) are adopted to 
explain the identical location of the two intensity sets. Finally, intensity correlation 
quotient (ICQ) is used to identify whether the staining intensities are associated in a 
random (ICQ~=0), dependent (0 <ICQ ≤0.5) or segregated (0>ICQ≥ -0.5) manner. 
Nonparametric sign test is carried out to judge whether the median of differences 
between two sets of intensity values equals 0 (ICQ=0) (Li et al, 2004). 
In a group of cells, ICA plots for GPR50 and surface BACE1 (Figure 5.4.A) 
exhibited a random staining (mixed with dependent and segregated manners) with a 
slightly negative skew.  This pattern indicates that GPR50 and surface BACE1 
tended to localise in different cells in this group. The Pearson’s correlation 
coefficient (Rr=0.08, Table 5.5.A) supported the hypothesis that these two proteins 
had very low correlation. However, Mander’s overlap coefficient (R=0.432) 
demonstrated that there were cell parts retained with both GPR50 and surface 
BACE1. 68.4% of pixel intensities in GPR50 channel matched those in surface 
BACE1 channel, while 16.6% in the latter matched with those in the former. The 
ICQ value revealed a significant positive correlation between the two, but the 
possibility cannot be ruled out that GPR50 and surface BACE1 from two adjacent 
cells might come into contact at the indivisible conjunction sites of the cells, and this 
is the main concern when investigating co-localisation in a clump of cells. 
With respect to GPR50 and total BACE1 in this group of cells (Figure 5.4.B, Table 
5.5.B), it was shown that the staining of GPR50 was likely to be dependent on that of 
total BACE1 (with ICA plot positively skewed), but there were pixels of GPR50 
below the average value that segregated with their paired total BACE pixels. This 
was because there were some BACE1-expressing cells with no endogenous GPR50 
and this resulted in a percentage of pixel pairs as {GPR50=0, total BACE1=Y}.  
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Correspondingly, the staining of total BACE1 somehow depended on that of GPR50, 
but a part of the above average pixels excluded with their GPR50 partners (again, 
these are {GPR50=0, total BACE1=Y}). This observation reflected an imbalance of 
the total pixel quantities and intensity strength between GPR50 and total BACE1, 
which was indeed the case with this group of cells. All GPR50 intensities matched 
those of total BACE1 (M1=1), while only 32.1% of the latter matched with the 
former. The significant positive ICQ (0.029) indicated very low co-localisation, 
largely due to the fact that the amount of total BACE1 outweighed that of GPR50 in 
cell groups. 
 
Figure 5.4 Intensity correlation analysis of GPR50 with surface BACE1 or total BACE1 in a 
cluster of cells. A) GPR50 (red) and surface BACE1 (green); B) GPR50 (red) and total BACE1 
(blue), represented by their split ICA plots and scatter-plot of intensities. The yellow shut 
line indicated region of interest (ROI) that was analysed. 
 
Table 5.5 ICA parameters for co-localisation analysis of GPR50 with surface BACE1 or total 
BACE1. A) GPR50 and surface BACE1; B) GPR50 and total BACE1 in a cluster of cells 
Co-localisation parameters Rr R ch1:ch2 M1 M2 ICQ P-value 
A)GPR50 V.S. surface BACE1 0.08 0.432 0.515 0.684 0.166 0.104 <0.05 
B)GPR50 V.S. total BACE1 0.046 0.622 0.05 1 0.321 0.029 <0.05 
In conclusion, the correlation between paired pixel intensities of GPR50 and cell 
surface BACE1 in a cell group was very weak. Even though there were overlapping 
pixels in the two channels, the staining pattern of GPR50 and cell surface BACE1 in 
a cell group was not dependent. However, in a single cell expressed with both 
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GPR50 and cell surface BACE1, their staining patterns were significantly dependant 
(see chapter 3, Figure 3.11). Thus, the correlation of the two proteins’ staining in a 
cell group was largely averaged by their exclusive expression pattern.  
5.3.1.2 Intensity Profiles of endogenous GPR50, cell surface BACE1 and total 
BACE1 in HEK293 cells 
To better address the observation that GPR50 and surface BACE1 seem to not co-
localise in a group of cells, intensity profiles were generated cell by cell (Figure 5.5), 
and the cell-cell adhesion sites were avoided when plot lines were drawn across the 
cells. The red and green profiles for GPR50 and cell surface BACE1 normally had 
two peaks at both ends, indicating the sites of the plasma membrane on the two sides 
of cells. The blue profile for total BACE1 included continuous contents in the middle, 
which reflects that BACE1 was also expressed in the intracellular organelles, 
presumably in the Golgi, the early endosomes and the late endosomes or cytosolic 
sites (see chapter 2, Figure 2.10). It was confirmed that in this group, cells expressed 
with endogenous GPR50 tended to have no or very little surface BACE1 (cells 3 and 
8), and vice versa (cells 2, 4, 5, 6 and 9). Cells 1 and 7 had peaks of red and green at 
the same position (indicated by an open arrow), so they were potential cells that 
might show co-localisation of GPR50 and cell surface BACE1.  Yet, even in these 
two cells, there were high levels of GPR50, but low levels of surface BACE1. Thus, 
in a group of cells, GPR50 and cell surface BACE1 appeared to localise in an 
exclusive manner. A possible explanation for this observation is that in cells 






Relation  between GPR50 and surface BACE1 Cell number Symbol in the figure 
GPR50 with little or no surface BACE1 3,8  
Surface BACE1 with little or no GPR50 2,4,5,6,9  
Potential co-localisation  1,7  
Figure 5.5 Intensity profiles of GPR50, cell surface BACE1 and total BACE1 in HEK293 cells 
of a group. A) GPR50 (red); B) surface BACE1 (green); C) total BACE1 (blue); D) merged 




5.3.1.3 Correlation of expression levels of GPR50 to the percentage of cell surface 
BACE1 in clustered HEK293 cells 
Results by immunocytochemistry suggested that HEK293 cells endogenously 
expressing a high level of GPR50 tended to have a low level of BACE1 at the cell 
surface. To further investigate this, statistical analysis was performed to assess the 
relationship between the level of endogenous GPR50 and the percentage of cell 
surface BACE1 in groups of cells. 
1) Cell number optimisation 
The number of HEK293 cells cultured on the coverslips has a strong effect on the 
performance of the cell surface labelling technique. Therefore, the cell plating 
density was explored, initially by plating the normal number of cells into in a 12-well 
plate (Trial 1, 5×104 cells/coverslip, Table 5.6). The cells formed clusters due to the 
fast-growing nature of HEK293. Then, there were several attempts to keep HEK293 
more scattered by reducing the cell number, but there was a strikingly increased 
degree of cell death as the cells were more diluted. The minimum number for the 
cells to survive the surface labelling was 1×104 cells/coverslip, in which only 20 
photos were obtained due to poor cell viability. It was also noticed that the 
decreasing cell number led to more dead cells, and this did not prevent the remaining 
cells from forming clusters. Therefore, there were a minimum number of cells 
needed to guarantee a healthy pool of cells, and to allow successful cell surface 
labelling and the possibility of running a statistical analysis. Finally, the ideal cell 
number was confirmed (Optimised, Table 5.6), which was 2×104 cells/coverslip.  
2) Statistical analysis 
The area with GPR50 expression (red channel, GPR50Area) was calculated, 
indicating its expression level in each cell cluster. The area of cell surface BACE1 
(green channel) divided by that of total BACE1 (blue channel) was computed as the 
proportion of BACE1 located at cell surface (BACE1Sur.Per). The areas with protein 
expression were masked according to the given values of threshold automatically 
calculated by ImageJ. The calculation of the masked areas was run through the 
measurement command in a batch to avoid bias.  
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Firstly, Pearson’s correlation analysis was run to analyse the relationship between 
GPR50Area and BACE1Sur.Per. There was a significant negative correlation 
between the two proteins only under the optimised condition (Table 5.6). This means 
that there is a small percentage of endogenous BACE1 located at the plasma 
membrane in cells expressed with endogenous GPR50, which supports the ICA 
results from the images and might indicate that endogenous GPR50 facilitates 
BACE1 internalisation.  Further statistical analysis was performed on data obtained 
under the optimised condition. 




Trial 1 Trial 2 Optimised 
BACE1Sur.Per 
Starting cell number 5×104 1×104 2×104 
Cluster number 50 20 50 
Cell number in a cluster 20-127 1-14 3-30 
Pearson Correlation -.072 .173 -.470 
Sig. (2-tailed) .620 .465 .001** 
**. Correlation is significant at the 0.01 level (2-tailed). 
GPR50Area: the area with GPR50 expression in each cell group 
BACE1Sur.Per: the percentage of cell surface BACE1 as a fraction of total BACE1 in each cell group 
It was noticed that even in the optimised experiment, the cell number in a cluster was 
not stable, ranging from 3 to 30. Thus, I tested whether cell number was one of the 
factors affecting BACE1Sur.Per (Figure 5.6). It was found that the more cells there 
were in a cluster, the higher the expression level of endogenous GPR50 was. 
Surprisingly, there was a significant decrease of BACE1 proportion at the cell 
surface with the cell number increasing. In order to find out if the negative effect of 
GPR50Area on BACE1Sur.Per could be attributed to the increasing cell number, a 
general linear model was run including 3 predictors: cell number, GPR50Area, and 
cell number×GPR50Area. As is shown in Table 5.7, both cell number and 
GPR50Area had significant negative effects on BACE1Sur.Per, while cell 
number×GPR50Area contributed a small positive trend. This indicates that the more 
cells there were in a cluster, the more likely the cell number and GPR50 expression 
level had a combined impact on BACE1 proportion located at cell surface. The 
equation of the model is: BACE1Sur.Per=17.689-0.647 CellNumber-0.110 
GPR50Area+0.006 CellNumber×GPR50Area. Thus, endogenous GPR50 does have 
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an effect on the percentage of endogenous BACE1 localised at the surface of 
HEK293 cells, even after accounting for the effect of the cell number. 
 
Figure 5.6 Scatter plots for GPR50 expression level, cell surface BACE1 proportion and cell 
number. A) GPR50Area~ CellNumber, B) BACE1Sur.Per~ CellNumber and C) BACE1Sur.Per~ 
GPR50Area under optimised condition 
Table 5.7 Predication of the general linear model for cell surface BACE1 proportion 
BACE1Sur.Per=a+b× CellNumber+c× GPR50Area+d× CellNumber ×GPR50Area 
 F P-value B 
Corrected model a 8.534 0.00013**  
Cell number 8.514 0.005** -0.647 
GPR50 6.293 0.016* -0.110 
Cell number× GPR50 3.035 0.088$ 0.006 
a. Adjusted r2=0.316 
** p<0.01, *p<0.05, $p<0.1, 
 
This result suggests a possibility that GPR50 may affect BACE1 trafficking. 
However, I am aware that this is an incomplete experiment, due to lack of proper 
replicates. Therefore, none of these data can be drawn into a conclusion without 
further investigation.  
5.3.2 The effect of exogenous GPR50 on the subcellular localisation of  
endogenous BACE1 
It was analysed in 5.3.1 that GPR50 is possibly playing a role in the sorting system 
of BACE1. This hypothesis was further investigated by looking at the distribution of 
BACE1 in different organelles with or without the overexpression of GPR50 or 
GPR50del. The same amount and volume of empty vector pDEST40 was transfected 
as control. Three identical replicates were performed for both cell types: HEK293 
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and primary cortical neurons, in which endogenous levels of β-secretase activity 
were found (Kao et al, 2004; Lefranc-Jullien et al, 2005). The percentage of BACE1 
in different subcellular compartments was predicted by that of subcellular markers 
and was compared between different conditions in pair (p40 VS GPR50; p40 VS 
GPR50del; GPR50 VS GPR50del). 
5.3.2.1 The subcellular fractionation of endogenous BACE1/Bace1 and subcellular 
compartment markers 
Mature BACE1 (mBACE1, 65 kDa) in HEK293 cells was detected in bottom 
fractions, and sometimes there were two bands, which might be different 
intermediate forms of BACE1 in the process of secondary modifications (Figure 
5.7.A). These doublets were quantified together as mature BACE1, and they were 
mainly co-fractionated with the plasma membrane marker VLA-2α and the ER 
marker calreticulin (Figure 5.8). Immature BACE1 (imBACE1, 55 kDa) were found 
in lighter fractions that contained the early endosomes and the microsomes 
(fragmented ER).  
Endogenous Bace1 detected in the primary cortical neurons (E18, DIV3) is identical 
to that observed in E18 mouse brain (see chapter 2) (Figure 5.7.B). The majority of 
Bace1 in cultured neurons was mature Bace1 (mBace1), at around 65 kDa and 
appeared highly glycosylated. It was generally located across all the fractions, but 
was enriched in middle fractions, where β-catenin was found (Figure 5.9). The 55 
kDa immature Bace1 (imBace1) was mainly dispersed in heavier fractions, which 
were dominated by the ER marker calreticulin.  
It is interesting that BACE1 in HEK293 cells and Bace1 in neurons seemed to be 
localised at different ends of the fractions. This indicates that the allocation of mature 
β-secretase/immature β-secretase among light membranes and heavy membranes is 
not identical in the two cell types, which might result in different trafficking systems 
of BACE1/Bace1, distinct distribution of β-secretase activity and diversified 






Figure 5.7 Subcellular fractionation of cell lysates transfected with pDEST40, GPR50 or 
GPR50del in A) HEK293 cells; B) primary cortical neurons. Subcellular compartment markers: 
VLA-2α for plasma membrane, EEA1 for early endosomes, calreticulin for ER, β-catenin for 
external organelles and p115 for cis-Golgi. For HEK293 cells, western blotting was 
performed to confirm that the plasmids were successfully transfected and expressed. For 







Figure 5.8 The distribution proportion of immature BACE1, mature BACE1, VLA-2α, EEA1 and calreticulin in each sucrose 
fraction in HEK293 cells. ImBACE1: immature BACE1; mBACE1: mature BACE1. 
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Figure 5.9 The distribution proportion of immature Bace1, mature Bace1, β-catenin, p115 and calreticulin in each sucrose 
fraction in mouse primary cortical neurons. ImBace1: immature Bace1; mBace1: mature Bace1. 
To answer the question whether GPR50/GPR50del are involved in BACE1/Bace1 
trafficking, statistical analysis were applied by correlating the percentages of 
BACE1/Bace1 to those of different compartment markers under the conditions 
overexpressing GPR50/GPR50del, compared with the control condition p40. 
5.3.2.2 Comparing interaction terms of the general linear models 
The general equation of the general linear model was BACE1/Bace1 = a+ 
b×marker+c×dummy variable+d×dummy variable×marker. This model tested 
whether BACE1/Bace1 fractionated with a particular subcellular compartment and 
whether BACE1/Bace1 fractionation with a particular subcellular marker was 
changed by overexpressing GPR50 or GPR50del. 
1) HEK293 cells 
Predictors of general linear model for mBACE1/imBACE1 in HEK293 cells 
included subcellular markers for the early endosome, plasma membrane and ER 
(EEA1, VLA-2α and calreticulin), group membership (p40, GPR50, GPR50del 
transfected groups) and the interaction term (the products of subcellular markers and 
group membership). The test results of the fitted model for BACE1 in HEK293 cells 
are listed in Table 5.8-5.9. The observed significance or trend of significance of each 
predictor, together with the predicted effects for the interaction terms of significance 
or with a trend of significance are summarised in Table 5.10. 
As GPR50 is able to increase BACE1 activity in HEK293 cells (Grünewald, 2011), it 
was hypothesised that GPR50 overexpression would facilitate the co-fractionation of 
mBACE1 with the plasma membrane or the early endosomes, the two putative sites 
for BACE1 activity. GPR50del does not have the same effect on BACE1 activity as 
GPR50, so a different influence between the two on BACE1 fractionation was 
expected.   
According to the general linear model, in HEK293 cells, the percentage of mBACE1 
distributed in the sucrose fractions were significantly correlated with all the three 
markers for the plasma membrane (positive), the early endosomes (negative) and the 
ER (negative). ImBACE1 distribution had a trend of association only with the early 
endosomes (positive) (Table 5.10).  As mBACE1 has much higher activity than 
imBACE1 (Zhong et al, 2007), my results indicated that BACE1 activity mainly 
occurred in the plasma membrane.  
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Compared with the p40 control, the overexpression of either GPR50 or GPR50del 
resulted in a trend of more mBACE1 co-fractionated with VLA-2α (Table 5.10), 
suggesting a larger percentage of mBACE1 distributed at the plasma membrane. Yet, 
there was an opposite direction for imBACE1 only in GPR50 overexpressed cells, in 
which imBACE1 was less associated with the plasma membrane. Thus, GPR50 had 
an additional effect on imBACE1 distribution compared with GPR50del. There was 
no significant difference of BACE1 percentage in any compartment between groups 
GPR50 and GPR50del. However, the predicted slopes suggested that the ratio of 
mBACE1/imBACE1 associated with the plasma membrane in GPR50-transfected 
HEK293 cells was apparently larger than that in p40-transfected or GPR50del-
transfected cells. Thus, my observation supported the hypothesis that the increase of 
BACE1 activity upon GPR50 overexpression in HEK293 cells is at least partly 




Table 5.8 A summary of the general linear model for mature BACE1 in HEK293 cells  
 
mBACE1, GPR50× VLA-2α mBACE1, GPR50del× VLA-2α mBACE1, (GPR50 VS GPR50 del)×VLA-2α 
Adjusted r2=0.215 Partial Eta Squared P-value Adjusted r2=0.180 Partial Eta Squared P-value Adjusted r2=0.475 Partial Eta Squared P-value 
Corrected model 0.248 0.00022** Corrected model 0.215 0.001** Corrected model 0.497 3.4×10-10** 
GPR50 0.027 0.172 GPR50del 0.024 0.205 GPR50 VS GPR50del 0.000 0.909 
VLA-2α 0.218 0.000046** VLA-2α 0.199 0.00011** VLA-2α 0.494 1.2×10-11** 
GPR50 × VLA-2α 0.048 0.069$ GPR50del×VLA-2α 0.040 0.097$ (GPR50 VS GPR50del) 
×VLA-2α 
0.000 0.881 
Predicted slopes P40: 0.519; GPR50: 1.286 Predicted slopes P40: 0.519; GPR50del : 1.239 Predicted slopes GPR50: 1.286; GPR50del : 1.240 
mBACE1, GPR50× EEA1 mBACE1, GPR50del× EEA1 mBACE1, (GPR50 VS GPR50 del)×EEA1 
Adjusted r2=0.049 Partial Eta Squared P-value Adjusted r2=0.049 Partial Eta Squared P-value Adjusted r2=0.074 Partial Eta Squared P-value 
Corrected model 0.089 0.095$ Corrected model 0.089 0.093$ Corrected model 0.113 0.042* 
GPR50 0.000 0.993 GPR50del 0.001 0.852 GPR50 VS GPR50del 0.001 0.825 
EEA1 0.089 0.012* EEA1 0.088 0.012* EEA1 0.113 0.005** 
GPR50× EEA1 0.000 0.987 GPR50del× EEA1 0.002 0.721 (GPR50 VS GPR50del) 
×EEA1 
0.003 0.670 
Predicted slopes P40: -0.352; GPR50: -0.357 Predicted slopes P40: -0.352; GPR50del : -0.266 Predicted slopes GPR50: -0.357; GPR50del : -0.266 
mBACE1 GPR50 × Calreticulin mBACE1 GPR50del × Calreticulin mBACE1, (GPR50 VS GPR50 del)×Calreticulin 
Adjusted r2=0.008 Partial Eta Squared P-value Adjusted r2=0.017 Partial Eta Squared P-value Adjusted r2=0.035 Partial Eta Squared P-value 
Corrected model 0.050 0.322 Corrected model 0.058 0.250 Corrected model 0.076 0.144 
GPR50 0.000 0.998 GPR50del 0.000 0.879 GPR50 VS GPR50del 0.000 0.861 
Calreticulin 0.049 0.064$ Calreticulin 0.058 0.044* Calreticulin 0.076 0.021* 
GPR50×calreticulin 0.000 0.997 GPR50del× 
Calreticulin 
0.001 0.819 (GPR50 VS GPR50del)× 
Calreticulin 
0.001 0.788 
Predicted slopes P40: -0.321; GPR50:- 0.322 Predicted slopes P40: -0.321; GPR50del : -0.402 Predicted slopes GPR50: -0.320; GPR50del : -0.403 




Table 5.9 A summary of the general linear model for immature BACE1 in HEK293 cells  
 
imBACE1, GPR50× VLA-2α imBACE1, GPR50del× VLA-2α imBACE1, (GPR50 VS GPR50 del)×VLA-2α 
Adjusted r2=0.215 Partial Eta Squared P-value Adjusted r2=0.014 Partial Eta Squared P-value Adjusted r2=-0.016 Partial Eta Squared P-value 
Corrected model 0.072 0.163 Corrected model 0.055 0.272 Corrected model 0.027 0.599 
GPR50 0.040 0.095 GPR50del 0.020 0.241 GPR50 VS GPR50del 0.004 0.596 
VLA-2α 0.002 0.706 VLA-2α 0.018 0.268 VLA-2α 0.018 0.270 
GPR50 × VLA-2α 0.070 0.027* GPR50del×VLA-2α 0.040 0.125 (GPR50 VS GPR50del) 
×VLA-2α 
0.007 0.486 
Predicted slopes P40: 0.431; GPR50: -0.308 Predicted slopes P40: 0.431; GPR50del : -0.071 Predicted slopes GPR50: -0.308; GPR50del : -0.070 
imBACE1, GPR50× EEA1 imBACE1, GPR50del× EEA1 imBACE1, (GPR50 VS GPR50 del)×EEA1 
Adjusted r2=0.025 Partial Eta Squared P-value Adjusted r2=-0.001 Partial Eta Squared P-value Adjusted r2=-0.004 Partial Eta Squared P-value 
Corrected model 0.066 0.197 Corrected model 0.041 0.408 Corrected model 0.046 0.357 
GPR50 0.000 0.958 GPR50del 0.002 0.694 GPR50 VS GPR50del 0.003 0.662 
EEA1 0.066 0.032* EEA1 0.040 0.099$ EEA1 0.043 0.085$ 
GPR50× EEA1 0.000 0.925 GPR50del× EEA1 0.008 0.452 (GPR50 VS GPR50del) 
×EEA1 
0.010 0.399 
Predicted slopes P40: 0.207; GPR50: 0.226 Predicted slopes P40: 0.207; GPR50del : 0.078 Predicted slopes GPR50: 0.225; GPR50del : 0.078 
imBACE1 GPR50 × Calreticulin imBACE1 GPR50del × Calreticulin imBACE1, (GPR50 VS GPR50 del)×Calreticulin 
Adjusted r2=-0.041 Partial Eta Squared P-value Adjusted r2=-0.037 Partial Eta Squared P-value Adjusted r2=-0.041 Partial Eta Squared P-value 
Corrected model 0.003 0.973 Corrected model 0.007 0.921 Corrected model 0.003 0.976 
GPR50 0.001 0.825 GPR50del 0.003 0.646 GPR50 VS GPR50del 0.001 0.821 
Calreticulin 0.002 0.725 Calreticulin 0.000 0.999 Calreticulin 0.002 0.730 
GPR50×calreticulin 0.002 0.728 GPR50del× 
Calreticulin 
0.007 0.488 (GPR50 VS GPR50del)× 
Calreticulin 
0.002 0.727 
Predicted slopes P40: -0.087; GPR50:- 0.001 Predicted slopes P40: -0.087; GPR50del : 0.087 Predicted slopes GPR50: 0.000; GPR50del : 0.088 




  Table 5.10 A summary of the predictors of significance or with a trend of significance in the general linear model for mature BACE1 and 
immature BACE1 in HEK293 cells 
HEK293 cells 





















$ +ve (0.00011)** Increased (0.097)



























ER NS NS NS NS NS NS 
**p<0.01, *p<0.05, 0.05<$P<0.1, NS: not significant, +ve: positive, -ve,negative, reference group = p40, the predicted slopes for the 
interaction terms of significance or with a trend of significance are listed. 
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2) Primary cortical neurons 
Predictors of general linear model for mBace1/imBace1 in primary cortical neurons 
included subcellular markers (β-catenin, p115 and calreticulin), group membership 
(p40, GPR50, GPR50del transfected groups) and the interaction term (the products of 
subcellular markers and group membership). The test results of the fitted model for 
Bace1 in primary cortical neurons are listed in Table 5.11-5.12. The observed 
significance or trend of significance of each predictor, together with the predicted 
effect for the interaction terms of significance or with a trend of significance are 
summarised in Table 5.13. 
In primary cortical neurons, GPR50del overexpression had a trend of decreasing 
Bace1 activity compared with the control and a significant suppressing effect 
compared with GPR50 overexpression (see chapter 4). Overexpressed GPR50 had no 
effect compared with the control. Therefore, it was hypothesised that, compared with 
p40 or GPR50, the transfection of GPR50del would decrease the association of 
mBace1 distribution with that of the plasma membrane or the early endosomes, or 
would enhance the association of imBace1 distribution with that of the ER.  
In this general linear model, the distribution percentage of mBace1 was significantly 
correlated to β-catenin (positive) and p115 (negative) no matter which two groups 
were compared. ImBace1 was always associated with calreticulin (positive).  This 
indicates that, in primary cortical neurons, mBace1 was co-fractionated with the 
plasma membrane but excluding cis-Golgi, while imBace1 was co-fractionated with 
calreticulin. The interaction term had a trend of significance when correlation 
between both forms of Bace1 and calreticulin in groups p40 and GPR50del was 
compared. The trends for mBace1 (decreased) and imBace1 (increased) were 
opposite, which meant that in neurons transfected with GPR50del, there was a trend 
of less mBace1 but more imBace1 co-fractionated with the ER marker calreticulin, 
compared with the control group p40. Thus, GPR50del overexpression appeared to 
retain imBace1 in the ER and to impede Bace1 maturation, which will decrease 
BACE1 activity. This effect was unique to GPR50del, even though there were no 
significant differences of Bace1 distribution between cell groups with overexpressed 
GPR50 and overexpressed GPR50del. This observation supported the hypothesis that 
the potential of GPR50del but not GPR50 in decreasing Bace1 activity in primary 
cortical neurons is partly explained by causing less Bace1 undergoing maturation.
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Table 5.11 A summary of the general linear model for mature Bace1 in primary cortical neurons  
 
mBace1, GPR50× β-catenin mBace1, GPR50del× β-catenin mBace1, (GPR50 VS GPR50 del)×β-catenin 
Adjusted r2=0.538 Partial Eta Squared P-value Adjusted r2=0.757 Partial Eta Squared P-value Adjusted r2=0.478 Partial Eta Squared P-value 
Corrected model 0.558 4.6×10-12** Corrected model 0.768 1.7×10-21** Corrected model 0.500 2.7×10-10** 
GPR50 0.018 0.270 GPR50del 0.005 0.568 GPR50 VS GPR50del 0.007 0.500 
β-catenin 0.539 4.8×10-13** β-catenin 0.767 3.2×10-23** β-catenin 0.484 2.4×10-11** 
GPR50 × β-catenin 0.038 0.108 GPR50del×β-
catenin 
0.011 0.385 (GPR50 VS GPR50del) 
×β-catenin 
0.015 0.320 
Predicted slopes P40: 1.064; GPR50: 0.735 Predicted slopes P40: 1.064; GPR50del : 0.947 Predicted slopes GPR50: 0.735; GPR50del : 0.946 
mBace1, GPR50× P115 mBace1, GPR50del× P115 mBace1, (GPR50 VS GPR50 del)×P115 
Adjusted r2=0.030 Partial Eta Squared P-value Adjusted r2=0.027 Partial Eta Squared P-value Adjusted r2=0.023 Partial Eta Squared P-value 
Corrected model 0.071 0.169 Corrected model 0.068 0.183 Corrected model 0.064 0.207 
GPR50 0.000 0.963 GPR50del 0.000 0.956 GPR50 VS GPR50del 0.000 0.993 
P115 0.071 0.026* P115 0.068 0.029* P115 0.064 0.034* 
GPR50× P115 0.000 0.906 GPR50del× P115 0.000 0.889 (GPR50 VS GPR50del) 
×P115 
0.000 0.982 
Predicted slopes P40: -0.159; GPR50: -0.143 Predicted slopes P40: -0.159; GPR50del : -0.140 Predicted slopes GPR50: -0.143; GPR50del : -0.140 
mBace1 GPR50 × Calreticulin mBace1 GPR50del × Calreticulin mBace1, (GPR50 VS GPR50 del)×Calreticulin 
Adjusted r2=0.025 Partial Eta Squared P-value Adjusted r2=0.026 Partial Eta Squared P-value Adjusted r2=-0.031 Partial Eta Squared P-value 
Corrected model 0.066 0.199 Corrected model 0.068 0.187 Corrected model 0.013 0.827 
GPR50 0.003 0.628 GPR50del 0.027 0.176 GPR50 VS GPR50del 0.008 0.466 
Calreticulin 0.044 0.081$ Calreticulin 0.010 0.409 Calreticulin 0.000 0.932 
GPR50×calreticulin 0.006 0.523 GPR50del× 
Calreticulin 
0.050 0.063$ (GPR50 VS 
GPR50del)× Calreticulin 
0.013 0.350 
Predicted slopes P40: 0.440; GPR50:0.206 Predicted slopes P40: 0.440; GPR50del : -0.171 Predicted slopes GPR50: 0.206; GPR50del : -0.171 




Table 5.12 A summary of the general linear model for immature Bace1 in primary cortical neurons  
 
imBace1, GPR50× β-catenin imBace1, GPR50del× β-catenin imBace1, (GPR50 VS GPR50 del)×β-catenin 
Adjusted r2=-0.012 Partial Eta Squared P-value Adjusted r2=-0.022 Partial Eta Squared P-value Adjusted r2=-0.042 Partial Eta Squared P-value 
Corrected model 0.031 0.543 Corrected model 0.021 0.692 Corrected model 0.002 0.989 
GPR50 0.008 0.458 GPR50del 0.002 0.688 GPR50 VS GPR50del 0.001 0.838 
β-catenin 0.011 0.385 β-catenin 0.016 0.290 β-catenin 0.000 0.900 
GPR50 × β-catenin 0.017 0.278 GPR50del×β-
catenin 
0.005 0.542 (GPR50 VS GPR50del) 
×β-catenin 
0.001 0.762 
Predicted slopes P40: -0.310; GPR50: 0.034 Predicted slopes P40: -0. 310; GPR50del : -0.084 Predicted slopes GPR50: 0.034; GPR50del : -0.084 
imBace1, GPR50× P115 imBace1, GPR50del× P115 imBace1, (GPR50 VS GPR50 del)×P115 
Adjusted r2=0.006 Partial Eta Squared P-value Adjusted r2=-0.012 Partial Eta Squared P-value Adjusted r2=0.002 Partial Eta Squared P-value 
Corrected model 0.048 0.341 Corrected model 0.031 0.543 Corrected model 0.044 0.376 
GPR50 0.000 0.902 GPR50del 0.000 0.907 GPR50 VS GPR50del 0.000 0.983 
P115 0.045 0.079$ P115 0.029 0.157 P115 0.044 0.080$ 
GPR50× P115 0.001 0.752 GPR50del× P115 0.001 0.768 (GPR50 VS GPR50del) 
×P115 
0.000 0.957 
Predicted slopes P40: -0.104; GPR50:- 0.149 Predicted slopes P40: -0.104; GPR50del : -0.158 Predicted slopes GPR50: -0.149; GPR50del : -0.158 
imBace1 GPR50 × Calreticulin imBace1 GPR50del × Calreticulin imBace1, (GPR50 VS GPR50 del)×Calreticulin 
Adjusted r2=0.434 Partial Eta Squared P-value Adjusted r2=0.400 Partial Eta Squared P-value Adjusted r2=0.405 Partial Eta Squared P-value 
Corrected model 0.458 4.1×10-9** Corrected model 0.426 2.9×10-8** Corrected model 0.431 2.2×10-8** 
GPR50 0.012 0.368 GPR50del 0.021 0.230 GPR50 VS GPR50del 0.003 0.667 
Calreticulin 0.451 2.0×10-10** Calreticulin 0.424 1.0×10-9** Calreticulin 0.416 1.7×10-9** 
GPR50×calreticulin 0.021 0.236 GPR50del× 
Calreticulin 
0.040 0.098$ (GPR50 VS 
GPR50del)× Calreticulin 
0.005 0.581 
Predicted slopes P40: 0.920; GPR50:1.270 Predicted slopes P40: 0.920; GPR50del : 1.490 Predicted slopes GPR50: 1.270; GPR50del : 1.490 




  Table 5.13 A summary of the predictors of significance or with a trend of significance in the general linear model for mature Bace1 and 
immature Bace1 in primary cortical neurons 
primary cortical neurons 






























ER +ve (0.081)$ NS NS 
Reversed 
 +ve→-ve (0.063) $ NS NS 
imBace1 
Plasma 
membrane NS NS NS NS NS NS 
Cis-Glogi -ve (0.079) $ NS NS NS 
-ve 
(0.080) $ NS 




 (0.098) $ 
+ve 
(1.7×10-9) ** NS 
**p<0.01, *p<0.05, 0.05<$P<0.1, NS: not significant, +ve: positive, -ve,negative, reference group = p40, the predicted slopes for the 





In this chapter, the relationship between endogenous GPR50 level and the percentage 
of endogenous BACE1 at the surface of HEK293 group cells was investigated. In 
most of the cells, GPR50 and cell surface BACE1 seemed to express in an exclusive 
manner. Statistical analysis showed that endogenous GPR50 expression level in 
HEK293 cells was negatively correlated with the proportion of cell surface BACE1 
level against total BACE1 level. This indicates that GPR50 is likely to be involved in 
the trafficking of BACE1 at the endogenous level. However, this result requires 
replication before a solid conclusion can be drawn.  
Further investigation demonstrated that GPR50 plays a part in the subcellular 
localisation of BACE1, and that GPR50 and its deletion/SNP variant (GPR50del) 
may have differential effects in different cell lines.  
In HEK293 cells, GPR50 transfection resulted in a trend of more mature BACE1 
(mBACE1) and less immature BACE1 (imBACE1) associated with the plasma 
membrane (VLA-2α). GPR50del had a similar positive trend of significant effects on 
the correlation between mBACE1 and the plasma membrane, but had no effect on 
imBACE1, compared to either p40 or GPR50. The plasma membrane is one of the 
putative sites of BACE1 activity, and imBACE1 has much less β-secretase activity 
than mBACE1 (Zhong et al, 2007). Thus, my observations are in agreement with the 
BACE1 activity assay results that GPR50, but not GPR50del increases BACE1 
activity in HEK293 cells (Grünewald, 2011). One potential mechanism is that 
GPR50 helps to adjust the ratio of mBACE1/imBACE1 at the plasma membrane. 
This ability of GPR50 has already been suggested by the result of correlation 
between the level of endogenous GPR50 and the ratio of cell surface BACE1/total 
BACE1. The traditional theory is that BACE1 becomes mature once the protein 
moves out of the trans-Golgi network (TGN), and then cycles between the TGN, the 
plasma membrane and the early endosomes (Huse et al, 2000). My results also 
demonstrated that imBACE1 in HEK293 cells was not significantly associated with 
the plasma membrane. However, GPR50 overexpression significantly reduced the 
variance of imBACE1 distribution explained by that of the plasma membrane marker. 
Thus, the decreased amount of BACE1 at the cell surface when the cells are 
expressed with GPR50 might be the immature isoform of BACE1. This is interesting 
and more investigation on the distribution of mBACE1 and imBACE1 in different 
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cellular compartments may help to understand the complicated trafficking network of 
BACE1 and its sites of functional cleavage. 
In primary cortical neurons, GPR50del overexpression appears to alter Bace1 
distribution to a larger extent than GPR50 overexpression, reflected by more 
immature Bace1 correlated with the ER (calreticulin), compared with the control 
condition. This indicates that more pro-Bace1 is likely to be retained in the ER in 
GPR50del transfected cells, thus less Bace1 becomes mature and enzymatically 
active. The potential effect of GPR50del in Bace1 maturation might explain the 
result that GPR50del overexpression in neurons shows a trend of reducing Bace1 
activity (chapter 4), because less mature Bace1 is transported to Bace1 cleavage sites. 
In summary, I have found that GPR50/GPR50del might be one of the regulators 
involved in the complex network of the BACE1/Bace1 trafficking system. Also, my 
results demonstrated how complicated the network of β-secretase trafficking could 
be, and it could even be diversified and associated with different modulators 
affecting different isoforms of BACE1 (immature and mature) during the cleavage of 
different substrates in different cell lines. 
5.4.1 The GPR50 C-terminal tail might be a key region that mediates the role 
of GPR50 in β-secretase trafficking 
I and others have shown that GPR50 and the variant GPR50del demonstrate diversity 
in the regulation of BACE1 activity, not only in HEK293 cells, but also in mouse 
primary cortical neurons. Interestingly, in the trafficking experiment of BACE1 
demonstrated in this chapter, the two isoforms of GPR50 seem to have effects that 
are consistent with their effects, in the corresponding cell types, in the BACE1 
activity assays {(Grünewald, 2011), my chapter 4}. My results provide insights for 
the discussion about the close relation between β-secretase trafficking system and its 
activity levels.  
It is notable that the variation in the peptide sequence of GPR50del is confined to the 
C-terminal domain, a structure that is believed to be a key region for G-protein 
coupled receptors to exert their functions, including modification during activation 
and protein-protein interaction. GPR50 has a long C-terminal domain (CTD), 
occupying over half of its protein sequence (residues 295 – 617). Deleting either the 
N-terminal or the C-terminal of GPR50 changes its subcellular location, with more 
162 
 
protein retained in the internal compartments (Grünewald, 2011; Li et al, 2011). Full 
length GPR50 and the CTD can be translocated to the perinuclear area and nuclear 
compartment respectively by co-expressing with TIP60, while GPR50 lack of CTD 
is not affected (Li et al, 2011). In addition, deletion of GPR50 CTD suppresses the 
inhibitory effect of GPR50 on the melatonin receptor MT1 signalling without 
affecting their heterodimerisation, suggesting that the GPR50 CTD modifies the 
interaction of other binding partners to MT1 (Levoye et al, 2006).  GPR50 del does 
not display an altered localisation pattern compared to GPR50 (Grünewald, 2011), 
but the deletion/SNP in the CTD of this variant may damage or modify the 
interaction between GPR50 and its interactors.  
The yeast two-hybrid study using both the CTDs of GPR50 and GPR50del as bait 
identified overlapping interactors of the two, but also potentially unique binders, for 
example SNX6 of GPR50 CTD and RTN3 of GPR50del CTD (Grunewald et al, 
2009). BACE1 was not identified in the screen, and there is no direct evidence 
showing that an altered interaction exists between GPR50-BACE1 and GPR50del-
BACE1. Therefore, it is also possible that GPR50 and GPR50del influence the 
trafficking of BACE1 by interacting with its known sorting regulators, such as SNX6 
and RTN3, which are both proved transporters of BACE1 (Okada et al, 2010; Shi et 
al, 2009). However, the initial association between GPR50/GPR50del and their 
differentiated interactors needs to be verified. 
5.4.2 Summary 
Here I showed that in HEK293 cells, GPR50 seems to increase the ratio of 
mBACE1/imBACE1 at the cell surface, opposite to the sorting direction of RTN3 on 
BACE1 (Deng et al, 2013; Shi et al, 2009), which may correspond to their opposite 
effects on BACE1 activity. In neuronal cells, GPR50del overexpression appears to 
favour mature Bace1 exit from the external compartments and immature Bace1 
retaining in the ER, which is identical to the transporting orientation of RTN3 on 
BACE1 (Deng et al, 2013; Shi et al, 2009) and RTN3 on GPR50del (Grünewald, 
2011). This suggests that the regulative effects on BACE1 localisation and activity 
by GPR50/GPR50del might be RTN3-related. The connection between GPR50 and 




5.4.3 Further experiments 
In this chapter, I have found the answer to my original question: GPR50/GPR50del 
indeed has a role in regulating BACE1 trafficking. However, there is seemingly a 
discrepancy in the results obtained by the cell surface labelling technique and the 
subcellular fractionation. It appears that in HEK293 cells, cells expressed with 
endogenous GPR50 have reduced ratio of cell surface BACE1/total BACE1 (cell 
surface labelling technique), while GPR50 overexpression has a potential in 
increasing the ratio of mBACE1/imBACE1 in the plasma membrane (subcellular 
fractionation). These two observations are not necessarily contradictory. On the one 
hand, the cell surface labelling technique did not distinguish mBACE1 from 
imBACE1; on the other hand, and more importantly, there are two putative 
functional sites of BACE1 activity: one on the cell surface and the other in the 
internal compartment-the endosomes. There is a dynamic circulation of BACE1 
between the two sites. Locating at the cell surface is not the opposite of being 
localised in the endosomes. Instead, accumulation in the one site might lead to 
accumulation in the other site. Even if the majority of cell surface BACE1 is mature, 
it can undergo internalisation to the endosomes, while BACE1 in the endosomes can 
also be recycled to the cell surface. To further clarity this situation, the next step is to 
use imBACE1/mBACE1-specific antibody to examine which isoform(s) can be 
localised at the cell surface. Then, a time-lapse internalisation experiment of cell 
surface BACE1, with or without the overexpression of GPR50, could be performed. 
Specific organelle markers are required to identify where BACE1 is directed to after 








6 Co-expression of GPR50 and 





In previous chapters, the subcellular sites at which GPR50 potentially interacts with 
BACE1 were identified. Next, I wanted to investigate in which regions the 
interaction between GPR50 and BACE1 could occur. As BACE1 has high activity 
levels in the brain, I investigated the relationship between mRNA levels of GPR50 
and BACE1 in brain regions of human and mouse using data from public resources 
(BrainCloud for human; BrainStars for mouse). Then, I sought to look at the protein 
expression of endogenous Gpr50 and Bace1 in adult mouse brain. Identification of 
co-localisation regions of the two may indicate a regulatory role of Gpr50 on Bace1 
function, or vice versa.  
6.1.1 GPR50 distribution in the sub-regions of brain tissue 
GPR50 was originally cloned from a human pituitary cDNA library (Reppert et al, 
1996). GPR50 protein is detected consistently in the pituitary and hypothalamic 
regions of adult human, sheep, rat, mouse and hamster by immunohistochemistry 
(Drew et al, 2001; Drew et al, 1998; Sidibe et al, 2010). Recently, 
immunohistochemistry and real-time qPCR studies have revealed an enlarged 
distribution of Gpr50 in several new brain areas of rodents (Batailler et al, 2012; 
Grunewald et al, 2012), including some sub-regions of the cortex (i.e. entorhinal 
cortex), the hippocampus (i.e. CA1), and the amygdala.  These observations suggest 
that, apart from being potentially functional in the neuroendocrine system, GPR50 
may play a role in the memory processing and storage. 
Our group has published a thorough report on the mRNA levels and protein levels of 
Gpr50 in mouse brain during embryonic development and in the early adulthood 
when brain development continues through puberty (Grunewald et al, 2012). Gpr50 
mRNA was detected with low expression levels from E13, peaked at E18 and 
increased again at week 5. At the developmental time-points E18 and P7, Gpr50 
appeared to be highly expressed in specific regions, such as in the thalamus, the 
hypothalamus, the midbrain, the pons and the medulla. In particular, Gpr50 mRNA 
was more highly expressed in the frontal regions (i.e. the entorhinal cortex, the 
olfactory bulb) at week 5 only.  
In E18 mouse brain, Gpr50 protein expression had high levels in the frontal cortex, 
the posterior cortex and the hypothalamus; moderate levels in the thalamus and the 
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medulla; and minor levels in the midbrain and the pons (Grunewald et al, 2012). In 
adult mouse brain, the expression sites of Gpr50 protein were the neurons in the 
hypothalamus, the cortex, the dentate gyrus, the superior colliculus, the pons; the 
vimentin-negative cells in the hypothalamic regions; and the neurotransmitter-related 
cells in the brain stem, such as the noradrenergic nuclei in the locus coeruleus, the 
serotonergic nuclei in the pontine grey and the dopaminergic nuclei in the substantia 
nigra. Other researchers have revealed slightly different sites of Gpr50 protein 
distribution in mouse brain. For instance, Sidibe and Batailler reported that there was 
no immunoreactivity of Gpr50 in the mouse hippocampus (Batailler et al, 2012; 
Grunewald et al, 2012; Sidibe et al, 2010). This might be attributed to the different 
strains and sexes of the mice used for investigation. 
6.1.2 BACE1 distribution in the sub-regions of brain tissue 
BACE1 is abundantly expressed in brains of both normal human and Alzheimer’s 
disease (AD) patients (Coulson et al, 2010; Vassar et al, 1999). In human, BACE1 
transcripts were found with robustly higher expression in various brain sub-regions 
and the pancreas than other peripheral tissues. In situ hybridisation signal of Bace1 
was observed in multiple regions of the adult rat brain, with the strongest signal in 
the hippocampus, the cortex, and the cerebellum (Vassar et al, 1999). In mouse, 
during the prenatal and postnatal stage, Bace1 mRNA was detected in the rudimental 
brain, cranial and spinal ganglia, kidney, and developing hematopoietic organs 
(Marcinkiewicz & Seidah, 2000). In adult mouse brain, Bace1 mRNA had high 
levels in the pyramidal cells in layers III and V of the cortex and in the dorsal 
thalamus, and peaked in the CA1 and dentate gyrus of the hippocampus 
(Marcinkiewicz & Seidah, 2000). 
The expression of Bace1 protein in mouse brain was robust during the prenatal stage, 
and was enhanced after birth, especially during the first postnatal week (Hebert et al, 
2008). The protein level of mouse Bace1 in the brain lysates was decreased after 4 
weeks and remained stable up to 1 year old. Bace1 was widely distributed in the 
adult mouse brain, with the highest protein level detected in the cerebellum (Hebert 
et al, 2008). Yet, Bace1 protein was predominantly expressed in the mouse primary 





6.1.3 Introduction to experiments 
In this chapter, I investigated the mRNA levels of GPR50 and BACE1, as well as 
where their expression is correlated, using publicly available data (BrainCloud, 
BrainStars). The protein levels of Gpr50 and Bace1 in the key brain regions of adult 
C57BL/6 mouse were further analysed by fluorescent immunohistochemistry.  
6.2 Materials and methods 
6.2.1 Summary of expression data from public database 
6.2.1.1 The mRNA expression data of human GPR50 and BACE1 from BrainCloud 
The BrainCloud database (Colantuoni et al, 2011) provides data of genome-wide 
gene expression in the human post-mortem dorsolateral prefrontal cortex (DLPFC) 
grey matter of normal subjects across the lifespan (PFC for prenatal subjects). The 
269 samples were collected from both male (N=177) and female (N=92), with an age 
range from -0.50 to 78.23 years (negative numbers refer to the prenatal age 
calculated back from day 0). The ethnicity of the subjects includes Caucasian 
(N=112), African American (N=147), Asian (N=6) and Hispanic (N=4).  
The normalised expression levels of selected genes (GPR50 and BACE1) are log2 of 
the ratio of sample signal to the reference signal (reference: pooled RNA from all the 
subjects). The length of the probes is 70 bp. The probe for GPR50 (Illumina 22996) 
is located within exon 2, from 1472 bp to 1541 bp, recognising both variants: GPR50 
and GPR50del. The probe ID for BACE1 (Illumina 1634) is located within exon 1, 
from 17 bp to 86 bp, recognising all the five known variants: BACE1 a-e (see 
chapter 2, Figure 2.1). Statistical analysis was performed using SPSS 19 software 
(IBM Armonk, New York). Comparisons of expression levels for each gene among 
categorical factors were made with a general linear model. Findings where p<0.05 
were considered significant. Correlation between expression levels of GPR50 and 
BACE1 were tested by Pearson’s correlation analysis or by fitting the general linear 
model with the main effects and/or the interaction effect of the significant factors. 
6.2.1.2 The mRNA expression data of mouse Gpr50 and Bace1 from BrainStars 
The BrainStars (or B*) database (Kasukawa et al, 2011) has a genome-wide 
expression profile in 51 adult mouse CNS regions (Table 6.1). All the mice were 
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male 5-week old Balb/c mice. Each CNS region was collected from 30-150 mice and 
was sampled every 4 hours (5-25 mice at each time point). The RNA of pooled 
samples from the 6 time points was purified and measured with Affymetrix 
GeneChip Mouse Genome 430 2.0 arrays. Every CNS region was independently 
sampled twice (N=2). All expression values were log2-transformed. The probe IDs 
for Gpr50 and Bace1 analysed in this chapter were “1450346_at” and 
“1455826_a_at”, the basic description of which can be found in NetAffx™ Analysis 
Centre (http://www.affymetrix.com/analysis/index.affx). Probe 1450346_at detects 
one isoform of mouse Gpr50 (Ensembl ID: ENSMUST00000070449), and probe 
1455826_a_at detects two isoforms of mouse Bace1 (Ensembl ID: 
ENSMUST00000034591; ENSMUST00000078111 ). The analysis of expression 
levels of Gpr50 and Bace1 and their correlation was assessed by the general linear 
model. 
Table 6.1 The 51 adult mouse CNS regions investigated in BrainStars database 





lateral septal nucleus LS Telencephalon 6.1318 10.3178 
retrosplenial cortex RS Telencephalon 6.3180 9.6215 
cerebral cortex motor Cx motor Telencephalon 6.3941 9.7967 
cerebral cortex cingulate Cx cingulate Telencephalon 6.3210 10.1160 
olfactory bulb anterior OB anterior Telencephalon 6.7000 9.7020 
olfactory bulb posterior OB posterior Telencephalon 6.5443 9.7473 
piriform cortex Pir Telencephalon 6.7011 9.3700 
olfactory tubercle Tu Telencephalon 6.5230 9.3621 
ventral subiculum ventral S Telencephalon 6.6795 9.5336 
CA1 (hippocampus) CA1 Telencephalon 6.3631 9.1722 
CA2 / CA3 (hippocampus) CA2/CA3 Telencephalon 6.4274 9.3791 
dentate gyrus (hippocampus) DG Telencephalon 6.3326 9.6029 
amygdala anterior A anterior Telencephalon 6.3624 9.8866 
amygdala posterior A posterior Telencephalon 6.5208 9.7353 
globus pallidus GP Telencephalon 6.4735 9.5616 
caudate putamen lateral CPu lateral Telencephalon 6.4077 9.8646 
caudate putamen medial CPu medial Telencephalon 6.2898 9.7176 
mediodorsal thalamic 
nucleus 
MD Thalamus 6.3562 9.4823 
ventral anterior thalamic 
nucleus / ventrolateral 
thalamic nucleus 
VA/VL Thalamus 6.3335 10.2648 
ventral posteromedial 
thalamic nucleus / ventral 
posterolateral thalamic 
nucleus 
VPM/VPL Thalamus 6.2017 9.8543 
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lateral geniculate body LG Thalamus 6.4602 9.9836 
medial geniculate nucleus MG Thalamus 6.2462 9.5314 
habenular nucleus Hb Thalamus 6.4523 8.8036 
mammillary body M Hypothalamus 7.1142 9.7956 
median eminence ME Hypothalamus 9.4463 8.8700 
suprachiasmatic nucleus SCN Hypothalamus 6.5090 9.2723 
medial preoptic area MPA Hypothalamus 7.0264 9.5304 
supraoptic nucleus SO Hypothalamus 6.5360 10.5202 
paraventricular 
hypothalamic nucleus 
Pa Hypothalamus 6.5810 9.2265 
subparaventricular zone 
ventral 
SPa ventral Hypothalamus 6.9833 9.1177 
subparaventricular zone 
dorsal 
SPa dorsal Hypothalamus 7.4874 9.5330 
dorsomedial hypothalamic 
nucleus 
DM Hypothalamus 7.7009 8.9431 
ventromedial hypothalamic 
nucleus 
VMH Hypothalamus 6.5731 10.1043 
arcuate hypothalamic 
nucleus 
Arc Hypothalamus 9.0252 9.3724 
lateral hypothalamus LH Hypothalamus 6.5443 9.7238 
periaqueductal gray PAG Mesencephalon 6.2105 9.5862 
superior colliculus SC Mesencephalon 6.6232 9.3494 
inferior colliculus IC Mesencephalon 6.2050 9.6536 
ventral tegmental area VTA Mesencephalon 6.5783 9.4713 
substantia nigra SN Mesencephalon 6.3696 9.9221 
dorsal tegmental nucleus Tg Mesencephalon 6.5031 9.5541 
pontine nucleus Pn Pons 6.5253 9.6754 
medial vestibular nucleus MVe Pons 6.3779 9.7901 
cerebellar cortex vermis Cb vermis Cerebellum 6.3211 9.5993 
cerebellar cortex lobe Cb lobe Cerebellum 6.2273 9.5838 
cerebellar nucleus Cb nucleus Cerebellum 6.1686 10.2940 
spinal cord anterior spinal cord 
anterior 
spinal cord 6.2284 10.0596 
spinal cord posterior spinal cord 
posterior 
spinal cord 6.2664 9.9500 
retina Retina Misc 6.1448 9.6205 
corpus pineal Pineal Misc 6.3815 8.9608 
pituitary Pituitary Misc 6.5628 8.6560 





6.2.2 Immunohistochemistry (IHC) 
The 12-week old female C57BL/6 mice were killed by cervical dislocation. This was 
performed by the technicians in Biomedical Research Resources Unit, Western 
General Hospital, Edinburgh. The mouse brains were immediately transferred to ice 
cold PBS, followed by the fixation in 70% ethanol at 4oC for 12 hr (Grunewald et al, 
2009; Grunewald et al, 2012). The fixed brains were embedded in paraffin wax and 
cut into 6 μm coronal sections (Bregma: -1.64 mm) on a Leica microtome. Sections 
were placed onto microscope slides (Superfrost Plus adhesion, 25 mm×75 mm×1 
mm, Fisher Scientific) and dried at 37oC overnight.  
Sections were de-waxed through a series of alcohols: 100% xylene 5 min×2, 100% 
ethanol 5 min×2, 70% ethanol 5 min×2, running tap water 5 min, dH2O 5 min. The 
sections were loaded onto the Shandon Sequenza slide racks (Thermo Scientific) and 
washed with PBS for 5 min. Tissues were permeabilised with 0.1% Triton X-100 
(Sigma) in PBS for 30 min, followed by two washes with PBS/0.02% BSA. Proteins 
were denatured by 6 M guanidine hydrochloride in 50 mM Tris-HCl (pH 7.4) for 10 
min, followed by three washes with PBS/0.02% BSA. Then sections were incubated 
with 10% donkey serum (from secondary antibody host, Sigma) in PBS/0.02% BSA 
for 1 hr. All the above mentioned steps were performed at room temperature. After 
the blocking, slides were incubated with the primary antibodies diluted in PBS at 4oC 
for 16 hr. The primary antibodies used in this chapter include: GPR50 goat (1:10, 
Santa Cruz), BACE1 rabbit2 (1:300, Covance), BACE1 goat (1:50, R&D) (See Table 
2.2 for details). Slides were washed three times with PBS/0.02% BSA and blocked 
again with 10% donkey serum in PBS/0.02% BSA at room temperature for 30 min. 
Sections were incubated at room temperature for 1 hr with fluorescent secondary 
antibodies (Alexa Fluor® donkey-anti-goat/rabbit 488/594, Invitrogen, see Table 2.3) 
diluted in PBS/0.02% BSA/10% donkey serum, followed by three washes with 
PBS/0.02% BSA. Coverslips were mounted onto slides using Mowiel/DAPI (Vector 
labs) and stored at 4oC before viewing. 
6.3 Results 
6.3.1 The mRNA expression levels of GPR50 and BACE1 in human DLPFC 
As the samples of human post-mortem DLPFC grey matter (PFC for prenatal 
subjects) collected in BrainCloud came from individuals with different ages, each 
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data point was viewed as a single case, irrespective of gender or ethnic background. 
Therefore, outliers were not removed from the dataset.  The mRNA expression 
profiles of human GPR50 and BACE1 are shown in Figure 6.1. The fitted curves 
represented by the red dots were generated by local regression analysis (adapted 
from BrainCloud). 
The most significant changes of expression for both genes occurred during the 
prenatal stage (week 14-20). In particular, there was a peak of GPR50 level at foetal 
week 17. BACE1 mRNA level appeared to increase continuously during the prenatal 
period. Both of the two genes were stably expressed on average after birth, but with 
great variance among individuals.  
Then two factors were taken into account that might influence the expression levels 
of GPR50 or BACE1 thus contributing to the covariance of the correlation between 
the two genes: 
1) Age. GPR50 expression was identified in the dentate gyrus of elderly 
individuals and AD patients (Hamouda et al, 2007). BACE1 is the key 
enzyme in the pathology of age-dependent AD (Vassar et al, 1999).  
2) Sex. GPR50 has been identified as a risk factor for bipolar disorder in female 
subjects (Thomson et al, 2005). BACE1 levels in human hippocampus were 
found correlated with sex (Marballi et al, 2012).  
Meanwhile, because the expression patterns of GPR50 and BACE1 have shown 
obvious differences between gestational period and the period after birth, the data 





Figure 6.1 The mRNA expression profiles of GPR50 and BACE1 in human DLPFC, adapted 
from BrainCloud. The corresponding region of foetal samples was PFC. 500 ng of each total 
RNA sample was used for transcription to obtain the mRNA expression level. The age scale 
was demonstrated differently for prenatal subjects (in gestational weeks) than in all the 
other subjects who were sampled after birth (in years). Each black dot represents an 
individual subject. The red dots represent Loess fit (separate fit for foetal data and for the 






6.3.1.1 Correlation between mRNA expression levels of GPR50 and BACE1 in 
human PFC during the prenatal stage 
The timespan of prenatal stage in this dataset was from 14 to 20 weeks of gestation. 
The age of the prenatal subjects was not correlated with sex (p=0.266). The general 
linear model was run to assess the main effects of age and sex on GPR50 and 
BACE1 mRNA levels (Table 6.2). The ANOVA/ANCOVA analysis was used to test 
for differences.  It is revealed that GPR50 levels were not affected by the foetal age 
(p=0.312) or sex (p=0.613). The prenatal BACE1 level was significantly associated 
with age (p=3.2×10-7), but not affected by sex (p=0.892). BACE1 mRNA level in 
PFC was positively correlated with the foetal age (r=0.736, p=1.4×10-7, Figure 6.2). 
Further, there was a trend of positive correlation between the mRNA levels of 
prenatal GPR50 and BACE1 in human PFC during the gestational week 14-20 
(r=0.271, p=0.1, Table 6.3).  
Table 6.2 The general linear model using gestational week and sex to predict prenatal 
GPR50 and BACE1 mRNA level in human PFC 





0.580 0.565 0.032  
Week 1.054 0.312 0.029 1.761 
Sex 0.260 0.613 0.007 0.075 





20.066 1.2×10-6** 0.541  
Week 39.581 3.2×10-7** 0.531 10.094 






Figure 6.2 The scatterplot of prenatal BACE1 mRNA level and gestational week in human 
PFC 
Table 6.3 The Pearson’s correlation analysis of prenatal GPR50 and BACE1 mRNA levels 
during the gestational week 14-20 in human PFC 
Correlations 
Week 14-20 BACE1_prenatal 
GPR50_prenatal Pearson Correlation 0.271 
Sig. (2-tailed) 0.100 
N 38 
 
6.3.1.2 Correlation between mRNA expression levels of GPR50 and BACE1 in 
human DLPFC sampled after birth 
The age of subjects sampled after birth ranged from 2 days to 78.23 years. The age of 
the “after birth” subjects was not correlated with sex (p=0.191). The general linear 
model was run to assess the main effects of age and sex on GPR50 and BACE1 
mRNA levels. The ANOVA/ANCOVA analysis was used to test for differences.  
The mRNA expression of neither GPR50 nor BACE1 was affected by age or sex 
(p>0.05, Table 6.4).  However, the levels of GPR50 and BACE1 mRNA after birth 
were negatively correlated, even though the correlation was very week (r=-0.140, 




Table 6.4 The general linear model using age and sex to predict GPR50 and BACE1 mRNA 
level in human DLPFC sampled after birth 





0.559 0.573 0.005  
Age 0.855 0.356 0.004 -0.001 
Sex 0.185 0.667 0.001 0.013 





0.061 0.940 0.001  
Age 0.002 0.968 0.000 5.6×10-5 
Sex 0.123 0.726 0.001 0.022 
Table 6.5 The Pearson’s correlation analysis of GPR50 and BACE1 mRNA levels in human 
DLPFC sampled after birth 
Correlations 
 BACE1_after birth 
GPR50_after birth Pearson Correlation -0.140 
Sig. (2-tailed) 0.033* 
N 231 
*. Correlation is significant at the 0.05 level (2-tailed). 
 




Next, a general linear model to predict BACE1 mRNA level after birth 
(BACE1_after birth) was fitted using sex, age and GPR50 mRNA level after birth 
(GPR50_ after birth) as main effects and including the interaction term of sex and 
GPR50_ after birth, age and GPR50_ after birth (Table 6.6). The age of the subjects 
or the interaction of age and GPR50_ after birth did not have significant effects 
(p>0.05), while the sex had a trend of influencing BACE1_ after birth (p=0.054). 
Interestingly, both GPR50_ after birth (p=0.029) and the interaction of sex and 
GPR50_ after birth had a significant effect on BACE1_ after birth (p=0.002). 
Importantly, the correlation between GPR50_ after birth and BACE1_ after birth 
occurred in female subjects (r=-0.372, p=0.001), but not in male subjects (r=0.0024, 
p=0.977) (Figure 6.4).   
Table 6.6 The general linear model with the interaction term to predict BACE1 mRNA level 
in human DLPFC sampled after birth 
BACE1_after birth F P-value Partial Eta 
Squared 
B 
Corrected model  
Adjusted r2=0.041 
2.962 0.013* 0.062  
Age 0.060 0.806 0.000 0.000 
Sex 3.761 0.054$ 0.016 0.136 
GPR50_ after birth 4.807 0.029* 0.021 -0.968 
Age × GPR50_ after birth 0.338 0.562 0.001 0.863 
Sex ×GPR50_ after birth 9.849 0.002** 0.042 0.004 
** p< 0.01 level, * p< 0.05, $p< 0.1. 
 
Figure 6.4 The scatterplot of mRNA levels of GPR50 and BACE1 in human DLPFC sampled 
after birth in male and female subgroups  
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6.3.2 The mRNA levels of Gpr50 and Bace1 in Balb/c mouse 
Next, the mRNA expression of Gpr50 and Bace1 in mice was investigated using the 
data retrieved from the BrainStars database. All these mice had the same strain 
(Balb/c), age (5 weeks, adult) and sex (male). The analysis was designed to study the 
mRNA levels of Gpr50 and Bace1 across sub-regions of the mouse brain. The 
mRNA expression profiles of Gpr50 and Bace1 in 51 CNS regions of adult Balb/c 
mouse (Table 6.1) are shown in Figure 6.5 and 6.7 (adapted from BrainStars). Gpr50 
mRNA was expressed with dominant levels in the median eminence (ME) and the 
arcuate hypothalamic nucleus (Arc). Bace1 mRNA had expression in multiple brain 
regions, with the highest levels in the lateral septal nucleus (LS), the supraoptic 
nucleus (SO) and the cerebellar nucleus (Cb nucleus). Interestingly, these three areas 
with robust Bace1 expression had lowest Gpr50 levels, while some other areas with 
high Gpr50 expression, for instance the median eminence, had minor Bace1 levels. 
The mRNA levels of Gpr50 and Bace1 across all the 51 CNS regions of adult Balb/c 
mouse were negatively correlated in general, revealed by Pearson’s correlation 
analysis (r=-0.398, p=0.004, Table 6.7, Figure 6.7.A). Further analysis showed that, 
there was a significantly negative correlation between the mRNA levels of the two 
genes across the telencephalon sub-regions (r=-0.496, p=0.043, Figure 6.7.B). A 
trend of significance was identified across the sub-regions of hypothalamus (r=-0.523, 
p=0.081).  No significant correlation of Gpr50 and Bace1 mRNA was found across 
the thalamus (p=0.570) or the mesencephalon (p=0.239). The relationship between 
the levels of the two genes was not investigated in sub-regions (pons, cerebellum, 





Figure 6.5 The expression profile and distribution map of Gpr50 mRNA in 51 CNS regions 
of adult Balb/c mouse. The figures were cited from BrainStars. For abbreviations of the 







Figure 6.6 The expression profile and distribution map of Bace1 mRNA in 51 CNS regions 
of adult Balb/c mouse. The figures were cited from BrainStars. For abbreviations of the 







Table 6.7 The Pearson’s correlation analysis of adult mouse Gpr50 and Bace1 mRNA levels 
across 51 CNS regions and across CNS sub-regions of adult Balb/c mouse                                       
 N r P-value 
All 51CNS regions 51 -0.398 0.004** 
Telencephalon 17 -0.496 0.043* 
Thalamus 6 -0.296 0.570 
Hypothalamus 12 -0.523 0.081$ 
Mesencephalon 6 -0.569 0.239 
Pons 2 - - 
Cerebellum 3 - - 
spinal cord 2 - - 
Misc 3 - - 
** p< 0.01 level, * p< 0.05, $p< 0.1, - not tested ( N<4) 
 
 
Figure 6.7 The scatterplots of mRNA levels of Gpr50 and Bace1 across different CNS 
regions of adult Balb/c mouse in A) all 51 CNS regions and B) sub-regions of CNS. Misc: 





6.3.3 The protein levels of endogenous Gpr50 and Bace1 across the brain 
regions of wild-type C57BL/6 mice 
Three brains of female adult C57BL/6 mice were used to investigate the protein 
levels of endogenous Gpr50 and Bace1 by fluorescent immunohistochemistry (IHC). 
6.3.3.1 The detection of Bace1 protein in adult mouse brain by 
immunohistochemistry 
The specific staining by the BACE1 rabbit2 antibody in adult mouse brain was 
verified through the pre-absorption with its blocking peptide (Figure 6.8). The 
BACE1 goat antibody co-localised with the BACE1 rabbit2 antibody in most of 
brain regions (Figure 6.9.A, an example of the cortical area). However, an additional 
signal was detected only by the BACE1 goat antibody in the thalamic region (Figure 
6.9.B). The difference in the detection by these two antibodies might be related to 
their different antigens, as the antigen of BACE1 rabbit2 antibody is within the 
cytosolic C-terminal, while the antigen of BACE1 goat antibody is located at the 
extracellular N-terminal. The peptide for the goat antibody was not available to 
further test its specificity in the IHC application. Therefore, the BACE1 rabbit2 
antibody was used in the following IHC experiments.  
It was found that Bace1 protein was widely distributed across the coronal section of 
adult mouse brain (Figure 6.10), with high expression levels at the amygdalar 
nucleus, the endopiriform nucleus, the neuronal layer II/III/V of isocortex, the CA2 
of hippocampus, the arcuate nucleus and the dorsomedial nucleus of the 
hypothalamus; moderate levels in layer IV of the isocortex, the CA1/CA3 and the 
dentate gyrus of the hippocampus, the ventromedial hypothalamic nucleus and the 
lateral hypothalamic area; nearly not detectable in the thalamic region (by the 
BACE1 rabbit2 antibody). The olfactory bulb and the cerebellum were not tested in 
this experiment. The high levels of Bace1 protein in the cortex and hippocampus of 




Figure 6.8 Immunostaining of Bace1 in adult mouse brain by A) BACE1 rabbit2 antibody; B) BACE1 rabbit2 antibody pre-incubated with its blocking peptide. This 
was a coronal section of a female C57BL/6 mouse brain. The dissected position was roughly at Bregma: -2.75 mm. a-c: hippocampal sub-fields; d: cortex. CA3: 







Figure 6.9 Bace1 co-staining by rabbit2 and goat antibodies in A) cortex and B) thalamus of 
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Figure 6.10 The expression of Bace1 protein in adult mouse brain. BLAa: basolateral amygdalar nucleus, anterior part; BMAp: basomedial 
amygdalar nucleus, posterior part; EPd: endopiriform nucleus, dorsal part; I-VI: layer I-VI of cortex; CA1-3: Cornu Ammonis 1-3; DG: dentate 
gyrus; ARH: arcuate hypothalamic nucleus; DMHa: dorsomedial nucleus of the hypothalamus, anterior part; VMH: ventromedial 
hypothalamic nucleus; LHA: lateral hypothalamic area; LH: lateral habenula; MD: mediodorsal nucleus of the thalamus; CL: central lateral . 
The map in the bottom panel was adapted from the Allen Brain Atlas. 
  








6.3.3.2 The co-localisation of Gpr50 and Bace1 in the brain of female adult C57BL/6 
mouse 
The expression levels of Gpr50 protein in female CD1 adult mouse have been 
investigated previously (Grunewald et al, 2012). I repeated this experiment using the 
same IHC protocol and the same GPR50 goat antibody in female C57BL/6 adult 
mouse brain (olfactory bulb and cerebellum not included). I found similar expression 
pattern and distribution of endogenous Gpr50 in C57BL/6 mice although with 
several differences from CD1 mice (Table 6.8). The high level of Gpr50 protein in 
the hypothalamus of C57BL/6 mice was identical to what was observed for CD1 
mice (Grunewald et al, 2012). Gpr50 was also found strongly expressed in the 
cortical region, especially in the entorhinal cortex, piriform cortex and amygdala. 
While Gpr50 expression was only identified in the dentate gyrus (DG) of the 
hippocampus in CD1 mice (Grunewald et al, 2012), I also saw highly expressed 
Gpr50 in the pyramidal layer of CA1, CA2 and CA3 in C57BL/6 mice. Previously, it 
was reported that Gpr50 is expressed in the pyramidal layer of CA1 in female Wistar 
rat, but not in male C57BL/6 mouse using a different antibody (Batailler et al, 2012). 
Therefore, there might be differences in expression levels of Gpr50 protein between 
species, strains or sexes. 
Next, Gpr50 and Bace1 were doubly immunostained in adult mouse brain. There was 
no cross-immunoreactivity between primary antibodies GPR50 goat/BACE1 rabbit2 
and the secondary antibodies for other species (shown by immunocytochemistry in 
chapter 2, Figure 2.22). Here, the no primary antibody control showed a clean 
background (Figure 6.11), which guaranteed that there was no unspecific staining 
from the secondary antibodies or auto-fluorescence in the brain tissue.  
The co-labelling of the two proteins was found in several areas (Figure 6.12, Table 
6.8). The strongest co-localisation occurred in the CA2 pyramidal neurons of 
hippocampus, the neuronal layer II/III/V of isocortex and the dorsomedial nucleus of 
the hypothalamus. Weaker co-localisation of Gpr50 and Bace1 was found at the 
basolateral amygdalar nucleus and the ependymal layer of the third ventricle. 
Interestingly, Gpr50 and Bace1 appeared to only co-localise in a certain type of cells 
in the basolateral amygdala (BLA). BLA contains two main cell types (Pare & 
Gaudreau, 1996). The most common type is a spiny multipolar neuron with a 
dominant dendrite giving it a pyramidal appearance. These cells are excitatory 
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projection neurons because they have long axons. Gpr50 and Bace1 seemed to co-
localise in this type of neurons. The second cell type consists of a morphologically 
heterogeneous group of less spiny neurons with a locally ramifying axon (Pare & 
Gaudreau, 1996). There were particularly high levels of Gpr50 in the second type of 
neurons. This is intriguing, as these neurons are immunoreactive for GABA 
(McDonald & Augustine, 1993), and thus may be the site where GPR50 interacts 
with proteins related to GABA transmission such as PICK1, SLC12A5/ KCC2, 
MADD, identified by the yeast two-hybrid study (Grunewald et al, 2009). In addition, 
there was no clear co-localisation in the thalamus, as very little if any Bace1 was 
detected. 
 
Figure 6.11 No primary antibody control for fluorescent IHC in adult mouse brain. The 
brain section was stained according to the normal IHC protocol. The incubation of primary 
antibodies GPR50 goat and BACE1 rabbit2 were skipped. DAR488: secondary antibody 
donkey-anti-rabbit 488; DAG594: secondary antibody donkey-anti-goat 594. The white 




Figure 6.12 Co-localisation of Gpr50 and Bace1 in C57BL/6 mouse brain. CA2: Cornu 
Ammonis region 2 of hippocampus; layer II/III: neuronal layer II/III of isocortex; BLA: 
basolateral amygdalar nucleus; DMH: dorsomedial nucleus of the hypothalamus; 3v: the 
third ventricle; MD: mediodorsal nucleus of the thalamus. The solid-head arrows indicated 
potential cells with co-localisation of Gpr50 and Bace1. The open-head arrow indicated a 
type of neurons in BLA with particularly high levels of Gpr50.  
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 Table 6.8 The distribution of endogenous Gpr50 and Bace1 in adult female C57BL/6 
mouse brain and the co-localisation between the two proteins 
Region Gpr50 protein level* Bace1 protein level Co-localisation 
Isocortex ++ +++ √ 
Frontal cortex × ++ × 
Posterior cortex ×  ++ × 
Motor cortex + ++ × 
Somatosensory cortex ++ +++ √ 
Visual cortex ++ +++ √ 
Entorhinal cortex ++ (→ +++)  +++ √ 
Piriform cortex ++ (→ +++) +++ √ 
Olfactory Bulb NA NA NA 
Hippocampus + (→ +++) +++ √ 
Dentate gyrus medial blade 
polymorph layer + (→ ++) ++ √ 
CA1 pyramidal layer - (→ +++) ++ √ 
CA2 pyramidal layer - (→ +++) +++ √ 
CA3 pyramidal layer - (→ +++) ++ √ 
Amygdala ++ (→ +++) ++ √ 
Striatum - - × 
Thalamus ++ - × 
Hypothalamus +++ +++ √ 
suprachiasmatic nucleus ++ NA NA 
paraventricular nucleus + + × 
ependyma of 3rd ventricle +++ + √ 
dorsomedial hypothalamus ++ (→ +++) +++ √ 
ventromedial hypothalamus ++ ++ √ 
lateral hypothalamus + ++ √ 
arcuate nucleus ++ +++ √ 
median eminence ++ + NA 
Cerebellum + NA NA 
Purkinje cell layer + NA NA 
Cerebellum other - NA NA 
* The protein levels of Gpr50 in female CD1 adult mouse were adapted from (Grunewald et al, 2012). 
Similar expression levels were observed in C57BL/6 mouse (using the same IHC protocol and GPR50 
goat antibody). Alterations were marked by symbols in the parentheses.  
+++: strong expression, ++: moderate expression, +: low expression, -: no expression, NA: not 




In this chapter, I investigated the expression patterns of GPR50 and BACE1, as well 
as the correlation of their levels in human brain and mouse brain. In human 
prefrontal cortex (PFC) during the prenatal stage (week 14-20), the mRNA levels of 
GPR50 and BACE1 appeared to have a trend of positive correlation. This is expected, 
as multiple genes with neuronal functions are up-regulated during the foetal 
development. Yet, the expression of the two genes was negatively correlated in 
human dorsolateral prefrontal cortex (DLPFC) of subjects sampled after their birth, 
and this suggests additional roles of GPR50 and BACE1 across the life span, apart 
from their overlapping function in neuronal development. The negative correlation 
between the mRNA levels of the two genes was also seen across the central nervous 
system (CNS) in male Balb/c mice at a time point of 5 weeks (early adolescence for 
mice). Interestingly, this negative co-regulation of Gpr50 and Bace1 seems to be 
enriched in the telencephalon and the hypothalamus sub-regions, in which the co-
localisation of their proteins was found in adult C57BL/6 mice. 
6.4.1 The co-expression of GPR50 and BACE1 in human PFC 
Human PFC has been widely investigated due to its crucial role in memory, 
personality, social behaviour and executive function. The expression correlation of 
certain genes in this region can provide clues to understanding its development, 
functions and related disorders. For instance, De novo mutations in a number of 
genes that function in the neurogenesis in the foetal prefrontal cortex (dorsolateral 
and ventrolateral) are critical to the pathophysiology of schizophrenia, and these 
genes formed a network significantly enriched for transcriptional co-expression and 
protein-protein interaction (Gulsuner et al, 2013).  
6.4.1.1 GPR50 and BACE1 in human PFC during the prenatal stage 
The function of GPR50 might be implicated in the physiological activities that occur 
during the foetal week 17, as its mRNA level reached a peak in this week. In the PFC 
at 17 weeks of gestation, large mature pyramidal neurons appeared in the interface of 
the middle and low third of the cortical plate (Mrzljak et al, 1988). These neurons 
had basal dendrites with growing secondary structures and apical dendrites extending 
to the outer part of the marginal zone. Therefore, the peak of prenatal GPR50 
expression might be associated with the maturation, in particular the extension of the 
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pyramidal neurons in the cortical plate of the PFC. This is in line with the function of 
GPR50 in promoting neurite outgrowth (Grunewald et al, 2009). Also, the week 17 
of human gestation is a time point when additional types of neurons was seen in the 
subplate zone of the PFC, such as the inverted pyramidal neurons (Mrzljak et al, 
1988). Hence, GPR50 may be also related to certain processes of neurogenesis.  
The BACE1 mRNA level in human PFC increased persistently during the gestational 
weeks 14-20. The cellular growth in the human foetal forebrain can be divided to 
two-phases, an exponential phase from 13 to 20 weeks of gestation and a linear 
increasing phase from approximately 22 weeks of gestation to term (Samuelsen et al, 
2003). The exponential phase appeared to correspond to a robust process of 
neurogenesis before gestational week 20 (Malik et al, 2013). Therefore, my 
observation supports a role of BACE1 in neuronal development, which has been 
suggested by its cleavage of neural cell adhesion molecules (Hitt et al, 2012). 
Furthermore, this function of BACE1 is most likely to be related to Notch signalling, 
which controls the balance of neurogenesis and astrogenesis in the hippocampus 
during early development and can be induced by BACE1 cleavage of Jagged1 (Hu et 
al, 2013a).   
GPR50 and BACE1 have overlapping roles in neuronal development. This agrees 
with my finding that their RNA levels in PFC demonstrated a trend of positive 
correlation during gestational weeks 14-20. As GPR50 is involved in the regulation 
of β-secretase activity {(Grünewald, 2011); my chapter 4}, it is worthwhile to further 
investigate if GPR50 has a role in balancing the release of active neural cell adhesion 
molecules. 
6.4.1.2 GPR50 and BACE1 in human DLPFC sampled after birth 
In subjects whose samples were collected after birth, the mRNA levels of GPR50 
and BACE1 in DLPFC were negatively correlated, opposite to the trend in the 
prenatal subjects. Interestingly, this negative correlation was contributed by their 
levels in females. Therefore, the co-regulation of GPR50 and BACE1 expression in 
human DLPFC from the period of postnatal development to adulthood was sex-
specific.  
Previous studies have shown that the functions of both GPR50 and BACE1 are 
related to females. The association of GPR50 gene polymorphism with mental 
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disorders increased in significance in female subjects (Thomson et al, 2005). 
Elsewhere, the regulation of BACE1 expression and function has a link to females, 
as a recent study showed that BACE1 mRNA and protein levels could be down-
regulated, thus reducing amyloid plaque formation in the brain of aromatase-
deficient APP transgenic mice after estrogen treatment (Li et al, 2013). Thus, my 
results strengthened the importance of investigations on the function of GPR50 and 
BACE1 in terms of the striking physiological differences between sexes. For 
example, studies of the signalling system mediated by sex hormones are helpful to 
elucidate the roles of GPR50 and BACE1, as well as their association in brain 
illnesses. Further analysis of the correlation between GPR50 and BACE1 expression 
can be performed in the female “after birth” subset with the life scale being divided 
into periods related to estrogen, such as before menstrual onset, during menstrual 
period and after menopause. 
6.4.2 The co-expression of Gpr50 and Bace1 in mouse brain 
In Balb/c adult mouse, the mRNA levels of Gpr50 and Bace1 were negatively 
correlated across multiple CNS regions. This correlation appeared to result from their 
levels across the telencephalon and the hypothalamus. The co-regulation of these two 
genes might be associated with their functional interaction in relevant areas, such as 
in the brain sub-regions observed with co-localisation of their proteins in C57BL/6 
mouse.  
6.4.2.1 The co-expression of Gpr50 and Bace1 in the CA2 region of mouse brain 
GPR50 and BACE1 may have cooperating functions in the brain activities that are 
related to memory, as the two proteins are strongly co-localised in the hippocampus 
of the adult mouse brain, especially the CA2 sub-field. CA2 appears to be located at 
the key position of the cortico-hippocampal disynaptic circuit, as its pyramidal 
neurons are strongly excited by their distal dendritic inputs from the entorhinal 
cortex, and in turn excite the neurons in CA1 (Chevaleyre & Siegelbaum, 2010). 
Recent studies showed that the regulation of plasticity at CA2 synapses might play a 
role in different sorts of learning and memory, including the hippocampus-dependent 
spatial memory, contextual learning and social recognition memory (Chevaleyre & 
Siegelbaum, 2010; Hitti & Siegelbaum, 2014; Wintzer et al, 2014).  
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My results showed that BACE1 is a CA2-enriched molecule. Even though BACE1 
overexpression caused damage to memory in BACE1 transgenic mice and BACE1 
deletion seems to rescue those deficits in AD mice (Ohno et al, 2007; Ohno et al, 
2004), it is not clear whether the phenotypes are related to BACE1 levels or Aβ 
amounts. BACE1 knockout mice exhibited an age-dependent deficit in spatial 
reference memory and had synaptic dysfunctions in the CA1 and the CA3 (Laird et 
al, 2005; Wang et al, 2014a; Wang et al, 2008a). Therefore, the normal function of 
BACE1 is related to cognition. No BACE1 loss-of-function studies so far have been 
performed in the CA2 region, possibly because of the difficulty in distinguishing this 
structure. However, it will be interesting to do so, as the high expression level in 
CA2 may reveal new explanations for the link of BACE1 function to different sorts 
of memory. Gpr50 expression is almost equally high in the pyramidal neurons of 
CA1, CA2 and CA3. The protein of GPR50 was found in postsynaptic densities 
{(Grunewald et al, 2012); my chapter 3}, the components of which are closely 
related to the molecular mechanisms of learning and memory (Nagura et al, 2012; 
Nicholson et al, 2004). Thus, the hippocampal expression of GPR50 may suggest 
that the function of this protein is associated with the maintenance of memory and 
learning ability and its interaction with BACE1 in CA2 relating to synaptogenesis 
and synaptic plasticity is a good start to study this hypothesis.  This will help to 
understand the role of GPR50 and BACE1 in neuronal development in a later 
postnatal stage.  
6.4.2.2 The co-expression of Gpr50 and Bace1 in the hypothalamus of mouse brain 
The hypothalamic co-expression of Gpr50 and Bace1 proteins in C57BL/6 mice was 
mainly observed in the arcuate nucleus (ARH) and the dorsomedial nucleus (DMH). 
One should be aware that the Bace1 mRNA level in the DMH of Balb/c mice was 
relatively low compared to C57BL/6 mice. This genetic diversity might reflect a 
behavioural or physiological difference in relation to the function of DMH between 
the two strains. 
The level of corticosterones in GPR50 knockout (KO) mice was elevated (Ivanova et 
al, 2008), which indicates that GPR50 expression under normal conditions might be 
associated with the suppression of glucocorticoid overproduction, which is 
stimulated by corticotropin. Proopiomelanocortin (POMC) is the precursor molecule 
of intermedin, corticotropin, β-endorphin and Met-enkephalin. A previous study in 
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C57BL/6 mice showed that Bace1 in ARH was expressed in 30% POMC neurons 
(Meakin, 2013). Thus, the co-localisation of Gpr50 and Bace1 in ARH may suggest 
that the physical association of the two proteins is correlated with the hormone 
releasing in the hypothalamic-pituitary-adrenal (HPA) axis. Bace1 was not co-
localised with appetite-inducing neuropeptide Y (NRY) or agouti-related peptide 
(AgRP) (Meakin, 2013). However, the deletion of Bace1 gene resulted in an 
enhanced expression of NRY/AgRP, which might be associated with the increasing 
appetite in BACE1 KO mice (Meakin et al, 2012). Interestingly, the deletion of 
Gpr50 gene did not have effects in the levels of NRY/AgRP (Bechtold et al, 2012). 
This may indicate that the putative interaction of Gpr50 and Bace1 in ARH is less 
associated with food intake. 
The high expression level of GPR50 in the DMH is closely related to the regulation 
of leptin signalling, as leptin deficient mice had decreased level of Gpr50 in the 
DMH, which is recovered by leptin feeding (Bechtold et al, 2012). This function of 
GPR50 in the maintenance of leptin efficacy is specific to thermogenesis, as GPR50 
KO mice had lower expression of a thermogenin, uncoupling protein 1 and entered a 
state of topor when fasted (Bechtold et al, 2012).  BACE1 KO mice also had 
alterations in leptin signalling. When on a high-fat diet, BACE1 KO mice were 
protective against the metabolic inefficiency in wild-type mice, as they were 
observed with improved glucose disposal and insulin sensitivity, and reduced leptin 
levels (Meakin et al, 2012). These measures of increased energy expenditure may be 
related to an increased thermogenesis, which could be suggested by the increased 
expression of uncoupling proteins in the brown adipose tissue and skeletal muscle. 
This apparent opposite role of GPR50 and BACE1 in energy expenditure might be 
associated with their negatively correlated trend of mRNA expression across the 
hypothalamus. In particular, the co-localisation of Gpr50 and Bace1 in the DMH 
may be linked with a balanced status of the leptin signalling in the process of 
thermogenesis. 
6.4.3 Further studies 
My results demonstrated that GPR50 and BACE1 have correlated expression with 
overlapping functions in certain areas of the brain, and this extends the findings in 
previous chapters that the two proteins interact putatively in cells. To reveal more 
evidence of the association between GPR50 and BACE1, it would be beneficial to 
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determine and correlate the expression levels and properties of the two proteins in 
human post-mortem brains of mentally related illnesses (i.e. AD, bipolar disorder, 
schizophrenia) or relevant animal models. By comparing with healthy/wild-type 
control, we may evaluate the possible modification of GPR50 and BACE1 as 
individual factors, as well as their co-operational effects upon development of brain 








7 The investigation of Gpr50 
expression in Alzheimer’s 





Results in previous chapters have provided clues for the function of GPR50 through 
its potentials in the regulation of BACE1 expression and activity in cultured cells, as 
well as their co-regulated expression pattern and co-localisation in the brain. To 
further investigate the role of GPR50 in the pathology of brain diseases, in this 
chapter, I made use of an Alzheimer’s disease (AD) mouse model and examined the 
characteristics of Gpr50 expression during the process of Aβ deposition, which is 
one of the hallmarks of AD. 
7.1.1 The investigation of AD in mouse models 
During the last two decades, a number of AD mouse models have been generated in 
order to understand the etiological mechanism of AD, and to look for effective 
treatments of relative symptoms, as well as to perform preclinical tests of new drugs. 
These models have generally been created to recapitulate the known processing 
features of AD, together with the introduction of genetic risk factors to promote 
earlier pathology. Most models showed functionally defective cognition and amyloid 
plaques aggregation in the brain, but none of them exhibit the full range of human 
AD properties, particularly the occurrence of neuronal loss. Moreover, 
neurofibrillary tangles were generated only when human tau was overexpressed or 
mutant tau with a greater likelihood of forming tangles was used. The AD mouse 
models generally used can be divided into the following types {summarised from 
reviews (Chin, 2011; Hall & Roberson, 2012)}. 
a) Human APP transgenic models 
Both mutations in the APP sequence and a copy number increase of the APP gene 
can lead to the pathogenesis of AD. Aggregation of mouse Aβ is not as effective as 
that of human Aβ, probably because of the sequence differences of APP within the 
Aβ section between the two species (Hall & Roberson, 2012). Also, mouse Aβ is less 
efficient in causing cognitive deficits (Hall & Roberson, 2012).  Overexpression of 
human APP, particularly with mutations is one of the most frequently used measures 
to develop AD phenotypes in mice. The commonly adopted APP mutations include: 
Swedish (K670N/M671L) (Haass et al, 1995) located at BACE1 cleavage site, which 
is more likely to be processed via the amyloidogenic pathway; London (V717I) 
(Goate et al, 1991) and Indiana (V717F) (Murrell et al, 1991) within the γ-secretase 
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cleavage site, favouring the production of Aβ42; Dutch (E693Q) (Levy et al, 1990) 
and Iowa (D694N) (Grabowski et al, 2001), within the Aβ region, elevating 
generation of Aβ40 and inducing hereditary cerebral haemorrhage; Arctic (E693G) 
(Nilsberth et al, 2001), decreasing α-secretase processing of APP. 
b) Presenilin mutant models 
Presenilin functions as the subunit of γ-secretase and mutations in the two presenilins 
PS1 and PS2 (i.e. PSEN1-M146V) lead to familial early-onset AD (Tokuhiro et al, 
1998), which has identical symptoms and neuropathology to more commonly seen 
sporadic AD. The introduction of presenilin mutations in mice accelerated the 
production of Aβ42 without affecting levels of Aβ40 (Jankowsky et al, 2004). 
Furthermore, familial early-onset AD is a relatively rare form and only accounts for 
less than 6% of all AD cases (Hausner et al, 2014), so a presenilin mutant is normally 
combined with APP to produce double or multiple transgenic models (Holcomb et al, 
1998; Lok et al, 2013). 
c) Aβ transgenic model 
Directly expressing Aβ peptide in mice can exclude the effects of APP 
overexpression, so the pathological features of these mice derive purely from the 
deposition of amyloid plaques. However, although this model successfully 
demonstrates amyloid pathology, there is no literature reporting the deficits in 
memory and learning ability of these mice (McGowan et al, 2005). It will be 
controversial if a supposed AD model fails to show loss-of-function behavioural 
symptoms.  
d) Apolipoprotein E models 
The E4 variant apolipoprotein E (APOE-e4) is known as a genetic risk factor for 
late-onset sporadic AD (Sadigh-Eteghad et al, 2012). In the human general 
population, there are three major alleles of the gene for Apolipoprotein E, APOE-e3 
(77%), APOE-e4 (15%) and APOE-e2 (8%) (Tai et al, 2011). Compared to 
individuals with no APOE-e4, the risk for developing AD is 2-3 fold in those with 
one copy of APOE-e4 and 12-fold in people with two copies of this allele (Kim et al, 
2009). Human APOE knock-in (KI) mice have been generated to investigate the 
effect of APOE on Aβ deposition (Mann et al, 2004). Crossing APOE-e4 KI mice 
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with different APP transgenic mice could alter the ratio of Aβ40:Aβ42 (Fryer et al, 
2005), or enhance Aβ generation at a young age (Bales et al, 2009). Moreover, the 
cholesterol levels in APOE-e4 KI mice were greatly altered, which is closely related 
to the production and clearance of Aβ (Mann et al, 2004). Thus, APOE-e4 KI/APP 
mice might be also useful in the elucidation of the lipid metabolism state in AD. 
e) Multi-transgenic models 
As mentioned above, presenilin mutation does not account for more prevalent 
sporadic AD, and is not sufficient for the mice to develop cognitive deficits and 
amyloid plaques. Therefore, the double transgenic model APP/PS1 is more usually 
generated to develop AD symptoms, as well as to increase the Aβ42/Aβ40 ratio to 
enhance pathological toxicity. Additionally, tau pathology may be developed in these 
models by introducing human tau mutation. The triple transgenic mice (APP/PS1/tau) 
demonstrated aggravated tau formation and neuronal loss compared to tau mice 
(Oddo et al, 2003; Wirths & Bayer, 2010). The latter is normally used as a 
frontotemporal dementia model rather than an AD model, because the tau mutation 
does not lead to AD pathology as the deposition of amyloid plaques and tau 
aggregation seem to be two independent processes. Double transgenic mouse 
APP/tau is also available, with more severe tau pathology than tau mice (Perez et al, 
2008).  
Although these mice only show the main pathological hallmarks of AD, the diversity 
of different transgenic lines provides powerful tools for research in various aspects, 
with varying degrees of phenotypes and specific combinations. Moreover, AD mice 
can be crossed with other mouse models to investigate the function of a particular 
protein involved in AD, for example, APP transgenic mice crossbred with GPR50 
knockout mice will be useful to study the side effects of the complete wipe-out of 
this protein under AD conditions. Other considerations when selecting an AD mouse 
model include: gene promoters, mice strain background, transgenic techniques (for 
instance, knock-in technology can be applied). 
7.1.2 TgSwDI AD mouse model 
The AD model TgSwDI used in this chapter is APP transgenic mice with a pure 
C57BL/6 background (Davis et al, 2004a). Swedish double mutation 
(K670N/M671L) and vascular Aβ-associated Dutch (E693Q)/Iowa (D694N) were 
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introduced to the longest isoform APP770, as a gene cassette by promoter Try 1.2, 
which induces high levels of neuron-specific expression and is expressed from 
postnatal day 7, preventing potential early neurodevelopmental impairments.  
The cleavage of the Swedish-APP results in a global elevation of both Aβ42 and 
Aβ40 (Gau et al, 2002).  The Dutch mutation is protective of Aβ40 from proteolysis 
and renders APP a highly fibrillogenic feature (Kumar-Singh, 2009).  The Iowa 
mutation has similar properties of cytotoxicity and aggregation as the Dutch mutation 
(Van Nostrand et al, 2001). The Dutch/Iowa mutant showed with a reduced clearance 
of amyloid across the blood-brain barrier, leading to cerebrovascular amyloidosis in 
blood vessel walls (Davis et al, 2006). These mice developed abundant diffuse but 
non-fibrillar plaques in the cortical parenchyma and compact fibrillar microvascular 
deposits in the thalamus (Davis et al, 2004a). Diffuse plaques mainly consist of 
neuritic Aβ42 which exist also in the healthy aged brain but are more abundant in the 
AD brain (Bengtsson et al, 2013), while the main component of cerebrovascular 
plaques is neuritic and non-neuritic Aβ40 (Xu, 2011). The Dutch/Iowa mutation 
favours the production of Aβ40 and the overall ratio of Aβ40:Aβ42 in TgSwDI mice 
is approximately 10:1 (Davis et al, 2004a).  
The pathological feature of this AD mouse is early-onset with accumulation of 
amyloid plaques and severe cerebral amyloid angiopathy as age increases. These 
mice develop Aβ plaque-like deposits from the age of 3 months, with a progressive 
and widespread accumulation up to 12 months. The vascular Aβs are fibrillar, with 
strong thioflavin S staining, and occasionally showing signs of micro-haemorrhage. 
The initial regions with the appearance of Aβ are the subiculum, the hippocampus, 
and the cortex at the age of 3 months. As the TgSwDI mice grow to 6 months, the 
affected areas extend to the olfactory bulb and the thalamus. By the age of 12 months, 
the Aβ deposition spreads throughout most of the forebrain. Accordingly, ELISA 
quantification of vascular Aβ showed that the levels of Aβ40 and Aβ42 are 12- and 
14- fold higher respectively in the forebrain micro-vessels than in the whole 
forebrain tissue homogenates of TgSwDI mice at the age of 12 months. 
Deficits in spatial reference memory (performance in Barnes maze) were found in 
TgSwDI mice from 3 months old (Xu et al, 2007). Impairments in novel object 
recognition, social recognition memory (intruder test) and contextual fear 
conditioning (electric foot shock test) were identified at 9 months (Medeiros et al, 
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2011). No differences in mobility and coordination (Rotarod), strength (inverted 
crawl test), muscle endurance (wirehang test), or anxiety (light/dark box test) were 
shown in these animals (Xu et al, 2007).  
The TgSwDI mouse is an AD model that can be adopted to investigate different 
degrees of severities of AD, the pathological mechanism that develops with age, as 
well as distinct phenotypes related to either diffuse Aβ peptides in the cerebral 
parenchyma or fibrillar plaques in the cerebral vasculature. 
7.1.3 Introduction to experiments 
One study showed that GPR50 was expressed in the neurodegenerative neurons in 
the brains of elderly individuals and AD patients (Hamouda et al, 2007). Therefore, 
in this chapter, I examined if Gpr50 had any meaningful characteristics of expression 
in an AD model TgSwDI mice. The expression pattern and levels of Gpr50 in both 
young (3 months) and old (9 months) TgSwDI mice and their wild-type littermates 
were investigated by immunohistochemistry, focusing on AD-affected brain regions, 
the entorhinal cortex and the hippocampus. Correlation analysis between Gpr50 
levels and Aβ deposits were performed to further answer the question whether Gpr50 
is correlated with AD. 
The two brain areas I selected are essential parts of the system that control memory. 
The hippocampus works as a sorting centre for the information to be memorised, 
processed and passing through, while the actual memory codes are recorded at 
various regions of the cortex (Insausti, 1993; Insausti et al, 1993). The entorhinal 
cortex (EC) is considered to be the interface between the neocortex and the 
hippocampus. On the one hand, the output of the EC, through the perforant pathway, 
is the main cortical source of input into the hippocampus; on the other hand, EC, 
together with the subiculum, provides the major output of the hippocampus (van 
Groen et al, 2003). EC is believed to receive highly-processed inputs from sensory 
processes and cognitive functions. Neurons in different layers of the EC project to 
subdivisions of the hippocampal formation, providing the input from the cortical 
region. The deep layers, especially layer V, receive one of the three main outputs of 
the hippocampus and, in turn, reciprocate connections from other cortical areas that 
project to superficial EC (Czajkowski et al, 2013). The output of the hippocampus 
particularly targets deep layers V and VI of EC, which consecutively are the source 
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of far-reaching reciprocal projections in the cortex and the subcortical projections to 
the septum, the striatum, the amygdala and the thalamus. Each of the responding 
pyramidal cells in layer V has an axon reaching toward the white matter, with half of 
these neurons also extending an axon to superficial layers II and III. Hence, neuronal 
cells in layer V of EC play a role of transition station in the cortical functional 
network. To specify the expression of Gpr50 in the cortex, I concentrated on the 
layer V of EC. 
Both the hippocampus and the entorhinal cortex are among the first regions of the 
brain to suffer damage in AD (Van Hoesen et al, 1991) and were found abundantly 
harboured with Aβs in TgSwDI mice (Davis et al, 2004a). Furthermore, they are 
amongst the areas in which I found the co-localisation of Gpr50 and Bace1 in wild 
type adult mouse brain (see chapter 6), so investigating these areas could be relevant 
to my studies. 
7.2 Materials and methods  
7.2.1 Alzheimer’s disease mouse model TgSwDI 
The TgSwDI mice (Tg) and wild-type (WT) control mice were littermates with a 
C57BL/6 background. The mouse brain sections were kindly provided by Professor 
Karen Horsburgh (University of Edinburgh). The hemi-brains of 3 months and 9 
months animals were fixed with 4% paraformaldehyde and were paraffin-embedded. 
All cohorts (WT3, Tg3, WT9 and Tg9) contained 8 animals. Two consecutive 
sections for each animal were placed on one glass slide (6 µm, coronal, Bregma:-
1.28 mm). Two sets of slides (for Aβ and GPR50 separately) including consecutive 
and non-consecutive sections were used (Table 7.1). 
Table 7.1 The two sets of slides for staining Aβ and Gpr50  
Slides WT3 Tg3 WT9 Tg9 
Consecutive N=6 N=4 N=4 N=5 
Not consecutive N=2 N=4 N=4 N=3 
Total N=8 N=8 N=8 N=8 
WT3: wild-type, 3 months; Tg3: transgenic, 3 months;  





The method of immunohistochemistry was adapted from the protocol used in 
Professor Horsburgh’s lab. The sections were incubated at 60oC for 20 min to melt 
the wax, and then rehydrated through a series of alcohols: 100% xylene 15 min, 100% 
ethanol 10 min, 100% ethanol 5 min, 90% ethanol 5 min, 70% ethanol 5 min, 
running tap water 5 min, dH2O 5 min. The set of slides for Aβ were subjected to wet-
heat induced antigen retrieval in citrate buffer (pH 6.0). After an incubation of 20 
min at 100oC, the slides were cooled at room temperature for 10 min and washed in 
PBS. The other set of slides were kept un-retrieved for GPR50 staining, as I found 
this was better for the GPR50 antibody staining (shown later, Figure 7.5, 7.6). The 
sections were blocked in PBS+20% donkey serum (+1% BSA) at room temperature 
for 2 hr. 1% BSA was omitted for GPR50 sections in this case, where the goat 
antibody (G-15, Santa Cruz) was used, with a view of reducing the possibility of 
interference between goat polyclonal antibodies and BSA. After the blocking, the 
sections were incubated with primary antibodies overnight at 4oC. Mouse 
monoclonal antibody Aβ 6E10 (SIG-39320, sigma) is reactive to amino acid residue 
1-16 of Aβ and specific to human isoforms. Sections were washed 3×5 min with PBS, 
followed by incubation with secondary antibodies donkey-anti-mouse 488 and 
donkey-anti-goat 488 separately, for 2 hr at room temperature. Again, sections were 
washed 3×5 min with PBS before mounting with VECTASHIELD® HardSet 
Mounting Medium containing DAPI (Vector Laboratories, H-1500). 
7.2.3 Imaging and statistical analysis 
Two brain regions were selected and photographed. For the entorhinal cortex, layer 
V, confocal images were captured on a Nikon A1R confocal laser-scanning 
microscope (×60, oil) with an image size of 512×512 using the software NIS 
elements. The hippocampal region was photographed on a Zeiss Britmac fluorescent 
microscope (×5, dry) with an image size of 1024×1024 using the software Envision. 
When more than one image was required to cover the hippocampal structure, photos 
were stitched by the software Adobe Photoshop CS2 (Figure 7.1.A). The whole 




Total Aβ burden or Aβ-affected area was defined as the percentage of test area 
occupied by immunoreactive Aβ-like plaques (Abeta_Area). Gpr50 expression level 
was represented by the percentage of test area immunoreactive with the GPR50 goat 
antibody (Gpr50_Area). It is not recommended to use the intensity of Aβ/Gpr50 
signals as the expression levels. On the one hand, it is difficult to distinguish the 
specific signal from cell to cell, especially those adjacent cells that were both 
expressed with Aβ; on the other hand, the calculation of fluorescence intensity is 
easily affected by the background, in particular the Gpr50 signal, which was not very 
strong. All the quantification was performed automatically with an ImageJ macro in 
order to standardise the analysis across sections/slides. For the auto-thresholding of 
Aβ, the Triangle algorithm (Zack et al, 1977) was used, while that of Gpr50 applied 
Tsai’s method which attempts to preserve the moments of the original image in the 
thresholded result (Tsai, 1985). The two methods are auto-threshold procedures 
bundled in ImageJ as “Triangle” and “Moments”. Values were averaged when 
duplicate sections were adopted. The statistical assessments were carried out in the 
software package SPSS 19.  
 
Figure 7.1 Preparation work for the quantification in the hippocampus. 1) A photo that 
covered the top side of the hippocampus; 2) a photo that covered the bottom side of the 
hippocampus in photo 1). A) Photos (1 & (2 were stitched together to cover the whole 
hippocampus; B) an example of the ROI for the hippocampus.  
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7.2.4 The removal of outlier data 
Briefly, outliers are those data points that show extreme patterns to the rest of the 
dataset. There are two types of outliers: 1) they are generated during the process of 
collection, data conversion, methodology failure, initial determination mistake, etc. 
In this case, the aberrance is produced due to measurement errors and is not 
representative of extreme cases that may occur by chance. Therefore, the removal of 
these outliers is necessary; 2) they are caused by pure chance and can only be 
interpreted by randomness of sampling. In other words, there is no reason to exclude 
these deviated values from the analysis. Thus, the removal of outliers must be 
carefully considered, and evidence must be provided to fully explain the aberration.  
All photos were renamed and quality checked. The ones with obvious crushed or 
damaged brains (Figure 7.2.B) were excluded. This was a process of removing 
potential outliers prior to the quantification and the analysis. 
 
Figure 7.2 Quality checking of photos prior to the analysis. A) A normal brain suitable for 
assessment; B) a crushed brain to be excluded. 
The post hoc method to identify outliers is Tukey’s box and whisker plot, which sets 
the inner and outer fences of the dataset based on calculation of quartiles (Figure 
7.3.A). Inner fences: [Q1-1.5 IQR, Q3+1.5IQR], outer fences: [Q1-3IQR, Q3+3IQR], 
Q1: the first quartile, Q3: the third quartile, IQR: Inter Quartile Range=Q3-Q1. A 
data point located between inner and outer fences is a possible outlier. An extreme 
value beyond the outer fences is a probable outlier.  
The potential outliers were inspected cautiously. This included the setting of 
confocal parameters, the depths of tissue that were photographed, comparison with 
the other parts of the brain, comparison with the other replicate, comparison with 
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other animals in the same cohort, the automatic threshold used and the running of 
ImageJ macro. For the dataset of Abeta_Area, one outlier “#668 left” (labelled 13 in 
Figure 7.3.B) was removed due to its plaque like staining for 3 months wild-type 
mice. The other two large potential outliers in 9 months wild-type mice were kept, 
because they could be extreme values that might occur occasionally in old animals. 
No obvious mistake was identified in other checking-up processes. The same 
approach was applied to the dataset of Gpr50_Area as a variable (Figure 7.3.C). It 
was found that one Gpr50 value in cohort TgSwDI 9 months (10.976, #251 right, 
labelled 60 in Figure 7.3.C) was an extraordinarily large value compared to other 
animals in the same cohort (around 2.5-fold of most others), as well as to its own 
replicate (5.741, #251 left). More importantly, it seemed that this photo was over-
thresholded which could not be avoided when using the auto-threshold (Figure 7.4). 
Therefore, this data point was omitted as an outlier and “#251 left” was used as the 
mean for animal 251. No other outliers were identified by the box plot after removal 
of this value. Brain sections that were excluded from analysis are summarised in 
Table 7.2. 
There were 8 animals (maybe less after the outlier removal) in each of the four 
cohorts. Every data point came from the mean of two consecutive sections for each 
animal. If one section was identified as the origin of an outlier, the value of the other 




Figure 7.3 The method of identifying outliers. A, Tukey’s box and whisker plot; tests of 




Figure 7.4 The original photos and post-threshold photos of Gpr50 in the entorhinal 
cortex layer V of animal 251. A) #251 right; B) #251 left. “Left” and “right” meant the two 
consecutive replicate sections on one slide for each animal. 
Original photo Post-threshold photo 
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Table 7.2 Brain sections excluded from the analysis 





number for analysis 
Cortex   WT3 668L N=8 for each group 
Hippocampus WT3 663R, 664L, 664R, 665L, 
667R, 668L, 668R 
  N=6 
Tg3 655R, 658L 660L, 660R  N=7 
WT9 265R, 266R   N=8 
Tg9 249L, 249R, 251L,251R   N=6 





Cortex   Tg9 251R N=8 for each group 
Hippocampus WT3 666L   N=8 
Tg3 655R, 658L 660L, 660R  N=7 
WT9 261L, 262L, 265R, 267R, 
270R, 
  N=8 
Tg9 255R   N=8 
L: left; R: right. “Left” and “right” meant the two consecutive replicates on one slide for each animal.   
7.3 Results 
7.3.1 Optimisation of Gpr50 staining in TgSwDI mice 
In chapter 6, the expression pattern of Gpr50 in female mouse brain of the C57BL/6 
strain was described and compared with previous publications. It was shown that the 
expression of mouse Gpr50 was mainly expressed in the cortex and the hippocampus 
in addition to the usually identified regions in the hypothalamus.  
The brain sections used in this chapter were fixed with 4% paraformaldehyde, a 
fixation method that commonly requires antigen retrieval (D'Amico et al, 2009). 
However, our only applicable GPR50 antibody in immunohistochemistry, GPR50 
goat failed to provide a quality staining after the heat-induced antigen retrieval, with 
diminished signal and unaccountable background (Figure 7.5, 7.6). On the contrary, 
the detection of Aβ requires antigen retrieval. Therefore, the staining of GPR50 and 




Figure 7.5 The cortex of 9 months TgSwDI mice stained with GPR50 goat antibody in A) a 
non-retrieved brain section and B) a heat retrieved brain section. C) No primary antibody 
control, non-retrieved. Scale bar: 50 µm. 
Immunofluorescence labelling of Gpr50 in these sections was found in the cells of 
the third ventricle ependymal layer (Figure 7.6), but not as predominant in the 
hypothalamic region as in previously reported literature or my observation in chapter 
6. It is possible that the fixation method caused differences in staining patterns, as 
was previously noted (Grunewald et al, 2012).  However, the detection in the 
neuronal cells in the pyramidal layer of the hippocampus and the layers with neurons 
in cortex was not affected. Both soma and axons of the neurons were found with 
Gpr50 immunoreactivity (Figure 7.5). Additionally, there was dispersed punctuate 
staining detected throughout the section. This was not associated with any of the 
animal cohorts or any particular cell type, as this staining pattern was present in all 
the sections. I did not see the punctuate pattern in sections that were fixed by 70% 
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ethanol (see chapter 6), thus it is possible that these puncta were generated during the 
fixation or storage of the sections. Because the pattern was rather homogenous, the 
original photos were not modified and were subjected to quantification with the 
existence of this noise.   
 
Figure 7.6 The hypothalamus of 9 months TgSwDI mice stained with GPR50 goat antibody 
in A) a non-retrieved brain section and B) a heat retrieved brain section. C) No primary 
antibody control, non-retrieved. Scale bar: 50 µm. 3v: the third ventricle. The white arrow 
indicated an ependymal cell expressed with Gpr50. 
7.3.2 Aβ and Gpr50 in the entorhinal cortex  
7.3.2.1 Aβ and Gpr50 in the layer V, entorhinal cortex of TgSwDI mice 
Aβ and Gpr50 were both detected in the entorhinal cortex of 9 months TgSwDI mice 
(Figure 7.7). Diffuse Aβ plaques were detected in the layer V, which possibly 
indicates a damaged interchange of cortical-hippocampal system and may also 
eventually lead to an impaired memory. The signal of Gpr50 was seen mainly in the 
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pyramidal neurons, especially at the axons in layer II, III and V. It was not known if 
Aβ and Gpr50 were localised in the same neurons as the double staining was not 
available due to the failure of Gpr50 to be fully stained after the antigen retrieval 
(Figure 7.5, 7.6).  
 
Figure 7.7 The immunofluorescence labelling of Aβ and Gpr50 in the entorhinal cortex of 
9 months TgSwDI mice. I~VI refer to different layers of the entorhinal cortex (EC). One of 




The expression levels were indicated by the percentage of targeting area with Gpr50 
immunoreactivity (Gpr50_Area), in the same way as how Aβ burden (Aβ_Area) was 
calculated. Representative images of staining in the layer V of the entorhinal cortex 
and the analysed data obtained through ImageJ are presented in Figure 7.8, Table 7.3 
and Table 7.4.  
 
Figure 7.8 Representative photos of Aβ and Gpr50 in the entorhinal cortex layer V of the 
four mouse cohorts of A) 3 months wild-type; B) 3 months TgSwDI; C) 9 months wild-type; 




Table 7.3 The expression percentage of Aβ and Gpr50 in the entorhinal cortex layer V 
Animal  
number 
Age Phenotype Entorhinal cortex, 
layer V 
Aβ GPR50 
662 3 months Wild-type 0.6915 4.5345 
663 3 months Wild-type 1.145 4.5175 
664 3 months Wild-type 1.378 2.8785 
665 3 months Wild-type 0.741 2.973 
666 3 months Wild-type 0.9525 4.944 
667 3 months Wild-type 0.778 2.8 
668 3 months Wild-type 1.738* 2.931 
669 3 months Wild-type 0.9165 6.0115 
654 3 months Transgenic 1.904 2.644 
655 3 months Transgenic 1.6885 3.13 
656 3 months Transgenic 1.16 3.329 
657 3 months Transgenic 2.0595 3.372 
658 3 months Transgenic 1.7995 3.8715 
659 3 months Transgenic 1.8975 4.647 
660 3 months Transgenic 1.611 3.9365 
661 3 months Transgenic 1.8305 3.0985 
261 9 months Wild-type 1.4675 4.712 
262 9 months Wild-type 1.3675 3.0845 
263 9 months Wild-type 1.37 3.891 
264 9 months Wild-type 1.329 3.7515 
265 9 months Wild-type 1.2915 2.7655 
266 9 months Wild-type 1.7175 3.6725 
267 9 months Wild-type 2.106 2.7685 
270 9 months Wild-type 1.176 5.1175 
245 9 months Transgenic 3.6395 3.6225 
246 9 months Transgenic 4.4825 4.1465 
247 9 months Transgenic 5.427 4.94 
248 9 months Transgenic 5.632 3.8315 
249 9 months Transgenic 3.965 4.3395 
251 9 months Transgenic 4.0665 5.741* 
255 9 months Transgenic 4.894 3.9565 
257 9 months Transgenic 3.125 4.945 
*Single hemi-brain section used. All other data represent 
the mean of two consecutive hemi-brain sections.  
The percentage of test area occupied by the 
immunoreactivity of Aβ or Gpr50 was calculated as their 
expression levels in this area. All the quantification was 
performed automatically in ImageJ. Values were averaged 
from the duplicate sections. In case of an outlier identified 





Table 7.4 A summary of expression percentage of Aβ and Gpr50 in the entorhinal cortex 
layer V 
Age Phenotype Mean±Standard Deviation, N 
Aβ Gpr50 
3 months Wild-type 1.1737±0.6904, 8 3.9488±1.2169, 8 
3 months Transgenic 1.7438±0.2728, 8 3.5036±0.6234, 8 
9 months Wild-type 1.4781±0.2985, 8 3.7204±0.8610, 8 
9 months Transgenic 4.4039±0.8724, 8 4.7675±0.7138, 8 
N: sample size 
 
Next, a general linear model was fitted to analyse whether there were differences in 
the expression levels of Aβ and Gpr50 in the layer V of the entorhinal cortex among 
the four cohorts (3 months wild-type, 3 months TgSwDI, 9 months wild-type, 9 
months TgSwDI). The main effects “Age”, “Phenotype” and the interaction term of 
the two were examined as the category factors. The model performed a two way 
ANOVA (2×2 factorial ANOVA) to assess the differences of Aβ or Gpr50 levels.  
As is shown in Table 7.5.A, this model fits well for Aβ levels (F (3, 28) =50.541, 
Adjusted R2=0.827, p<0.01).  The Aβ level was significantly associated with the age 
or phenotype of the mice (Age, F (1, 30) =50.173, p<0.01; Phenotype, F (1, 30) 
=69.771, p<0.01). There were also differences in Aβ levels in subgroups with the 
same age or the same phenotype (Age×Phenotype: F (1, 30) =31.680, p<0.01). 
According to Table 7.4, the Aβ amounts in the layer V of the entorhinal cortex were 
increased in TgSwDI mice compared with wild-type mice at both 3 months and 9 
months; and were elevated with age, from 3 months to 9 months in both wild-type 
and TgSwDI mice. These results are in line with the known properties of Aβ 
deposition in this AD mouse model and the observation of increased Aβ levels 
during normal aging (Davis et al, 2004a; Mintun et al, 2006).  
This model was not significant to account for the variance of Gpr50 levels in this 
region (F (3, 28) =1.654, Adjusted R2=0.059, p=0.200, Table 7.5.B). This means that 
differences in age and phenotype did not account for the variance in Gpr50 levels. 
No significant differences in Gpr50 expression were identified between 3 months and 
9 months (Age, F (1, 30) =1.287, p=0.266), or wild-type and transgenic animals 
(Phenotype, F (1, 30) =0.194, p=0.663). The interaction term of Age and Phenotype 
had a trend of significance (Age×Phenotype: F (1, 30) =3.481, p=0.073), indicating 
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that there might be differences in Gpr50 expression in subgroups such as between 
wild-type and TgSwDI mice at the same age, or between 3 months and 9 months 
mice with the same phenotype. Therefore, post hoc analysis was performed on Gpr50 
levels in the entorhinal cortex layer V in pairwise comparisons using unpaired 
Student’s t-test (see 7.3.2.2 and 7.3.2.3).  
Table 7.5 The general linear model to predict the expression levels of Aβ and Gpr50 in the 
layer V of the entorhinal cortex among the four mouse cohorts  




3, 28 50.541 2.0×10-11** 0.844 
Age 1, 30 50.173 1.0×10-7** 0.642 
Phenotype 1, 30 69.771 4.4×10-9** 0.714 
Age× Phenotype 1, 30 31.680 5.0×10-6** 0.531 




3, 28 1.654 0.200 0.151 
Age 1, 30 1.287 0.266 0.044 
Phenotype 1, 30 0.194 0.663 0.007 
Age×Phenotype 1, 30 3.481 0.073$ 0.111 
$ p<0.1, ** p<0.01.  
df: degrees of freedom (between-groups df, within-groups df) 
7.3.2.2 Is the expression level of Gpr50 altered in the layer V of the entorhinal cortex 
in TgSwDI mice compared to the wild-type control? 
In the layer V of the entorhinal cortex, it was found that there was no significant 
alteration of Gpr50 expression in young TgSwDI mice compared to wild-type 
littermates at the age of 3 months (Figure 7.9.A, p=0.378). Diffuse plaques of Aβ 
were not abundant in the cortex at this stage (see Table 7.4). However, in older 
animals at the age of 9 months, there was a trend of elevation identified of Gpr50 





NS: not significant, p= 0.378>0.1; $: a trend of significance, 0.05< p=0.091<0.1; N=8 
Figure 7.9 Comparison of Gpr50 expression in the entorhinal cortex layer V of TgSwDI 
mice with that of wild-type mice at 3 months or 9 months. The differences in means were 
tested using the unpaired Student’s t-test. 
7.3.2.3 Is the expression level of Gpr50 in the layer V of the entorhinal cortex related 
to age? 
No significant alteration of Gpr50 expression in the layer V of the entorhinal cortex 
was identified between 3 months and 9 months wild-type mice (Figure 7.10.A, 
p=0.672). Yet, there was a significant increase of Gpr50 levels in this region of 9 
months transgenic mice compared to their 3 months littermates (Figure 7.10.B, 
p=0.014). Thus, the expression level of Gpr50 in the layer V of the entorhinal cortex 
was related to age in transgenic animals only. 
 
NS: not significant, p= 0.672>0.1; *: significant, p=0.014<0.05; N=8. 
Figure 7.10 Comparison of Gpr50 expression in the entorhinal cortex layer V of mice 
between 3 months and 9 months in A) wild-type or B) TgSwDI. The differences in means 
were tested using the unpaired Student’s t-test. 
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7.3.2.4 Is the expression level of Gpr50 in the layer V of the entorhinal cortex 
correlated to that of Aβ? 
It was shown in the last section that in TgSwDI mice the expression level of Gpr50 
was significantly higher in older animals than in young animals. This modulation 
was not totally contributed by age, because no significant alteration was found 
between young and old wild-type animals. To answer the question whether Gpr50 
expression is associated with the AD pathogenesis, Pearson’s correlation analysis 
was performed to evaluate the potential link between Aβ and GPR50 in TgSwDI 
mice by using a combined dataset of 3 months and 9 months animals. As expected, 
there was a positive correlation between the expression levels of Aβ and Gpr50 in the 
entorhinal cortex, layer V (Figure 7.11, r=0.498, p=0.050). 
 
Figure 7.11 Correlation between the expression levels of Aβ and Gpr50 in the layer V of 
the entorhinal cortex of TgSwDI mice.  EC: entorhinal cortex. 
7.3.3 Aβ and Gpr50 in the hippocampus  
7.3.3.1 Aβ and Gpr50 in the hippocampus of TgSwDI mice 
There were two distinguished staining patterns of Aβ in the hippocampus, revealed 
by the mouse monoclonal antibody Aβ 6E10 (Figure 7.12.A). The commonly 
identified plaques were localised mainly in the polymorph layer of the dentate gyrus 
and occasionally in the molecular layer of the dentate gyrus, the lacunosum-
moleculare stratum and the oriens layer of CA1, as well as the stratum radiatum of 
CA2 and CA3 (Figure 7.12.A, 7.13.D). There was also a perinuclear cytoplasm-like 
neuronal staining in the pyramidal layer of CA1. By comparing the observation with 
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other cohorts, it was found that there was no such signal identified in 3 months or 9 
months wild-type groups (Figure 7.13.A, C), confirming that it was not endogenous 
mouse App. Yet, a moderate amount of a slightly punctate pattern was spotted in 3 
months transgenic group in the pyramidal layer of CA1 (Figure 7.13.B).  This 
implied that the signal was not human APP, but Aβ peptide, showing up early-onset 
accumulation at a young age and increasing with age.  
Gpr50 was found allocated orderly in the pyramidal layer of CA1 with axons 
projecting to the stratum radiatum, while weaker signal was also detected in the 
pyramidal layer of CA2, CA3 and the granular layer of the dentate gyrus (DG) 
(Figure 7.12.B). The staining pattern of Gpr50 in other cohorts was rather similar 




Figure 7.12 The immunofluorescence labelling of Aβ and Gpr50 the in the hippocampus of 
9 months TgSwDI mice. A) Aβ, enlarged area: a) CA1, pyramidal layer, b) dentate gyrus (DG), 
Po, polymorph layer; B) Gpr50; C) a distribution map of hippocampal Gpr50 and Aβ (larger 
font indicates main sites). So/sp/sr/slm: oriens layer/pyramidal cell layer/stratum radiatum 
/lacunosum-moleculare stratum of CA1; mo/sg/po:  molecular layer/granular 
layer/polymorph layer of DG. Scale bar: 100 µm. The map of mouse hipocampus was 




Figure 7.13 Aβ in the hippocampus of the four mouse cohorts. A) 3 months wild-type; B) 3 
months TgSwDI; C) 9 months wild-type; D) 9 months TgSwDI. The white square indicated an 
enlarged region of the CA1 pyramidal layer. Scale bar: 200 µm. 
Even though both Aβ and Gpr50 were identified in the hippocampus, they were 
predominantly located in different layers (see Figure 7.12.C). Therefore, the 
correlation between Aβ peptide and Gpr50 in the whole hippocampal region was 
analysed. Quantification of the percentage with protein expression in the 
hippocampus region was performed on areas with hand-drawn boundary according to 
Allen brain atlas (see Figure 7.1). This is similar to the method of correlating the 
protein levels in lysates by western blotting. The data of the expression percentage of 
Aβ and Gpr50 in the hippocampus (obtained through ImageJ) are presented in Table 




Table 7.6 The expression percentage of Aβ and Gpr50 in the hippocampus 
Animal  
number 
Age Phenotype Hippocampus 
Aβ GPR50 
662 3 months Wild-type 0.2325 3.465 
663 3 months Wild-type 0.18* 3.148 
664 3 months Wild-type - 1.9675 
665 3 months Wild-type 0.665* - 
666 3 months Wild-type 0.352 4.667* 
667 3 months Wild-type - 1.5065 
668 3 months Wild-type 0.579* 3.615 
669 3 months Wild-type 0.339 3.701 
654 3 months Transgenic 3.796 3.4645 
655 3 months Transgenic 1.512 2.617* 
656 3 months Transgenic 2.5555 3.005 
657 3 months Transgenic 1.21 3.3055 
658 3 months Transgenic 2.2495 4.771* 
659 3 months Transgenic 1.2975 1.893 
660 3 months Transgenic - - 
661 3 months Transgenic 1.6035 1.332 
261 9 months Wild-type 0.116 4.35* 
262 9 months Wild-type 0.318 2.315* 
263 9 months Wild-type 0.1685 6.134* 
264 9 months Wild-type 0.404 2.0415 
265 9 months Wild-type 0.274* 3.329* 
266 9 months Wild-type 0.325* - 
267 9 months Wild-type 0.3175 2.726* 
270 9 months Wild-type 0.481 3.857* 
245 9 months Transgenic 1.5905 1.5905 
246 9 months Transgenic 1.1645 1.1645 
247 9 months Transgenic 1.2965 1.2965 
248 9 months Transgenic 1.501 1.501 
249 9 months Transgenic - - 
251 9 months Transgenic 2.825 2.825 
255 9 months Transgenic 3.353 3.353* 
257 9 months Transgenic 2.281 2.281 
* Single hemi-brain section used; -Structure missing or 
damaged. All other data represent the mean of two 
consecutive hemi-brain sections. 
The percentage of the hippocampus (defined by hand-
drawn shut lines) occupied by the immunoreactivity of Aβ 
or Gpr50 was calculated as their expression levels in this 
region. All the quantification was performed automatically 
in ImageJ. Values were averaged from the duplicate 
sections. In case of an outlier identified in one animal, its 




Table 7.7 A summary of the expression percentage of Aβ and Gpr50 in the hippocampus 
Age Phenotype Mean±Standard Deviation, N 
Aβ Gpr50 
3 months Wild-type 0.3913±0.1920, 6 3.1529±1.0816, 7 
3 months Transgenic 2.0320±0.9222, 7 2.9126±1.1215, 7 
9 months Wild-type 0.3005±0.1175, 8 3.5361±1.4106, 7 
9 months Transgenic 4.7459±0.7034, 7 2.0016±0.8366, 7 
 
The general linear model analysed the main effects of age and phenotype, and the 
interaction effect of age and phenotype (age×phenotype) on the expression levels of 
Aβ and Gpr50 in the hippocampus among the four cohorts.  
As is shown in Table 7.8.A, there were significant differences in the Aβ levels in the 
hippocampus between 3 months and 9 months mice (Age, F (1, 23) =29.645, p<0.01), 
and between wild-type and TgSwDI mice (Phenotype, F (1, 23) =156.480, p<0.01). 
The Aβ level in the hippocampus was also affected by “Age×Phenotype” (F (1, 23) 
=31.423, p<0.01).  Therefore, according to the means shown in Table 7.7, the Aβ 
level in the hippocampus of 3 months TgSwDI mice was significantly higher than 3 
months wild-type mice and lower than 9 months TgSwDI mice. This confirmed 
previous reports that the hippocampus is one of the first regions that were affected by 
AD, and the Aβ deposition increases with age (Allen et al, 2007; Schuff et al, 2009).  
The model was not sufficient to account for the variance of Gpr50 levels in the 
hippocampus (F (3, 24) =2.327, Adjusted R2=0.128, p=0.100, Table 7.8.B). The 
expression of hippocampal Gpr50 was not associated with age or age×phenotype 
(Age, F (1, 26) =0.381, p=0.543; Age×Phenotype, F (1, 26) =2.291, p=0.143), but 
was significantly related to phenotype (F (1, 26) =4.308, p=0.049). This is interesting, 
so post hoc analysis was further performed on Gpr50 levels in the hippocampus in 




Table 7.8 The general linear model to predict the expression levels of Aβ and Gpr50 in the 
hippocampus among the four mouse cohorts 
A) Aβ df F P-value Partial Eta 
Squared 
Corrected model  
Adjusted r2=0.898 
3, 21 71.100 3.6×10-11** 0.910 
Age 1, 23 29.645 2.1×10-5** 0.585 
Phenotype 1, 23 156.480 3.4×10-11** 0.882 
Age× Phenotype 1, 23 31.423 1.5×10-5** 0.599 




3, 24 2.327 0.100 0.225 
Age 1, 26 0.381 0.543 0.016 
Phenotype 1, 26 4.308 0.049* 0.152 
Age×Phenotype 1, 26 2.291 0.143 0.087 
* p<0.05, ** p<0.01 
df: degrees of freedom (between-groups df, within-groups df) 
 
7.3.3.2 Is the expression level of Gpr50 altered in the hippocampus of TgSwDI 
mouse compared to the wild-type control? 
By the unpaired Student’s t-test, no significant alteration of Gpr50 expression was 
observed between the wild-type mice and the TgSwDI mice in the 3 months cohorts 
(Figure 7.14.A), similar to what was observed in the layer V of the entorhinal cortex. 
Interestingly, there was a significant decrease of Gpr50 levels in the hippocampus of 
9 months TgSwDI animals compared with their wild-type littermates. And this was 






NS: not significant, p= 0.690>0.1; *: significant, p=0.033<0.05, N=7. 
Figure 7.14 Comparison of Gpr50 expression in the hippocampus of TgSwDI mice with 
that of wild-type mice at 3 months or 9 months. The differences in means were tested 
using the unpaired Student’s t-test. 
7.3.3.3 Is the expression level of Gpr50 in the hippocampus related to age? 
To determine whether Gpr50 expression in the hippocampus was regulated with the 
increasing age, Gpr50 levels were compared between 3 months and 9 months mice, 
in both wild-type and transgenic cohorts. No significant alteration of Gpr50 
expression was identified in either phenotype (Figure 7.15), which agreed with the 
finding in the general linear model that age does not affect Gpr50 levels in the 
hippocampus (7.3.3.1).  
 
NS (left): not significant, p= 0.580>0.1; NS (right): not significant, p=0.113>0.1; N=7. 
Figure 7.15 Comparison of Gpr50 expression in the hippocampus between 3 months and 9 
months mice of A) wild-type or B) TgSwDI. The differences in means were tested using the 




7.3.3.4 Is the expression level of Gpr50 in hippocampus correlated to that of Aβ? 
No significant correlation of Gpr50 levels and Aβ amounts was found in the 
hippocampus of TgSwDI mice (r=-0.394, p=0.183, Figure 7.16), which coincided 
with the observation that the expression level of Gpr50 in the hippocampus was 
unchanged in TgSwDI mice from 3 months to 9 months. Hence, the potential role of 
Gpr50 associated with AD may be related to certain brain regions, such as in the 
entorhinal cortex. 
 
Figure 7.16 Correlation between the expression levels of Gpr50 and Aβ in the 
hippocamous of TgSwDI mice 
7.4 Discussion 
In this chapter, I studied the expression levels of Gpr50 and its correlation with Aβ in 
an AD mouse model TgSwDI mice. My results showed that in the entorhinal cortex 
layer V, Gpr50 expression was significantly enhanced in older TgSwDI mice 
compared to younger TgSwDI mice, and showed a trend of elevation compared to 
wild-type littermates. Accordingly, a notable positive correlation between Gpr50 
levels and Aβ deposition was identified in the entorhinal cortex layer V. In the 
hippocampus, Gpr50 expression was significantly decreased in older TgSwDI mice 
compared with age-matched wild-type control. No significant correlation of Gpr50 
expression and Aβ deposition was found in the hippocampus.  
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My data provide further evidence for the association of GPR50 with AD, as it was 
confirmed that Gpr50 expression in the entorhinal cortex layer V was altered during 
a later stage of AD (9 months in TgSwDI mice), and its level was significantly 
elevated as the severity of the illness rose with age. Importantly, this response of 
Gpr50 was relevant to the major hallmark of AD pathology: the accumulation of 
amyloid plaques. Also, my results lead to a further speculation if the down-regulation 
of Gpr50 in the hippocampus is an indication of other aspects of AD, for instance the 
cognitive impairments, or whether it is involved with other complications of this 
disease that fail to exhibit in this model, for example, the neuronal loss. 
7.4.1 What is the implication of the alteration of GPR50 expression in TgSwDI 
mice? 
The parameter for assessing Gpr50 expression levels in this experiment is the 
percentage with Gpr50 immunoreactivity of certain regions (the entorhinal cortex 
layer V and the hippocampus). In wild-type C57BL/6 mice, Gpr50 was co-localised 
with mature neuronal marker NeuN, but not with GFAP, or O4 which marked 
astrocytes and oligodendrocytes respectively (Grunewald et al, 2012). This is further 
confirmed by my results that the staining of Gpr50 was mostly detected in neurons 
with apparent axons in both wild-type and TgSwDI mice, supporting the neuronal 
functions of Gpr50.  
It is worth noting that 3 months old is referred to as the lower age limit of mature 
adult mice that are past development, while middle age group that begins to show 
senescent changes typically starts from 10 months old. The developmental features 
of cells especially neurons may be almost viewed as equal between 3 months and 9 
months mice, as there would be no either further neuronal extension or neuronal 
damage in the span of the two ages. Also, there were no data about appreciable 
neuronal loss identified in TgSwDI mice up to 9 months. Therefore, an increase of 
Gpr50 levels in 9 months TgSwDI mice compared to 3 months in the entorhinal 
cortex, layer V indicated that there were more neurons activated to express Gpr50 in 
this area, rather than different cell sizes. This is interesting as Gpr50 in TgSwDI 
seems to follow the similar pattern to the accumulation of Aβ burden with increasing 
age, as well as a speculated elevation of Bace1 activity. As both Gpr50 and most of 
Bace1 seem to express in neuronal cells, more functional explanation might be 
achieved by correlating the “burden” of these two than that of Gpr50 and Aβ.  
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Note that the diffuse Aβ in the entorhinal cortex is not the major form of the 
extracellular Aβ plaques in this model, which is dominated by microvascular Aβ 
deposits in the thalamic region (Davis et al, 2004a). It will also be interesting to 
correlate the expression levels between Gpr50 and Aβ using quantitative real-time 
PCR to compare the mRNA level or using western blotting of brain sub-region 
homogenates to compare the protein level in their separately dominant areas.  
Importantly, the decrease of Gpr50 expression in the hippocampus of 9 months 
TgSwDI animals may be related to different neurodegenerative processes between an 
elderly AD case and a normal aging case, while the cortex or at least the entorhinal 
cortex, layer V might be the area to investigate the pathological mechanism of this 
disease.  
7.4.2 Is Gpr50 involved in the neurotransmitter signalling system in AD? 
The endocrine system in AD patients is disturbed, as indicated by an increased level 
of glucocorticoids (GCs) circulation (de Quervain et al, 2004; Dhikav & Anand, 
2007; Notarianni, 2013). GCs are synthesised in the adrenal cortex and highly 
responsive to chronic stress. These steroid hormones cause effects by coupling to the 
hippocampus-based glucocorticoid receptor (GR), which is activated after the 
binding and in turn boosts the up-regulation of anti-inflammatory factors and 
suppresses the pro-inflammatory factors. The function of hypothalamic-pituitary-
adrenal (HPA) axis was disordered in AD, which triggered the adrenal cortex to 
release GCs in response to stress (Woulfe et al, 2002). Triple transgenic AD mice 
(3×TgAD) harbouring swAPP, PS1 (M146V) and tau (P301L) exhibited amyloid 
plaques and tangles with dysfunctional synapse. Administration of GR antagonist 
mifepristone (RU486) significantly improved the pathological and cognitive 
outcomes of these mice, indicating that the rescue of the glucocorticoid system 
highlights a ponderable effective treatment for AD (Baglietto-Vargas et al, 2013). 
GPR50 has long been identified as having a potential to regulate the outputs of 
neuronal activity and hormone production in HPA axis, due to its high expression 
levels in the hypothalamic regions (Drew et al, 2001; Drew et al, 1998) and co-
localisation with Nogo-A, Abca2 and Cdh8 in both adult and E18 mouse brain 
(Grunewald et al, 2012). Gpr50 knockout mice showed an elevated level of 
corticosterone circulation combined by in vitro data that Gpr50 knockdown in rat 
227 
 
pituitary cells attenuates TIP60-dependent GR signalling (Li et al, 2011). This 
suggests an impaired GCs feedback to GR, influenced by the lacking of Gpr50. A 
similar effect occurs in AD in terms of the GCs-GR interaction, exemplified by the 
hypercortisolemia and a GR-signaling insufficiency (Notarianni, 2013). I observed a 
down-regulation of Gpr50 in the hippocampus of old TgSwDI mice, and a trend of 
up-regulation in the entorhinal cortex, layer V. Therefore, the effect of Gpr50 on 
GCs-GR system in AD might be region-specific and highly responsive to other sites 
of the brain. In this case, the altered hippocampal Gpr50 may be linked with a 
dysfunctional GCs-GR system. Furthermore, the entorhinal cortex contributes the 
hippocampal inputs. Lesions of the enthorinal cortex resulted in a transient 
redistribution of GR expression in the hippocampus, a decrease in the dentate gyrus 
while an increase the CA1 sub-field (O'Donnell et al, 1993).  The status of the 
entorhinal cortex seems to send signal to the regulation of GR. Thus, the observation 
that more neurons expressed with Gpr50 in the entorhinal cortex, layer V as AD 
develops might be a preliminary signal of rescue to the diminished GR signalling in 
the hippocampus. Further investigations are required to reveal the levels of GCs and 
GR in this transgenic model, hence to answer the question if Gpr50 is associated with 
the hypofunction of GCs-GR system in AD.   
The melatonin-related receptor (MT) signalling pathway is also damaged in AD 
cases. Interestingly, the affected expression of MT1 is region-specific, with increased 
level in the hippocampus but decreased level in the cortical area (Brunner et al, 2006; 
Savaskan et al, 2001; Savaskan et al, 2002). These regulative effects are opposite to 
those on Gpr50 in TgSwDI mice. It is known that GPR50 can work as an antagonist 
to MT1, preventing its binding to agonist and G protein by forming heterodimer with 
it (Levoye et al, 2006). It is possible that Gpr50 expression changes under AD 
conditions are responsive to the dysregulation of MT1 functions, and related to the 
disrupted homeostasis of melatonin signalling in AD. 
Other irregular endocrine activities recognised in AD patients include deficits in 
cholinergic, serotonergic, noradrenergic, dopaminergic, GABAergic and 
somatostatinergic neurotransmitter system (Reinikainen et al, 1990). For example, 
ablating muscarinic M1 receptor (M1R) in TgSwDI and 3×TgAD mice exacerbated 
AD pathological features and cognitive impairments (Medeiros et al, 2011). 
Elsewhere, increased binding to serotonin receptors (5-HT1A, 5-HT2A) was found in 
vascular AD brains compared with normally aged controls, and positively correlated 
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to cognition (5-HT1A) (Elliott et al, 2009), while the density of 5-HT2A and 5-HT6 
declined in neurons of AD brains compared with age-matched control (Lorke et al, 
2006).  Gpr50 was found co-localised with 5-hydroxytryptamine (5-HT, serotonin, 
serotonergic marker), tyrosine hydroxylase (dopaminergic and noradrenergic marker), 
and dopamine beta hydroxylase (noradrenergic neuronal marker) in the adult mouse 
brain stem, suggesting that it might function as a receptor for neurotransmitters 
(Grunewald et al, 2012). The yeast two-hybrid study also showed a potential role of 
GPR50 in the GABA transmission putatively via the interaction with PICK1, 
SLC12A5/ KCC2 or MADD (Grunewald et al, 2009).  
The signal transduction of above-mentioned M1R and 5-HT receptor is influenced by 
the regulator of G protein signalling (RGS) family (Muma et al, 2003). One of the 
members, RGS4 escalates the GTPase activity of Gi/o and Gq/11 proteins and the 
GTP hydrolysis in turn accelerates the termination of G protein-coupled receptor 
(GPCR) signalling. RGS4 is located in a major susceptibility locus (chromosome 
1q21-q22) for schizophrenia identified by genetic linkage and association analysis, 
combined with quantitative studies showing a decreased RGS4 expression in the 
prefrontal cortex of schizophrenia patients (Chowdari et al, 2002; Gu et al, 2007; 
Morris et al, 2004). Down-regulated mRNA levels of RGS4 splice variants were also 
found in AD patients (Emilsson et al, 2006), which may be the explanation of 
reduced RGS4 protein levels in the AD parietal cortex, and responsible for the 
diminished M1 cholinergic signalling in AD. Interestingly, siRNA-mediated gene 
silencing of RGS4 resulted in the up-regulation of GPR50 (Vrajova et al, 2011), 
which might be related to my results of the enhanced Gpr50 expression in the 
entorhinal cortex of TgSwDI mice.  
In summary, the alteration of Gpr50 expression in TgSwDI mice might be a response 
to a malfunctioning network of the signalling system in this AD-affected model. 
7.4.3 Suggested future experiments 
My results have demonstrated that Gpr50 expression level in the hippocampus is 
likely to be associated with certain aspects of AD pathogenesis, such as 
neurodegeneration. Its levels in the entorhinal cortex, layer V may indicate the 
severity of diffuse Aβ deposition. To further verify these observations, I emphasise 
that it is essential to investigate the putative interactors of Gpr50 observed in the 
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TgSwDI mouse model. The following additional experiments can be carried out to 
further reveal the causes or effects of altered GPR50 expression in AD: 
1) Measure the levels of Bace1 expression and activity in the brain regions of 
TgSwDI mice where Gpr50 expression was found altered, and correlate the 
levels of the two proteins; 
2) Perform immunoprecipitation between Gpr50 and potential interactors that 
are presumed to be affected in TgSwDI mice (Bace1); 
3) Assess expression levels of interactors that are known to play a role in AD 
and might help to explain the alteration of Gpr50 expression in TgSwDI mice 
(GR, MT1, RGS4); 
4) Cross TgSwDI mice with Gpr50 KO mice and monitor the body weight, body 
temperature, activity frequencies, cognitive function and pathological 
appearance of the animals; 
5) Cross TgSwDI mice with GPR50 interactor-deficient mice (melatonin 
receptor) and study the levels of Gpr50; 













In this thesis, my investigations expanded the knowledge of mental disorder risk 
factor GPR50, by linking its function with a key enzyme of major brain diseases 
BACE1 and by further revealing its altered expression during the progression of 
Alzheimer’s disease (AD). I have shown that GPR50 is physically associated with 
BACE1, and has a potential in regulating the function of BACE1 at the cell surface 
and the synapse (chapter 3). The mechanism by which GPR50 modulates β-secretase 
activity may be different in non-neuronal cells compared to neuronal cells, as GPR50 
overexpression demonstrated different regulatory trends on BACE1 expression and 
trafficking (chapter 2/5). Also, the C-terminal tail of GPR50 appears to be essential 
to its general function, because GPR50del reduced β-secretase activity in neurons in 
comparison to GPR50 (chapter 4). The protein levels of Gpr50 in AD model 
TgSwDI mice exhibited age-related region-specific alterations, and were correlated 
with the quantity of Aβ deposition in the entorhinal cortex layer V (chapter 7).  
8.1 GPR50 co-localises with BACE1 at functional sites 
Both GPR50 and BACE1 are membrane-bound proteins. GPR50 is primarily located 
at the cell surface. This feature is common to GPCRs, which sense molecules outside 
the cells and activate intracellular signal transduction pathways and ultimately trigger 
cell responses. The co-localisation sites of GPR50 and BACE1 are generally external. 
They are found co-localised at the cell surface and filopodia/lamellipodia-like 
structures in a subset of non-neuronal HEK293 cells, when endogenously expressed; 
at the cell surface and neurites in neuronal SH-SY5Y cells when exogenously 
expressed; and at spines and axonal terminals in primary neurons (chapter 3). This 
suggests potential roles for the interaction of GPR50 and BACE1 in 
neurodevelopment and cell signalling. 
8.1.1 The cell surface 
The cell surface is one of the putative BACE1 activity sites. It is still not clear 
whether the Aβ generation occurs at the plasma membrane or the early endosomes, 
but the shedding of CAMs is most likely to take place at the cell surface. For 
example, BACE1 selectively sheds contactin-2 at the cell surface, and tightly 
regulates the surface expression of this CAM (Gautam et al, 2014). Elsewhere, 
BACE1 cleavage of voltage-gated sodium channel β4 subunit (Navβ4) accelerated 
neurite extension that could be promoted by Navβ4 itself, but reduced the number of 
filopodia-like protrusions (Miyazaki et al, 2007). GPR50 and BACE1 have an over-
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lapping role in extending neurites. Therefore, GPR50 may mediate BACE1 activity 
on molecules expressed at the cell surface or external compartments. Yet, GPR50 
overexpression also resulted in an increase in filopodia formation, opposite to the 
effect of BACE1 on Navβ4 shedding. This may suggest that neurite extension and 
filopodia protrusion are two independent processes.  
8.1.2 The synapse 
In the nervous system, synapse is the structure which passes signals from one neuron 
(or nerve cell) to another. BACE1 is present in presynaptic terminals, with a subset 
in close proximity to synaptic active zones (Kandalepas et al, 2013). In an AD mouse 
model and human AD brains, BACE1 accumulates at synaptophysin-positive 
dystrophic neurites around amyloid plaques, suggesting that Aβ is released from 
presynaptic terminals where BACE1 cleaves APP (Kandalepas et al, 2013). Other 
BACE1 substrates that may be processed in the presynaptic terminal include NRG1, 
Jagged 1 and CHL1. 
Strong co-localisation of GPR50 and BACE1 at the dendritic spines and the axon 
terminals indicates that their interaction may be implicated in synapse functions. 
Specifically, endogenous Gpr50 and Bace1 co-fractionate in the synaptic vesicles 
from adult mouse brain (chapter 3). Gpr50 is also located in the post-synaptic 
densities, showed by myself and others (Grunewald et al, 2012). This expression 
profile is similar to that of Nogo-A and Nogo-A receptor, NgR, which are expressed 
at both pre-synaptic and post-synaptic sites (Grunewald et al, 2012; Wang et al, 
2002). Contrary to NgR, GPR50 rescues the inhibitory effect on neurite outgrowth 
when interacting with Nogo-A. Also, the Nogo-A~NgR1 interaction limits synaptic 
plasticity in part by restricting the expression of glutamate receptors (NMDA/AMPA 
receptor) and GABA transmission (GABA B receptor/GIRK1) (Murthy et al, 2013; 
Peng et al, 2011), the processes that may be associated with GPR50 (Grunewald et al, 
2009).  In addition, NgR is able to trans-activate the phosphorylation of EGFR 
without binding to it, and this process is required for mediating the inhibition of axon 
regeneration and myelination (Koprivica et al, 2005). Hence, there is a possibility 
that the presynaptic pool of GPR50 takes a part in BACE1 activity, while the 
postsynaptic pool responds to the cleavage product of BACE1, for instance, the 
EGF-like domain of NRG1.  
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Furthermore, BACE1 cleavage-mediated NRG1/ErbB4 signalling is required for 
synaptic transmission (Savonenko et al, 2008). Reduced presynaptic cleavage of 
NRG1 upon BACE1 deletion impaired the regular signalling of postsynaptic ErbB4, 
which resulted in a decreased spine density and schizophrenia-like 
cognitive/behavioural deficits (Savonenko et al, 2008). In neuronal cells, alteration of 
GPR50 function (GPR50del) potentially affected neuronal β-secretase activity. Also, 
in mouse brain, the strongest co-localisation of Gpr50 and Bace1 was seen in CA2 
pyramidal neurons (chapter 6), the synaptic plasticity of which is associated with 
different types of learning and memory (Chevaleyre & Siegelbaum, 2010; Hitti & 
Siegelbaum, 2014; Wintzer et al, 2014), and a region demonstrates abnormalities 
early in the onset of schizophrenia and bipolar disorder (Benes et al, 2001; Focking 
et al, 2011; Leranth & Ribak, 1991). Thus, the presynaptic interaction of GPR50 and 
BACE1 may suggest a coordinating role in synaptic functions and may be important 
in the maintenance of normal cognition. 
8.2 GPR50 and its illness-related variant have distinct effects on β-secretase 
activity  
In chapter 4, it was shown that GPR50del but not GPR50 potentially suppressed β-
secretase activity in neuronal cells, which corresponds to an effect of impeding 
Bace1 maturation (chapter 5). This regulation trend is opposite to what was observed 
in HEK293 cells, in which GPR50 but not GPR50del is an effector of BACE1 
activity (Grünewald, 2011), and this matches with a potentially increased ratio of 
mature BACE1/immature BACE1 in the plasma membrane fractions (chapter 5). 
Thus, the modulation direction of the two transcripts of GPR50 is consistent with 
their respective roles in the β-secretase trafficking system in respective cell lines. 
Interestingly, both cell lines showed higher activity when over-expressing GPR50 
compared to GPR50del. As the BACE1 activity level in HEK293 cells is low, the 
putative supressing effect by GPR50del is probably difficult to detect; whereas the 
Bace1 activity in neurons is high, the up-regulating ability of GPR50 is not as 
obvious as in HEK293 cells.   
Previous studies have reported that some GPCRs regulate the localisation of 
secretases in the amyloidogenic pathway, thus affecting the production of Aβ 
peptides. The overexpression of GPR3 led to an increased localisation of mature γ-
secretase in the detergent resistant membranes at cell surface and this measure 
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promoted the generation of Aβ40/42 peptides (Thathiah et al, 2009). Activation of δ-
opioid receptor caused enrichment of BACE1 and γ-secretase in the late 
endosomes/lysosomes, and enhanced the activities of both secretases specifically for 
Aβ production (Teng et al, 2010). Note that both cell surface and endocytic 
compartments are arguably the sites for β-/γ-secretase cleavage. In mouse primary 
cortical neurons overexpression of GPR50del seems to retain Bace1 in the ER, thus 
there is a trend of decreasing Bace1 activity; whereas, in HEK293 cells, GPR50 
overexpression tends to result in a higher percentage of mature BACE1 but 
significantly less immature BACE1 distributed in the cell surface fractions. This 
observation in HEK293 cells may partly explain why BACE1 activity is up-regulated 
upon GPR50 transfection, as immature BACE1 is much less active than mature 
BACE1 (Zhong et al, 2007). 
The C-terminal polymorphisms of GPCRs may affect their surface trafficking, 
secondary structure folding and responsiveness to ligand binding (Spomer et al, 
2014). The C-terminal tail of GPR50 is required for its plasma membrane 
localisation and is essential for the binding of C-terminal interactors, i.e. TIP60 (Li et 
al, 2011). For GPR50 non-C-terminal interactors, for instance MT1, deletion of 
GPR50 C-terminal tail retained the ability to heterodimerise with MT1 but its 
inhibitory effect on MT1 was removed (Levoye et al, 2006). The deletion of residues 
502-505 (TTGH) and Thr532Ala substitution do not affect the cellular localisation of 
GPR50, but enhanced its potential in neurite outgrowth (Grünewald, 2011). It has not 
been investigated which part of GPR50 physically binds to BACE1, but the two 
variations included in GPR50del are sufficient to affect its function by differentially 
regulating BACE1 activity in different cell lines.  
The action of holding Bace1 in the ER by GPR50del may indicate a direct interaction 
with immature BACE1 and interrupt its maturation, a regulation mechanism that has 
been suggested for presenilin and the cellular prion protein (Griffiths et al, 2011; 
Hebert et al, 2003). While wild-type presenilin1 has a neuroprotective effect, mutant 
presenilin1 facilitates the generation of neurotoxic Aβ partly by increasing the 
transcription of BACE1 and correspondingly β-secretase activity (Giliberto et al, 
2009). Thus, mutations in BACE1 regulators may imply an exchange between the 
neuroprotective and neurodegenerative roles. In this case, GPR50del seemingly has 
deleterious effects as it is associated with an increased susceptibility to bipolar 
disorder (BD) and schizophrenia. However, the negative effects represented by 
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presenilin1 mutations require the molecules in the amyloidogenic cascade, for 
instance APP and γ-secretase (Giliberto et al, 2009). On one hand, the inhibitory 
effect of GPR50del leads to insufficient BACE1 cleavage of neural CAMs, which 
may result in neuronal loss; on the other, excessive NRG1-ErbB4 signalling has been 
seen in BD and schizophrenia (Hahn et al, 2006; Wang et al, 2014b), thus the GPR50 
variation (GPR50del)  might be responsible for reducing NRG1-dependent  ErbB4 
activation . As it is not known which BACE1 substrate(s) GPR50 acts on, whether 
mutations in GPR50 generate adverse or favourable effects under diseased conditions 
has not been adequately investigated. 
The positive impact of the GPR50 full-length isoform on BACE1 activity in 
HEK293 cells counteracted the negative effects of RTN3/Nogo-C (Grünewald, 2011), 
which may indicate that GPR50 and RTN3 bind to BACE1 in a competitive manner. 
This result is concomitant with the finding that in BACE1 trafficking network, RTN3 
retains BACE1 in the ER, whereas GPR50 overexpression assists in more mature 
BACE1 releasing to the cell surface, two opposite directions of regulating β-
secretase activity. Further investigation is called for on whether GPR50 and RTN3 
form a complex with BACE1 at the same time and therefore cooperate to maintain 
the general activity level of β-secretase under healthy conditions. Malfunction of 
either GPR50 or RTN3 in mental diseases will affect BACE1-dependent cleavage. 
Dysregulation of GPR50 may include the variations in GPR50del that apparently 
facilitate the inhibitory effect of RTN3 (impeding BACE1 maturation). 
8.3 What can we conclude from the investigation of GPR50 in the AD 
TgSwDI mouse model? 
8.3.1 Why is GPR50 level regulated in AD mouse brain? 
A unique feature of TgSwDI mice is that the brain parenchyma accumulates diffuse 
nonfibrillar plaques, while the thalamic microvessels harbour compact, fibrillar and 
thioflavine-S-positive amyloid deposits (Van Vickle et al, 2008). In chapter 7, I 
showed that in the entorhinal cortex layer V, Gpr50 expression level is increased 
with age in TgSwDI mice (transgenic, 3 months VS 9 months), but not in wild-type 
littermates, and the elevation is positively correlated with Aβ accumulation. 
Therefore, the expression level of Gpr50 might be responsive to that of Aβ level.  
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In the human brain and AD mouse models, diffuse plaques mainly consist of Aβ42 
(Morrissette et al, 2009). Interestingly, Aβ42 itself is a transcription regulator. Aβ42, 
or its active fragment Aβ25-32, can stimulate the expression and function of several 
membrane receptors, including TrkA (Bulbarelli et al, 2009), p75 neurotrophin 
receptor (Chakravarthy et al, 2010), and insulin receptor (Bartl et al, 2013). This can 
potentially contribute to the pathogenesis of AD through downstream regulation 
cascades such as Akt/GSK3β, ERK/MAPK, NF-κB, Jun N-terminal kinase (JNK) 
and RhoA/ROCK signalling pathways. For instance, Aβ42 activates the expression 
of BACE1 via the JNK/c-jun signalling pathway and potential post-transcriptional 
mechanism (Guglielmotto et al, 2012; Sadleir & Vassar, 2012). It is possible that 
GPR50 is also a target of Aβ42 in the feedback loop of the amyloidogenic pathway 
during AD development. Additionally, the Swedish double mutation in APP is 
associated with increased β-secretase activity (Citron et al, 1992), so an increase of 
Bace1 activity is expected in TgSwDI mouse brain.  Considering the interaction 
between Gpr50 and BACE1 revealed in this thesis, it will be interesting to test if the 
increased level of Gpr50 is required to coordinate with an inflated Bace1 activity in 
the entorhinal cortex. 
Additionally, it is noted that in the hippocampus, there is no alteration of Gpr50 
expression between young and old TgSwDI mice, and Gpr50 is not correlated to Aβ 
in density. This may be consistent with the observation that the immunoreactivity of 
Gpr50 and Aβ was detected in different sub-regions of the hippocampus. However, 
Gpr50 and Aβ were also located in different cell parts of the same cell layers (i.e. the 
CA1 sub-division). This implies that the putative association between Gpr50 and 
Aβ42 may be linked by a mediator, such as Bace1. 
8.3.2 What do we know about the role of GPR50 in AD? 
The level of Gpr50 in the hippocampus is down-regulated in older TgSwDI mice 
compared with the wild-type control (9 months, wild-type VS transgenic), and has a 
trend of elevation in the entorhinal cortex, the main input/output structure for the 
hippocampus (chapter 7). This asynchrony of Gpr50 regulation may indicate a 
dissociated role in the two brain regions, such as in learning ability and nonspatial 
memory (Ross & Eichenbaum, 2006; Shohamy et al, 2000). Hippocampus-dependent 
reference spatial memory (performance in Barnes maze) is found impaired in 
TgSwDI mice as early as 3 months old (Xu et al, 2007), a time point at which no loss 
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of Gpr50 was found in the hippocampus. The motor learning and coordination 
(rotarod analysis) showed no deficits in TgSwDI mice at an old age (12 months old), 
but they approached the novel object in an open field more quickly. This suggests 
that non-spatial memory is differentially affected from spatial memory in TgSwDI 
mice (Xu et al, 2007). Thus, it may be more practical to investigate the link of 
GPR50 to nonspatial memory, such as the object recognition memory, which may 
also be dependent on the hippocampus (Cohen et al, 2013). Moreover, Gpr50 
expression in the hippocampus appears to respond to the severity of AD related to 
age and thus might be related to late-onset AD.  
Levels of synaptophysin immunoreactive presynaptic terminals were found 
decreased in the hippocampus of different APP-overexpressing mice and this 
synaptotoxicity is believed to be independent of APP mutations (Mucke et al, 2000). 
Also, dentate gyrus neurons in the hippocampus of TgSwDI mice showed reduced 
frequency and amplitude of GABAA receptor-mediated miniature inhibitory 
postsynaptic currents, and decreased extrasynaptic tonic inhibitory current (Liang et 
al, 2014). In chapter 3, I showed that endogenous Gpr50 was present in presynaptic 
vesicles of adult mouse brain, and was suggested to mediate Bace1 cleavage which 
can occur in neural CAM-containing presynaptic terminals. Gpr50 was also localised 
in PSD-95 immunoreactive postsynaptic densities, the putative site where GPR50 
counteracts the inhibiting effect of Nogo-A (Grunewald et al, 2009). Thus, the loss of 
Gpr50 in the hippocampus of 9 month-old TgSwDI mice may be associated with the 
hippocampal synaptotoxicity in these animals. This suggests that GPR50 might exert 
functions in maintaining the integrity and plasticity of synapses during the late 
adulthood, and this function broadens its role in the neuronal development (i.e. 
synapse formation) in postnatal stage. This function of GPR50 is supported by my 
finding that GPR50 and BACE1 putatively interact at synapse (chapter 3), as BACE1 
is required for regulating synaptic inputs to hippocampal pyramidal neurons (Wang 
et al, 2014a). In particular, GABAergic synapses in the hippocampus are likely to be 
one of the major targets of GPR50, as some key proteins in GABA transmission 





8.3.3 How does the function of GPR50 in the hippocampus/entorhinal cortex 
link to that in HPA-axis? 
TgSwDI mice, GPR50 KO mice and BACE1 KO mice share a range of metabolic 
deficits related to HPA-axis, including elevated levels of circulating glucocorticoids 
in serum, reflecting a response to stress (Freeman et al, 2012; Ivanova et al, 2008; 
Meakin et al, 2012). This may indicates that GPR50 and BACE1 have coincidental 
functions in maintaining HPA-axis activity. 
Generally, the hippocampus undertakes the negative feedback mechanism to control 
the regular level of glucocorticoids secreted by the adrenal gland (Phillips et al, 
2006). Glucocorticoid receptors (GR) are abundantly expressed in the hippocampus, 
while overactive glucocorticoid can cause damage to the hippocampus, which 
consequently results in insufficient GR signalling (Phillips et al, 2006). This 
regulative model fits with what was found about Gpr50 in TgSwDI mice. Gpr50 
expression in the hippocampus may be diminished in response to abnormally high 
glucocorticoid levels (that can be induced by stress), a situation that will blunt the 
normal GR signalling activation mediated by Gpr50 (Li et al, 2011).  
The entorhinal cortex receives one of the largest cortical projections of midbrain 
dopaminergic neurons (Loughlin & Fallon, 1984). Dopamine is released by the 
arcuate nucleus of the hypothalamus, an area that was seen with strong co-
localisation of Gpr50 and Bace1 (chapter 6). Damage of dopamine systems has been 
observed in AD with Parkinsonism and in schizophrenia, such as the dysfunction of 
dopamine D2 receptor (Joyce et al, 1998a; Joyce et al, 1998b; Murray et al, 1995; 
Seeman, 1987). Dopamine is capable of facilitating or suppressing the synaptic 
responses in the entorhinal cortex depending on the concentration applied (Caruana 
et al, 2006). Higher concentrations of dopamine in the rat brain hyperpolarise 
responses in layer II neurons and depolarise responses in layer V neurons of the 
entorhinal cortex (Pralong & Jones, 1993). A recent study showed that rewarding 
stimulation of the lateral hypothalamus induces a dopamine-dependent suppression 
of synaptic responses in the entorhinal cortex (Hutter et al, 2013). Thus, the level of 
Gpr50 in the entorhinal cortex layer V of TgSwDI mice might be closely connected 
with its level in dopaminergic neurons of the hypothalamus, as the functional states 
of both areas are greatly influenced by the dopamine level.  
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Furthermore, Gpr50 and Bace1 mRNA levels appeared to be negatively correlated 
across the hypothalamic regions (chapter 6). This may indicate that GPR50 has a role 
in counteracting the deleterious aspects of BACE1 function in the endocrine system, 
such as the hyper-signalling through releasing the EGF-like domain from NRG1 
cleavage. Subcutaneous injections of NRG1 especially EGF in rats resulted in 
hyperdopaminergic abnormalities, which were correlated with schizophrenia-like 
behavioural deficits, such as lower prepulse inhibition (Nawa et al, 2014). This 
neuropathological impairment was thought to result from the over-activation of ErbB 
receptors by EGF.  Therefore, BACE1 has a potential to damage the homeostasis of 
dopamine synthesis and metabolism if its function is not restrained. GPR50 is 
expressed in dopaminergic neurons. In particular, Gpr50 strongly co-localises with 
Bace1 in the ARH and DMH, which are the hubs of the endocrine regulation, 
including the dopamine release and circulation. Thus, my findings have strengthened 
the crucial function of GPR50 in neurotransmitter signalling, probably by interacting 
with BACE1.  
8.4 Future work 
This thesis provides preliminary evidence for the interaction between GPR50 and 
BACE1. The regulation of GPR50 on neuronal β-secretase activity was highlighted. 
The potential of GPR50 in β-secretase activity-depending mechanisms (expression 
and trafficking) was demonstrated in both non-neuronal and neuronal cell lines, and 
primary neuronal cultures. The influence of GPR50-BACE1 interaction was 
confirmed by revealing the association of GPR50 with one of the medical-
meaningful molecules from BACE1 cleavage-Aβ, which strengthened the link of 
GPR50 to brain diseases. The studies of GPR50’s effects on BACE1 function reflect 
a new angle for investigating the pathogenesis of mentally related illnesses, but there 
are critical gaps to fill in. The most relevant points are addressed below. 
1) Does GPR50 C-terminal polymorphism affect its interaction with 
BACE1?  
In chapter 3, the interaction between the insertion form of GPR50 and 
BACE1 was demonstrated, while in chapters 4 and 5, GPR50 deletion/SNP 
form (GPR50del) was shown with a differentiated potential in regulating 
BACE1 properties from the full-length form (GPR50). It is important to 
further investigate if the physical interaction of BACE1 with GPR50 is 
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altered upon deletion/SNP; for example, whether the co-immunoprecipitation 
of BACE1 and GPR50 is strengthened or weakened. This will partly explain 
the enrichment of GPR50del in BD patients. 
2) Is the regulative action of GPR50 on β-secretase activity substrate-
specific?  
BACE1 cleavage has multiple explanations with occasional contradictory 
effects in brain activity, reflected by its role in normal function maintenance 
and illness pathology. This performance is attributed to β-secretase activity 
on different substrates. Therefore, it is essential to assess which substrate 
cleavage is GPR50-dependent, so as to answer the question which part of, or 
direction of BACE1 function, is GPR50 involved in. 
3) Is the interaction of GPR50 and BACE1 supported by loss-of-function 
studies? 
This thesis mainly focused on the effect of GPR50 gain-of-function on β-
secretase activity. However, before we draw the conclusion that GPR50 is 
required for BACE1 function, it is essential to validate the results by loss-of-
function studies (i.e. the Gpr50 RNAi studies attempted in chapter 4).  It must 
be determined whether BACE1 activity and regulation are altered in GPR50 
deletion cells or GPR50 KO animals. Also, the performance of Gpr50 in 
BACE1 KO and BACE1-overexpressing animals should be established, 
which will provide in vivo evidence for the involvement of GPR50 in BACE1 
function. 
4) What part do co-interactors play in the interaction of GPR50 and 
BACE1? 
The putative GPR50 interactors (i.e. RTN3/Nogo, SNX6) are important 
regulators of β-secretase activity, and have been functionally confirmed to be 
related to BACE1-dependent brain diseases. This link is emphasised as a part 
of the hypothesis in this thesis that the interaction between GPR50 and 
BACE1 is mediated via co-interactors. It will provide more validation by 
studying whether GPR50 plays a part in the biochemical function of 
RTN3/Nogo/SNX6 or vice versa, which is sequentially connected to the 
modulation of BACE1 activity. GPR50, BACE1 and co-interactors may 
function as a protein complex, and the dysfunction of any part will contribute 




5) Is the interaction of GPR50 and BACE1 region-specific in the brain? 
In chapter 6, I showed that Bace1 expression is strikingly high in the CA2 
region of the hippocampus and hormone-releasing areas of the hypothalamus 
(ARH, DMH). These regions also express high levels of Gpr50, and thus 
have strongest co-localisation of Gpr50 and Bace1. It is of high relevance to 
explore whether the interaction of GPR50 and BACE1 is restricted, or 
concentrated, in these brain regions, and what BACE1 substrates are involved. 
The Cre/loxP recombination system can be applied to develop mice with 
deletion of Gpr50 restricted to a sub-region or a specific cell type, such as the 
pyramidal cells of the hippocampal CA2 region (Tsien et al, 1996). Analysing 
BACE1 functions and the levels of certain substrates, in selected regions with 
deficient Gpr50 expression, will highlight which part of the brain activity is 
controlled by GPR50-BACE1 interaction. 
6) Are the findings of GPR50 in AD mouse model applicable to human AD 
and other related mental disorders? 
The TgSwDI mice used in this thesis partly cover the behavioural and 
functional defects in AD. It is necessary to take a further step for evaluating 
how useful the observations of Gpr50 in this AD model are, in order to 
explain the role of this protein under actual AD or other AD-like conditions. 
Thus, it is required to assess the expression profile of GPR50 in human post-
mortem brains of mentally related diseases (i.e. AD, schizophrenia, BD), and 
to correlate GPR50 characteristics with those of BACE1, relevant substrates 
and cleavage products. 
7) Does GPR50 interact with BACE1 substrates? 
Interacting with BACE1 substrates is an extra mechanism that can contribute 
to the regulation of BACE1 activity. For instance, GPR50 is known to be a 
regulator of APP interactor TIP60 and ABCA2. If GPR50 mediates the 
transcription and trafficking of APP or other substrates, it will in part explain 
the alteration of β-secretase activity upon GPR50 overexpression. 
In summary, future work should further examine the interaction between GPR50 
and BACE1 with a focus on their functions in both neurodevelopment under 
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